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 Abstract 
Accelerator Mass Spectrometry (AMS) is an extremely sensitive nuclear physics isotope 
ratio technique with growing application to clinical pharmaceutical drug development.  
The papers discussed in this commentary demonstrate a wide variety of clinical study 
designs that incorporate the use of radiocarbon (14C) as a tracer, with subsequent 
analysis by AMS.  The focus of the commentary is application of AMS as an enabling 
technique aimed towards novel investigations of the absorption, distribution, 
metabolism, excretion and pharmacokinetics (ADME-PK) of new therapeutic drugs in 
humans.   The impact and contributions to this field of research are demonstrated 
through discussion and critical examination of selected examples of the author’s peer-
reviewed publications in this area.  The first use of AMS in a clinical study for a new 
drug in development is included, along with other ADME-PK studies with potential new 
medicines.  The commentary details the expanding scope of AMS over recent years to 
encompass experiments designed to yield previously unattainable data.  
Developments of scientific practices, where the author has contributed intellectual, 
leadership and practical insight to achieve significant improvements in the generation 
of knowledge, are highlighted throughout the commentary.  The ongoing and future 
development of AMS, as well as the emergence of techniques as potential alternatives 
to AMS to provide deep insight into the research of new medicines are also discussed. 
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 Glossary, Abbreviations and Definitions  
[underlined bold in the text] 
Term Definition 
Absolute bioavailability (F) F is the fraction of an extravascular dose 
of unchanged drug that reaches the 
systemic circulation, commonly known as 
absolute bioavailability (also see 
bioavailability below).  To determine F, an  
intravenous reference dose 
administration is necessary 
ADME Absorption, Distribution, Metabolism and 
Excretion 
Allometric scaling Inter-species prediction of 
pharmacokinetic parameters, typically 
scaled relative to body weight or surface 
area 
Antineutrino (ῡ) A lepton antimatter particle emitted 
along with an electron during radioactive 
β--decay 
ANU (Australian National University) 
Sugar/Sucrose 
is a crop of sugar harvested in 1969-1971 
with a precisely defined 12C:13C:14C ratio; 
used as a standard for normalisation of 
data from the AMS and as a quality 
control 
AMS Accelerator Mass Spectrometry 
AUC Area Under the drug concentration:time 
Curve 
Autoinduction Where the administration of a drug leads 
to increased expression of a given 
metabolising enzyme responsible for the 
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metabolism of that drug.  Typically 
observed following repeated dosing  
Autoradiolysis Dissociation of molecules by free radicals 
from nuclear radiation; cleavage of one or 
several chemical bonds resulting from 
exposure to high-energy flux 
Bioanalytical/bioanalysis Analysis of drug (or metabolite) in 
biological matrix using an individual 
analyte specific assay 
Bioavailability Fraction of the dose of drug that reaches 
the systemic circulation 
Biosphere The ecosystem of the earth and living 
organisms that inhabit it 
Bq Becquerel – unit of radioactivity; 60 dpm 
= 1 Bq 
B-Raf A gene on chromosome 7q34 that 
encodes a protein of the raf/mil family of 
serine/threonine protein kinases 
14C A radioactive isotope of carbon 
Carbon carrier A known (usually petrochemical) source 
of carbon added to samples as an isotope 
dilutor 
Cathode Graphite (or gas) sample holder for 
analysis by AMS 
CCK Cholecystokinin 
Cold Terminology often used when describing 
non-radiolabelled doses or samples [as 
opposed to “hot” for radioactive] 
cpm and dpm cpm - counts per minute; the number of 
radioactive particles (electrons in the 
context of this commentary) directly 
detected by a scintillation counter.  The 
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value for cpm is adjusted for counting 
efficiency to provide the number of 
disintegrations per minute (dpm). 
dpm = [cpm/(% efficiency)]x 100 
CL (clearance) Clearance –the volume of blood from 
which drug is irreversibly removed per 
unit time (eg. L/h) 
COPD Chronic Obstructive Pulmonary Disease 
Cross-over study design Study design where two or more dose 
administrations are given on separate 
occasions to the same subject (with a 
washout period between doses) 
Cryogenic transfer Process by which carbon dioxide gas (at 
circa -70°C) in a sealed quartz glass tube is 
transferred and solidified under vacuum 
into a borosilicate glass tube (at 
circa -190°C) driven by the temperature 
differential of the environment in the two 
tubes 
Cytochromes P450; CYP3A4 A group of mixed function oxygenases 
responsible for metabolism of over 85% 
of marketed drugs (Kwon, 2001); CYP3A4 
is the most prevalent isoform 
Disproportionate metabolites Metabolites present in humans at higher 
concentrations than in (at least one) of 
the toxicology study species 
Direct AMS Analysis of samples by AMS (without any 
chromatographic separation) to provide 
total radioactivity data 
DMPK Drug Metabolism and Pharmacokinetics 
Dosimetry A series of experiments that are used to 
calculate dose of ionising radiation that 
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will be received by the human body 
EMA European Medicines Authority 
Emax The maximum energy carried by an 
electron emitted during β-—decay 
FDA (US) Food and Drug Administration 
Flip-flop kinetics Phenomenon observed if the rate of 
absorption is slower than the rate of 
elimination (or if one of the distribution 
rates is slower than elimination rate) 
First pass metabolism The process by which drugs absorbed 
from the gastrointestinal pass through 
the liver where they are metabolised (to 
varying degrees) before reaching the 
systemic circulation 
FTIH First Time In Human 
GSK GlaxoSmithKline Research and 
Development Ltd. 
Hepatic extraction Removal of the drug by the liver from the 
blood flowing through it (via metabolism 
or biliary elimination) prior to it reaching 
the systemic circulation as defined by the 
extraction ratio 
HPLC High Performance Liquid Chromatography 
ICH M3 International Conference on 
Harmonisation M3 – ICH guideline M3(R2) 
on non-clinical safety studies for the 
conduct of human clinical trials and 
marketing authorisation for 
pharmaceuticals; combines regulatory 
positions across the world 
Intrinsic clearance intrinsic ability for the liver to remove 
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drug by metabolism – determined in vitro 
(eg. in hepatocytes) therefore not limited 
by blood flow or by protein binding 
Isotope dilution Isotope ratio of a sample is quantitatively 
altered usually by the addition of a known 
amount of a selected isotope in order to 
deliberately alter the isotopic ratio eg. an 
organic substance originating from 
petrochemical sources is depleted of 14C. 
Therefore when added to a biological 
sample with a given 14C:12C ratio, the 
effect is to quantitatively increase the 
ratio of 12C 
IV Intravenous administration 
keV kiloelectron Volts 
KIE Kinetic Isotope Effect 
LC Liquid Chromatography 
LC+AMS Bioanalytical assay of specific individual 
analyte isolated through off-line 
fractionation following liquid 
chromatography with subsequent analysis 
by AMS (distinct from metabolite profiling 
where multiple analytes i.e. drug and 
metabolites, are analysed) 
LC-MS Liquid Chromatograph interfaced to a 
Mass Spectrometer (often shortened to 
this even when MS fragmentation is 
carried out ie. LC-MS/MS or LC-MSn) 
LoD Limit of Detection; the lowest quantity of 
analyte that can be distinguished from 
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the absence of a signal for that analyte 
within a stated confidence (eg. a multiple 
of signal:noise ratio) 
LoQ Limit of Quantification; lowest 
concentration at which the analyte can be 
detected with predefined bias and 
precision 
LSC Liquid Scintillation Counting/Counter; a 
method of quantifying decay through 
radioactive emissions 
Mass balance (in vivo) Recovery of the radioactive dose 
administered via collections of excreta 
(urine and faeces mainly) 
Mass (of drug) equivalents per unit 
sample volume eg. pg trametinib 
equiv./mL 
Concentration of total drug-related 
material is converted from radioactive 
units to a mass that relates to parent drug 
based on the administered specific 
activity of the dose 
MDR1-MDCKII Multi-Drug Resistance Madin-Darby 
Canine Kidney (cell monolayers) 
MEK Mitogen-activated protein Kinase 
Metabolite Product of metabolism 
(biotransformation of parent drug, or of 
another metabolite) 
Metabolite profiling An assessment of the presence and 
quantification of the range of drug 
metabolites observed in any post-dose 
matrix analysed.  A metabolite profile is 
typically performed by 
radiochromatography 
Microdose Drug administered to humans does not 
exceed 1% of the NOAEL in animals, or 1% 
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of the predicted pharmacologic dose 
based on animal data, or as 100 μg of a 
new drug, whichever dose is lowest. 
Microtracer An isotopically labelled substance 
(radioactive or stable isotope) 
administered intravenously concomitant 
to a considerably higher extravascular 
dose.  The microtracer dose is low enough 
to avoid any perturbance of the 
pharmacokinetics of the extravascular 
dose 
Modern Terminology used to denote the 14C 
present at the natural level in 1950 [13.56 
dpm/g C].  A term inherited from 
radiocarbon dating by AMS, but still used 
in other AMS applications  
MS Mass Spectrometry 
NMR Nuclear Magnetic Resonance 
spectroscopy 
NOAEL No Adverse Effect Level [relates to 
absence of toxicity in animal toxicology 
studies] 
Parametric release An approach through which sterility 
procedures for dose manufacture is 
established for non-labelled product and 
the same procedure then applied 
to 14C-labelled drug, to expedite release 
for intravenous dosing to humans 
PET Positron Emission Tomography 
P-glycoprotein Permeability glycoprotein; a cell 
membrane bound efflux transporter of 
xenobiotics 
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Pharmacokinetics Study of the time course of drug 
absorption, distribution, metabolism, and 
excretion – described through 
mathematical models 
Polymorphic In respect to enzymes responsible for 
metabolism of xenobiotics, distinctly 
different expression populations exist (eg. 
poor and extensive metabolisers)  
Radiocarbon dating Determination of carbon isotope ratios in 
a sample to provide a chronological date 
RDM Radioactive Drug-related Material i.e. 14C-
parent drug and metabolites which still 
contain the 14C label (≈ Total radioactivity) 
Specific radioactivity Radioactivity per unit mass (or mole) of a 
stated element or compound 
SSAMS Single Stage Accelerator Mass 
Spectrometer 
Sv Sievert ; unit of committed effective dose 
of ionising radiation exposure 
t1/2 Pharmacokinetic parameter: describes 
the period of time for a given 
concentration of analyte to be reduced to 
exactly half of it’s initial concentration by 
clearance 
Radioactivity parameter: describes the 
time taken for the activity of a given 
amount of a radioactive substance to 
decay to half of it’s initial value 
Time-adjusted proportional pools Plasma samples combined such that the 
volume of each included in the pool is 
proportional to the time period between 
collections.  The drug concentration in the 
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pool is equivalent to that of the AUC(0-t) 
(where t is the time the last sample was 
taken that is included in the pool). 
(Hop et al., 1998) 
tmax Time at which maximum concentrations 
of analyte are present in the systemic 
circulation [observed] 
TopCount Equipment for radiodetection using solid 
scintillant in a microplate  
Total Radioactivity Sum of all 14C radiolabelled (drug related) 
material in any given sample 
Tributyrin 1,2,3-tributyrylglycerol; commonly used 
as a carbon carrier in graphitisation 
UPLC Ultra High Pressure Liquid 
Chromatography 
Volume of distribution Theoretical volume of body fluid that 
would be required to contain the total 
amount of drug at the same 
concentration as that measured in 
biological fluid (blood, plasma or serum) 
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Scope of the Commentary 
 
This commentary will focus on some of the applications of Accelerator Mass 
Spectrometry (AMS) to drug development specific to the experience and expertise 
gained by this author in support of experiments conducted by GlaxoSmithKline 
Research and Development Ltd. (GSK).  Many applications that are described in the 
commentary are well established, if not widely adopted today.  This however, is a 
relatively recent advent and the commentary is based upon the progressive 
development history of the technique in which the author played a significant role, as 
evidenced by the publications. 
 
Clinical applications are the focus of this commentary and therefore there is only brief 
mention of applications that have also taken place under the author’s stewardship, 
such as non-clinical studies, eg. in vivo animal and in vitro efforts.  Additionally, 
applications which are often inextricably linked to AMS, such as microdosing in 
humans are also largely excluded from this commentary.  References that included 
such work where the author has contributed are provided for completeness in 
Appendix 1 of the commentary (Cahn et al., 2013), (Mahar et al., 2012). 
 
The commentary is based upon papers centered around the theme of AMS use to 
support human ADME studies and intravenous microtracer pharmacokinetic studies.  
These will be described in more detail later, but importantly the learnings from 
application of AMS to the support of these studies, by this author, has driven 
significant developments of the science in this field.  The knowledge derived from 
these works has then enabled confident design of a combined human 
ADME/microtracer study for a new drug in development.  The details of this will be 
covered in the future perspectives section of this commentary.  Longer term future 
aspirations for AMS in drug development are also addressed. 
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 1. Introduction  
 
The following sections will provide background information on the principles of the 
application of radioisotopes as tracers in the study of pharmacokinetics and drug 
metabolism in the development of medicines.  In particular, the use of the isotope 14C 
and its measurement in biological matrices using AMS will be addressed.  A selection 
of published works by this author, which demonstrate novel application of AMS in drug 
development, will then be presented and will form the main basis for this 
commentary.  Throughout the commentary, evidence will be shown for the 
contribution that this author has made to the field of biomedical AMS over many 
years.  Finally, the possible directions for future development and advancement of this 
area of science will be outlined. 
 
1.1. Pharmacokinetics and Drug Metabolism 
 
The study of drug metabolism and pharmacokinetics (DMPK) concerns the processes 
of absorption, distribution, metabolism and excretion (ADME) of drugs and the 
mathematical description of concentrations of a drug and its metabolites over time.  
DMPK data are used in the safety evaluation of drugs throughout their development 
towards safe and efficacious medicines, and thereafter as marketed products. 
 
1.2. Use of radioisotopes as metabolic tracers in drug 
development 
 
Radioisotopes, in particular 3H and 14C, are widely used in the pharmaceutical industry 
as radioisotopic tracers to facilitate an understanding of the ADME properties of new 
drugs under development as future medicines.  They provide the ability to trace a drug 
and its metabolites through living organisms by differentiating it from the myriad of 
other endogenous molecules present.  This information is of use in determining the 
metabolic fate of the drug and in confirming the validity of the animal species used in 
toxicology studies to support administration to humans.  Although 3H is widely used 
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for in vitro studies and in early experiments in drug discovery, due to its facile inclusion 
in chemical structures and high specific activity, loss of the isotope from molecules 
due to tritium exchange limits its use in vivo.  For in vivo studies, particularly those 
conducted in humans, 14C is the preferred radioisotopic tracer for the following 
reasons: 
1) It can be chemically incorporated into the structural skeleton of a drug 
molecule. 
 
2) It can be located in specific molecular moieties that are metabolically stable 
thus allowing the molecule and any drug-related metabolites to be 
quantitatively traced through the relevant experiments. 
 
3) The half-life of radioactive decay of 14C is 5700 ± 30 years (as recently assessed 
(Kutschera, 2013)) and therefore places no time restrictions on experiments. 
 
4) 14C is a low energy β--emitter (Emax = 156 keV) and therefore presents few 
safety concerns (although there are still limitations in terms of its 
administration to human subjects; see below and (ICRP, 1992)). 
 
5) 14C has a relatively small kinetic isotope effect (KIE) (discussed further below). 
 
6) The rate of radioactive decay is unaffected by environmental factors (eg. 
temperature, pH, molecular form) and so their measurement is fully 
quantitative without the need for authentic matched standards. 
 
The use of 14C has a number of practical limitations however, due to the long decay 
half-life of this isotope (Kutschera, 2013).  Relatively high radioactive doses lead to the 
need for dosimetry to assess the burden of ionising radiation exposure to human 
subjects in the context of clinical trials with 14C-labelled drugs.  Equally, even with 
administration of such relatively high doses of 14C, the data generated may be 
truncated due to inadequate sensitivity of measurement of the radioactivity present in 
samples over sufficient periods of time (Bowers et al., 2013) as depicted in Figure 12. 
20 
 
To achieve relatively short sample counting times a large number of 14C atoms must be 
present in the sample if decay counting is to be used as the detection methodology 
(see section 1.3.1).  However, the long half-life does allow a more relaxed approach to 
be taken with regard to sample handling and analysis times as the 14C content will not 
be reduced significantly within the normal timeframe of experimentation.  This is not 
the case for shorter half-life tracers such as 11C (β+-emitter commonly used in PET 
imaging), which has a half-life of only 20 minutes; leading to severe limitations on the 
practicalities regarding the timescale of its application and detection, although this 
isotope also has its place in drug development and research, and indeed has been used 
alongside 14C in at least one clinical study (Wagner et al., 2011). 
 
As stated above, inclusion of 14C in organic molecules does not lead to significant 
kinetic isotope effects.  The KIE is the change in the rate of a chemical reaction when 
one of the atoms in the reactants is substituted with one of its elemental isotopes.  
Formally, it is the ratio of rate constants (k) for the reactions involving the light (kL) 
and the heavy (kH) isotopically substituted reactants as described in Equation 1: 
 
    𝑲𝑰𝑬 =  𝐤𝐋
𝒌𝑯
    (Equation 1) 
 
It can be seen from Equation 1 that the larger the relative mass of the isotopes the 
greater the magnitude of the KIE.  The relative difference in atomic mass between the 
light and heavy isotopes decreases as the atomic mass increases.  In the case of 
tritium, there is a 3-fold difference from its lighter 1H isotope.  This has been shown to 
lead to changes in reaction times by specific enzymes in the order of 2.5-fold 
(Damgaard, 1977).  For 14C, there is only a 1.2-fold mass difference from its lighter 12C 
isotope, which results in an essentially negligible impact on reaction rates (see work on 
carboxylation of 13C-ribulose biphosphate (Roeske and O'Leary, 1985)).  Moreover, 
such small KIEs are likely to be indistinguishable from experimental biological 
variations in vivo.  In short, incorporation of 14C into a molecule will have no significant 
impact upon potential reaction paths or rates and hence no significant effect upon the 
biological fate of the molecule under investigation. 
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 1.3. Measurement of 14C 
 
14C is commonly quantified by measuring the number of electrons emitted over a given 
time during β--decay by a technique known as liquid scintillation counting (LSC).  A 
calibrated LSC converts the number of electrons detected to the number of decay 
events for any given period of time.  Typically, the raw units of radioactive 
measurement from an LSC instrument are counts per minute (cpm), which are then 
converted to disintegrations per minute via instrument calibration*.  Disintegrations 
per minute (dpm) is the fundamental unit of radioactivity and other units are derived 
from this (1 Becquerel = 60 dpm, 1 Curie = 2.22 x 1012 dpm). 
 
Liquid scintillation counters have been in common use in drug metabolism laboratories 
for many years with the first commercial instrument having been built in 1954 
(reviewed by (Lappin, 2015)).  The energy of emitted electrons is absorbed by the 
liquid scintillant's π orbital electrons, which re-emit the energy upon returning to the 
ground state, as photons of light.  Early instruments suffered from high background 
(equivalent to 100 dpm or more) and as with any analytical instrumentation, the 
higher the background, the lower the signal to noise ratio and therefore the poorer the 
sensitivity (i.e. the higher the limit of detection (LoD)).  In scintillation counting, there 
are a variety of sources of potential background, including cosmic radiation, chemical 
luminescence from scintillants and electronic noise.  To address the sensitivity issue, a 
combined approach was taken to reduce noise, ranging from use of lead shielding (to 
reduce cosmic radiation ingress) to sophisticated electronic solutions and complex 
scintillation cocktail developments.  The background in modern LSC instruments is 
about 10 dpm.  Traditionally, the limit of quantification (LoQ) for LSC is defined as 
multiples of background (typically two to three-fold, depending on the laboratory).  A 
typical LoQ for LSC is 25 dpm (Lappin and Temple, 2006). 
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* Liquid scintillation counters are calibrated using a quench curve that can involve complex 
mathematical algorithms.  The details of this technique are outside of the scope of this commentary.  
Methods of quench curve correction are discussed in Chapter-8 of Lappin and Temple (2006). 
 In liquid scintillation counting the sample is dissolved in a chemical cocktail consisting 
of a solvent and a liquid scintillator thus bringing the radionuclide into close molecular 
contact with the scintillator.  Liquid scintillation counting was - before the advent of 
AMS and indeed remains so for relatively high radioactive content samples - the 
preferred method for analysing relatively low energy emitters such as β-particles 
(electrons), which are produced during the radioactive decay of 14C (Equation 2):  
 
   𝐶614   𝑁714  + e
- + ῡ  (Equation 2) 
 
As shown by the reaction above, by emitting an electron (a negatively charged 
β-particle) and an electron antineutrino (ῡ ), a 14C neutron decays to a proton and 
the 14C transmutes to the stable (non-radioactive) isotope nitrogen-14 (14N). 
Due to the long half-life of 14C (as stated in the previous section; 5700 years, or ~3 
billion minutes), only 2 × 10–8% of the 14C in a sample decays in one minute, making 
decay counting extremely inefficient. 
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 1.3.1 Analytical Sensitivity 
 
Although manufacturers of liquid scintillation counters have taken steps to reduce 
background noise through the use of multiple photomultipliers, comprehensive 
shielding and complex electronics, the LoQs are still somewhat restricted for the 
reasons discussed below. 
 
Notwithstanding noise from instrument electronics, the limitation on the LoQ for LSC is 
dependent upon the ability to measure a given number of electrons emitted from an 
analyte radionuclide, against those electrons arising from background radioactivity.  
The LoQ in LSC is defined statistically, typically by counting a sufficient number of 
decay events to achieve a 95.5% confidence interval (i.e. within two standard 
deviations of the mean).  It therefore follows that the fewer the number of decay 
events in any given period, the longer the count time on the instrument as shown in 
Equation 3: 
 
         (Equation 3)* 
𝒕 = 𝟏
𝒄𝒑𝒎
�
𝟐𝟎𝟎%𝟐𝝈�𝟐 
 
Where t is the count time,  
σ is the standard deviation, 
2%2σ (often shortened as shown here to %2σ ) is the 95.5% confidence interval of a 
determined value being within two standard deviations of the mean value. 
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* Equation 3 uses cpm; the conversion to dpm by the computer software of the LSC, takes into 
account efficiency of the counting process within the LSC instrument. 
 
 To demonstrate the impact of the above, if 1 million cpm are counted to 2%2σ, then a 
count time of only 0.6 seconds is required.  If 10 cpm are counted to 2%2σ then the 
count time increases to 16.6 hours.  The count times therefore become impractically 
long for samples containing low amounts of 14C. 
 
In addition to the above, complex statistical methods have to be applied for very low 
level counting by LSC, to enable reliable background subtraction.  These are outside of 
the scope of the current commentary, but typically involve estimating background 
over 3 to 5-fold the time required for sample measurement.  Reliable low level LSC can 
therefore be extremely time consuming and may take up to several days per sample. 
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 The number of disintegration events for a radioisotope, in any given time period, is 
dependent upon its radioactive t½ as shown in Equation 4.  This defines the maximum 
specific activity for any given isotope: 
 
dpm/mol = (ln2/ t½) x Avogadro's constant   (Equation 4) 
 
The natural Log of 2 (ln2) = 0.6931, 
t½ for 14C = 5700 years = 3.0 x109 minutes, 
Avogadro's constant = 6.0221 x 1023 atoms or molecules per mole, 
 
Thus, every mole of 14C emits 1.39 x 1014 dpm, 
 
Thus, to generate 1 dpm, 4.33 x109 atoms of 14C are required. 
 
As stated in section 1.3, in most laboratories the LoQ for LSC is 25 dpm, which means 
that approximately 1 x 1011 atoms of 14C have to be present in the sample, thus 
limiting the sensitivity to the high picomole range. 
 
To highlight the impact of this inefficiency of LSC, in the world of archeology 
for radiocarbon dating of famous artefacts such as the Shroud of Turin using LSC, a 
large piece (probably around the size of a handkerchief) would have been required to 
be sampled, by destructive analysis, for sufficient sensitivity to be achieved.  It was 
largely for these reasons that a more sensitive method of 14C detection was sought, 
which culminated in the development of accelerator mass spectrometry (AMS) in the 
mid-1970s (Bennett et al., 1977). 
 
The advent of AMS provided sufficient sensitivity improvement over that of LSC to 
allow dating through analysis of only a few milligrams of material (Damon et al., 1989).  
The first experiment applying AMS to investigations in the biomedical field occurred in 
1997 (see section 1.5).  AMS was subsequently applied to drug development. 
 
26 
 
AMS was adopted into use for drug development because it was recognised that 
certain clinical studies carried an unacceptably high risk of radioactive exposure to 
human volunteers if supported by LSC.  In retrospect it became clear that in some 
cases studies would not have attained ethical approval without the extremely sensitive 
analysis offered by AMS (see section 3.2.2).  For example, a human radiolabel study 
was not conducted for such ethical reasons for dutasteride, a 5α-reductase inhibitor, 
due to its extremely long elimination half-life in humans (approx. 5 weeks) and 
excretion mass balance could only be assessed using a 19fluorine-NMR (19F-NMR) 
approach (GSK data on file).  Although beyond the scope of this commentary, 
applying 19F-NMR to mass balance studies is problematic as it relies on a fluorine atom 
being present in the structure of the molecule of interest and it is insensitive in 
comparison to AMS. 
 
Although 14C is a commonly used isotopic tracer, 13C is also used, particularly in studies 
in humans, because it has the advantage of being a stable isotope and so there are no 
issues of radioactive exposure.  There is however a significant disadvantage with 13C; 
an inherently higher LoQ because of its relatively high background. 
 
The natural abundance of 13C is around 1.1% of total carbon in the living biosphere, 
whereas 14C is present as the rare isotope at one part per trillion (1:1012).  Doubling the 
concentration of both isotopes in 1 mg of carbon requires 900 nmol of 13C, but only 
98 amol of 14C.  Assuming equivalent detection of the two isotopes, this produces a 10 
billion times increase in sensitivity for compounds labeled with 14C over those labeled 
with 13C. 
 
This commentary focuses solely on the application of 14C in AMS and drug 
development. 
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 1.3.2 Application of AMS 
 
AMS has been used instead of, or as a supplemental analytical tool to, LSC for the 
following reasons: 
 
1) Reduced radiation burden.  In instances where the drug under development 
has shown retention of either the parent drug or RDM (radioactive drug related 
material) in non-clinical studies (see clinical study example in Commentary 
paper 2, section 3.2) a clinical study can be successfully conducted using a 
vastly reduced amount (in the region of a thousand fold) of radioactivity in the 
dose, thus leading to reduced exposure of the subject to ionising radiation.  
Studies in paediatric or patient populations further re-enforce the need to keep 
radiation burden to a minimal level. 
 
2) Flexibility of study design, e.g. multiple doses.  The possibility of reduced 
radiation burden to the subject then allows for more than one radioactive dose 
to be administered if required, either as pulse doses (see Commentary paper 5, 
section 3.5) or even as multiple repeat doses of radioactivity (Iyer et al., 2012).  
Prior to the advent of AMS such studies in human subjects were extremely 
rare. 
 
3) The ability to extend sample collection over longer periods of time.  It is 
possible to monitor the pharmacokinetics and excretion of the drug under 
investigation such that samples can be collected for weeks or even months 
after dosing (see Commentary papers 2 and 3, sections 3.2 and 3.3, and 
(Clifford et al., 1998)), rather than just for up to one week which is the 
conventional approach for human ADME studies.  When using higher doses of 
radioactive drug, subjects can only be discharged from the clinic once levels 
being excreted have reached acceptable amounts.  AMS allows for very low 
levels of radioactivity to be administered thereby enabling subjects to be 
released from clinics at any time and they may even return at later dates to 
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provide more samples should there be a requirement to further define the 
excretion profile. 
 
4) Concomitant dosing.  The design and application of the microtracer study has 
been revolutionised through the use of AMS (see Commentary papers 6 and 7, 
section 3.6). 
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 1.3.3 Sample preparation (Graphitisation) for AMS  
 
Unlike LSC, where radioactive samples are added directly to liquid scintillant, samples 
for analysis by AMS require prior preparation to extract elemental carbon (‘graphite’) 
prior to isotope ratio measurement.  This occurs via a two step process of oxidation to 
CO2 and then reduction to graphite (Vogel, 1992); see Equation 5 and Equation 6 
below.  AMS provides an isotope ratio of 14C : 12C from which 14C per mg carbon is 
derived (see section 1.3.5).  It is important to note here that for a reliable 
measurement to be made the sample preparation process must preserve the isotope 
ratio of the initial sample and KIEs (known as isotope fractionation in this context 
(Vogel, 1992)) that might occur during sample preparation must be avoided.  Such a 
disruption to the isotope ratio during graphitisation can occur when excess nitrogen is 
present in the sample – urine samples are prone to this effect so care must be taken to 
ensure that this is minimised through sample dilution or increased time for 
the cryogenic transfer step to occur.  The mechanism for the nitrogen effect remains 
obscure, but has been observed empirically (Vogel et al., 2010). 
 
Quartz tubes containing the “biological sample” with the addition of supplemental 
carbon source (carbon carrier) as required (see section 1.3.5.1 and Figure 5) and 
copper (II) oxide wire (in excess at ~50 mg) are dried under vacuum in a centrifugal 
evaporator.  The quartz tubes are then sealed into separate evacuated larger quartz 
tubes prior to combustion at 900°C for two hours.  The CO2 thus formed is 
cryogenically transferred into evacuated borosilicate tubes containing zinc powder and 
titanium dihydride blend at 8.3:1, w:w ratio (~160 mg) and cobalt catalyst (~6 mg) and 
the tubes are sealed using a high temperature torch, as shown in Figure 1, Figure 2 and 
Figure 3.  The reduction tubes are then heated to 500°C for 4 hours, followed by 550°C 
for 6 hours to complete the graphitisation process (see the oxidation and reduction 
reactions summarised below).  Carbon as graphite, deposited on the cobalt, is pressed 
into aluminium cathodes and analysed by AMS. 
 
From the above description it can be seen that sample preparation is a demanding 
process, taking up to three days post preparation of the biological sample itself in 
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readiness for the graphitisation phase of the sample preparation.  This explains the 
interest in finding alternative approaches to a more rapid sample preparation 
procedure or avoidance of it entirely, such as direct injection of harvested gas (CO2) 
directly into the AMS instrument source (see section 1.4). 
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Figure 1.  Stage 1 graphitisation rig (photograph of set up at GSK*). 
Dried sample is sealed into an evacuated tapered quartz tube containing copper (II) oxide, then subsequently placed in a furnace. 
Combustion Stage: 
CuO + Sample (containing carbon)   (900°C for 2 hours)  Cu + CO2 + H2O (Equation 5) 
Vacuum port 
Oxy-propane 
torch 
Large tapered quartz tube 
– with inner tube 
containing sample and CuO 
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*  Photograph provided with permission from GSK. 
  
 
 
 
 
 
 
 
 
Figure 2.  Diagram of graphitisation* – showing the set up for cryogenic transfer of CO2. 
Following sample combustion, the quartz tube is inserted into the Y-piece, gas transferred and the sealed reaction tube is placed back into the 
furnace. 
 
Note – plastic disposable Y-piece (as shown in the diagram above) was changed to re-usable metal unit (shown in the photograph below) following 
investigation in our laboratory which demonstrated no sample-to-sample carryover occurred.
To Vacuum Manifold
Plastic “Y”
Glass Wool
Dry Ice Slush
Liquid N2 Zn + TiH2
Sealed Reaction Tube
Graphite on cobalt
Combusted sample plus CuO
Quartz Tube
Cobalt Powder
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*  Diagram prepared by the author. 
  
 
Figure 3.  Stage 2 graphitisation rig (photograph of set up at GSK*). 
Reduction Stage (following cryogenic transfer of CO2 from combustion tube):  
2Zn + 2TiH2 + 3CO2  (500°C for 4 hrs + 550°C for 6 hrs [+Cobalt])  2ZnO + 2TiO + 2H2O + 3C     (Equation 6) 
 
Dewar 
containing dry 
ice/ isopropanol 
slurry 
Large tapered 
quartz tube – 
from Stage 1 
Re-usable metal Y-piece Borosilicate tube – 
with inner tube 
containing cobalt 
catalyst (outer tube 
contains Zn and TiH2) 
Dewar 
containing 
liquid nitrogen 
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*  Photograph provided with permission from GSK. 
 The graphite pressed into the cathode is ionised using a sputtering caesium ion beam 
(Cs+) which generates negative carbon ions; this is crucial as it removes the possibility 
of interference from 14N-, which is unstable and does not survive past the ion source.  
The 12C, 13C and 14C ions produced are separated based on their mass/charge ratio, 
sequentially accelerated to high velocities using a high potential difference 
(250kV-10 MV; depending on the AMS design), and separately counted.  The results 
are typically expressed as isotope ratios, which are normalised to the ratio provided by 
the consensus value standard (see section 1.3.5), thus accounting for any variability in 
instrument response.  The radiocarbon content of the graphite samples can then be 
calculated based upon carbon content, sample volume analysed, extraction recovery 
and initial specific activity to provide the drug or drug-related material concentration 
(a detailed explanation is given in sections 1.3.5 and 1.3.5.1). 
 
Unlike decay counting, which counts electrons emitted during β--decay, AMS counts 
individual 14C atoms and, typically, just 1000 are considered adequate to give a reliable 
result to provide statistical assurance to the 3% precision level ((√1000/1000)x100 = 
3%)*.  
 
However, taking into account differences in background 14C content between sample 
types and the larger amount of sample that can be analysed by LSC, the inherent 
sensitivity of the AMS instrument translates in practice to a 300 to 500-fold lower limit 
of quantification for direct AMS measurements compared with total radioactivity 
analysis using LSC.  To put this into context, if the LoQ by LSC for a plasma sample is 
25 dpm/mL, then with AMS the LoQ is between 0.08 – 0.05 dpm/mL.  With generation 
of good cathode currents (> 5 µAmp high energy for 12C+1; see later in this section), 
analysis times are usually in the region of < 10 minutes per cathode for biomedical 
work, whereas for carbon dating, to achieve higher precision, lower throughput can be 
tolerated and the analysis time per cathode can take several hours of measurement.   
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*As an aside, for radiocarbon dating purposes the desired precision is usually at the 1% level, which 
requires upwards of 10,000 counts [(√10000/10000)x100 = 1%] 
 
 
1.3.4 AMS instrumentation 
The architecture of a standard 250kV AMS instrument used for biomedical AMS (Young et al., 2008) is shown in Figure 4 below.  This design of 
instrument provided all of the AMS data generated by GSK, from 2005 onwards. 
 
 
 
Figure 4.  Schematic of Single Stage Accelerator Mass Spectrometer (SSAMS) instrument at GSK*. 
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*  Reproduced by kind permission of National Electrostatics Corp., Madison, Wisconsin, USA. 
 The graphite samples in the aluminium cathodes are placed on a wheel which is loaded 
into one of the two MC-SNICS (Multi-Cathode Source of Negative Ions by Caesium 
Sputtering), depicted in green in Figure 4.  Multiple ionic species are generated by the 
source including monoionic 12C-, 13C-, 14C- and 16O-, as well as molecular species such 
as 12CH2- and 13CH-.   
 
The mixed ion beam is pre-accelerated through the first electrostatic analyser (ESA; 
red in Figure 4), which removes some interfering ions and then directs the beam 
towards the first analysing magnet (blue in Figure 4) that sequentially selects for 
masses of 12, 13 and 14 in “jumping cycles” of 500 µs, 2100 µs and 0.1 second, 
respectively.  This initial crude filtering of ions selects for 12C-, 13C- and 14C-, but also 
allows molecular interferences of the same m/z values (such as 12CH2-) to pass through 
towards the accelerator.  The anionic beam passes into the acceleration tube where 
ions are accelerated through a potential difference of 290 kV*.  The beam enters a cell 
containing low-pressure argon (known as the molecular dissociator) where molecular 
species are destroyed, as they collide with the gas, leaving only monoionic species.  
Through this process electrons are stripped from the outer orbitals of mono-anionic 
carbon species resulting in cations ranging from C+1 to C+4, with the singly charged 
species being the most abundant at this energy.  Creation of positively charged carbon 
ions removes interference from all of the remaining molecular isobars such as 12CH2+ 
and 13CH+, since these are unstable in the molecular dissociator.  After the acceleration 
tube the ions pass through the second analysing magnet, which further separates out 
the ions by mass/charge ratio and hence the singly charged ions are selected.  12C+1 
and 13C+1 are quantified by Faraday cups, whilst 14C+1 ions then pass through to a final 
ESA which focuses the ion beam to the detector and removes any remaining 
background interference.  The detector is a silicon surface barrier detector that counts 
individual atoms of 14C+1 that are incident upon it.  The instrument thus generates 
measurements of the ratios of the three isotopes of carbon (12C, 13C and 14C) present in 
the graphite sample.  
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* Ions are extracted out of the ion source by a potential difference of -40kV and accelerated by a 
final potential difference of up to +250kV, thereby producing total potential difference of 290kV 
 1.3.5 Data acquisition and calculations 
 
Analysis of sample radiocarbon within an environment where it is present in the 
atmosphere and many surrounding organic molecules is very challenging.  There is 
therefore a vital need for a thorough understanding of the carbon inventory for any 
sample under analysis.  Typically a sample analysed by AMS requires between 1-2 mg 
carbon for a reliable measurement.  In some cases the sample provides this mass of 
carbon during graphitisation.  For example, plasma is consistently 4.1% carbon (see 
section 3.1.4) and so 49 μL will provide 2 mg carbon.  Not all sample types contain 
adequate amounts of carbon, urine for example is only approximately 0.5 % carbon 
(Kim et al., 2011).  These types of sample are supplemented with a known amount of 
additional carbon (called “carbon carrier”).  Ideally carbon carrier is derived from 
petrochemical sources that are essentially devoid of 14C*.  Addition of carbon carrier 
that contains 12C but not 14C, dilutes the 12C:14C isotopic ratio and therefore this has to 
be taken into account during any calculations as described in section 1.3.5.1.  Fractions 
collected from liquid chromatography contain very low levels of carbon and so require 
the addition of carbon carrier prior to analysis, but this is a somewhat special case 
discussed in section 1.3.5.1.  This isotopic dilution is an extremely useful approach, 
particularly when the total carbon content of the sample of interest is negligible (say in 
the nanogram range and can be effectively made inconsequential by the addition of an 
excess of carbon from the carrier – often 1000x dilution) which allows the 
denominator of the below equation (Equation 7) to effectively be a fixed and known 
value.  This then facilitates the interpretation of the data from the AMS to provide 
the 14C content for unknown samples. 
 
The 14C : 12C ratio of a sample =  
 
Total 14C (drug + biological sample + carrier) 
          (Equation 7) 
Total 12C (drug + biological sample + carrier) 
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* Some batches of carbon carrier derived from petrochemicals have been known to contain 14C and 
this is discussed below. 
Thus, AMS measures the 14C:12C content of a sample derived from all sources of carbon 
in the sample. 
 
The 14C:12C ratio of a sample is normalised using data generated from a known 
certificated standard eg. Australian National University Sugar (ANU) which is 
graphitised for analysis by AMS.  Another set of synthetic graphite instrument 
standards are also run to monitor instrument background and further process controls 
to check that no cross-contamination, or environmental contamination has occurred.  
The 14C : 12C isotope ratio data provided are then used to calculate concentration 
values for prepared biological samples as described below. 
 
AMS data are provided as isotope ratios, with the most important one being 14C:12C, 
although 13C:12C are measured to ensure that the transmission ratio of all measured 
carbon isotopes remains constant throughout the analysis with no fractionation. 
 
Due to the origins of AMS in carbon dating, the instrument output is typically 
expressed in units of percent Modern Carbon, which can be confusing for those 
involved in development of pharmaceuticals.  Modern, being 100%, is defined as the 
atmospheric 14C:12C isotope ratio in 1950.  Because of atmospheric bomb tests after 
this date, background pMC had risen and ANU sugar (used as an AMS standard) 
harvested in 1969-1971 is certified at a consensus value of 150.61 pMC.  1 Modern, or 
100 pMC is defined as follows: 
 
100 pMC = 0.01356 dpm/mg C (Mook and Plicht van der, 1999)  
 
Thus,    pMC x 0.0001356= dpm14C/mg C 
 
and    (dpm14C/mg) x mg C in sample = dpm14C 
 
and   dpm14C / volume of sample (µL) x 1000 = dpm14C /mL. 
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The dpm14C/mL value and specific activity of the drug dosed are used to calculate mass 
per unit volume (eg. pg/mL) values. 
 
So,   (dpm14C/mL)/ specific activity (dpm/pg) = pg/mL  
 
The fact that ANU sugar is used as a universal single concentration standard for 
instrument data normalisation may seem questionable considering that samples 
analysed may be quite different in concentration to this standard.  However, AMS is 
known to be linear over five orders of magnitude (Vogel and Love, 2005), (Keck et al., 
2010) and of course the sample analysed in the instrument is always the same matrix 
(graphite) so there are no matrix variability effects to cause any analytical differences.  
For bioanalytical (LC+AMS) assay applications there would be additional spiked 
biological matrix matched standards prepared as further sample processing standards. 
 
It is important to state that the assay range is impacted by the specific activity of the 
material used to prepare standards.  The back-calculation of data from the AMS, to 
mass concentration of drug and drug-related material for samples is equally impacted 
by the specific activity of the dosed material. 
 
Carbon carriers are chosen from petrochemical sources that are essentially devoid 
of 14C due to their vast geological age.  The choice of carrier has changed over the past 
decade or so; in fact GSK’s early practice (before 2004) was to use tributyrin as a 
carrier.  Tributyrin was the carrier used by the Lawrence Livermore National 
Laboratories (LLNL), California, USA (the first practitioners of biomedical AMS).  
Although a convenient material to use for such a purpose, containing less than modern 
levels of 14C, tributyrin did still contain 14C (at 26 pMC when sourced from Aldrich 
Chemical Co.) and so it seemed counter intuitive to deliberately add this in to materials 
low in 14C.  Liquid paraffin was subsequently used until around 2008, but this was 
difficult to pipette (required in very small volume) due to its viscosity.  Use of liquid 
paraffin was therefore prone to error which could have a large effect on data 
generated (as stated it provides the total carbon value).  The author advocated the 
switch to an aqueous based carbon carrier, which resulted in sodium benzoate 
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solution (prepared in chromatography grade water to a concentration of 90 mg/mL) 
being selected, which is now in common use.  The level of carbon present in the 
sodium benzoate solution was calculated on the basis of the molecular weight of the 
solid material which was known to be pure.  The data from the AMS and the carbon 
content of the sodium benzoate solution (58%) are combined to provide radiocarbon 
levels for each sample. 
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 1.3.5.1 Calculation of analyte concentration from an isotope ratio 
 
AMS provides a measurement of the 14C:12C isotope ratio in units of pMC, but these 
data have to be converted to mass concentrations of drug in a given body 
compartment to be useful in drug development applications.  Typically, the 
compartment sampled is blood plasma and so the required units of drug concentration 
are mass of drug per volume plasma (typically ng, or pg drug per mL of plasma). 
 
As stated above, to calculate the drug concentration from the isotope ratio requires 
knowledge of the total carbon in the sample, as described by Equation 8 below 
(Salehpour et al., 2008). 
 
In some cases, such as when the total radioactivity (14C) of plasma is measured, there 
is sufficient naturally occurring carbon present within the sample (the limitation is 
dependent upon AMS instrument design but typically a minimum of 1 mg carbon is 
required) to allow sufficient graphite to be prepared for analysis.  
 
  K = (Rm – Rn) Ψ (W/L)  (Equation 8) 
 
Where K = analyte concentration (mass equivalents per unit volume), 
Rm = 14C:12C isotope ratio of analyte (pMC), 
Rn = natural background 14C:12C isotope ratio of the sample (pMC), 
Ψ = carbon mass fraction in the sample, 
W = molecular mass of the analyte, 
L = specific molar radioactivity (pMC/mole). 
 
In other cases the sample does not contain sufficient carbon to allow direct analysis as 
depicted in Figure 5.  Under these circumstances additional carbon is added in the 
form of "carrier carbon" (see section 1.3.5).  Providing vast excess of carbon carrier is 
added to the sample then Ψ in Equation 8 is assumed to be the mass of carbon carrier 
added. 
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 In the early days of biomedical AMS it was thought that carrier carbon merely bulked 
up the mass of carbon to facilitate analysis, for sample handling and generation of 
sufficient current from the ion beam.  Where samples were analysed directly, for 
example where a small volume of urine was taken for analysis, then the "carrier 
carbon" hypothesis was correct.  In the case of LC fractions, however, it was found that 
another factor had to be taken into account when adding carbon to the sample, 
namely the procedural recovery.  Plasma samples are solvent extracted and analysed 
by LC and therefore there are potential procedural losses during the process.  The 
addition of carrier alters the isotope ratio in such a way that Equation 8 assumes 100% 
of the original analyte in the matrix (e.g. plasma) is recovered in the fraction.  Any loss 
of sample in extraction, or LC separation, results in a proportional error to the 
calculation of mass of drug per volume sample from the isotope ratio. These losses 
have to be taken into account in any calculation of mass of drug per volume sample, as 
shown in Equation 9 by including an additional function, θ, which represents the 
fraction of the analyte recovered.  The value for θ ranges from 0-1 (Lappin et al., 2008) 
(also see Figure 5). 
 
K = (RD Φ)/(Lm θ)    (Equation 9) 
 
K = mass concentration of drug, 
RD = Rm-Rn (as defined in Equation 8) 
 
Φ is the equivalent of Ψ (in Equation 8), but whereas Ψ is the intrinsic carbon in the 
sample, Φ is the amount of carbon added as "carrier".  It assumes that the mass of 
carbon in the sample (eg. LC fraction) is negligible as volatiles such as LC solvents are 
evaporated off leaving insignificant levels of contaminants such that ideally only 
carbon from drug-related material remains.  The total carbon present is then equal to 
that added as the carrier.  The amount of carrier carbon added is often in excess of 
1000-fold of that present in the sample. 
 
Lm = specific activity (expressed in terms of pMC/mass). 
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θ = fraction recovered, i.e. if there is a procedural loss of 20% during extraction and 
preparation by LC, then θ = 0.8. 
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Figure 5.  Outline of the procedures for analysis by AMS depending on sample origin*. 
Total 14C analysis by AMS [without (1) and with (2) addition of carbon carrier], metabolite profiling (3) and isolated individual analyte assay by 
LC+AMS (4). 
14C 
Labelled 
Drug 
Total 14C 
analysis 
of sample
<1 mg total 
carbon
>1 mg total 
carbon
eg. 50µL Plasma 
[~4% carbon]
Add carbon 
carrier *
Graphitisation
Analysis by AMS
Metabolite 
profile or
Quantification of 
specific analyte
Separation of 
components 
eg. by 
chromatography
Specific analyte isolated 
eg. individual fraction
– carbon carrier added *
Fraction graphitised  & analysed by AMS; 
Account for procedural recovery (θ)
Full Profile ; all fractions 
- carbon carrier added *
All graphitised  & analysed by AMS – total recovery assessed 
[assumes equal across all analytes]
* Carbon carrier =  20µL aq. 90mg Sodium Benzoate/mL [58% carbon]  ie. ~1mg carbon
(2)
(1)
(3)
(4)
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*  Prepared by the author. 
 1.4. Instrumentation advances 
 
A brief history of development of AMS instrumentation is provided in Appendix 7.  The 
most recent evolutions of the AMS instrument technology – further reduction in the 
footprint of the instruments – can be seen in the schematic in Appendix 9.  A 
photograph of the GSK SSAMS is shown in Figure 6. 
 
Instrument size reduction was a useful practical improvement in itself, but the real 
breakthrough was around sample introduction and interfacing of the instrument with 
direct introduction of gas (carbon dioxide from the combusted sample, with a helium 
carrier).  This approach removed much of the resource-intense, low sample 
throughput of the graphitisation process, whilst offering apparent further improved 
sensitivity.  Particularly for metabolite profiling, this improvement in sample 
throughput could bring a step change in the application of AMS to drug development 
by removing the time-consuming graphitisation process.  There are at this time only a 
very few systems capable of this in an automated fashion (Bronk et al., 2004), (Wacker 
et al., 2013), (Roberts et al., 2013), (van Duijn et al., 2014) and there are limited data in 
the public domain to demonstrate the improvements over graphite (the author is 
currently working with others to see if this can be addressed, but this is outside the 
scope of this commentary).  Sample-to-sample carry-over seems to be a constant 
concern for the analysis of gas, but again there is hope that this can be managed 
and/or reduced with further interfacing and instrument development research.  
Certainly some drug development research, such as for paediatric drug applications, is 
being established through such technological advances (Mooij et al., 2014). 
 
Currently, sample preparation via liquid chromatography is performed to produce 
fractions that are collected into separate tubes or well plates, followed by off-line 
analysis by AMS.  Because of the off-line nature of the analysis, the term LC+AMS is 
now commonly used, rather than LC-AMS which would infer a direct on-line interface 
between the LC and the AMS.  Gas (CO2 injection) sources are being investigated that 
would directly couple the LC and the AMS, but the engineering challenges have not 
been overcome at the time of writing this commentary and so the fraction collection 
46 
 
method persists.  Details of efforts to couple the LC to the AMS (Thomas et al., 2013) 
are outside the scope of this commentary, although the author has collaborated with 
groups who are working on gas interfacing (Daniel et al., 2013).  
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Figure 6.  Photograph of the GSK SSAMS*. 
Ion source 1 (of 2) containing a sample holder wheel can be seen on the right, with the high energy deck in the background. 
MC-SNICS 1 
Sample wheel 
 
High energy 
deck (in cage) 
Low energy 
magnet  
Acceleration tube 
(view obscured by 
low energy 
magnet) 
48 
*  Photograph provided with permission from GSK. 
 1.5. First Biomedical uses of AMS for 14C 
 
Although analysis of 14C by AMS dominates the applications of AMS in general, the 
technology has been used for analysis of 55 radionuclides and for a very wide range of 
applications covering everything from analysis of extraterrestrial materials, 
environmental applications and archaeological or geological dating (carbon and other 
elements) (Kutschera, 2013).  A poignant example of the use of AMS for analysis of a 
radionuclide is that employed for the calculation of radiation doses received by the 
survivors of the Hiroshima and Nagasaki atomic bomb explosions in August 1945.  63Ni 
(half-life of 100.1 years) was produced by fast A-bomb neutrons via the reaction 
from 63Cu (copper).  The analysis of copper samples from sources such as lightning 
rods of buildings at various distances from the blast epicentres, including that from the 
roof of the now Hiroshima Peace Memorial, has allowed such an assessment of 
radiation to be made, many years after it occurred (Ruhm et al., 2007). 
 
Prior to the emergence of AMS the toxicity of environmental carcinogens were tested 
in animals at inappropriately high doses due to the limitations of suitably sensitive 
analytical technology.  The use of AMS for biomedical applications first appeared at 
LLNL, California, in the 1990s to determine the relevance of high-dose animal data for 
human exposure (Turteltaub et al., 1997).  The dose-response curves for 14C-MeIQx 
(2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline; one of a range of 
mutagenic/carcinogenic heterocyclic amines formed during the cooking of protein-rich 
foods) were determined in rodents at low doses under both single-dose and chronic 
dosing regimens.  Historically, the human exposure to MeIQx had been estimated to 
range from ng/person/day to a few microgram/person/day.  In contrast, as inferred 
above, animal studies had previously been conducted at doses in excess of 
10 mg/kg/day.  MeIQx-DNA adduct levels in a variety of tissues were compared 
following oral administration of 14C-MeIQx at doses over four orders of magnitude.  
Adducts in humans were shown to be around 10-fold higher compared to the mouse, 
but the biological significance remains debatable.  This study demonstrated the utility 
of AMS as a very sensitive analytical tool that could facilitate new experimental 
designs. 
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 GSK first used 14C AMS in a range of in-vitro and non-clinical studies before embarking 
on application of the technique to clinical study support ((Young and Ellis, 2007) and 
unpublished works). 
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 1.6. Applications of 14C AMS in drug discovery and development 
 
Experiments conducted on new drugs in development using AMS across the 
pharmaceutical industry were first focussed on human ADME studies for molecules 
that had persistent retention such as long pharmacokinetic elimination half-lives or 
high melanin binding where radioactive exposure to 14C would be problematic.  
Following these initial applications there was a shift of focus to microdosing studies 
and more recently to microtracer studies. 
 
It should be noted, however, that there have been a wide variety of applications of 
biomedical 14C AMS, well beyond the uses for human ADME and clinical microtracer 
studies that the author has focussed on in this Commentary.  It is worth mentioning 
some of these here, in outline, particularly those that may yet have application in 
exciting areas of research in the pharmaceutical industry; indeed the author is aware 
that some of these new applications are already being progressed (see below). 
 
Most of the applications of AMS in the pharmaceutical industry have been on “small 
molecule” DMPK-type applications.  There have, however, been some applications to 
investigate ADME properties of larger molecules such as peptides and proteins (Rickert 
et al., 2005), (Lappin et al., 2006), (Vlaming et al., 2015); fundamental systems biology 
applications to investigate production of different cell types in humans, e.g. production 
only at birth or generated throughout lifetime (Shapiro et al., 1991), (Heinemeier et al., 
2013); investigations of drug uptake into tissues other than blood cells or the systemic 
circulation (Chen et al., 2010) and (Lappin et al., 2013a); tracing the fate of 
nanoparticles in vivo (Wang et al., 2014); metabolic flux measurements (Stewart et al., 
2010); and target turnover assessments (personal communication with Dr. Graham 
Lappin) - labelling of the biological target itself rather than the drug to investigate the 
rate at which a target is turned over and thus facilitate development of a better 
understanding of what attributes of drugs are required to provide pharmacological 
engagement to ultimately produce efficacy.  This latter application may turn out to be 
the most impactful advance for biomedical AMS in drug discovery and development.  
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 2. Works published 
2.1. Introduction 
 
A comprehensive listing of the author’s contributions to the field of AMS based 
research in general, including further peer reviewed publications, conference poster 
abstracts, book chapters, invited conference speaker listings and external 
collaborations, is provided in Appendix 1. 
 
During drug development and particularly before large scale clinical trials are carried 
out, there is an expectation from regulatory authorities that the drug metabolism and 
pharmacokinetics of the drug are understood.  It is of course also good scientific 
practice and in the interest of the drug development researchers that the molecule 
under development as a medicine is well established for safety assessment purposes. 
The human ADME study is a cornerstone of this assessment. 
 
AMS has been used for investigations in a number of human ADME studies in the 
author’s laboratory (Young et al., 2001), (Hughes et al., 2008), (Harrell et al., 2013), 
(Bowers et al., 2013), (Mamaril-Fishman et al., 2014), (Dave et al., 2014) and (Negash 
et al., 2015).  These have ranged from initial investigative or pilot approaches (Young 
et al., 2001) to those where we have investigated highly potent, low dose drugs for 
intended inhaled use (Hughes et al., 2008), (Harrell et al., 2013), (high dose) low 
specific radioactivity drugs (Mamaril-Fishman et al., 2014), (Negash et al., 2015), 
repeat dose design to investigate enzyme autoinduction (Dave et al., 2014), and 
“hybrid LSC-AMS” studies where both scintillation counting and AMS instrumentation 
were required to provide the data (Bowers et al., 2013).  In all cases, the study designs 
at the outset, or samples generated from the studies necessitated the use of AMS to 
allow the study to deliver on its objectives.   
 
Seven peer reviewed research papers, which included major contributions from the 
author of this commentary (Appendix 3) were selected for critical review for the 
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purpose of this commentary.  Five of these papers include reports of human ADME 
studies.  
 
Additionally, a significant and more recent development in the utility of AMS is its 
application to enable the generation of intravenous pharmacokinetics of new drugs 
through the microtracer approach (see section 3.6).  Two of the seven papers were 
selected for critical assessment to address this application and a planned combination 
human ADME/microtracer study is also outlined (section 4.1). 
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 3. Principal papers published as basis for this Commentary 
 
1) Young, G., W. Ellis, J. Ayrton, E. Hussey and B. Adamkiewicz (2001). "Accelerator 
mass spectrometry (AMS): recent experience of its use in a clinical study and the 
potential future of the technique." Xenobiotica 31(8-9): 619-632. 
 
2) Young, G. and W. J. Ellis (2007). "AMS in Drug Development at GSK." Nuclear 
Instruments and Methods in Physics Research B 259: 752-757. 
 
3) Bowers, G. D., D. Tenero, P. Patel, P. Huynh, J. Sigafoos, K. O'Mara, G. C.Young, E. 
Dumont, E. Cunningham, M. Kurtinecz, P. Stump, J. J. Conde, J. P. Chism, M. J. Reese, Y. 
L. Yueh and J. F. Tomayko (2013). "Disposition and metabolism of GSK2251052 in 
humans: a novel boron-containing antibiotic." Drug Metab Dispos 41(5): 1070-1081. 
 
4) Harrell, A. W., S. K. Siederer, J. Bal, N. H. Patel, G. C. Young, C. C. Felgate, S. J. 
Pearce, A. D. Roberts, C. Beaumont, A. J. Emmons, A. I. Pereira and R. D. Kempsford 
(2013). "Metabolism and disposition of vilanterol, a long-acting β(2)-adrenoceptor 
agonist for inhalation use in humans." Drug Metab Dispos 41(1): 89-100. 
 
5) Dave, M., M. Nash, G. C. Young, H. Ellens, M. H. Magee, A. D. Roberts, M. A. Taylor, 
R. W. Greenhill and G. W. Boyle (2014). "Disposition and metabolism of darapladib, a 
lipoprotein-associated phospholipase A2 inhibitor, in humans." Drug Metab Dispos 
42(3): 415-430. 
 
6) Denton, C. L., E. Minthorn, S. W. Carson, G. C. Young, L. E. Richards- Peterson, J. 
Botbyl, C. Han, R. A. Morrison, S. C. Blackman and D. Ouellet (2013). "Concomitant oral 
and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with 
BRAF V600 mutation-positive solid tumors." J Clin Pharmacol 53(9): 955-961. 
 
7) Leonowens, C., C. Pendry, J. Bauman, G. C. Young, M. Ho, F. Henriquez, L. Fang, R. A. 
Morrison, K. Orford and D. Ouellet (2014). "Concomitant oral and intravenous 
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pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours." Br J 
Clin Pharmacol 78(3): 524-532. 
 
These specific papers were selected as they provide a measure of the breadth of 
application of AMS by the author, particularly around the theme of human ADME and 
clinical microtracer studies.  They also demonstrate the impact of the studies and their 
contribution to the advancement of this field of research. 
 
Each of the papers is summarised and discussed in section 3.1 to section 3.8 below. 
See Appendix 3 for supporting letters from lead authors and detail of the 
contributions made by this author to each of these published works.  
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 3.1. Commentary paper 1 
 
Young, G., W. Ellis, J. Ayrton, E. Hussey and B. Adamkiewicz (2001). "Accelerator mass 
spectrometry (AMS): recent experience of its use in a clinical study and the potential 
future of the technique." Xenobiotica 31(8-9): 619-632. 
 
3.1.1. Objectives 
 
The use of AMS for a pilot human ADME study was described in this study with the 
following objectives: 
 
1) To determine the rates and routes of excretion of a new chemical entity (NCE), 
GI181771 (a CCK-A agonist for potential use in appetite suppression), following 
oral administration to healthy volunteers. 
 
2) To determine the biotransformation pathways for GI181771 in humans. 
 
3) To investigate the utility of AMS to facilitate human ADME with reduced 
radiation burden to the subjects. 
 
Studies designed to meet these objectives by applying AMS are relatively 
commonplace today within the pharmaceutical industry (and certainly within GSK).  
However, at the time this work was conducted (around 2000-2001) no such clinical 
study had been previously reported.  Commentary paper 1 was the first to report the 
application of AMS for the analysis of samples obtained in a clinical study with a NCE.  
Prior to this publication others had conducted preliminary and evaluation studies with 
pharmaceuticals, but these were using in vitro dilutions to scale from the range of LSC 
to AMS (Kaye et al., 1997), (Garner et al., 2000), or from studies involving human 
volunteers in nutritional research.  Such a study was the analysis of folic acid in a single 
subject with the low 14C dose added to dietary intake on a single occasion, and 
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subsequent assessment of extended elimination of the dose (3.7 kBq) over one year 
(Clifford et al., 1998). 
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 3.1.2. Clinical study design 
 
In this clinical study, six healthy male human volunteers were administered 2.7 mg 
of 14C-GI181771 (121 Bq), which equated to an exposure to ionising radiation of only 
0.06 µSv, as shown in Figure 7.  This was more than 1000-fold lower than for most 
conventional radioactive dose human ADME studies and nearly 17-fold below the 
targeted threshold of ionising radiation exposure of 1 µSv.  At the time, this was seen 
as a very attractive proposition, i.e. to be able to conduct a clinical study with 
radiocarbon labeled drug producing exposure to ionising radiation at such a low level.  
At targeted exposures of <1 µSv certain approvals and enabling work were not 
required, such as those to facilitate dosimetry (see section 1.2). 
 
To put the level of radioactivity used in such studies (and subsequent ionising radiation 
exposure) into context, a 70 kg human adult subject’s natural 14C content is in the 
region of 3.7 kBq (Vogel et al., 2010), so this clinical study barely raised the exposure to 
ionising radiation in the study subjects to above background (<5% increase). 
 
As the regulatory authorities became more familiar with the concept of AMS and the 
consequential lowering of 14C doses, over the intervening years and in several parts of 
the world, up to 37 kBq can now be administered to human subjects without the need 
for dosimetry data*.  These changes accelerate study implementation and reduce the 
enabling package resource burden placed upon such clinical experiments. 
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*  The assumption being that a dose of 37 kBq will produce an exposure to ionising radiation of 
<1 µSv. 
  
 
 
 
 
 
14C-GI181771* 
 
 
 
Figure 7.  Schematic of clinical study design 1. 
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Design: 
6 Healthy human subjects; 
Single oral dose of 2.7 mg 14C-GI181771  
(121 Bq) 
Samples : 
• Blood for serum [for parent drug & RDM concentrations & 
metabolite profiling] 
 
• Faeces and urine [for mass balance and metabolite profiling] 
Main data outputs: 
• Parent drug concentrations in serum (by LC-MS) 
 
• Total radioactivity in serum (by direct AMS) 
 
• Excretion mass balance assessment (by direct AMS) 
 
• Metabolite profile (faeces only; by LC+AMS) – insufficient sensitivity for 
metabolite profiling of serum due to the tiny 14C dose administered.  
 
o Definition of limits of detection by direct AMS (and LC+AMS) for 
a range of different biological matrices  
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*  Structure was not included in Commentary paper 1 
 3.1.3.  Clinical study data output and impact 
 
Despite the extremely low amount of radioactivity administered, mass balance in 
recovery of administered radioactivity was achieved (mean of 92.2%; standard 
deviation (SD) of 16.1%).  It was shown that systemic concentration of total 14C was up 
to 8-fold greater than for parent drug.  Total 14C is a measure of RDM and represents 
exposure to parent drug plus its metabolites (or those metabolites retaining the 14C 
tracer).  GI181771 was therefore extensively metabolised, resulting in 8-fold greater 
exposure of metabolites compared to parent drug.  Bearing in mind that this drug was 
thought to act locally in the gut, without the need for absorption into the systemic 
circulation, these data contribute to decision making relevant to safety cover for 
systemic metabolites in animal species when extrapolated to humans. 
 
This study showed the potential of AMS to support extremely low 14C dose 
administrations to humans, as well as defining its limitations since it turned out that 
the dose of 14C-labelled drug was too low for all study endpoints to be achieved.  The 
situation was exacerbated by the fact that the drug was designed to be poorly 
absorbed (for treatment of appetite suppression through local action in the gut).  Due 
to adverse pharmacology in the preceding clinical study (GSK data on file), the human 
ADME study under discussion had to be re-designed with a reduction in the clinical 
dose only a short time before dosing.  The 14C dose was reduced by 20-fold (radiolabel 
dose material had already been prepared) which then compromised the endpoint of 
metabolite profiling for blood serum samples.  Indeed, were this drug to have been 
filed for marketing approval, it is likely that a further human ADME study would have 
been required to deliver on the initial study objectives.  In retrospect, the study could 
have been more appropriately designed, but these were the early days of AMS and 
there was little experience with required 14C doses and the sensitivity of the assays.  
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 Data from the study nevertheless provided a good understanding of the drug’s ADME 
properties at an early stage of clinical development, well in advance of progression to 
large scale clinical trials*.  Despite the 8-fold difference in RDM to parent drug, the 
only metabolite of GI181771 detected in human faeces was an acyl glucuronide of 
parent drug (see Figure 5 of the paper) and this was minor in magnitude.  It was known 
from pre-clinical work for this drug (unpublished) that the acyl glucuronide was 
present as the major metabolite in bile from rat.  Nowadays, a bile collection would be 
included in the clinical study design (see section 3.4.4) and had this been available at 
the time then perhaps a better understanding of whether the glucuronide 
concentration was decreased due to breakdown back to parent drug by gut microflora 
activity could have been ascertained (Hawksworth et al., 1971). 
 
Such data provision around the development of understanding of metabolite 
exposures in safety testing is in alignment with not only good scientific practice, but 
also with the expectations set out in regulatory guidance (FDA, 2008).  The data has 
significant impact upon assessments for potential drug-drug interactions where 
therapies are co-administered.  Again, there is guidance in place that describes 
expectations of regulatory authorities and re-enforces the need for generation of 
knowledge in this regard ((FDA, 2012) and (EMA, 2013); Appendix V).  
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*  The paper used the term “radiocarbon”, rather than (total) radioactivity as is commonly used.  
Radiocarbon has since been seen as a misleading term, when used in the way it was in the paper, as it 
does not properly describe what is being reflected by the measurement of radiocarbon (and carbon in 
general) in the samples, i.e. radiocarbon being the traced isotope, but effectively the traced molecule 
itself is being measured and not just the carbon it contains. 
 
  
This paper (note that the study was published in 2001) also discussed the possible 
future direction of the technology for biomedical applications – much of which came 
to pass over the years since this publication, including microdosing (see Scope of 
Commentary), parent drug pharmacokinetics by AMS (see Commentary papers 6 and 
7), analysis of late timepoint samples (see Commentary paper 2), smaller sample sizes 
(Salehpour et al., 2008), use of other isotopes (eg. 41Ca, 129I (Vogel and Love, 2005)), 
the need for increased sample throughput via simpler sample preparation and/or on-
line interfacing (Thomas et al., 2013), (Wacker et al., 2013) and instrument size and 
cost reduction possibilities (Klody et al., 2005). 
 
Some of these advances, at least in part, have become reality due to the published and 
presented works of the author (see Appendix 1).  This author was encouraged by other 
scientists in the field to present and publish our work since we were, and still are, 
unique amongst pharmaceutical companies in our advancement of AMS capabilities. 
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 3.1.4. Technical considerations and reflections 
 
Some of the technical approaches taken in this work* were deemed to be poor 
practice and were subsequently improved upon with continued application 
experience.  At the time of conducting this clinical study, the practice for carbon 
content assessment was to analyse all samples that were likely to have measurable 
endogenous carbon present so that the individual sample carbon was known and used 
in the calculation of the isotope ratio conversion to derive the unknown 14C 
concentration (see section 1.3.5).  Subsequent to this, following investigations at other 
laboratories ((Keck et al., 2010), Xceleron Inc. – communicated through GSK sponsored 
study reports) and GSK’s own experience, it was found that in most instances, where a 
carbon carrier was not added, particularly for whole blood or blood plasma samples, a 
generic value could be used (e.g. in the region of 4.1% for plasma).  It was found that 
the carbon content of such samples (at least from healthy human subjects) did not 
vary greatly, i.e. coefficient of variation of < 5% (Kim et al., 2011).  It is therefore 
recognised that a generally small, but acceptable, error will occur.  This is deemed to 
be acceptable since it is outweighed by inherent biological variations and other 
accepted analytical variabilities (typical tolerances of +/- 15% for bioanalytical assays).  
Also, the effort required to analyse carbon content of all samples is outweighed by 
acceptance of the potential level of error that is implicit by using a generic value.  It 
would, however, be ideal (as long as the measurement of carbon content is accurate 
enough) for it to be measured for every individual sample, as is the approach with the 
gas ion source used in a recent modification to the AMS interface (van Duijn et al., 
2014), particularly for sample types that are notoriously non-homogeneous such as 
faecal sample preparations. 
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* An example being the use of a slurry for preparation of faecal homogenates; pipetting difficulties due 
to the nature of the material involved.  This was improved upon through use of a freeze drying 
approach, to produce a powder that could be more easily handled in small, representative quantity for 
mass balance data provision. 
 Through analysis of clinical samples the limits of quantification for a range of biological 
matrices were defined (see Table 4 in Commentary paper 1).  This encompassed both 
direct analysis by AMS and LC+AMS approaches.  This fundamental information helped 
the author and colleagues to design many subsequent studies through development of 
the understanding of what influence endogenous carbon has on detection limits.  Also, 
what could be achieved through different sample clean-up procedures, such as protein 
precipitation or chromatographic separations, became clearer through design and 
conduct of these experiments 
 
In these early works, concerns about inadvertent cross-contamination (of 14C) were 
significant for researchers in this field.  Therefore, precautions were taken to try to 
avoid the likelihood of this occurring, notwithstanding the fact that the environment 
which surrounds us contains 14C in the form of 14CO2.  Typical precautions taken 
included use of segregated clean laboratory approaches, disposable laboratory 
supplies wherever possible, work procedures which entailed processing samples of 
low 14C content ahead of those containing higher levels and use of human subjects 
(and animals) naive to 14C study exposure.  Over time and through extensive research, 
it has been determined in our laboratory that contamination is indeed an issue for 
both the sample preparation areas and equipment, as well as for the AMS ion source 
itself, but with meticulous practices, these issues are manageable. 
 
All of the analysis of samples detailed in this paper used a 5 MV tandem accelerator 
instrument, and it was not until 2005 that GSK’s own instrument (a single stage 250 kV 
accelerator) came into use (see section 1.3.4).  The data generated by these two 
different types of AMS were the subject of a separate publication by this author and 
co-workers ((Young et al., 2008) – not listed as one of the papers providing the basis 
for this Commentary).  In brief summary, this publication provided bioanalytical data 
showing that for the analysis of biological samples (blood, plasma and urine) spiked
 with a range of low level concentrations of 14C, below those that could be detected by 
LSC, equivalent data (correlation coefficient values of >0.99 for all matrices) were 
provided through analysis of separate graphites generated from the same biological 
samples on the 5 MV and the 250 kV instruments. 
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 It is worth noting that a direct comparison of two GSK SSAMS instruments (see 
Appendix 8) was carried out through analysis of the same graphite samples on both 
instruments and the data (unpublished) showed remarkable reproducibility with 
percent differences of <5% for all graphites (albeit <20 in number), measured as being 
>20 pMC and about 3-fold the acceptable limit generated for background carbon 
carrier in our laboratory.  This was as expected since the reproducibility of the AMS 
instruments for analysis of carbon is well founded (Damon et al., 1989) and indeed is 
the basis for consensus values being generated for AMS as inter-laboratory standards 
(see section 1.3.5). 
 
These type of data supported the production of increased numbers of what are 
termed compact, or sub-compact, AMS instruments and these are now in common use 
for the analysis of carbon in both the biomedical and wider carbon dating fields. 
Much of the practical work included in Commentary paper 1 was groundbreaking at 
the time* and provided the foundation for later sample preparation and study designs, 
both within GSK and beyond to the wider biomedical AMS field. 
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*  The extremely low specific activity material used required that a new approach was taken to 
assess the radiochemical purity of the dosed material.  Common practice is now as per this study, 
i.e. to check the purity of the high specific activity material that is initially synthesised and of the 
cold material drug substance that it would be formulated with, but not to assess the final (blended 
or re-crystallised) drug product itself. 
 
 3.2. Commentary paper 2 
 
Young, G. and W. J. Ellis (2007). "AMS in Drug Development at GSK." Nuclear 
Instruments and Methods in Physics Research B 259: 752-757.  This paper contains 
elements of review of previous works by this author, but also contains original 
research which is the focus of this section of the commentary. 
 
3.2.1. Objectives 
 
The novel use of AMS for a low radioactive dose clinical study for a compound with 
potential for prolonged retention of radioactive drug-related material was described 
with the following objectives: 
 
1) To provide information on rates and routes of excretion of the NCE, SB773812, 
including extension of excreta collections in anticipation of retention of 
drug-related material. 
 
2) Provision of metabolite profiling (biotransformation) data. 
 
3) To investigate the feasibility of achieving acceptable mass balance for a low 
dose of 14C with incomplete/interval collections of excreta. 
 
3.2.2. Clinical study design 
 
SB773812 is a high affinity D3, 5-HT2A , 5-HT2C and 5-HT6 receptor antagonist, that was 
being developed for treatment of antipsychotic-like behaviour (Catafau et al., 2011).  
A human ADME study was conducted in Phase 1 of development due to uncertainty 
over which toxicology species should be used for assessment of safety cover limits.  It 
is important in drug development to understand the ADME profile in the species used 
in the toxicology (safety assessment) studies, so that the relevance, or otherwise, to 
humans can be established as the data from humans becomes available. 
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 In the rat, elimination of the dose of 14C-SB773812 was complete by 96 hours 
post-dose, whilst in the dog elimination was protracted, with radioactivity continuing 
to be excreted 312 hours after dose administration (GSK internal reports and (Iverson 
and Smith, 2016)).  There were also metabolic route differences between the 
toxicology study species, such that in rat the main metabolic pathway was cleavage of 
the ether bond, whilst in dog N-demethylation and N-oxidation were the principal 
metabolic routes.  The differences in the ADME profile of SB773812 between the non-
clinical species made the human ADME study difficult to design e.g. how long blood 
and excreta samples should be collected for. 
 
Due to the slow elimination of drug-related material in the dog, a second study in this 
species was performed following a single dose of 14C-drug to enable tissue and excreta 
metabolite profiles to be monitored over a 13 day period.  In this second study the 
major metabolite in dog plasma and several organ tissues, at 312 hours was M9 
(N-demethylated SB773812, see Figure 8, known to be a target pharmacologically 
active metabolite). 
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Figure 8.  Biotransformation of SB773812 to M9 (N-demethylated metabolite of SB773812). 
The structures show the positions of the 14C-label.  
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 A clinical study was therefore designed as outlined in Figure 9, to take account of the 
concerns (based on data from the dog) that there may be considerable retention of 
drug-related material in humans and therefore excess exposure to ionising radiation, 
were the usual magnitude of 14C dose to be administered.  It is worth pointing out that 
in cases where the metabolism of a drug varies across species, the design of the clinical 
study often becomes complicated.  Moreover, the radioactive dose that can be 
administered is very difficult to assess in terms of being sufficient for subsequent 
analysis but at the same time, not to cause excessive exposure to ionising radioactivity. 
The advent of AMS, where doses of 14C could be reduced considerably, ameliorated 
these difficulties considerably. 
 
The dose of radioactivity in the current study was kept low (18.5 kBq, being ~200-fold 
lower than that used conventionally) and the excreta collection period was extended 
out to eight weeks, with interval (24 h) collections of excreta weekly and then bi-
weekly after the initial two week continuous collection.  The interval collections were 
included due to logistical limitations on incarceration of the human subjects beyond 
the initial two week period, and because a full understanding of the (potential) extent 
of retention of drug or metabolites was warranted, so as to put the human data into 
context with the animal data. 
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Figure 9.  Schematic of clinical study design 2. 
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Design: 
5 Healthy human subjects; 
Single oral dose of 16 mg 14C-SB773812  
(18.5 kBq) 
Samples : 
• Blood for plasma [for parent drug & RDM concentrations & 
metabolite profiling] 
 
• Extended collections of Faeces and Urine [for mass balance and 
metabolite profiling] - with weekly and bi-weekly interval collections 
after 15 days to 8 weeks 
Main data outputs: 
• Parent drug concentrations in plasma (by LC-MS) 
 
• Total radioactivity in plasma (by direct AMS) 
 
• Excretion mass balance assessment (by direct AMS) 
 
• Metabolite profiles of all matrices (plasma by LC+AMS; other matrices by 
Topcount) 
 
o Established limit of possibility for reliable metabolite profiling 
[0.06 dpm on column for multiple metabolites; >7 in this instance 
(see Figure 10)] 
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 3.2.3. Clinical study data output and impact 
 
In this study, the sensitivity of AMS was such that mass balance of 14C recovery was 
achieved (mean of 77.1%; SD of 5.4%, for continual excreta collection to two weeks) 
despite the low dose of radioactivity and the need for extended collections, with 
intervals, to provide extrapolated cumulative recovery (increased to 86.4%).  As shown 
in this paper (Figure 4), total radioactivity was still above background in plasma 
samples at 480 hours post-dose (LoQ was ~ 1 ng SB773812 equivalents/mL), with a 
terminal elimination half-life of >150 hours, confirming that elimination of SB773812 
related material in human was protracted and was comparable to dog.  Thus, the 
decision to adopt the low 14C dose approach for this study was well justified. 
 
The example chromatographic profile in Commentary paper 2 (Figure 2) (Young and 
Ellis, 2007) shows a detailed profile containing multiple metabolite peaks, obtained 
from only 0.06 dpm injected onto the HPLC column.  To put this into context, this is 
approximately 3,000-fold lower than could be achieved using a scintillation counting 
approach, such as Topcount (Bruin et al., 2006).  Through analysis of the metabolite 
profiles generated against time after dosing, M9 was determined as being largely the 
causal agent for the protracted elimination profile, demonstrating predisposition for 
this metabolite to accumulate upon repeat dosing.  Despite the slow elimination of M9 
(and other metabolites of SB773812) sufficient cover in the toxicology species for the 
major active metabolite was demonstrated and the other major metabolites were well 
represented in both toxicological species. 
 
The data provided evidence that the dog was the more relevant toxicology species for 
safety assessment of SB773812 and contributed to the position for validation of the 
toxicology species used in the safety assessment program for this drug under 
development. 
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 3.2.4. Technical considerations and reflections 
 
In addition to the clinical study described above, Commentary paper 2 also described 
the first use of AMS in providing metabolite profile data from a clinical study where 
scintillation counting approaches did not provide sufficient sensitivity to deliver on the 
experimental objectives.  The author termed the type of application of AMS to clinical 
experiments, where conventionally high doses of radioactivity were used (circa 
3.7 MBq) and where many of the study objectives could be met using non-AMS 
approaches, as “hybrid LSC - AMS” studies. 
 
These were distinct from experiments that were designed to be supported by AMS, for 
most endpoints by first intent, particularly during the transition stage when AMS was 
not well established for use in biomedical experiments.  In the initial stages, where GSK 
had access to the AMS, studies were often designed without much consideration being 
given to the potential need to resort to the use of this technology, although this 
approach changed radically over time.  In this study, the samples required dilution (by 
a factor of 25) as the 14C concentrations were too high for more direct analysis by AMS, 
but were also too low in radioactive content to be analysed by alternative 
radiodetection methods.  This provided useful experience in metabolite profiling by 
AMS.  Through such work, our laboratory was able to establish the frequency with 
which to fractionate samples (a requirement for both metabolite profiling and 
individual analyte measurement by AMS; see Figure 10) to be able to reconstruct high 
quality chromatograms providing a suitable level of resolution.  In this respect, it is 
important to be able to generate metabolite profiles that fully describe the range and 
quantity of metabolites present in any given sample so that the data can be used 
(along with metabolite identification) to build a thorough understanding of the ADME 
of the drug under test. 
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 Through experience, fraction collections of one every 12 seconds for the whole 
chromatogram have become normal practice for separations by HPLC, when using a 
chromatographic mobile phase flow rate of 1 mL/minute.  This has generally facilitated 
provision of very detailed chromatograms with sufficient resolution between closely 
eluting peaks to allow quantification of each individual, but particularly the major, 
drug-related component.  It is worth pointing out that our laboratory have used UPLC 
less frequently as the methods transferred to our laboratory, for support by AMS, have 
been previously developed on HPLC systems.  For metabolite profiling of clinical 
samples using detection by AMS, retention time comparisons need to be made with 
chromatograms generated from non-clinical samples and it is important to maintain 
consistency between the experiments carried out across the species since AMS does 
not provide structural identification of the analytes (other than 14C:12C content).  If 
UPLC is used, with inherently shorter chromatographic separation times versus HPLC, 
more rapid fraction collections are required to maintain analyte peak resolution.  At 
this time little data can be found in the literature which provides metabolite profiles 
generated using UPLC with detection by AMS, although there is evidence that UPLC is 
being used (Xu et al., 2012) and that the fractions analysed in at least one case (see 
Figure 1 of (Morris et al., 2015)) are not frequent enough to provide resolution of 
many of the individual drug metabolites present in the samples. 
 
On occasion the frequency of collection has been increased in our laboratory to as 
many as one fraction every three seconds, but for a chromatographic run time of, for 
example 60 minutes per sample, this generates a logistically unmanageable number of 
samples for individual graphitisation (1200 fractions), which equates to about three 
working weeks of continual sample graphitisation for one scientist.  This approach has 
only been used for special cases where there has been a need to improve resolution 
for a portion of the chromatographic run.  Based on this experience, our group invoked 
the practice of not collecting all of the chromatogram in an effort to reduce the 
number of fractions that had to be graphitised (as was the case for profiling in this 
clinical study), but sometimes found that this led to a need for repeat of work and so 
was inefficient and not a thorough investigation of the samples.  Calculation of 
recovery of drug-related material from the LC system is a necessity when the 
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percentage contribution of each component is converted to actual concentrations and 
to provide confidence that the chromatogram is suitably representative of everything 
drug-related that was present in the initial sample.  Therefore, current practice is 
typically for all fractions to be collected for subsequent analysis by AMS, which 
increases the initial work load, but often reduces the requirement for re-analyses. 
 
The sample preparation described above is extremely labour intensive and thus makes 
the desire for a more on-line LC-AMS approach very appealing (Thomas et al., 2013) 
(see section 1.4).  In contrast to this, especially early on in the use of AMS for such 
biomedical investigations, other scientists in the field used relatively infrequent 
fractionation such as only one fraction for every 30 seconds, or even one per minute 
(Buchholz et al., 1999), (Garner et al., 2002).  This led to a loss of resolution and, in the 
author’s opinion, a reduction in overall quality of the data through poor definition of 
peak retention time and quantity of each individual component.  However, such 
practices were to some degree understandable as the costs associated with analysis of 
large numbers of samples by AMS were (and still are) often seen as prohibitive, or 
resource use inefficient.  Over time, the practices that were established in our 
laboratory, as in Figure 10, have become more commonly applied across the 
biomedical AMS field in such experiments (eg. (Lee et al., 2016)). 
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Figure 10.  Comparison of fraction collection frequencies. 
(a) Reproduced from Buchholz et al., 1999* – 
fractions collected only once every minute 
leading to generation of a histogram. 
(b) Reproduced from Commentary paper 2 – fractions 
collected every 12 seconds leading to generation of 
a detailed reconstructed chromatogram. 
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*  Reprinted with permission from BUCHHOLZ, B. A. et al.,  Copyright (1999) American Chemical Society. 
In Commentary paper 2, this author put forward the potential that automation of the 
graphitisation process may be developed as a path towards higher throughput 
analysis.  This has not materialised in any tangible and significant way (there is a low 
throughput automated approach which is commercially available, but is targeted at 
carbon dating laboratory use with preparation of up to only 21 samples per day; the 
Automated Graphitisation Equipment (Ionplus, 2016)).  Instead, as stated earlier, 
advances have been made to increase throughput via direct gas interfacing of an 
elemental (usually termed CHN) analyser, to the AMS (van Duijn et al., 2014).  This is a 
promising approach, but is still in the early phases of adoption. 
 
Commentary paper 2 encompasses a number of different experiments spanning eight 
years of application of AMS to non-clinical (in vitro and animal) and clinical 
investigations.  These works defined the reach of AMS in drug development and also 
provided focus on where it could add most value as an enabling technology.  There 
were instances when AMS was applied where the decision to do so was perhaps 
questionable (eg. in vitro metabolism assessments at extremely low concentrations 
(data on file at GSK)), but in any case the experiences gained were used to design 
improved experiments that followed, with definition of frequency of fraction collection 
being a good example of that.  AMS was usually applied in these experiments because 
the drug was potent and therefore would be low dose, providing a challenge to 
sensitivity limits for conventional detection methodologies. 
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 3.3. Commentary paper 3 
 
Bowers, G. D., D. Tenero, P. Patel, P. Huynh, J. Sigafoos, K. O'Mara, G. C.Young, E. 
Dumont, E. Cunningham, M. Kurtinecz, P. Stump, J. J. Conde, J. P. Chism, M. J. Reese, Y. 
L. Yueh and J. F. Tomayko (2013). "Disposition and metabolism of GSK2251052 in 
humans: a novel boron-containing antibiotic." Drug Metab Dispos 41(5): 1070-1081. 
 
3.3.1. Objectives 
 
1) To determine the rates and routes of excretion of a novel boron containing 
NCE, GSK2251052 (AN3365), following oral administration to healthy 
volunteers. 
 
2) To determine the biotransformation pathways for GSK2251052 in humans. 
 
3) To investigate the utility of AMS to provide systemic exposure data 
supplemental to that provided by LSC. 
 
3.3.2. Clinical study design 
 
The study involved a high dose of 1500 mg 14C-GSK2251052 (0.6 MBq) by the 
intravenous route (driven by the high predicted therapeutic dose) as outlined in Figure 
11 and necessitated support by AMS for analysis of late timepoint plasma samples.  
The intravenous route was used as this drug was intended for treatment of systemic 
infections in a critical care setting.  The high sensitivity of AMS was required due to the 
anticipated low concentrations of drug-related material in plasma and the low specific 
activity of the dose (the radioactive dose was towards the low end of a conventional 
dose of 14C to humans (commonly 3.7 MBq is administered)).  
 
In a previous ADME study with 14C-GSK2251052 in the rat, excretion of radioactivity 
was not complete with evidence of melanin binding of drug-related material through 
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retention in the uveal tract of the eye, to 840 hours after dosing (unpublished 
material).  The resultant dosimetry calculations then limited the radioactive dose in 
humans to 0.69 MBq, so as not to exceed the 100 µSv regulatory limit (lower end of 
Category IIa, ICRP 1992; see Appendix 10). 
 
In this clinical study, there was an apriori extended excreta collection period of 14 days 
since the radioactive dose was too low to allow the assessment of excreted 
radioactivity to be used as release criteria for the volunteers – normal practice in a 
mass balance study.  There was an objective to obtain a thorough understanding of the 
systemic exposure to drug-related material, particularly as some concerns existed 
about the potential mechanism for retention arising from the novel mechanism of 
action for this drug (Mendes et al., 2013) (binding of the cycloboronate ring to inhibit 
the bacterial enzyme, Leucyl tRNA synthetase, which prevents protein synthesis and 
thus bacterial growth). 
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14C-GSK2251052 
 
Figure 11.  Schematic of clinical study design 3. 
B
O
OOH
C14
NH2
OH
Design: 
6 Healthy human subjects; 
Single intravenous infusion dose of 
1500 mg 14C-GSK2251052 over 1 hour 
(0.6 MBq) 
Samples : 
• Blood for plasma [for parent drug & RDM concentrations] 
 
• Faeces and urine [for mass balance and metabolite 
profiling]; collections over extended timeframe of 14 days 
Main data outputs: 
• Parent drug & M3 (see Figure 13) concentrations in plasma (by LC-MS) 
 
• Total radioactivity in plasma (by LSC & direct AMS beyond 48 hours post-dose) 
 
• Excretion mass balance (by LSC) 
 
• Metabolite profile (faeces and urine by TopCount) - No metabolite profiling 
conducted for plasma (see section 3.3.3) 
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 3.3.3. Clinical study data output and impact 
 
AMS was used for the analysis of late timepoint blood plasma samples, where the 
amounts of 14C had reduced to below the lower limit of quantification (870 ng 
GSK2251052 equivalents/mL of plasma; 20 dpm/mL) for analysis by LSC.  Good 
concordance was observed between the data provided through use of LSC for early 
timepoints (plasma analysis), and of AMS for analysis of samples at later timepoints as 
shown in Figure 12. 
 
The total radioactivity data were compared to liquid chromatography with mass 
spectrometric detection (LC-MS) data for parent drug and a particular individual non-
active metabolite, M3 (oxidation of GSK2251052 to a carboxylic acid metabolite; see 
Figure 3 of the paper and Figure 13 in this commentary). 
 
Systemic concentrations of total radioactivity closely aligned to the sum of the 
systemic concentrations of parent drug and M3, thereby indicating that no significant 
quantities of other metabolites were present.  Further to this, parent drug elimination 
half-life in plasma was defined as being much shorter (11.6 hours) than for total 
radioactivity, i.e. parent drug and metabolite(s) (96 hours).  This longer half-life for 
RDM, largely driven by reduced clearance (see Table 1 in the paper), was similar to 
that of the M3 metabolite (~77 hours) and it was therefore not necessary to conduct 
further metabolite profiling analysis on plasma samples.  This significantly reduced the 
resources/costs that were required to support the study. 
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 Figure 12.  Concentration- time plot showing the transition from LSC data to AMS data for total radioactivity in plasma. 
(Adapted from Figure 3 in Commentary paper 3, with addition of error bars and indicators of analytical technique applied). 
Mean (n=6) plasma concentrations of metabolite M3 (●, ng/mL) and total plasma radioactivity (●, ng GSK2251052 equivalents/mL ). 
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Left of the vertical dashed line, plasma radioactivity concentrations were measured using LSC (before 48h).  Right of the dashed line, the plasma radioactivity concentrations were 
measured using AMS (48 hours and later).  LoQ for the LC-MS specific assay for M3 was 5 ng/mL ; LoQ for AMS for total radioactivity was 27.2 ng GSK2251052 equivalents/mL. 
 Good mass balance was achieved (95% (range from 92.7 to 99.9%) within 192 hours, 8 
days) with the majority of excretion of RDM via the urine (a mean of 87.4% of the 
dose).  GSK2251052 was eliminated both as unchanged drug in the urine (it was absent 
from faeces) and as metabolites, with the M3 as the only other major RDM present in 
urine.  There was nevertheless, continued excretion of radioactivity into the urine 
throughout the 14 days of collections (see Figure 4 in the paper showing only M3 
present in the later timepoint (120 – 336 hours) pooled urine sample), consistent with 
the long half-life of the M3 metabolite in plasma. 
 
This type of information (overall body burden to drug-related material) is important as 
it provides knowledge from which assessments of likelihood for accumulation of drug 
and metabolites can be determined upon repeated administration (i.e. the marked 
differences between clearance of parent drug versus RDM in this case highlight the 
need for this knowledge). 
 
The paper also investigated the mechanism of formation of the major metabolite, M3.  
Alcohol dehydrogenase and aldehyde dehydrogenase were implicated in the formation 
of M3 via in vitro and in vivo experiments.  Both of these are polymorphic enzymes so 
there is an inherent risk associated with variability in extent of metabolism across 
individuals (Eriksson et al., 2001).  These risks need to be considered as lack of 
antibiotic efficacy could occur in some patients, e.g. in the case of subjects who are 
extensive metabolisers of GSK2251052 (to M3).  An example population may be 
alcoholics who have induced levels of ALDH due to ethanol abuse (Nilius, 1983). 
 
Unfortunately, around the time of conducting the human ADME study, antibiotic 
resistance issues occurred in the clinic in a separate efficacy study for GSK2251052, 
which precluded further development of this molecule and so further mechanistic 
studies were abandoned. 
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Figure 13.  Biotransformation of GSK2251052 to M3 (carboxylic acid metabolite of GSK2251052). 
The structures show the position of the 14C-label. 
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 3.3.4. Technical considerations and reflections 
 
As can be seen from Figure 12 above, taking into account variability around the 
independent sample analysis conducted for the specific LC-MS assay of the M3 
metabolite and the direct analysis by AMS for total radioactivity (as indicated by the 
error bars), the mean data from both data sets from around 72 hours after dosing is 
close to superimposable, justifying the decision made not to conduct metabolite 
profiling on the plasma samples, as mentioned above. 
 
The total radioactivity data from analysis by direct AMS from this study led to 
development of our approach to defining the LoQ for radioactive drug related material 
in plasma, based upon specific activity of the drug being investigated.  This was 
achieved by measurement of endogenous radiocarbon from control blood plasma 
taken from 25 individual subjects and a statistical definition was made of confidence 
intervals for ability to discriminate drug-related material from background 
radioactivity.  It was established that the LoQ for drug related material could be 
defined at concentrations ≥15% above background with 99% confidence, or ≥10% with 
95% confidence, thus the default position became the former in most cases.  This LoQ 
assessment is in broad agreement with the work of other laboratories ((Keck et al., 
2010) and direct communication with Xceleron Ltd.).  The practice established in our 
group, of taking multiple predose plasma samples (one at screening of the subjects, 
one pre-study on Day -1 and one on Day 1 of the study), served to re-enforce the 
assurity of background radioactivity measured in each human subject.  Note that the 
accepted LoQ definition for LSC is more empirically determined (see section 1.3). 
 
The LoQ, which is expressed in dpm/mL of plasma, could then be converted into the 
units of drug equivalents per volume of plasma using the specific activity of the drug 
dose (e.g. expressed in units of dpm per picogram) to provide an LoQ in a comparable 
manner to other analytical techniques such as LC-MS, rather than in dpm as is the 
normal practice for LSC (see section 1.3). 
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 3.4. Commentary paper 4 
 
Harrell, A. W., S. K. Siederer, J. Bal, N. H. Patel, G. C. Young, C. C. Felgate, S. J. Pearce, 
A. D. Roberts, C. Beaumont, A. J. Emmons, A. I. Pereira and R. D. Kempsford (2013). 
"Metabolism and disposition of vilanterol, a long-acting β(2)-adrenoceptor agonist for 
inhalation use in humans." Drug Metab Dispos 41(1): 89-100. 
 
3.4.1. Objectives 
 
1) To determine the rates and routes of excretion of vilanterol (a potent, low dose 
long acting β2-agonist NCE for inhalation use), following oral administration to 
healthy volunteers. 
 
2) To determine the biotransformation pathways for vilanterol in humans. 
 
3) To examine the utility of AMS and duodenal bile collection to investigate biliary 
elimination of vilanterol in humans following an oral dose administration. 
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 3.4.2. Clinical study design 
 
The accepted practice for assessment of ADME in humans for inhaled therapies is 
through administration of 14C-labelled drug by surrogate routes, such as intravenous or 
oral administration.  There is precedent for the administration of 14C-labelled drug by 
inhalation to humans (Affrime et al., 2000), but it is fraught with logistical difficulties, 
not least being the fact that a dry powder of material incorporating the labelled drug is 
likely to be different in terms of physical properties, such as crystalline form and 
particle sizes from the marketed (non-labelled) medicine. 
The intravenous route is a surrogate for systemic exposure to drug related material 
absorbed via the lung and the oral route represents the majority of the dose 
swallowed and delivered to the gastrointestinal tract from an oral inhalation dose (see 
section 4.1.2). 
 
The intravenous route was not used in the human ADME (excretion balance) study for 
vilanterol due to radiolytic instability over the period required for manufacture and 
release of the dose*.  This study, depicted in Figure 14, therefore involved 
administration of vilanterol by the oral route only.  It is accepted that oral 
administration will not entirely represent the same rates and routes of ADME as per 
the entire dose administered by oral inhalation, but nevertheless it is accepted as a 
practically feasible surrogate approach by regulatory authorities for human ADME 
studies of inhaled therapies (Hughes et al., 2008), (Kagan et al., 2012). 
 
Autoradiolysis was found to be reduced through use of lower specific activity material, 
so although the therapeutic dose of this drug was predicted to be 25 µg, a higher total 
dose of 14C-vilanterol of 200 µg [74 kBq] was used in the human ADME study (see 
section 3.4.4 for further explanation of the reason for choice of dose).  Existing safety 
information, from prior toxicological and clinical studies, supported the administration 
of the supra-therapeutic dose of 200 µg of vilanterol to humans. 
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* Stability for up to two weeks was required.  Note that through the newer approach of parametric 
release , stability and sterility assurance for only 24 hours is required. 
  
 
 
 
 
 
 
 
 
14C-vilanterol 
 
Figure 14.  Schematic of clinical study design 4. 
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Cl
Design: 
6 Healthy human subjects; 
Single oral dose of 200 µg 14C-vilanterol  
(74 kBq) 
Samples : 
• Blood for plasma [for parent drug, RDM concentrations  
& metabolite profiling] 
 
• Faeces and urine [for mass balance and metabolite profiling] 
 
• Duodenal bile [for metabolite profiling] 
Main data outputs: 
• Parent drug concentrations (by LC-MS) 
 
• Total radioactivity in plasma (by direct AMS) 
 
o Derivation of pharmacokinetic parameters in plasma [very limited for parent 
drug*] 
 
• Excretion mass balance (by direct AMS) 
 
• Metabolite profiles (plasma, urine, faeces [bile not reported (see section 3.4.4)]; by LC+AMS 
and LC-MS); in vitro assessment of pharmacological activity of metabolites 
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*  Due to most concentrations being <LoQ of the specific LC-MS assay. 
 3.4.3. Clinical study data output and impact 
 
To estimate the extent of first pass metabolism of a drug in humans*, one approach is 
to compare the unchanged parent drug concentration with RDM in plasma, at an early 
sample timepoint following oral administration.  The choice of timepoint is a matter of 
judgement, but it should be late enough that the drug has had time to undergo 
significant absorption, but insufficient time to be metabolised in the systemic 
circulation.  Minimal first pass metabolism is indicated if the RDM and the parent drug 
are present at very similar concentrations, whereas a notable difference between 
parent and RDM concentrations is indicative of first pass metabolism. 
 
The assumption is that first pass metabolism occurs either in the wall of the 
gastrointestinal (GI) tract, in the liver before the drug reaches the systemic circulation, 
or a combination of both.  However, there are a number of caveats to this assumption:  
 
1) that the drug was stable in the GI tract prior to absorption (e.g. metabolism by 
the gut microbiota, or facile degradation in stomach acid were not significant. 
 
2) that systemic metabolism is not exceptionally rapid. 
 
3) that the incorporated radioisotope was in a position stable to metabolism, so 
that the core of the molecule is traced (see section 1.2). 
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* The importance of understanding the extent of first pass metabolism of the drug and indeed drug 
metabolism by the liver in general is discussed later (see section 4). 
 
 Notwithstanding these points, it is generally recognised that comparison of parent and 
RDM early in the absorption phase of a concentration-time profile gives a reasonable 
estimate of the magnitude of first pass metabolism (Lappin and Garner, 2005). 
 
In the case of vilanterol, at 30 minutes after dosing the mean concentration of the 
RDM in plasma was 935 pg vilanterol equivalents/mL (SD of 323 pg vilanterol 
equiv./mL), whilst parent drug was at a mean of only 2.3 pg/mL (SD was not calculated 
as vilanterol concentration was >LoQ in only one individual sample) or <0.5% of the 
circulating drug-related material as highlighted in Figure 15.   
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Figure 15.  Mean concentrations (n=6) of vilanterol and total radioactivity in plasma after oral administration of 14C-vilanterol 
to humans. 
(Adapted from Figure 2 in Commentary paper 4, with the addition of error bars.)
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The difference in mean plasma concentrations of radioactivity (pg vilanterol equiv./mL) versus concentrations of unchanged vilanterol (pg/mL) are highlighted on this 
concentration–time semi-log plot.  Note that the vilanterol data represents a quantifiable concentration in a single subject (at 14 pg/mL) at 0.5 hours after administration i.e. for 
five of the six subjects the concentrations were below the LoQ and treated as being zero for the purpose of representation of the mean data (2.3 pg/mL).   
 
 Additionally, in the mouse and rat, following oral administration of vilanterol, 
concentrations of unchanged parent drug were determined from samples taken from 
the cannulated hepatic portal vein (HPV) and compared to those of parent drug in 
plasma from the systemic (SYS) circulation (cardiac puncture) (see cartoon of first pass 
effect assessment in the rodent, through analysis of HPV and SYS samples; Figure 16).  
These investigations showed significantly higher concentrations (> 10-fold) of 
vilanterol in hepatic portal vein plasma, at 15 minutes after dosing, indicating 
extensive first pass metabolism in these species (GSK internal reports).  
Additionally, intrinsic clearance of vilanterol was very high in human liver microsomes 
in vitro and moderately high in microsomes prepared from the gastro-intestinal 
mucosa (GSK internal reports).  The commentary paper (Figure 5E) also shows that 
incubation of vilanterol with human hepatocytes in vitro resulted in complete 
metabolic turnover of vilanterol to metabolites.  All indications were therefore that 
vilanterol underwent significant first pass metabolism, including following oral dosing 
to humans.  This is of significance for vilanterol, as the extensive pre-systemic 
metabolism to inactive metabolites reduces the propensity for it to cause off-target 
side effects, including tachycardia, since the concentrations in the systemic circulation 
are very low indeed. 
 
A low mass balance of 14C-recovery was obtained for the clinical study (mean of ~72%, 
SD of 4.4%), although the overall reason for the low recovery was not clear.  In the 
paper, several arguments for the low recovery were presented, including technical 
limitations related to the low radioactive dose.  The most likely reason, in this author’s 
opinion, is the fact that there were measurable concentrations of above background 
radioactivity in plasma at the end of the collection period (168 hours), i.e. elimination 
of drug-related material was not complete.  There was a long terminal elimination 
half-life for total radioactivity (in excess of a mean of 146 hours; CV of 15%), which was 
not stated in the paper and yet excreta samples were only collected for 7 days after 
dosing.  The implication then is that near complete 14C-recovery was never likely to be 
achieved with this excreta collection period. 
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 As stated in the paper and in a supporting reference of historical mass balance data 
(Roffey et al., 2007), incomplete mass balance is common with an expectation that 
80% or greater is generally recovered using routine methodology, but it is recognised 
that the methodology used for this study could not be described as routine, as 
outlined i.e. low radioactive dose and use of AMS. 
 
The data obtained (see Commentary paper 4) showed that metabolite profiles could 
be provided by AMS, even for such a low dose of drug to human subjects.  The major 
metabolites observed in humans were appropriately present in the non-clinical species 
used in the safety evaluation of vilanterol, providing validation of the toxicology 
species used in development of this drug. This study highlighted the complications 
associated with determining the human ADME for potent low dose drugs for 
inhalation.  Nevertheless, mitigation of any concern around the poor mass 
balance 14C-recovery was the low therapeutic dose of vilanterol. 
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Figure 16.  Cartoon of sample analysis and exposure assessment in the rodent before and after first pass through the liver*. 
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*  With permission from GSK. 
 3.4.4. Technical considerations and reflections 
 
The major objective of an ADME study destined for submission to the regulatory 
authorities is to identify rates and routes of metabolism of the drug under test in 
humans.  Discovery of any metabolites unique to humans would be the outcome of 
major concern for this investigation.  However, the extremely low therapeutic dose for 
vilanterol, along with existing clinical safety data (GSK, 2016) and independent 
monitoring of several specific metabolites (using LC-MS assays) of known on-target 
potency in other clinical trials, may have been expected to negate the need for a 
human ADME study.  This, however, was not the view of at least one regulatory 
authority, so this study was designed to provide an increased level of understanding of 
the ADME-PK of vilanterol in advance of regulatory approval of the marketing 
application for this medicine. 
 
The supra-therapeutic dose of 200 µg (with associated lowered specific activity) that 
was selected for this study was chosen by the GSK clinical study team.  At the outset in 
the planning of the study, this author proposed that the study could be conducted at 
the therapeutic dose (25 µg, even with the dose of lowered ionising radiation) and that 
study objectives would still be met, but on this occasion that opinion was not 
supported by others in the clinical study team.  This highlights one of the challenges of 
collaborating with scientists who are unfamiliar with the AMS technology.  As 
experience with the AMS technology grows across the pharmaceutical industry, such 
arguments will be easier to make in the future. 
 
Until recently, it was common practice in drug development to limit biliary elimination 
data to the rat and less commonly from other species.  This is because bile duct 
cannulation surgery is required which is amenable to the rat, but difficult to ethically 
justify in the dog and particularly in the monkey.  Data on biliary excretion in humans 
was almost always absent and assumptions were made from extrapolation purely from 
the rat.  The likelihood of a compound being excreted in bile is in part related to its 
molecular weight and the threshold above which this is more likely, than via renal 
elimination, varies across species (Hirom et al., 1972).  Other factors, including active 
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transport, further complicate prediction from animals to humans (Fagerholm, 2008) as 
there are notable species differences in transporters (Chu et al., 2013).  It is potentially 
concerning that the only data pertaining to biliary excretion therefore comes from the 
rat, even though it is well known that these data could be misleading when applied to 
humans.  In some cases, analysis of faeces may provide some insight to biliary 
elimination in humans, but this may also be misleading if metabolites are formed by 
gut microflora.  In addition, metabolites formed in the liver and eliminated in bile can 
undergo further metabolism before excretion in the faeces, or they can be reabsorbed 
and be absent from the faeces altogether. 
 
Sampling of human bile was historically difficult to justify to provide a wider 
understanding of this route of elimination of drug related material in humans due to 
the invasive nature of the sample collection (Lennernas et al., 1992).  Several studies 
recruited healthy volunteers who have been fitted with oroenteric tubes, which 
facilitate the sampling of duodenal bile.  The majority of these studies used an 
adaptation of the Loc-I-Gut technique (Lennernas et al., 1992).  Nevertheless, the 
technical difficulty in sampling directly from the gallbladder or duodenum, not to 
mention high study running costs and the need for suitably qualified personnel, means 
that the studies are very rarely conducted. 
 
The vilanterol study applied a new approach to the collection of human duodenal bile 
using the Entero-testTM string, which has developed from seminal work conducted at 
GSK (Guiney et al., 2011).  The Entero-testTM is comprised of a weighted (steel ball 
bearing) and adsorbent nylon string, inside a gelatine capsule.  The proximal end of the 
string is attached to the cheek of the subject and the capsule is swallowed.  The 
capsule dissolves in the stomach and the string reaches the duodenum.  Contraction of 
the gall bladder is induced by a small food stimulus and a small portion of the bile 
(~1mL of the total volume which is likely between 350 and 600 mL per day (Boyer and 
Bloomer, 1974), (Davies and Morris, 1993), dependent on, for example, food intake), is 
adsorbed onto the string.  The string is then retrieved through the mouth and the bile 
collected for later analysis (the ball bearing becomes unattached and passes through 
the gastrointestinal tract). 
 
96 
  
Biliary secretion is a potentially major route of elimination of drugs and their 
metabolites from the body.  As a result, elimination of compounds by this route can 
impact the systemic exposure, toxicity and pharmacological effects of drugs.  In the 
absence of knowledge around the biliary disposition of a drug, the relative importance 
of different routes of metabolism and their relationship to overall clearance may be 
misinterpreted.  This makes the non-invasive Entero-testTM string approach a very 
attractive proposition for DMPK scientists to be able to gather this kind of information 
for new drugs in development.  It should be noted however, that Entero-testTM results 
in a single bile sample per subject and although it provides qualitative information on 
biliary metabolites, it does not provide data on the magnitude or kinetics of biliary 
elimination.  This type of information is best attained via an intravenous 
administration of drug (further detail provided below). 
 
In the case of the vilanterol study, very little information was gained from the 
Entero-testTM approach, which is in part likely due to the complications of the low dose 
and the oral dose route being used (potential for contamination of the bile with drug 
swallowed into the gastrointestinal tract).  However, there have been several 
experiments where the Entero-testTM approach has been more successfully applied in 
clinical studies.  In the human ADME study for GSK2140944, gepotidacin, a bacterial 
topoisomerase inhibitor (a new class of antibiotic), strings collected following 
intravenous administration were analysed in our laboratory (Negash et al., 2015).  The 
data obtained, as shown in the metabolism pathway schematic in Figure 17, indicated 
that the predominant metabolite present in faeces (M2) was not the same as that 
observed in bile (M4).  In fact, the data indicate that the metabolite M2, present in 
faeces, was likely due to hydrolysis of M4 (the major circulating metabolite of 
GSK2140944) by gut microbial activity, and this was subsequently not detected by 
metabolite profiling of faecal samples.  This clearly demonstrated the value of insight 
provided by analysis of the human bile, which otherwise would have been lost in the 
assessment of metabolite burden. 
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Figure 17.  Biotransformation of GSK2140944 to M4 (oxidative metabolite of GSK2140944) and M2 (hydrolysis product of 
M4) in human*. 
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 *  Structures reproduced with permission from NEGASH, K., et al., 2015, with addition of bile and faecal major metabolite indicators. 
 The Entero-testTM approach has been used by our laboratory in other human ADME or 
early microtracer studies for drugs in development ((Mamaril-Fishman et al., 2014) and 
unpublished works), where this has proven to be very valuable in elucidating routes of 
metabolism, such as direct glucuronidation of parent drug.  In such instances, had only 
faeces samples been analysed the significance of such metabolic routes and the 
metabolite burden to the humans would not have been fully understood.  This is 
because the glucuronide is converted back to the aglycone (parent drug) in the 
gastrointestinal tract (Hawksworth et al., 1971), meaning that the parent drug rather 
than the metabolite would have been observed in faeces. 
 
As highlighted above, several of these investigations demonstrate the value of the 
Entero-testTM method in providing a contribution to the overall understanding of 
ADME of the drug.  The approach is particularly useful when combined with a 
radioactive dose administered intravenously, as there is no complication from the 
potential contamination of the bile sample due to unabsorbed dose, as can be the case 
when it is administered by the oral route, i.e. any drug-related radioactivity detected 
on the string has to be present due to biliary elimination of drug-related material.  It is 
also noteworthy that the sensitivity of the AMS enables study designs and analyses 
that would otherwise be impossible to achieve; the bile sample volume collected 
represents a very small proportion of the total volume excreted and hence there is a 
low amount of drug-related material present (assuming biliary elimination of drug-
related material occurs), providing a challenge for detection by other means. 
 
With current knowledge of the microtracer approach (see an in depth explanation of 
the principles of this in section 3.6) it is possible that administration of vilanterol by the 
intravenous route for the human ADME study could have been attempted.  Dosing by 
the intravenous route would have provided information on pre-systemic metabolism 
through comparisons that could be made to data from the metabolite profile following 
oral dosing.  This would have enabled deconvolution of metabolism in the systemic 
circulation from that due to first pass metabolism following oral administration.  In 
fact, Commentary paper 4 overstates the surety of the extensive nature of first pass 
metabolism in the absence of this information. 
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 3.5. Commentary paper 5 
 
Dave, M., M. Nash, G. C. Young, H. Ellens, M. H. Magee, A. D. Roberts, M. A. Taylor, R. 
W. Greenhill and G. W. Boyle (2014). "Disposition and metabolism of darapladib, a 
lipoprotein-associated phospholipase A2 inhibitor, in humans." Drug Metab Dispos 
42(3): 415-430. 
 
 
3.5.1. Objectives 
 
1) To determine the rates and routes of excretion of an NCE, darapladib, following 
single intravenous and single and repeat oral (proposed therapeutic route) 
administrations to healthy subjects. 
 
2) To determine the biotransformation pathways for darapladib following both 
routes of administration and following single and repeat oral administration in 
humans. 
 
3) To utilise AMS to investigate the reason for altered pharmacokinetics of 
darapladib following repeated administration. 
 
3.5.2. Clinical study design 
 
Predictions of modelled systemic exposure, based upon the existing single oral dose 
elimination half-life pharmacokinetic data for darapladib (an inhibitor of lipoprotein-
associated phospholipase A2) in humans indicated that repeat dose administration 
would result in significant accumulation (130-200%) in the systemic circulation.  
However, following repeated administration of darapladib at oral doses up to 80 mg 
once daily, concentrations in plasma were only 30-60% higher compared to those after 
a single oral dose.  A likely hypothesis for this difference between the predictions and 
the subsequent clinical study data was that darapladib exhibited time-dependent 
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changes in its pharmacokinetics due to autoinduction of one or more of the enzymes 
involved in its metabolism, which then led to an increase in clearance of darapladib. 
 
A human ADME study was therefore designed to include a test of this hypothesis i.e. to 
investigate the extent, if any, of metabolic autoinduction following repeat oral dose 
administration of darapladib. 
 
The study, illustrated in Figure 18, was of a four stage cross-over design, as follows: 
 
Stage 1: a single intravenous administration of 8 mg of 14C-darapladib [1.85 MBq], 
followed by a minimum washout period of 21 days. 
 
Stage 2: administration of a single oral dose of 80 mg of 14C-darapladib [740 kBq], 
followed by a minimum washout period of 21 days. 
 
Stage 3: administration of non-labelled darapladib as daily 160 mg doses for 14 days. 
The doses were given in the form of enteric coated tablets as this molecule was prone 
to degradation under acidic conditions, such as those of the stomach, to produce a 
potentially genotoxic species, 4-fluorobenzyl chloride (see Figure 19). 
 
Stage 4: on Day 11 of stage 3, a single oral dose of 80 mg of 14C-darapladib [740 kBq] 
was administered. 
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Figure 18.  Schematic of clinical study design 5.
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Design: 
8 Healthy human subjects; cross-over – washout of 21 days minimum between the 
intravenous (stage 1) and oral dose (stage 2) 
 
(1) Single 3 hour intravenous infusion dose of 8 mg 14C-darapladib (1.85 MBq) 
 
(2) Single oral dose of 80 mg 14C-darapladib (740 kBq) 
 
(3) Repeat oral [cold] doses of 160 mg for 14 days 
 
(4) Single oral dose of 80 mg 14C-darapladib (740 kBq) [on Day 11 of stage 3] 
Samples : 
• Blood for plasma [for parent drug, 
RDM concentrations & metabolite 
profiling] 
 
• Faeces and urine [for mass balance and 
metabolite profiling] 
Main data outputs: 
• Parent drug & active metabolite (M4) concentrations in plasma (by LC-MS) following intravenous and 
oral administration 
 
• Total radioactivity in plasma (by LSC [intravenous dose] and by direct AMS [oral doses]) 
o Derivation of pharmacokinetics of darapladib in plasma following single intravenous and 
single and repeat oral doses 
 
• Excretion mass balance assessment (by LSC) 
 
• Metabolite profiles (plasma (by LC+AMS) & faeces (by TopCount); both routes and following single and 
repeat oral dose admin.  Urine was not profiled due to <1% dose excreted by renal elimination* 
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 *  It is common practice to make a judgement as to whether to carry out metabolite identification and quantification of excreta samples based on the percent of the dose 
excreted by that route. 
 Blood samples (for plasma) and excreta samples (faeces and urine) were collected over time for 
stages 1, 2 and 4.  All samples were analysed for total radioactivity by LSC or AMS as required.  
Plasma samples were additionally analysed by LC-MS specifically for parent drug and an 
equipotent pharmacologically active metabolite of darapladib (M4; SB553253), which is  depicted 
in Figure 19, to further establish the relationships between systemic exposure to active drug-
related material and clinical efficacy. 
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               4-fluorobenzylchloride 
Darapladib      SB553253 (M4) 
 
 
Figure 19.  Biotransformation of darapladib to SB553253 (N-desethyl metabolite of darapladib) & structure of 4-fluorobenzyl 
chloride. 
The structures show the position of the 14C-label, where present. 
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 3.5.3. Clinical study data output and impact  
 
This study was relatively complex in design, set out to assist with understanding of the 
pharmacokinetic properties and metabolism of darapladib following oral and 
intravenous administration and both single and repeated oral doses to humans.  The 
mean mass balance recovery for oral 14C-darapladib pulse dose administrations for 
stages 2 and 4 was >93% (SD of <8%) by 8 days after administration, whereas recovery 
was lower (mean of 86%; SD of 4.4%) at 21 days after intravenous administration 
(stage 1).  Following oral darapladib dose administration, a large proportion of the 
dose was either unabsorbed or cleared via first pass metabolism.  The slightly 
lower 14C-recovery (within the timeframe of the excreta sample collections) following 
intravenous administration may result from these dose route differences and may be 
compounded by the potential sequestration of darapladib (a tertiary amine with a pKa 
of 8.4) into lysosomes by virtue of its physicochemical properties (Kaufmann and Krise, 
2007) (i.e. darapladib is a cationic amphiphilic drug and has a very high volume of 
distribution of 833 L, indicating distribution into peripheral tissue compartments). 
 
The retention of drug-related material (all 14C dose stages of the study), combined with 
collection periods that did not allow full characterisation of concentrations of 
radioactivity in plasma to suitably late time points after administration, meant that 
extrapolated pharmacokinetics of total drug-related radioactivity could not be 
provided; e.g. extrapolation of AUC to infinity beyond the last time point sampled, 
would have been inappropriate, at >20% of the area under the drug concentration-
time profile, and as such prone to error (EMA, 2001).  The commentary paper did not 
explain the impact of this data absence, but this limitation is not critical for data 
interpretation as the AUC to the last timepoint provides an adequate assessment of 
the systemic exposure. 
 
The intravenous dose was included as from animal study data (GSK internal reports) it 
was predicted that absorption in humans would be low.  Therefore, if the study was 
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conducted with oral administration only, then analyses of faeces samples potentially 
containing unchanged parent drug would not help elucidate to what extent the parent 
drug had been absorbed prior to being excreted in faeces.  The intravenous dose and 
metabolite profiling of the faeces samples from both routes of administration 
indicated that absorption from an oral dose was much higher (at ≥43 %) than 
previously believed.  In fact, the metabolite profiling of faeces following intravenous 
administration showed a large proportion of intact parent drug to be present.  This 
indicated that absorption could be even higher than established through analysis of 
faeces samples after oral administration, i.e. otherwise intact parent drug present in 
the faeces collected following oral dosing may have been assumed to be entirely from 
unabsorbed dose.  This type of information is useful as it can, for example, guide dose 
formulation development if absorption was believed to be dissolution rate or solubility 
limited*, which was apparently not the case for darapladib. 
 
In stage 1, the pulse dose of radiolabelled darapladib fully reflects the totality of the 
drug-related material present in the system (in this case the human) at the time of 
sampling.  However, the pulse dose of radiolabelled drug in stage 4 of the study, 
following repeated oral cold dose administrations (stage 3) has a limitation in this 
regard, in that the drug-related material that is present in samples from the repeated 
doses of cold drug are not represented through calculation from the specific activity 
for the pulse dose.  This has the impact that chemical mass equivalents of drug and 
metabolites cannot be calculated for this stage of the study.  To explain this further, 
the administration of repeat doses of unlabelled drug causes an unquantifiable dilution 
of drug-related material in the systemic circulation, which makes it impossible to 
convert the radioactivity measurements to mass of drug equivalents.  This design 
limitation in some regards makes the alternative design of repeat tracer doses 
of 14C-labelled drug more attractive, as the isotopic dilution would not occur since 
there is no cold drug-related material present.  This type of design has its own 
limitations, with the main one of these being that the doses of radiation have to be 
very low indeed for each dose administered, so as not to administer cumulative 
excessive ionising radiation doses to each individual subject. 
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*  It must be borne in mind in the interpretation of the data however, that a solution dose is 
most often used in the human ADME study, rather than a solid dose formulation eg. tablet or 
capsule, which are more often the marketed form of the medicine. 
 The objective of understanding the reduced level of anticipated accumulation (as 
possibly caused by autoinduction) may have been compromised by discontinuation of 
the dosing of darapladib during the sample collection period in stage 4.  The dosing did 
continue for some of that period, through days 12-14 following dosing of 
the 14C-labelled darapladib on day 11, but not for the entire sample collection 
period.   Discontinuation of the dosing of an inducer will result in dissipation of 
induction over time as illustrated by the prototypical inducer, rifampicin (Niemi et al., 
2003), so it can be postulated that this may have occurred during stage 4 of this study.  
Assessment of accumulation is important in establishing repeat dose regimens for new 
medicines and in this instance it would appear that further investigations would be 
warranted to more fully investigate this phenomenon and any potential requirement 
for dose adjustment following repeated administration.  Feasibly this could include 
analysis of the pharmacokinetics of darapladib following repeated administration, 
where the dosing is continued beyond the timeframe carried out in this study, i.e. 
there is no possibility of dissipation of any autoinduction. 
 
The study showed that it was possible to generate a relatively high volume of data 
with provision of metabolite profiles for many chromatograms.  However, as indicated 
above, the experiments failed to show clear evidence of enzyme induction (the 
metabolite profiles were very similar following each of the oral pulse doses in stages 2 
and 4).  In part, as indicated in the paper, it is possible that the need to 
use time-adjusted proportional pools to keep the resources involved to a reasonable 
level may have contributed to this inability to fully investigate the ADME-PK.  However, 
the analyses did show reduction in drug-related material in plasma after the pulse 
dose of 14C-darapladib in stage 4 (AUC(0-t) of 320 dpm.h/mL) versus that in stage 2 
(AUC(0-t) of 420 dpm.h/mL).  It is stated in the commentary paper that darapladib is a 
substrate of both Cytochrome P450 isoform 3A (CYP3A) and the efflux transporter P-
glycoprotein (P-gp).  It was thus postulated that the lowered systemic exposure to 
drug-related material in stage 4 may indicate lesser absorption of darapladib across 
the enterocytes after repeated oral dosing, combined with greater extent of first pass 
metabolism and/or efflux transport through induction of enzyme and/or efflux 
transporter activity. 
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Through the course of large scale clinical trials these types of findings would be further 
investigated via generation of pharmacokinetics upon long term administration of the 
new drug under evaluation.  Additionally, both population pharmacokinetics in the 
presence of co-administered medications and specific drug-drug interaction studies 
would be used to further investigate propensity for inhibition and/or induction of the 
metabolism and transport of the drug, before and after it becomes a medicine (EMA, 
2013). 
 
The presence and quantification of potential human specific and disproportionate 
metabolites were highlighted in this study.  This can have far reaching ramifications for 
a drug under development, such as the need for additional safety studies, including 
dosing of the metabolite to animals in extreme cases where safety cannot otherwise 
be established (FDA, 2008).  In the case of darapladib, assessments of genotoxic 
liability, general safety cover and on-target pharmacological activity of the metabolites 
(i.e. their limited contribution to the activity of parent darapladib) meant that no 
further work was required. 
 
The genotoxic risk assessments were carried out as stipulated by regulatory guidance 
(ICH, 2011).  If a proven genotoxin is present either as an impurity, degradant or 
metabolite of a drug, there are wide ranging consequences for the drug as a potential 
medicine, including potential termination of the drug.  For darapladib, extensive 
assessments showed that loss of the fluorobenzene moiety from the structure of 
darapladib did not cause consistent genotoxic endpoints in the non-clinical studies 
conducted. Additionally, the enteric coating used for tablets and the administration of 
the oral solution dose along with food was shown to limit degradation to potentially 
produce 4-fluorobenzyl chloride. 
 
The M4 pharmacologically active metabolite (see section 3.5.2) was the only 
metabolite found to be present in plasma following intravenous administration of 
darapladib (1% of total RDM) and one of several minor metabolites present following 
oral administration.  None of the metabolites were greater than 6% of drug-related 
material in plasma and thus contributed little to the pharmacology of darapladib.  
Commentary paper 5 states that M4 was routinely analysed in all clinical studies for 
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darapladib, but the value added in doing this seems questionable (at least to this 
author) based on the data from this study. 
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 3.5.4. Technical considerations and reflections 
 
There was a minimum 21 day washout period between stage 1 and stage 2 of the 
darapladib study to attempt to ensure that there was no drug-related material present 
in samples from the intravenous dose administration when the first oral pulse dose 
was administered.  On reflection, the washout period between dosing phases of the 
cross-over was not long enough in this study, as was shown by the presence of 
radioactivity at above background levels in the predose samples from the oral dose 
session; predose samples contained about 20% of peak post dose concentrations.  
Pharmacokinetic data modelling was used to subtract concentrations of RDM residual 
from the intravenous dose session from those in the first oral dose session and 
although not ideal, there was no significant effect on the data or objectives of the 
study in this case.  This finding was useful for application to subsequent studies as a 
note of caution in the planning of the length of the washout period between dosing 
phases for cross-over study design, as demonstrated by Figure 25. 
 
Similar to the study for Commentary paper 4, LSC was used alongside AMS for certain 
elements of this darapladib study, with further demonstration of how these 
techniques can be used to complement each other.  The design could have been 
altered, as mentioned in the paper, through use of repeated administration 
of 14C-labelled doses instead of the use of single doses before and after repeated cold 
dose administrations, as was implemented.  Whether this type of repeat dose design is 
really necessary in general drug development is questionable as a plethora of repeat 
dose ADME data can be obtained through alternative approaches, such as with NMR 
and LC-MS, without the need for 14C-labelled drug (Dear et al., 2008). 
An unresolved issue in this paper was that of a very poor 14C recovery (only 20% 
recovery; unpublished data) from one individual subject, following the first oral dose 
administration.  Full investigation of the possible reasons for this provided no 
satisfactory answer for the cause of the low recovery, e.g. it was shown that this 
individual had very similar systemic exposure to drug-related material, so it was 
inferred that the subject had received the correct dose of 14C-darapladib.  In the 
author’s experience this finding has occurred in more than one clinical mass balance 
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study, but even after thorough investigations as to how it may have happened 
(including re-analysis of samples, checks of the collections of excreta made) no 
definitive reason has been evident.  I would speculate that a possible reason is the 
formation of pockets in the lining of the digestive tract which can fill with excreta and, 
as a result, the drug-related material is effectively held in the GI tract for an extended 
period leading to this poor 14C-recovery within the timeframe of the excreta 
collections.  This phenomenon is known as diverticulosis and is a relatively common 
condition in the elderly and sometimes caused by poor diet (with up to 5% prevalence 
in 18-40 year olds) (Tursi, 2016).  A possible solution to this could be to administer a 
laxative to such an individual in a future study, should this occur, in the hope that the 
improved recovery would be achieved, instead of having to exclude the data from this 
subject from the data set. 
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 3.6. AMS in Microtracer Studies for Intravenous 
pharmacokinetics 
 
Over recent years there has been some confusion around the nomenclature used to 
describe two distinctly different clinical study designs, namely that involving 
a microdose (which can be isotopically labelled or non-labelled), where the total dose 
of drug administered does not exceed 100 µg (ICH, 2009) and the study design which 
has become known as a microtracer, as described in this section of the commentary.  
The term microtracer has been widely adopted in an attempt to distinguish the study 
design outlined below, from a microdose design, although confusion remains through 
misuse of the terminologies (Ings, 2009), (Lappin et al., 2013b).  This commentary is 
concerned with the microtracer study design only and should not be confused with 
microdosing. 
 
Traditionally, clinical absolute bioavailability (F) data has been obtained through a 
cross-over study design, where subjects are administered the reference intravenous 
dose of drug in one dosing session, followed by a wash-out period, and then the 
extravascular dose in a separate session.  Obtaining absolute bioavailability data for 
drugs intended for extravascular administration was expensive and time consuming 
because of the need for the intravenous dose.  Administering a drug intravenously 
required safety toxicology (animal studies in two species) by this route of 
administration, suitable formulation development and often conduct of a prior clinical 
dose escalation study to establish a safe dose to be used to meet the objectives of the 
subsequent absolute bioavailability study. 
 
In some cases, drugs are so insoluble that it has not been feasible to develop 
intravenous formulations.  For example, there is good evidence that ezetimibe is 
absorbed through the GI tract into the systemic circulation following oral 
administration to humans (Patrick et al., 2002) and yet its absolute bioavailability is 
unknown because the drug is too insoluble to administer intravenously (Kosoglou et 
al., 2005). 
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 Additionally, most drugs are developed for therapeutic administration by the oral 
route and so enabling activities for administration by the intravenous route are often 
seen as surplus to requirement and wasteful of precious resources.  On the other 
hand, it has been known for many years that there is value in obtaining knowledge of 
the definitive pharmacokinetic parameters of clearance (CL), volume of distribution (V) 
and absolute bioavailability that comes from dosing by the intravenous route (Rowland 
et al., 1973). 
 
Absolute bioavailability is calculated as shown by Equation 10 below: 
 
 (Equation 10) 
 
Where AUC is area under the drug concentration:time curve. 
 
Absolutely bioavailability is also related to clearance as follows: 
 
Following intravenous administration, CLiv = [Doseiv/AUCiv] (Equation 11) 
 
Following oral administration, CLoral = F x [Doseoral/AUCoral]  (Equation 12) 
 
Thus : F= (CLoral x AUCoral)/Doseoral     (Equation 12a) 
 
The value for CLoral in Equation 12a has to be assumed to be the same as CLiv as it is 
only possible to measure clearance following an intravenous administration.  
 
The question therefore arises, is the assumption that CL is the same for both the 
intravenous and oral administrations a reasonable one?  The answer is that this is a 
reasonable assumption providing either (a) CL is independent of plasma drug 
F = 
AUC oral
AUC IV
Dose IV
Dose oral
x
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concentration, or (b) if CL is dependent upon drug concentration, then the plasma 
concentrations are the same following intravenous and oral administrations. 
 
Since little is known about the clearance of a drug, or whether its value is dependent 
upon plasma concentration or not prior to intravenous administration, then the ideal 
design for a study where absolute bioavailability is determined from separate 
intravenous and oral administrations, is one where the plasma concentrations attained 
are the same for both dose routes.  To achieve this however, good estimates for the 
volume of distribution (V) and absolute bioavailability (F) are necessary which, 
paradoxically, are not known with any certainty until after the intravenous dose has 
been given.  Moreover, there are often toxicological and formulation constraints that 
limit the intravenous dose that can be administered.  Consequently, it is not 
uncommon to see absolute bioavailability studies where the respective plasma drug 
concentrations following the oral and intravenous administrations are significantly 
different, with no comment being made regarding potential non-equivalent clearance 
(a recent example is the absolute bioavailability of tasimelteon where there was an 
approximate 5-fold difference in AUCs between the oral and intravenous doses (Torres 
et al., 2015)).  Furthermore, there are examples where the apparent absolute 
bioavailability appears to be in excess of 100% due to non-equivalent clearance (for 
example with the vitronectin receptor antagonist (SB-26512) (Ward et al., 2004).  
Non-equivalent clearance is also thought to be responsible for an approximate 10% 
error in the determination of F for phenytoin (Jusko et al., 1976).  Error in the 
calculation of F arising from non-equivalent clearance is rarely considered in absolute 
bioavailability studies, although the effect has been recognised for several decades. 
 
An alternative design to the two-way cross over absolute bioavailability study first 
emerged in the 1970s, where the oral and intravenous doses were given at the same 
time, with the intravenous dose isotopically labelled.  Plasma samples were analysed 
by methods that were capable of discriminating between the non-labelled and 
isotopically labelled drug.  In this way, both the oral and intravenous pharmacokinetics 
could be determined from a single set of plasma samples, thereby virtually eliminating 
any non-equivalent clearance effects. 
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In the first study of this type to be reported (Strong et al., 1975) N-acetlyprocainamide 
(NAPA) was administered by the oral route at a dose of 500 mg, and 250 mg 
of 13C-NAPA was administered simultaneously by the intravenous route.  The design 
was developed to address issues of non-equivalent clearance and to remove potential 
temporal effects between dose administrations.  There were however, some 
downsides to the approach taken: 
 
(1) The high intravenous 13C-NAPA dose led to much higher systemic 
concentrations of drug than by the oral route, which meant that the 
combination of the drug exposure from intravenous and oral doses was 
markedly different from that from the oral dose alone and complex kinetic 
modeling was used to deconvolute the data, to adjust for any differences in 
pharmacokinetics that arose due to the magnitude of the systemic exposure 
differences. 
 
(2) A better design would have been to administer the intravenous dose in such a 
small quantity, so that it did not significantly add to the oral drug 
concentration.  In this way, the measured drug concentrations in plasma 
arising from the oral dose could be assumed to equal the total drug 
concentration.  Measurements of isotopically labelled drug would also directly 
provide pharmacokinetics by this route and no deconvolution modelling 
would be required.  The available analytical sensitivity at the time however, 
placed constraints on how low the intravenous dose could be. 
 
Although this design was used a number of times (eg. (Atkinson et al., 1989), (Preston 
et al., 1999) and (Heikkinen et al., 2001)), it was not widely adopted because of the 
magnitude of the intravenous dose required.  Deconvolution modelling was seen as an 
unnecessary step compared to the cross-over absolute bioavailability study design.  
Moreover, the intravenous dose still required an extensive toxicology package and so 
this remained a major burden to study conduct.  This situation changed however, with 
the advent of biomedical AMS. 
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As AMS came to be used in drug development, it offered an extremely sensitive 
method of isotopic measurement (primarily for 14C).  This enabled the intravenous 
dose to be reduced to such a low level that it became much less likely to contribute to 
the drug exposure resulting from the oral dose.  In addition, the regulatory authorities 
reacted by essentially removing the need for safety toxicology at such low doses (ICH, 
2009).  With the requirement for intravenous dose route specific toxicology 
assessment removed, the way was now open for human intravenous pharmacokinetics 
to be obtained on a far more routine basis.  
 
A microtracer is an isotopically-labelled substance (which can be a radioactive or stable 
isotope; in the context of this commentary and the direct experience of the author it 
has only been the former) administered intravenously concomitantly with higher 
extravascular dose(s), meeting all of the following criteria: 
 
(1) The intravenous microtracer dose meets the regulatory guidelines for safety 
evaluation in terms of mass administered and solubility in aqueous (usually 
saline) formulation. 
 
(2) The intravenous microtracer dose is sufficiently low so that it can be 
reasonably expected not to perturb the pharmacokinetics of the extravascular 
dose.  
 
(3) Isotopic analytical methods are available that will allow discrimination 
between the pharmacokinetics derived from the intravenous and 
extravascular doses. For example, the LC-MS for the analysis of non-labelled 
drug and LC+AMS for the 14C-drug quantification. 
 
Note that in the early studies (eg. (Strong et al., 1975)) the extravascular and 
intravenous doses were given simultaneously.  This design has been improved upon 
more recently and it has become standard practice to administer the intravenous dose 
as an infusion (e.g. 15 minutes duration) timed to end at the oral tmax , i.e. the 
intravenous dose is administered concomitantly with the oral dose rather than 
simultaneously, to further minimise the possibility of non-equivalent pharmacokinetics 
116 
 
between the different dose routes (specifically during the absorption phase for the 
oral dose, which an infusion more closely mimics than does a bolus dose).  An infusion 
is also usually preferred over a bolus administration for safety reasons as the infusion 
pump can be turned off to halt drug delivery if there are adverse safety signals in the 
subject. 
 
A cartoon of the principles behind microtracer dosing, through administration of a low 
dose of drug by the intravenous route, along with a much higher dose by an 
extravascular route, is shown in Figure 20.  The intravenous dose must be sufficiently 
lower than the extravascular dose (usually by a factor of between 100 and 1000) so 
that it does not perturb the pharmacokinetics of the extravascular dose.  The cartoon 
shows the principle of systemic mixing of the two isotopic forms (14C-labelled and 
non-labelled) of the drug and the fact that during the extravascular elimination phase 
both will be cleared at the same rate independent of the isotopic form.  Samples taken 
for isotopic analysis and total drug concentration analysis therefore generate 
pharmacokinetic data for both the intravenous and extravascular routes of 
administration. 
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Figure 20.  Principles of isotope mixing in systemic circulation during microtracer studies*. 
14C-labelled drug from the intravenous dose is effectively diluted into the larger mass of non-labelled drug from the extravascular route dose. 
Intravenous dose of 14C-drug 
(microtracer)  
Extravascular dose of 
non-labelled drug 
Blood/Plasma
Blood samples taken 
over time
eg. oral dose of drug 
absorbed from GI tract
Clearance of drug 
from systemic circulation
See Figure 21
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*  Figure compiled by G Young and G Lappin. 
 In summary, the microtracer design has the following advantages over the traditional 
two-way cross-over study design: 
 
(1) Virtual elimination of non-equivalent clearance effects. 
 
(2) No intravenous toxicology assessment is required in non-clinical species*.  
The safety data for the intravenous dose can be qualified by the existing oral 
toxicity studies (ICH, 2009). 
 
(3) Intravenous formulation development can be more straightforward due to 
the low dose. 
 
(4) No clinical dose escalation study is required to support the intravenous dose 
 
(5) Removal of the temporal effect which might occur when there are two 
separate dosing occasions 
 
 
The concept of the microtracer approach is summarised in Figure 21. 
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*  If a novel formulation vehicle is employed for delivery of the intravenous dose, then local 
tolerance of the vehicle should be assessed (in a non-clinical haemolysis study). 
 
Figure 21.  Concomitant oral and intravenous dosing microtracer concept. 
(Adapted from Figure 1 of (Lappin, 2016) with permission). 
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 It should be noted that the microtracer could be stable label material rather than 14C; all of the author’s experience to date has been with 14C. See section 3.6 for expansion upon 
some of the pros and cons of use of each of these labels.  
 
 GSK has conducted several such clinical studies in recent years (Daley-Yates et al., 
2012), (Hoffmann et al., 2013), (Denton et al., 2013), (Leonowens et al., 2014) in 
different stages of clinical drug development.  In the instances when these studies 
were conducted late on in development, it was to fulfill either real or perceived 
regulatory requirements for provision of absolute bioavailability data (Commentary 
paper 6 – section 3.7 and Commentary paper 7 – section 3.8).  When the studies were 
conducted early in drug development (eg. (Daley-Yates et al., 2012), (Hoffmann et al., 
2013)) it was for definition of absolute bioavailability to help define the reason for 
variable systemic exposure following extravascular administration* or investigation of 
routes of elimination of drug via reactive pathways that may raise a safety concern 
(unpublished works). 
 
From the perspective of the pharmaceutical industry, it is the regulatory requirements 
for absolute bioavailability data that drives the conduct of these studies.  
Notwithstanding absolute bioavailability, intravenous dosing of a drug otherwise 
intended only for extravascular administration also provides a wealth of other 
information, including: 
 
(1) Assessment of biliary excretion. 
 
(2) First pass metabolism versus systemic metabolism. 
 
(3) Definition of pharmacokinetic parameters such as CL and V (as well 
as F). 
 
(4) Assessment of renal clearance. 
 
Additionally, there are applications beyond the scope of this commentary including: 
 
(1) Study of conversion from pro-drug to active drug. 
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 * Drugs with low absolute bioavailability tend to exhibit more variability in systemic concentrations 
achieved following extravascular dose administration. 
(2) Formation and elimination of active metabolites. 
 
(3) Pharmacokinetics of metabolite turnover.  
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 * Drugs with low absolute bioavailability tend to exhibit more variability in systemic concentrations 
achieved following extravascular dose administration. 
 It should be noted, that since the re-emergence of the microtracer approach as a 
favoured alternative to the traditional cross-over design for absolute bioavailability 
assessment, sparked by the use of 14C tracer for this purpose, a number of studies 
where a 13C-labelled tracer was used have been conducted (Jiang et al., 2012), (Schwab 
et al., 2013), (Cannady et al., 2015), (de Vries et al., 2016).  Advances in the sensitivity 
of LC-MS since the time of the first study of this type (Strong et al., 1975), has made 
the use of stable isotope feasible.  There are both pros and cons to the choice of which 
tracer to use (Xu et al., 2014), including considerations around required analytical 
sensitivity, inclusion of additional objectives over parent drug pharmacokinetics alone, 
requirement for pre-work to check for possible KIE (in particular where multiple labels 
have been incorporated (Jiang et al., 2012)), availability of labeled materials and assay 
development complexities.  It is a reflection of the sensitivity challenges 
for 13C-labelled tracer measurement that studies where this has been applied to date 
have all used at least a 100 µg dose, whereas AMS has utilised much lower doses, eg. 
Commentary paper 7.  This author has no direct experience of 13C microtracer designs 
but it is his opinion that, as stated in a previous publication (Young and Seymour, 
2015), sometimes there are reasons that 14C and AMS are avoided, beyond those 
relating to science, e.g. availability of equipment and expertise in pharmaceutical 
companies (all have LC-MS capability) and lack of transparency of the real costs 
associated with drug development activities in-house (versus external expenditure at a 
contract research organisation). 
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 Measurement of isotopic concentration by AMS relies upon the analyte 
chromatographic peak being free from contaminating 14C-labelled compounds which 
may occur, for example, if a 14C-labelled metabolite co-elutes with parent drug.  Unlike 
mass spectrometry, AMS has no ability to discriminate on the basis of the mass of the 
analyte and so the purity of the 14C-labelled analyte peak relies solely upon resolution 
by chromatography.  
 
A thorough investigation of the peak purity could include use of a second 
chromatographic separation system such as two-dimensional chromatography using 
two different separation modalities (eg. normal versus reversed-phase) (Simpson et 
al., 2010), but this is a very time consuming approach and therefore not practical on a 
routine basis.  In the case of a microtracer study, where the unchanged parent drug is 
the target analyte, a less robust but more routine approach is to use LC-MS for analysis 
of a time-window across the analyte peak to provide assurance of purity (Bryant et al., 
1996).  Given the very low dose administered intravenously, LC-MS may not be 
sufficiently sensitive to detect contaminating metabolites arising from this route of 
administration.  The oral dose is typically >100-fold higher however and so with the 
assumption that the same metabolite is formed by this route of administration, then 
LC-MS should be able to detect it. 
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 3.7. Commentary paper 6 
 
Denton, C. L., E. Minthorn, S. W. Carson, G. C. Young, L. E. Richards- Peterson, J. 
Botbyl, C. Han, R. A. Morrison, S. C. Blackman and D. Ouellet (2013). "Concomitant oral 
and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with 
BRAF V600 mutation-positive solid tumors." J Clin Pharmacol 53(9): 955-961. 
 
3.7.1. Objectives 
 
1) To determine the intravenous pharmacokinetics and absolute bioavailability of 
oral dose administration of the NCE, dabrafenib, using the novel clinical 
microtracer approach in B-Raf positive oncology patients. 
 
2) To determine the number of subjects required to generate the appropriate 
data and to show the advantage in design flexibility which allowed patients to 
quickly be moved onto much needed therapy for their cancer treatment. 
 
3.7.2. Clinical study design 
 
Intravenous pharmacokinetics (CL, V and t1/2) of dabrafenib (50 µg; 7.4 kBq) and 
absolute bioavailability following oral (150 mg) dosing was defined in oncology 
patients using the microtracer design, as outlined in Figure 22. Provision of this 
information improves the understanding of the drug ADME-PK.  This is important as it 
allows judgements to be made about the likelihood of inter-patient variability in 
bioavailability and, combined with data from other studies such as the human ADME, 
the extent of first pass metabolism can be assessed (see section 3.4.3). 
 
A separate human ADME study with 14C-dabrafenib was conducted in parallel (Bershas 
et al., 2013) to the microtracer study.  The emergent metabolism data was used in the 
development of the chromatographic separation method for the LC+AMS assay of 
plasma (to ensure integrity of parent isolation from metabolites for quantification 
following intravenous administration). 
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Figure 22.  Schematic of clinical study design 6. 
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Design: 
4 Patients with B-RAF mutation-positive solid tumours; 
 
Single 15 minute intravenous infusion dose of 50 µg 
14C-dabrafenib (7.4 kBq) concomitant to a single oral dose of 
150 mg dabrafenib  
o [Intravenous infusion started at 1.75 hours after 
oral dose to coincide with oral dose tmax] 
Samples : 
• Blood (for plasma) for parent drug from oral 
and intravenous doses 
       [& RDM from intravenous dose] 
Main data outputs: 
• Parent drug concentrations in plasma from oral dose (by LC-MS) 
 
• Total radioactivity in plasma from intravenous dose (by direct AMS) 
 
• Parent drug concentrations from the intravenous dose (by LC+AMS) 
 
o Derivation of pharmacokinetic parameters of dabrafenib in plasma including 
absolute bioavailability from the oral dose relative to the intravenous dose 
o Comparison of predictions of human intravenous PK with clinical data 
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 3.7.3. Clinical study data output and impact  
 
The mean (n=4 patients) absolute bioavailability of dabrafenib was determined as 
being high at 94.5%.  This high absolute bioavailability for dabrafenib reflects the low 
degree of variability in systemic exposure observed following oral administration 
(bioavailability range* of 79.3 to 106%).  Indeed, when absolute bioavailability is used 
as a decision making criterion for drugs in development, a minimal desired 
bioavailability limit is often set at around 20% (GSK developability criteria) in an 
attempt to minimise such variability across subjects.  Low bioavailability is not just a 
cause for concern as a potential source of patient-to-patient variability per se, but is 
also an inefficient delivery of the active moiety to the systemic target site. 
 
Dabrafenib is a substrate of the efflux transporter P-glycoprotein (P-gp) (data on file at 
GSK), which is located in tissues including the intestinal epithelium and has the 
potential to limit absorption through the GI tract (Yang and Liu, 2016).  However, 
dabrafenib also demonstrates a high permeability across epithelial monolayers 
(1.48 x 10-5 cm/s in an in vitro assessment in MDR1-MDCKII cell monolayers at GSK).  
The high permeability is postulated to negate potential efflux of dabrafenib at the gut 
wall and it is known that efflux by P-gp may sometimes have only minimal impact upon 
drug absorption (Wu and Benet, 2005), (Dufek et al., 2013).  The high permeability of 
dabrafenib supports the propensity for it to achieve high bioavailability following oral 
administration. 
 
The comparison of systemic exposure to parent drug versus that for RDM following 
intravenous administration of 14C-dabrafenib in this study and following oral 
administration of 14C-dabrafenib in the human ADME study (Bershas et al., 2013) 
showed that unchanged dabrafenib represented a very similar proportion of the total 
radioactive drug-related material in plasma (about 10%) by both routes of 
administration.  This is consistent with dabrafenib undergoing limited first pass 
metabolism (as demonstrated by the similar proportion of parent drug circulating from 
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* SD cannot be calculated due to GSK restrictions of access to the full data set. 
both dose routes), yet extensive metabolism (about 90% by both routes) in the 
systemic circulation. 
 
Dosing intervals are based upon the half-life of elimination of the drug (t1/2) as this 
parameter defines the time to reach steady state exposure (related to the number of 
repeated dose administrations).  Although dosing intervals are often fixed in relation 
to t1/2 alone, the half-life is itself a function of CL and V (Equation 13). 
 
  𝒕𝟏/𝟐 =  𝟎.𝟔𝟗𝟑 𝑽𝑪𝑳      (Equation 13) 
 
Clearance is dependent upon blood flow and as such it is affected by, for example, 
disease state, hepatic and renal function, age and drug interactions.  Changes of 
clearance can therefore have marked effects on the safety profile of the drug.  This 
understanding of the fundamental pharmacokinetic parameters of the drug can help 
with avoidance of future safety issues and can guide dosing regimens.  
The plasma clearance for dabrafenib was low at 12.0 L/h, being only about 30% of liver 
blood flow (blood to plasma ratio was about 0.5), which along with the high absolute 
bioavailability suggested low hepatic extraction and low first pass metabolism of 
dabrafenib.  This is consistent with the understanding of metabolism of dabrafenib 
from the microtracer and human ADME studies.  Dabrafenib had low volume of 
distribution (45.5 L) and although the clearance was also low there was a resulting 
short terminal half-life for dabrafenib after intravenous administration (2.6 h). 
 
The elimination half-life of dabrafenib was longer than anticipated from pre-FTIH 
predictions, particularly following oral administration, which showed flip-flop kinetics 
with a prolonged absorption phase after oral administration.  The term flip-flop is used 
to describe the pharmacokinetic phenomenon where the absorption rate is longer 
than the elimination half-life (that following oral administration, at 4.8 hours, was 
nearly two-fold greater than following intravenous administration) and has been 
observed for many drugs (Garrison et al., 2015).  This absorption rate limited, longer 
elimination half-life and protracted decline in concentrations of dabrafenib in plasma 
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from oral administration was seen as advantageous in providing a better chance for 
achieving efficacy with this drug. 
 
Dabrafenib has two known active metabolites (hydroxy-dabrafenib and 
desmethyl-dabrafenib) as shown in Figure 23 (and (Bershas et al., 2013)) both of which 
are B-raf kinase antagonists.  Concentrations of these metabolites in plasma (along 
with parent dabrafenib) have been measured in several clinical studies and constitute 
approximately 25% of the total pharmacological activity (data on file at GSK). 
 
Although this has not been done for the metabolites of dabrafenib, the microtracer 
approach enables PK of active metabolites to be studied.  Although 14C-labelled 
metabolite has to be synthesised, there is still no need for intravenous toxicology with 
a very low dose. If the parent drug is administered by the oral route and the 
metabolite is dosed by the intravenous route then the rate of metabolite formation 
and CL for the metabolite can be measured in the same way as for a prodrug (Annes et 
al., 2015). 
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Figure 23.  Biotransformation of dabrafenib to hydroxy-dabrafenib and desmethyl-dabrafenib. 
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 3.7.4. Technical considerations and reflections 
 
An LoQ that allowed definition of the intravenous PK of dabrafenib in plasma was 
achieved (1.86 pg dabrafenib/mL) and the assay was validated against outline criteria 
as described in the literature (Higton et al., 2012).  The assay was shown to be robust 
and this was demonstrated further post-analysis of study samples through an incurred 
sample re-analysis (ISR), where a proportion of the study samples were re-analysed 
and the results were found to be reproducible to the original results within criteria 
established apriori (repeat analysis results for more than two thirds of samples, within 
20% of original values).  At the time, there was little experience of carrying out such a 
robustness check using an LC+AMS assay approach, so it was re-assuring to observe 
that the assay applied could meet the limits of acceptable performance for this 
assessment.  It is now routine practice in our laboratory and for other AMS researchers 
involved in such clinical sample LC+AMS assay provision to carry out ISR ((Xu et al., 
2012) and personal communication with Xceleron Inc.). 
 
An additional advantage of the use of the 14C approach to the microtracer design (over 
and above 13C) is that an assessment can be made of total radioactivity to check on the 
validity of the LC+AMS data, i.e. notwithstanding analytical variability, the data 
provided by LC+AMS for parent drug cannot be higher than that provided for 
drug-related material by direct analysis by AMS (Young et al., 2014). 
 
It is also important to note that even at the time of writing this commentary, there are 
no regulatory guidelines that specifically embrace the bioanalytical LC+AMS assay 
approach and so it is beholden upon the practitioners (this author included) to apply 
defensible and appropriate quality scientific practice in the application of such 
methods. 
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 In the study detailed in Commentary paper 6, the LoQ for total radioactivity was 
considerably higher (due to less sample clean-up) than for the parent specific assay, at 
9.77 pg dabrafenib equivalents/mL.  Interestingly, although implied, there are no 
analytical method-focused regulatory guidelines whatsoever specifically for the 
analysis of total radioactivity in biological samples.  Best practices based on good 
science have been established at laboratories that conduct total radioactivity 
measurements, but nevertheless methods vary across laboratories. 
 
In contrast, there are bioanalytical regulatory guidelines that are applicable to the 
LC-MS assay (LoQ of 1 ng/mL) used in support of the considerably higher oral dose.  
This disparity in expectation of quality for these assay approaches (used to provide 
complementary data sets from the same clinical studies) has been the focus of AMS 
researchers in recent years (Young et al., 2014). 
 
The dabrafenib study showed that suitable data could be provided from a low number 
of subjects (n=4) through the concomitant dosing approach, with the assessment that 
this design inherently reduced data variability (Ma and Chowdhury, 2016).  
Additionally, the clinical pharmacokinetic data compared favourably with that from 
predictions made using allometric scaling from non-clinical studies, which gave further 
confidence in the data provided from this novel study design and application of AMS. 
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 3.8. Commentary paper 7 
 
Leonowens, C., C. Pendry, J. Bauman, G. C. Young, M. Ho, F. Henriquez, L. Fang, R. A. 
Morrison, K. Orford and D. Ouellet (2014). "Concomitant oral and intravenous 
pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours." Br J 
Clin Pharmacol 78(3): 524-532. 
 
3.8.1. Objectives 
 
1) To determine the absolute bioavailability of the NCE, trametinib, using the 
clinical microtracer approach in patients with metastatic cancer. 
 
2) To determine the number of subjects required to generate the appropriate 
data and to show the advantage in design flexibility which allowed patients to 
quickly be moved onto much needed therapy for their cancer treatment. 
 
3.8.2. Clinical study design 
 
Trametinib is a reversible and selective allosteric inhibitor of mitogen-activated protein 
kinase (MEK)1 and MEK2 activation and kinase activity.  The intravenous 
pharmacokinetics (CL, V and t1/2) of trametinib (5 µg; 7.4 kBq) and absolute 
bioavailability of oral (2 mg) dosing were defined in (n=4) oncology patients using the 
microtracer design. 
 
Prior clinical pharmacokinetic and tolerability data following oral administration to 
patients with advanced solid tumours (Infante et al., 2012) indicated that trametinib 
had an effective elimination half-life in plasma of 4 days.  The study also showed that a 
dose of 3 mg per day was poorly tolerated beyond the first cycle of treatment (up to 
21 days) and that the lower dose of 2 mg provided appropriate pharmacokinetics to 
meet efficacy requirements, indicating that trametinib has a narrow therapeutic index 
(Gilmartin et al., 2011). 
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 Based upon allometric scaling of pharmacokinetic data for trametinib in animals and 
the known systemic exposure data from oral administration to humans (GSK data on 
file), the likely systemic exposure from intravenous administration to humans was 
predicted.  The intravenous dose thus chosen (5 µg) was likely to be low enough to 
avoid any significant addition to the concentrations of trametinib in plasma from the 
oral dose (2 mg), resulting in a dose magnitude differential of 400-fold, as presented in 
Figure 24.  
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Figure 24.  Schematic of clinical study design 7. 
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Design: 
4 Patients with B-RAF mutation-positive solid tumours; 
 
Single 5 minute intravenous infusion dose of 5 µg 
14C-trametinib (7.4 kBq) concomitant to a single oral dose of 
2 mg trametinib  
 
o [Intravenous infusion started at 1.5 hours after oral 
dose to coincide with oral dose tmax] 
Samples : 
• Blood for plasma for parent drug from oral and 
intravenous doses [& RDM from intravenous dose] 
Main data outputs: 
• Parent drug concentrations in plasma from oral dose (by LC-MS) 
 
• Total radioactivity in plasma from intravenous dose (by direct AMS) 
 
• Parent drug concentrations from the intravenous dose (by LC+AMS) 
 
o Derivation of pharmacokinetic parameters of trametinib in plasma, 
including absolute bioavailability from the oral dose relative to the 
intravenous dose 
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 3.8.3. Clinical study data output and impact  
 
The study showed that trametinib had a low blood clearance of 0.94 L/h (only 1% of 
liver blood flow) and a very high volume of distribution (976 L).  The resulting 
elimination half-life for intravenous administration of trametinib was 10 days.   
 
In a separate human ADME study for trametinib (Ho et al., 2014) there was low mass 
balance 14C-recovery from patients following oral administration.  This can be 
explained by the intravenous data from this microtracer study as the observed 
elimination half-life of total radioactive drug-related material was 27 days, whereas 
the excreta collection period for the human ADME study was only 10 days. 
 
The mean (n=4) absolute bioavailability of trametinib at an oral dose of 2 mg was 
moderately high at 72.3% (range* of 45.7 to 92.8%), indicating limited likelihood for 
high inter-patient variability in systemic exposures following oral administration (see 
section 3.7.3).  The apparently narrow therapeutic index for trametinib therefore is 
less of a concern than otherwise would be the case, were it to demonstrate low 
bioavailability. 
 
This study indicated a relationship between the clinical PK of trametinib and 
bodyweight of the subjects, irrespective of route of administration (same variability 
and rank order across the subjects and dose routes).  The reasons for this relationship 
are likely related to the very high volume of distribution of trametinib, into deep tissue 
compartments, and indeed the intravenous PK profiles showing a rapid initial 
distribution phase followed by a protracted elimination phase support this slow 
elimination from tissues (see Figure 1 of Commentary paper 7).  Although it would 
appear that dosage adjustments may need to be considered based upon bodyweight, 
in fact analysis of data from wider clinical use has shown that factors including 
bodyweight do not have a clinically important effect on the exposure of trametinib 
(FDA, 2015).  Dosage adjustments are recommended however, based upon observed 
adverse effects following treatment with trametinib.  
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*  SD cannot be calculated due to GSK restrictions of access to the full data set. 
 3.8.4. Technical considerations and reflections 
 
From the purely technical standpoint, this study showed that high quality intravenous 
pharmacokinetic data could be provided from a total dose of only 5 µg (for a drug with 
a high volume of distribution), through the use of radiolabelled drug and an LC+AMS 
assay.  This clearly demonstrated that the sensitivity of the AMS for detection 
of 14C-labelled material is such that there can be considerable flexibility in microtracer 
study designs, which then allows intravenous doses much lower than often considered 
(usually 100 µg) to be used, if warranted. 
 
A low LoQ was achieved for the LC+AMS assay (1.1 pg trametinib/mL of plasma) and, 
as for the dabrafenib method, the assay was validated against outline criteria as 
described in the literature (Higton et al., 2012).  The LoQ for total radioactivity was, in 
this instance, lower than for the parent drug specific assay (at just 0.95 pg trametinib 
equivalents/mL).  The LoQ for the assay of dabrafenib by LC-MS, in support of the oral 
dose administration, was considerably higher (250 pg/mL). 
 
Also similarly to the dabrafenib microtracer study, this clinical study was carried out in 
parallel to the conduct of the human ADME study (conventional design, albeit in 
cancer patients rather than healthy subjects) (Ho et al., 2014).  The design for the 
microtracer study received input from FDA, who reviewed and endorsed the novel 
study design.  FDA did however recommend that the study be conducted in patients 
(due to perceived safety concerns) with the therapeutic oral dose of 2 mg, rather than 
at a lower dose of 1 mg in healthy subjects, as had been proposed initially.  Due to the 
efficiency of the (non-crossover) design, patients could quickly be entered into a 
rollover study, where they received the therapy after completion of this clinical 
pharmacology study; particularly of note as the design obviated the need for a lengthy 
washout period (likely in the region of 5 months), as would have been required for a 
traditional cross-over design arising from the long elimination half-life for 
trametinib-related material.  Such a lengthy washout period would potentially
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 exacerbate any temporal effects between the two dosing sessions, thereby providing 
inaccurate data (see section 3.6), particularly so in the case of such cancer patients 
with rapidly declining health. 
 
Interestingly, the human ADME study for trametinib used the highest possible 
radioactive dose as allowed by the dosimetry calculations (2.9 MBq; tracer of the same 
specific activity as used in the microtracer study).  The reason the authors cited for 
taking this approach included the fact that although they were aware that AMS was 
being used in human ADME studies, the data turnaround time would not readily allow 
discharge of the patients from the study based upon adequate (≥ 90%) mass 
balance 14C-recovery.  This is a reasonable assessment and one of the ongoing 
limitations of AMS, which could be addressed through use of improvements such as 
the gas interface approach (section 1.4). 
 
The dabrafenib and trametinib microtracer studies each only used four subjects.  The 
data obtained showed that there was no need for a larger number of subjects in such 
studies to provide definition of the intravenous pharmacokinetics.  At least 12 subjects 
are often deemed necessary for traditional cross-over design absolute bioavailability 
studies (Xu et al., 2015)*, (Ghim et al., 2016)* often because of variability arising from 
temporal effects.  For medicines being developed to treat patients with very limited 
lifespan projection (as was the case for both dabrafenib and trametinib), such 
reductions in the size and length of the clinical studies assists in overall drug 
development timelines and delivery of the medicine to those that need it most. 
 
In the case of trametinib the microtracer and human ADME studies were conducted in 
parallel but as separate studies, but this does raise the intriguing possibility of 
combining the studies.  This would not only save time and resources but could provide 
data within a single cohort of subjects.  This is certainly possible with a variety of 
options around the study design (for example, see section 4.1).  There has been at 
least one example of a study (Schwab et al., 2013) where a 13C microtracer was 
included as a concomitant intravenous dose along with 14C-labelled drug administered 
by the oral route in a double tracer design in a late stage human ADME study.
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*  As can be seen from the dates of these references, such studies are still being conducted, so 
there is yet scope for further adoption of the more efficient and scientifically superior microtracer 
approach. 
This seems a very efficient approach where a human ADME study is planned and 
absolute bioavailability information is required to meet the expectation of regulatory 
authorities, but has not yet been provided via another clinical study. 
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 4. Future perspectives 
 
4.1. Combination design: Human ADME and Microtracer 
 
The human ADME study is a regulatory requirement for the development of new drugs 
and although there is no specific requirement for intravenous pharmacokinetics, the 
regulatory authorities are increasingly requesting these data in the form of an absolute 
bioavailability study (Arnold and Lacreta, 2012), (EMA, 2015).  The current practice is 
to conduct the human ADME study and absolute bioavailability study separately, in 
two different cohorts of volunteers.  There is an opportunity, however, to combine the 
two studies into one clinical study, i.e. that in certain circumstances the microtracer 
design can be combined with the human ADME design.  There is also an opportunity to 
further refine this approach, to address not only development of orally dosed drugs, 
but also drugs intended for administration by other extravascular routes, e.g. dermal 
or inhalation. 
 
Administration of 14C-labelled drug by inhalation of dry powder is fraught with 
logistical difficulties, for the following reasons: 
 
(1) Incorporation of the labeled material into a dry powder, matching the 
commercial product in terms of physiochemical properties is challenging (e.g. 
control of fine particle mass and respirable fraction are critical to reproducible 
delivery to the lung). 
 
(2) Delivery of the dose to the human subject (and reliable quantification of the 
exhaled dose) is challenging in terms of containment and contamination risks.  
As detailed earlier (see section 3.4.2), the standard practice for assessment of 
ADME in humans for inhaled therapies is through administration of 14C-labelled 
drug by surrogate routes, such as intravenous or oral administration. 
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 (3) Assessment of systemic bioavailability of drug from an administration by 
inhalation is usually conducted via a clinical study (see section 3.8.4) separate 
to the human ADME study. 
 
The use of AMS with intravenous administration of a 14C-microtracer makes it feasible 
to carry out such clinical investigations efficiently.  It is difficult to predict the systemic 
exposure anticipated from an intravenous dose, based upon clinical data following 
inhalation as there are so many unknowns eg. fraction of the dose delivered from the 
device, fraction deposited in the lung and swallowed, absorption through the lung and 
the gut.  It is therefore important to keep the intravenous dose as low as possible to 
minimise the risk of non-equivalent clearance through a marked difference in the 
concentrations of drug present in the systemic circulation.  This would be a higher risk 
if a traditional cross-over study design was used. 
 
A study combining inhalation and intravenous routes of administration (as well as oral 
administration) has been designed at GSK for an NCE, GSK961081*, which at the time 
of writing has just completed the clinical dosing phases. 
 
Data from such a study will provide an understanding of the route specific metabolism 
of GSK961081, i.e. the comparison of extent of metabolism and biotransformation 
pathways following intravenous versus oral administration will highlight the impact of 
first pass metabolism on the relative systemic exposures of GSK961081 and 
metabolites (see section 3.4.3 and (Lappin and Garner, 2005)).  It is important to 
understand these aspects for drugs under development as metabolites formed by first 
pass through the (gut wall and) liver may undergo biliary elimination, thereby reducing 
systemic exposure to unchanged parent drug and drug-related material.  These 
questions can be key because it is otherwise not possible to distinguish absorption 
from first pass effects in respect to limited bioavailability without the intravenous 
reference dose.  Assuming the drug target is systemic (as opposed, for example, to 
luminal gut wall) then limited bioavailability has a consequential reduction on 
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*  The study was designed by this author several years ago but was delayed for project 
development reasons – at that time this particular design had not been conducted previously. 
apparent efficacy and a knock-on effect on dose selection.  Equally, in the case of 
patients with hepatic impairment, changes in hepatic extraction can lead to safety 
implications through a change in the pharmacokinetic profile of the drug (Yu et al., 
2014). 
 
As discussed previously, mass balance recovery is a regulatory requirement for new 
medicines.  For an inhaled therapy the designs used are a compromise to the ideal 
assessment of administration of the labelled drug via inhalation, due to the practical 
limitations mentioned. 
 
Assessment of bioavailability for an inhaled molecule will provide knowledge of the 
relative contribution to systemic concentrations of the drug via absorption by the 
lungs and through the gastrointestinal tract.  This is key to understanding, for example, 
the impact on pharmacokinetic variability in patients with compromised ability to 
inhale the drug. 
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 4.1.1. Objectives 
 
The main objectives of the clinical study will be –  
 
(1)  To compare total radioactivity in plasma relative to parent GSK961081, 
following a single intravenous microtracer of 14C-GSK961081 (concomitant with 
an inhaled non-radiolabelled therapeutic dose) and a single oral therapeutic 
dose of 14C-GSK961081.  
 
(2)  To determine the recovery and relative excretion of radioactivity in urine and 
faeces following a single intravenous microtracer of 14C-GSK961081 
(concomitant with an inhaled non-radiolabelled therapeutic dose) and a single 
oral therapeutic dose of 14C-GSK961081. 
 
(3) To estimate the absolute bioavailability of GSK961081 following oral 
administration and by inhalation. 
 
The clinical study design as outlined in Figure 25 (www.clinicaltrials.gov reference 
#NCT02663089) incorporates the intravenous microtracer approach concomitant to an 
inhaled administration (at a supra-therapeutic dose) as one discrete phase of a human 
ADME study.  GSK961081 contains a dual pharmacophore, as shown in Figure 25, with 
both long-acting β2 adrenoceptor agonist activity (LABA) and long-acting anti-
muscarinic activity (LAMA) in preclinical studies and is being developed for the 
potential treatment of chronic obstructive pulmonary disease (COPD) (Bateman et al., 
2013).   The second phase of the study will be an oral administration of GSK961081 at 
a therapeutic equivalent dose, as a cross- over in the same subjects following a 
washout period (two weeks).   The objectives of the study will only be achieved 
through the use of multiple analytical techniques and approaches, including AMS as a 
critical technology, due to both the low 14C doses and the nature of the new chemical 
entity involved, which is anticipated to have very low bioavailability, probably because 
of low absorption, based upon existing data from animal studies (data on file at GSK). 
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GSK961081 is susceptible to hydrolysis across the amide moieties (see Figure 25) which 
would result in a significant proportion of the substructure being without the 14C-label.  
It is recognised that depending upon the outcome of the human ADME study, it is 
possible that another 14C-labelled form of GSK961081 may need to be prepared so that 
the fate of the erstwhile non-labelled metabolite sub-structure can be traced in 
subsequent studies. 
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14C-GSK961081* 
 
 
 
Figure 25.  Schematic of clinical study design 8 (Potential future publication). 
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Design: 
6 Healthy human subjects; cross-over – washout of 2 weeks 
minimum between the intravenous /inhaled (session 1) and oral 
dose (session 2) 
 
(1) Single 1 hour intravenous infusion dose of 4 µg 
14C-GSK961081 (6.22 kBq), concomitant to a single inhaled 
dose of 1200 µg GSK961081 
o [Inhaled dose administered 5 minutes after 
intravenous infusion start] 
 
(2) Single oral dose of 200 µg [14C]-GSK961081 (322 kBq) 
Samples : 
• Blood for plasma [for parent drug, RDM concentrations & 
metabolite profiling] 
 
• Faeces and urine [for mass balance and metabolite 
profiling] 
 
• Duodenal bile [for metabolite profiling] 
Main (Planned) data outputs: 
• Parent drug concentrations in plasma from inhaled and oral doses (by LC-MS) 
 
• Parent drug concentrations in plasma from intravenous dose (by LC+AMS) 
 
• Total radioactivity in plasma (by direct AMS) 
 
o Derivation of pharmacokinetic parameters of GSK961081 in plasma 
 
• Excretion mass balance (by direct AMS from intravenous dose; by LSC from 
oral dose) 
 
• Metabolite profiles (plasma, urine, faeces, bile; by LC+AMS and LC-MS) 
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 *  Regions of pharmacophores; to the left of the blue dashed line is the muscarinic antagonist “head” and to the right of the red dashed line is the β-agonist “head”. 
 4.1.2. Anticipated clinical study endpoints  
 
The total radioactivity measurements in the systemic circulation will likely be provided 
by analysis by AMS for both intravenous and oral routes, as the concentrations of RDM 
are anticipated to be too low for analysis by LSC. 
 
Mass balance 14C-recovery will be supported by AMS and LSC for intravenous and oral 
doses respectively due to the different magnitudes of planned radioactive doses by 
these routes (6.22 kBq by the intravenous route and 322 kBq by the oral route).  The 
pharmacokinetics of parent drug will be provided by an LC+AMS assay (following 
intravenous) and by an LC-MS assay (following inhalation and oral administration). 
 
The doses chosen for the study are partly based upon knowledge of the 
pharmacokinetics of the molecule, but also on the proven understanding of what can 
be achieved using AMS, as demonstrated through all of the author’s previous works. 
 
The intravenous dose will be only 4 µg of 14C-GSK961081 against a concomitant 
inhaled dose of 1200 µg.  The inhalation dose being used is based on prior clinical 
safety data (Norris and Ambery, 2014) and ease of detection of systemic 
concentrations of the drug by LC-MS.  The intravenous dose was chosen based upon 
experience that acceptable data should be obtained from this magnitude of dose of 
drug (and specific activity) (Leonowens et al., 2014) and upon predictions of systemic 
exposures from the prior clinical studies with GSK961081 (data not shown here). 
 
Following inhalation of drugs to humans, lung deposition is variable and it can be the 
case that up to ~80% of the dose will be swallowed and delivered to the 
gastrointestinal tract, rather than deposited in the lung (Thorsson et al., 1998), 
(Borgstrom et al., 2006), (Newman et al., 2003).  At this time, it appears likely that the 
therapeutic dose for GSK961081 will be around 300 µg by the inhaled route, so the 
oral dose of 200 µg was chosen based upon an approximation of the fraction of such a 
therapeutic dose which will be swallowed (rounded for convenience from 240 µg, 
particularly as this will allow material of the same specific activity to be used for the 
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intravenous and oral doses, thereby simplifying production and release of 
the 14C-labelled material). 
 
In this potentially groundbreaking clinical study we will also aim to generate samples 
that will be used to characterise the metabolite profile of GSK961081 in plasma, urine, 
faeces, and duodenal bile, to provide a comprehensive understanding of the 
disposition of GSK961081 in humans.  The assessment of biliary elimination, for 
example, of GSK961081 by AMS following concomitant administration by the 
intravenous and inhalation routes will only reflect that following intravenous 
administration, as only the dose following that route of administration is radiolabelled.  
Nevertheless, along with metabolite profiles from other matrices the information will 
provide insight into the routes of metabolism and excretion for drug-related material 
that reaches the systemic circulation.  Although these data will be obtained from a 
non-therapeutic route of administration, it will be representative of a portion of the 
inhaled dose that enters the systemic circulation and as such still provides valuable 
information.  This will be helpful in building up the overall picture of rates and routes 
of the ADME of GSK961081 in humans and the mechanisms of drug safety of 
GSK961081 in humans will be much better understood. 
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 5. Conclusions and Further Work 
 
In the last two decades, AMS has developed from being a little known niche 
technology, only used as a last resort in drug development, to a more mainstream 
analytical tool that facilitates flexible clinical study designs, providing deep insights into 
the pharmacokinetics and metabolic fate of new drugs. 
 
Development of the AMS technology and its application to a variety of clinical studies, 
through the author’s contribution, as evidenced by publications, has been presented in 
this commentary. 
 
The sensitivity of AMS for detection of 14C-labelled drugs and metabolites has enabled 
reduced exposure to ionising radiation for human ADME studies, providing safety and 
ethical improvements that have negated the need for enabling animal studies with less 
complex dosing formulations and removal of the requirement for dosimetry.  AMS has 
enabled analysis of samples to later timepoints for more complete definition of 
distribution, metabolism and elimination and microtracer designs.  Microtracer studies 
provide important pharmacokinetic data such as plasma clearance, volume of 
distribution, absolute bioavailability, definition of extent of first pass metabolism and 
in combination with bile sample collection, a more thorough understanding of routes 
of metabolism.  A further advance is the use of repeat pulse doses of 14C-labelled drug 
to allow assessments of ADME-PK under chronic dosing conditions. 
 
Prior to the advent of AMS, some of these experiments required significant resources 
and supporting safety data, often to such an extent that the studies were not feasible.   
Some were most probably impossible to perform, such as an intravenous/oral 
cross-over study with long washout period in patients with progressive disease (for 
example, as would have been the case for trametinib).  Drug development therefore 
progressed in the absence of data, such as clearance, volume of distribution or 
absolute bioavailability, which then led to either prolonged development paths or in 
some cases, increased risk of clinical failure. 
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Furthermore, the ability to collect duodenal bile from humans non-invasively (the 
Entero-testTM method), along with the ability to administer 14C more readily by the 
intravenous route, provided a paradigm shift in the investigation of metabolite burden 
for drugs under development. 
 
The main contributions to the knowledge highlighted in the commentary were: (1) the 
first human ADME study supported by AMS for a new drug in development; (2) the 
investigation of the ADME of a drug with protracted retention in humans; (3) the 
human ADME of a high dose (thus low specific radioactivity) antibiotic drug; (4) the 
human ADME for a low dose inhaled respiratory drug by the surrogate route of oral 
administration; (5) the use of a complex repeat dose ADME study to investigate 
potential metabolising enzyme autoinduction for a drug in development, and (6) the 
use of the microtracer approach in oncology patients for two new chemical entities. 
 
A novel combination human ADME and microtracer design was also presented (see 
section 4) for a drug in development for treatment of COPD, which drew upon the 
experiences gained through application of AMS over many of the preceding published 
(and other) works of this author.  There has been a recent publication following a 
similar design, albeit for an oral administration cancer therapy drug, rather than an 
inhaled therapy (Morcos et al., 2016). 
 
Each of the published studies provided scientific advancement of the technical 
application of AMS and development of best practices, as well as study design 
improvements. 
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 This author’s view, which seems to be shared by at least some experts in the field of 
DMPK science (Smith, 2011), (Arnold and Lacreta, 2012), (Lappin, 2016), is that AMS is 
as yet underutilised and that future years may well demonstrate increased impact of 
the technology as a more routine tool in drug development.  This author hopes to see 
the ongoing and future development of AMS, to enable a new era of broadened 
applications (see section 3.6), as well as information rich clinical study designs earlier 
in drug development.  It would be particularly exciting to see the scientific advance of 
intravenous drug administration as the normal practice, rather than the exception, to 
provide deep insight into the research of many new medicines. 
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Appendices  
Appendix 1 : Contribution to the field of AMS research 
 
i) Works published – Listing of all peer-reviewed literature 
papers/articles/poster abstracts/book chapters published with Graeme C. 
Young as lead author or co-author: [Commentary papers included] 
 
AMS Technique related: 
 
1. Garner R.C., Barker J., Flavell C., Garner J.V., Whattam M., Young G.C., Cussans N., 
Jezequel S. & Leong D. 2000. A validation study comparing accelerator MS and liquid 
scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal 
extracts., J Pharm Biomed Anal, 24: 197-209.  
 
2. Young GC., Corless S., Felgate CC. & Colthup PV. 2008. Comparison of a 250 kV single-
stage accelerator mass spectrometer with a 5 MV tandem accelerator mass 
spectrometer – fitness for purpose in Bioanalysis, Rapid Commun Mass Spectrom, 22: 
4035-4042.  
 
3. Garofolo F., Dumont I., Martinez S., Lowes S., Woolf E., van Amsterdam P., Bansal S., 
Barra A.C.G., Bauer R., Booth B.P., Carrasco-Triguero M., DeSilva B., Dunn J., Gallicano 
K., Gouty D., Ho S., Hucker R., Jemal M., Katoril N., Le Blaye O., Lee J., Li W., Michael S., 
Nehls C., Nicholson R., Ormsby E., Tang D., Viswanathan CT., Weiner R. & Young G. 
2011. 2011 White Paper on Recent Issues in Bioanalysis and Regulatory Findings from 
Audits and Inspections, Bioanalysis, 3(18): 2081-2096.  
 
4. Lappin G., Seymour M., Young G., Higton D. & Hill H.M. 2011. AMS method validation 
for quantitation in pharmacokinetic studies with concomitant extravascular and 
intravenous administration, Bioanalysis, 3(4): 393-405. 
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5. Lappin G., Seymour M., Young G., Higton D. & Hill H.M. 2011. An AMS method to 
determine analyte recovery from pharmacokinetic studies with concomitant 
extravascular and intravenous administration, Bioanalysis, 3(4): 407-410. 
 
6. Dijksman J., Timmerman P., Abbott R., Barroso B., Kloeppel M.B., Companjen A., 
Golob M., Gordon B., Herling C., Knutsson M., Luedtke S., Rasmussen B. B., Stoellner 
D., Vieser E., Young G. & van Amsterdam P. 2012. Less is more; defining modern 
Bioanalysis.  Conference report 4th EBF Open meeting., Bioanalysis, 4 (6): 633-642. 
 
7. Higton D., Young G., Timmerman P., Abbott R., Knutsson M. & Svensson L. 2012. EBF 
recommendation: scientific validation of quantification by accelerator mass 
spectrometry, Bioanalysis, 4(22), 2669-2679. 
 
8. Daniel R., Mores M., Kitchen R., Sundquist M., Hauser T., Stodola M., Tannenbaum S., 
Skipper P., Liberman R., Young G., Corless S. & Tucker M. 2013. Development of a 
commercial automated laser gas interface (ALGI) for AMS, Nuclear Instruments and 
Methods in Physics Research Section B: Beam Interactions with Materials and Atoms, 
294: 291-295. 
 
9. Young GC., Seymour M., Dueker S., Timmerman P., Arjomand A. & Nozawa K. 2014. 
New Frontiers—Accelerator Mass Spectrometry (AMS): Recommendation for Best 
Practices and Harmonisation from Global Bioanalysis Consortium Harmonization 
Team, Aaps j, 16: 357-359. 
 
10. Timmerman P., Blech S., White S., Green M., Delatour C., McDougall S., Mannens G., 
Smeraglia J., Williams S. & Young G. 2016. Best practices for metabolite quantification 
in drug development: updated recommendation from the European Bioanalysis 
Forum, Bioanalysis, 8(12):1297-1305. 
 
Clinical microdose study related: 
 
11. Cahn A., Hodgson S., Wilson R., Robertson J., Watson J., Beerahee M., Hughes SC., 
Young G., Graves R., Hall D. & van Marle S. 2013. Safety, tolerability, 
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pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 
4 antagonist, in healthy male subjects: results from an open-label and from a 
randomised study, BMC Pharmacol Toxicol, 14: 14. 
 
12. Mahar K.M., Sehon C., Tai G., Haws T., Howe D., Nagilla R., Young G. & Danoff T. 2012. 
Comparison of a GSK706769 Microdose CYP3A4 Drug-Drug Interaction Study With a 
Previous Pharmacological Dose Study, 2012 American College of Clinical 
Pharmacology, Annual Meeting September 23rd-25th, San Diego, California, abstract 
#1393294. 
 
Clinical intravenous microtracer study related: 
 
13. Denton C.L., Minthorn E., Carson S.W., Young G.C., Richards-Peterson L., Botbyl J., 
Han C., Morrison R.A., Blackman S.C. & Ouellet D. 2013. Concomitant Oral and 
Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF 
V600 Mutation-Positive Solid Tumours, J Clin Pharmacol, 53(9): 955-961. 
[Commentary paper 6] 
 
14. Leonowens C., Pendry C., Bauman J., Young G.C., Ho M., Henriquez F., Fang L., 
Morrison R.A., Orford K. & Ouellet D. 2014. Concomitant oral and microdose 
intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid 
tumours, Br J Clin Pharmacol, 78(3), 524-532. [Commentary paper 7] 
 
Human ADME study related: 
 
15. Young G., Ellis W., Ayrton J., Hussey E. & Adamkiewicz B. 2001. Accelerator mass 
spectrometry (AMS) : recent experience of its use in a clinical study and the potential 
future of the technique, Xenobiotica, 31 (8/9): 619-632. [Commentary paper 1] 
 
16. Harrell A.W., Siederer S.K., Bal J., Patel N.H., Young G.C., Felgate C.C., Pearce S.J., 
Roberts A.D., Beaumont C., Emmons A.J., Pereira A.I. & Kempsford R.D. 2013. 
Metabolism and disposition of vilanterol, a long-acting β2-adrenoreceptor agonist for 
inhalation use in humans, Drug Metab Dispos, 41: 89-100. [Commentary paper 4] 
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 17. Bowers GD., Tenero D., Patel P., Huynh P., Sigafoos J., O’Mara K., Young GC., Dumont 
E., Cunningham E., Kurtinecz M., Stump P., Conde JJ., Chism JP., Reese MJ., Yueh YL. & 
Tomayko JF. 2013. Disposition and metabolism of GSK2251052 in humans: a novel 
boron-containing antibiotic, Drug Metab and Dipos, 41: 1070-1081. [Commentary 
paper 3] 
 
18. Dave M., Nash M., Young GC., Ellens H., Magee MH., Roberts A., Taylor M.A., 
Greenhill R. & Boyle G.W. 2014. Disposition and Metabolism of Darapladib, a 
Lipoprotein-Associated Phospholipase A2 Inhibitor in Humans, Drug Metab Dipos, 42: 
415-430. [Commentary paper 5] 
 
Assorted AMS related: 
 
19. Young G., Ayrton J. & Pateman T., A Handbook of Bioanalysis and Drug Metabolism 
(Chapter 11 : Isotope Drug Studies in Man), CRC Press, 2004. 
 
20. Young G.C. & Ellis W.J. 2007. AMS in drug development at GSK, Nuclear Instruments 
and Methods in Physics Research Section B: Beam Interactions with Materials and 
Atoms, 259: 752-757. [Commentary paper 2] 
 
21. In the search for new drugs, diverging roads for microdosing, Chemical & Engineering 
News, 91 (3), (2013) 9-13. Part contribution by Young G. 
 
22. Beaumont C., Young GC, Cavalier T. & Young M. 2014. Human absorption, distribution, 
metabolism and excretion properties of drug molecules: a plethora of approaches, Br. 
J.Clin. Pharmacol., 78(6): 1185-1200. 
 
23. Young GC. & Seymour M. 2015. Application of 14C-Accelerator MS in pharmaceutical 
development, Bioanalysis, 7(5): 513-517. 
 
24. Pene Dumitrescu T., Santos L., Hughes S.C., Pereira A., Young G., Hussey E., Charlton 
P., Baptiste-Brown S., Stuart J.S., Vincent V., Van Marle S.P. & Schmith V.D. 2016. A 
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first in human study to characterize the pharmacokinetics following administration 
of 14C-Umeclidinium (UMEC) to the axilla and palm of healthy male subjects, Clin. 
Transl. Sci., 9, 183-191. 
 
25. Bloomer J., Beaumont C., Dear G.J., North S. & Young G. 2016. Metabolite Safety in 
Drug Development (Chapter 12: Case Studies : GlaxosmithKline), John Wiley & Sons, 
Ed. Iverson S. & Smith D.A.  
 
Additional papers utilising AMS (GSK Sponsored) where Graeme C. Young provided 
support/input: 
 
26. Hoffmann, E., Wald, J., Lavu, S., Roberts, J., Beaumont, C., Haddad, J., Elliott, P., 
Westphal, C. & Jacobson, E. 2013. Pharmacokinetics and tolerability of SRT2104, a 
first-in-class small molecule activator of SIRT1, after single and repeated oral 
administration in man, Br J Clin Pharmacol, 75(1):186-196. 
 
27. Daley-Yates P., Norris, V., Ambery, C. & Preece, A. 2012. Early Clinical Evaluation 
of a Novel 5-Lipoxygenase Activating Protein (FLAP) Inhibitor (GSK2190915A). 
Pharmacokinetics, Bioavailability and Dose Form Selection: Influence of Age, 
Food, Drug Interactions and Regional Absorption (LPA112071, LPA112362, 
LPA114604); Proceedings of the British Pharmacological Society, BPS Winter 
Meeting 2012. 
 
28. Hughes, S. C., Shardlow, P. C., Hollis, F. J., Scott, R. J., Motivaras, D. S., Allen, A. & 
Rousell, V. M. 2008. Metabolism and Disposition of Fluticasone Furoate, an Enhanced-
Affinity Glucocorticoid, in Humans, Drug Metab Dispos, 36: 2337-2344. 
 
29. Mamaril-Fishman, D., Zhu, J., Lin, M., Felgate, C., Jones, L., Stump, P., Pierre, E., 
Bowen, C., Naderer, O., Dumont, E., Patel, P., Gorycki, P. D., Wen, B., Chen, L. & Deng, 
Y. 2014. Investigation of Metabolism and Disposition of GSK1322322, a PDF Inhibitor, 
in Healthy Humans Using Entero-Test® For Biliary Sampling, Drug Metab Dipos, 42: 
1314-1325. 
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30. Negash, K., Andonian, C., Felgate, C., Chen, C., Goljer, I., Squillaci, B., Nguyen, D., 
Pirhalla, J., Lev, M., Schubert, E., Tiffany, C., Hossain, M. & Ho, M. Nov 2015. The 
metabolism and disposition of GSK2140944 in healthy human subjects, Xenobiotica, 
19: 1-20. 
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 Clinical Trials.gov reference for the Human ADME study for GSK961081: 
https://www.clinicaltrials.gov/ct2/show/NCT02663089?term=GSK961081&rank=1 
 
ii) Invited speaker at International Conferences: 
• Drug Development Conference, London, 2005 
• AMS-10 (Accelerator Mass Spectrometry) Conference, San Francisco, USA, 2005 
• CosMos (Conference on Small Molecules), San Diego, USA, 2006 
• WW Pharmaceutical Congress, Philadelphia, USA, 2007 
• NJDMD (New Jersey Drug Metabolism Discussion Group), New Jersey, USA, 
2006 
• AMS Webinars (Xceleron sponsored), 2008 and 2014 
• APA Conference, Boston, USA, 2008 
• DMDG (Drug Metabolism Discussion Group), Cambridge, UK, 2009 
• ASMS (American Society of Mass Spectrometry), Philadelphia, USA, 2009 – 
Plenary presenter and AMS Session Chair 
• AMS in Pharmaceutical Research, Lawrence Livermore Nat. Lab, California, USA, 
2009 
• CPSA , Philadelphia, 2010 
• CVG (Calibration and Validation Group) conference, Montreal, Canada 2011 
• EBF (European Bioanalysis Forum) Conference, Barcelona, Spain, 2011 
• BioAMS Workshop, National Institute of Health, Maryland, USA, 2011 
• BABE (Bioavailability and Bioequivalence), Beijing China, 2013  
• EBF (European Bioanalysis Forum) Workshop [co-organiser and session co-
chair], Brussels, Belgium, 2015 
• ECDC (Exploratory Clinical Development Conference) London, 2007, 2010, 2012 
and 2015 
 
iii) Reviewer of multiple journal articles related to the field of biomedical 14C 
AMS, including articles published in Clinical Pharmacokinetics, Journal of 
Clinical Pharmacology, and Bioanalysis 
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iv) Chair of cross-Pharmaceutical company and Contract Research 
Organisation AMS user group since 2013 
 
v) Academic collaborations : 
• Active collaboration with ETH University, Zurich in development of AMS 
instrumentation and sample introduction 
• Historical collaboration on AMS interface development with 
Massachusetts Institute of Technology from ~2008-2012 
• Historical collaboration with Lawrence Livermore National Laboratory 
(Dept. of Energy), USA since 1997. 
 
Impact of published works demonstrated through h-Index = 11 ; i10-index = 12 ; 359 
citations based on 19 publications in Google scholar, as of March 2016. 
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Appendix 2: Reproduced principal papers 
See reproduced papers at the end of this commentary.  Permissions granted as 
detailed below - 
 
Paper 1) Reprinted with permission from Young, G., W. Ellis, J. Ayrton, E. Hussey and B. 
Adamkiewicz (2001). "Accelerator mass spectrometry (AMS): recent experience of its 
use in a clinical study and the potential future of the technique." Xenobiotica 31(8-9): 
619-632, Elsevier, Copyright 2001. 
 
Paper 2) Reprinted with permission from Young, G. and W. J. Ellis (2007). "AMS in Drug 
Development at GSK." Nuclear Instruments and Methods in Physics Research B 259: 
752-757, Copyright 2001. 
 
Paper 3) Reprinted with permission of the American Society for Pharmacology and 
Experimental Therapeutics.  All rights reserved.  Bowers, G. D., D. Tenero, P. Patel, P. 
Huynh, J. Sigafoos, K. O'Mara, G. C.Young, E. Dumont, E. Cunningham, M. Kurtinecz, P. 
Stump, J. J. Conde, J. P. Chism, M. J. Reese, Y. L. Yueh and J. F. Tomayko (2013). 
"Disposition and metabolism of GSK2251052 in humans: a novel boron-containing 
antibiotic." Drug Metab Dispos 41(5): 1070-1081 
 
Paper 4) Reprinted with permission of the American Society for Pharmacology and 
Experimental Therapeutics.  All rights reserved.  Harrell, A. W., S. K. Siederer, J. Bal, N. 
H. Patel, G. C. Young, C. C. Felgate, S. J. Pearce, A. D. Roberts, C. Beaumont, A. J. 
Emmons, A. I. Pereira and R. D. Kempsford (2013). "Metabolism and disposition of 
vilanterol, a long-acting β(2)-adrenoceptor agonist for inhalation use in humans." Drug 
Metab Dispos 41(1): 89-100 
 
Paper 5) Reprinted with permission of the American Society for Pharmacology and 
Experimental Therapeutics.  All rights reserved.  Dave, M., M. Nash, G. C. Young, H. 
Ellens, M. H. Magee, A. D. Roberts, M. A. Taylor, R. W. Greenhill and G. W. Boyle 
(2014). "Disposition and metabolism of darapladib, a lipoprotein-associated 
phospholipase A2 inhibitor, in humans." Drug Metab Dispos 42(3): 415-430 
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Paper 6) Reproduced with permission from Denton, C. L., E. Minthorn, S. W. Carson, G. 
C. Young, L. E. Richards- Peterson, J. Botbyl, C. Han, R. A. Morrison, S. C. Blackman and 
D. Ouellet (2013). "Concomitant oral and intravenous pharmacokinetics of dabrafenib, 
a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors." J Clin 
Pharmacol 53(9): 955-961.  John Wiley and Sons, Copyright 2013. 
 
7) Reproduced with permission from Leonowens, C., C. Pendry, J. Bauman, G. C. 
Young, M. Ho, F. Henriquez, L. Fang, R. A. Morrison, K. Orford and D. Ouellet (2014). 
"Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in 
subjects with solid tumours." Br J Clin Pharmacol 78(3): 524-532.  John Wiley and Sons, 
Copyright 2014. 
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Appendix 3: Letters from lead authors and GSK Position on common 
practice for authorship………………………………………………………………… 
 
Provided here are letters from lead authors of the papers upon which this 
Commentary is based, confirming Graeme C. Young’s input to these papers and the 
work which they report.  These are for Commentary papers 3, 4, 5, 6 and 7; Graeme C. 
Young was lead author on papers 1 and 2. 
Also included in this Appendix is a document to provide background to the GSK 
common practice for contribution to works and authorship of papers. 
 
See reproduced documents at the end of this commentary. 
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Appendix 4: Summary of Contributions by Graeme C. Young to each of 
the Commentary papers………………………………………………………………………… 
 
Commentary 
paper no. 
Title Contribution by  
Graeme. C. Young 
1 Accelerator mass 
spectrometry (AMS): recent 
experience of its use in a 
clinical study and the 
potential future of the 
technique. 
• Lead Author 
• Designed and conducted 
experiments 
• Provided analytical input to 
both studies described 
2 AMS in Drug Development at 
GSK. 
• Lead Author 
• Designed and conducted 
experiments 
• Champion of establishment 
of AMS Capability at GSK 
• Provided analytical input to 
all studies described 
3 Disposition and metabolism 
of GSK2251052 in humans: a 
novel boron-containing 
antibiotic. 
• Participated in research 
design 
• Provided analytical input 
and resources 
• Contributing author 
4 Concomitant oral and 
intravenous pharmacokinetics 
of dabrafenib, a BRAF 
inhibitor, in patients with 
BRAF V600 mutation-positive 
solid tumors. 
• Contributing author  
• Participated in research 
design 
• Provided analytical input 
and resources 
5 Metabolism and disposition of 
vilanterol, a long-acting β(2)-
adrenoceptor agonist for 
• Contributing author  
• Participated in research 
design 
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inhalation use in humans. • Provided analytical input 
and resources 
• Performed data analysis 
6 Disposition and metabolism 
of darapladib, a lipoprotein-
associated phospholipase A2 
inhibitor, in humans. 
• Contributing author  
• Participated in research 
design 
• Provided analytical input 
and resources 
• Performed data analysis 
7 Concomitant oral and 
intravenous pharmacokinetics 
of trametinib, a MEK 
inhibitor, in subjects with 
solid tumours. 
• Contributing author 
Participated in research 
design 
• Provided analytical input 
and resources 
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Appendix 5: Summary of author’s main contributions to the knowledge 
 
Advancement Detail Outcome 
Scientific and strategic:   
LC+AMS principle This author first proposed 
the principle in 1999, 
when all discussion was of 
use of AMS for total 14C 
and metabolite profiling 
applications – credit is due 
to others as outlined in 
this commentary for 
developing the microdose 
and microtracer 
principles, as well as 
specific methodologies 
such as the use of an IS 
LC+AMS term coined by 
this author to highlight the 
offline nature of this 
procedure (i.e. distinct 
from a hyphenated 
approach such as LC-MS); 
the approach is now in 
common use within the 
AMS field of research 
Harmonisation of 
validation procedures 
for LC+AMS assays 
This author has lead the 
drive to harmonise 
validation principles for 
clinical LC+AMS assays 
through chair of the inter-
company AMS service 
provider team 
Ongoing collaborations 
and publication to support 
agreed principles [(Young 
et al., 2014)] 
Entero-test human bile 
collection 
GSK laboratory first to use 
AMS in human ADME 
studies and IV microtracer 
studies for analysis of drug 
and metabolites in human 
bile 
Extremely insightful data 
produced on multiple 
studies showing routes of 
metabolism not detected 
by analysis of other 
matrices – now an 
approach being taken up 
across the industry 
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Novel design of 
combination human 
ADME with IV 
microtracer for an 
inhaled therapy 
This author has proposed 
a design which 
incorporates the 
intravenous 14C 
microtracer approach 
concomitant to an inhaled 
administration (at a supra-
therapeutic dose) as one 
discrete phase of a human 
ADME study ; the second 
phase is a cross-over oral 
administration of 14C-
labelled drug  
The study is in progress 
and the intent is to publish 
the outcomes 
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Technical 
advancements: 
  
Carbon carrier selection Switched from Liquid 
Paraffin to Aq. Sodium 
benzoate 
Provided advantages of 
reduction in data errors 
due to improved ease of 
handling (pipette volume 
increased from 1 µL of a 
highly viscous material, to 
20 µL of aqueous) 
Established frequency of 
chromatographic 
fractionation (12 
seconds for HPLC flow 
rate of 1mL/min.) – 
others performed 30 
second or even 1 minute 
fractions resulting in 
very poor resolution 
Developed a good 
understanding of 
fractionation frequency 
which lead to some 
standardisation 
Experiments are designed 
to maximise efficiency and 
scientific integrity – 
further increased 
frequency used where 
necessary to achieve 
chromatographic peak 
resolution (eg. as frequent 
as 3 second fractions) 
Sensitivity enhancement 
through analyte 
chromatographic peak 
concentration  
On occasions when AMS 
has been inadequately 
sensitive for metabolite 
profiles to be generated, 
our group has made up to 
4 injections of the same 
extract onto the LC 
So long as the 
chromatographic 
retention times are 
consistent enough to 
allow multiple repeat 
injections onto the LC, 
sensitivity improvements 
can be achieved 
Multiple predose clinical 
samples 
Championed the idea of 
taking three predose 
blood samples at 
screening visit, Day-1 and 
Day of dosing 
Establishes good 
understanding of control 
endogenous 
background 14C, in-study 
sample contamination 
and/or previous 14C 
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exposure of subjects 
Re-use of non-
disposable Y-piece for 
cryogenic transfer step 
of graphitisation 
Common practice to use 
only disposable items 
during graphitisation due 
to concerns around cross-
contamination 
Investigations in our 
laboratory showed that no 
sample to sample 
carryover occurred with a 
metal re-usable Y-piece 
[improved science and 
resource saving] 
Developed a novel 
approach to definition of 
the LoQ for radioactive 
drug related material in 
plasma (rather than eg. 
2x background as is the 
accepted empirical 
based practice for LSC) 
Defined LoQ based upon 
specific activity of the 
drug and statistical 
assessment of variability 
in endogenous 
background as well as 
measurement of 14C above 
that level 
LoQ can now be stated 
within limits of statistical 
confidence (as - x pg drug 
equivalents/mL) 
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Appendix 6: Ethics statement
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Appendix 7: AMS Instrumentation evolution 
 
The technical evolution of AMS instrumentation has been significant over recent 
decades (Synal, 2013).  Instruments have been simplified, the size and complexity 
reduced whilst their sensitivity has been honed to be applications driven.  A good 
example being the GSK SSAMS which was designed and built specifically for analysis of 
carbon, whereas larger instruments can analyse a range of elemental isotopes by 
virtue of their higher energies.  These developments have created wide spread use of 
AMS in modern research fields (Kutschera, 2013).  Today, commercial high-
performance instruments are in use in more than 100 AMS facilities around the world, 
although those conducting biomedical work are but a few. 
 
Voltages less than about 2.5 MV were thought to be inadequate for dissociating 
molecular background interferences until the ETH Zurich group demonstrated low 
background carbon AMS with 0.5 MV tandem accelerators (Synal et al., 2000).  This 
breakthrough lead to the development of the 250 kV SSAMS (Klody et al., 2005).  The 
first carbon-dedicated AMS system was built and tested around 2003.  The injector 
included two 40-sample ion sources, electrostatic and magnetic analysis, and fast 
sequential injection.  The gas stripper, analysing magnet, electrostatic analyzer, and 
detector were on an open air 250 kV deck – this was a shift from the previous tandem 
higher voltage accelerators which had to have their charging chain housed in a tank 
which contained an inert gas (SF6) to avoid discharge to the surrounding air.  Both 12C 
and 13C currents were measured on the deck after the stripper, and a solid silicon 
barrier detector was used for 14C ion incident counting.  Injected 12C and mass 13 (13C 
and 12CH) currents were also measured.  Initial test results showed precision 
for 14C/12C ratios and backgrounds for unprocessed graphite that were compatible with 
the requirements of 14C enriched biological sample measurements.  From this 
prototype the 250 kV SSAMS emerged as a commercially viable instrument and the 
second of these (in the world) was brought into service at GSK. 
 
The GSK instrument had additional safety features added to it, through our group’s 
input, over and above the initial manufacturer design.  These included automatic 
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earthing of the instrument upon any of the instrument cage doors being opened and x-
ray detection system with automatic instrument shut-down in the event of spurious x-
ray radiation being generated. 
 
Since installation in 2005, there have also been instrumental improvements such as 
changes to the caesium focussing to improve beam currents, leading to reduction in 
analytical run times.  Our instrument has also been enabled to accept gas, with 
successful production of ion beams from 5% CO2 with helium as a carrier gas (based on 
research by ETH University, Zurich, Switzerland (Wacker et al., 2013). 
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Appendix 8: Toward a unique AMS capability 
 
All of this work (Commentary papers 1 and 2 in particular) demonstrated the 
confidence building approach i.e. start with non-clinical, lower “value” studies (animal 
and in vitro studies) and progress towards clinical work.  GSK lead the field amongst 
pharmaceutical companies, with the author as the leading scientist behind these 
activities.  The power of the technique over a range of applications (sensitivity and 
benefit of selectivity for 14C-labelled drug analysis) was shown; both AMS targeted and 
what was termed “hybrid” study support.  These latter designs are those where the 
intent was to use AMS in combination with, or as an adjunct to, other techniques such 
as LSC, for analysis of samples containing higher amounts of radiocarbon.  The 
scientific impact of my work led to a justification for GSK to invest in the AMS 
technology.  This resulted in the 250 kV SSAMS instrument being purchased and a 
complete in-house capability being established at a cost of >£3M, with an assortment 
of specialised sample preparation and instrument laboratory suites, in addition to 
allocation of dedicated staff, at the GSK, UK Ware site in 2004*.  This was particularly 
important as no other pharmaceutical company had made such a move and in fact this 
is still the case, even though this author is aware that our laboratory are envied by our 
industry peers for our capability and experience level in that regard. 
 
 
180 
 
*  GSK initially established two AMS facilities, one in the UK (at the Ware site) with the other being 
at a site in Philadelphia USA, but long term, without a local champion the capability in the USA was 
not deemed to be providing enough business value and thus was dissolved. 
 
Appendix 9: Schematics of the GSK SSAMS and next generation AMS systems 
 
 
 
The Micadas and µCadas systems were designed and built by ETH, Zurich (Swiss Federal Institute of Technology)*.   
The key breakthrough in the size reduction to the prototype µCadas system is the change from argon to helium as the stripper gas 
providing improved stripping efficiency (similar at 50kV for helium as at 250kV for argon) thus less acceleration is required, which allows 
the low energy magnet to be directly coupled to the molecular dissociator.
3m
2.3m
Micadas (in grey)
µCadas (in red)
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*  Reproduced here by kind permission of ETH, Zurich.  Schematic of the GSK SSAMS reproduced by kind permission of National Electrostatics Corp., WI, USA. 
Appendix 10: Risks Associated with Ionising Radiations 
 
ICRP (International Commission on Radiological Protection) 1992 
 
Risk category Corresponding 
effective dose 
range (adults) 
(mSv) 
Level of risk Level of societal 
benefit  
Category I 
(~10-6 or less) 
<0.1 Trivial Minor 
Category II 
IIa (~10-5 or less) 
IIb (~10-4 or less) 
 
0.1 - 1 
1 – 10 
Minor to 
intermediate 
Intermediate to 
moderate 
Category III 
(~10-3 or greater) 
>10 Moderate Substantial 
 
182 
 
Accelerator mass spectrometry (AMS): recent
experience of its use in a clinical study and the
potential future of the technique
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1. The technique of accelerator mass spectrometry (AMS) is outlined.
2. The use of AMS in an initial validation study in animals is outlined. As part of the
validation of the technique, samples from the animal study were analysed by both liquid
scintillation counting (LSC) and, following dilution, by AMS. The results were similar.
3. The use of AMS in support of a clinical study is described. Six healthy male human
volunteers were administered 2.7mg [14C]-GI1817771 (121Bq; 3.3nCi) to produce an
exposure to ionizing radiation of 0.06 mSv. Mass balance in recovery of administered
radioactivity was achieved and information about the presence of systemically circulating
metabolites was gained.
4. The future potential of the technique of AMS is discussed.
Introduction
Accelerator mass spectrometry (AMS) is a very sensitive nuclear physics
technique that was developed in America in the 1970s. AMS has been used in
the analysis of a wide range of elements and its use in measurement of radiocarbon
(14C) to date archaeological samples ®rst appeared in the literature in the 1970s
(Bennett et al. 1977, Nelson et al. 1977). AMS uses a tandem van de Graa
accelerator to provide the potential energy to strip o the valency electrons of
negatively ionized atoms generating positively charged atoms which can then be
separated using conventional mass spectrometry. In the measurement of carbon by
AMS, the three isotopic species (i.e. 14C, 13C and 12C) are separated from each
other by virtue of their di erent energies and mass:charge ratios. AMS can
measure radiocarbon concentrations down to 1000th of the natural levels found
in living tissue and so is signi®cantly more sensitive than liquid scintillation
counting (LSC). AMS as an analytical tool for the pharmaceutical industry has
been recently comprehensively reviewed (Garner 2000).
The use of AMS for analysis of drugs and metabolites in biological matrices has
been discussed extensively but little original data have been presented in the
literature. A short communication demonstrating the feasibility of using AMS for
drug measurement has been published by Kaye et al. (1997), as has a paper
detailing validation of AMS for analysis of radiocarbon in biomedical samples
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(Garner et al. 2000). The AMS instrument upon which the validation work
described here was conducted (®gure 1) was established at The Centre for
Biomedical Accelerator Mass Spectrometry (CBAMS) Ltd, Sand Hutton, York,
UK. CBAMS Ltd became operational in 1998 and was cofunded by a group of
companies from the pharmaceutical industry, along with the UK Ministry of
Agriculture, Fisheries and Food (Central Science Laboratory) and the University
of York.
This paper describes the approach taken by Glaxo Wellcome Research and
Development Ltd to using the technology of AMS in the establishment of a facility
to handle samples that contain very low quantities of radiocarbon-labelled material
in the initial validation study. The paper also describes a clinical study where only
121 Bq (3.3 nCi) of a radioactively labelled new chemical entity ([14C]-GI181771)
was administered by the oral route to six healthy male human volunteers to allow
estimation of a mass balance of radioactivity of this compound in humans. The
paper also discusses the potential future of AMS in biomedical applications and its
possible impact on drug discovery and development in the pharmaceutical
industry.
Validation of AMS
As part of the validation of the technique of AMS in biomedical use, we
conducted an excretion balance and pharmacokinetics study in male Han Wistar
rats using [14C]-¯uticasone propionate ((6¬,11­ ,16¬,17 ­ )-6,9-di¯uoro-
11-hydroxy-16-methyl-3-oxo-17-propionyloxy-androsta-1,4-diene-17-carbothioic
acid S-¯uoromethyl ester), a chemical in general medical use for the treatment of
asthma and rhinitis. Samples of blood plasma and excreta from the animal study
were analysed by both LSC and, following dilution, by AMS, and the results were
similar. The design of the study and the results obtained are covered in detail in
Garner et al. (2000). It should be noted that when handling the low levels of
620 G. Young et al.
Figure 1. Accelerator mass spectrometry instrument at The Centre for Biomedical Accelerator Mass
Spectrometry Ltd, Sand Hutton, York. Reproduced by kind permission of CBAMS Ltd.
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radiocarbon in the samples destined for analysis by AMS, we took the approach of
designating a laboratory area and isolating it, and the equipment in it, from all
other routine use of radiocarbon. The laboratory was established in a temporary
building with access limited to only those persons who were directly involved in
work with very low level radiocarbon samples. `Clean laboratory’ techniques were
employed to minimize further the risk of contamination from other laboratory
areas. Following successful validation of the technique of AMS, from the per-
spective of Glaxo Wellcome Research and Development Ltd, using the animal
study samples, the laboratory was equipped with everything that was required to
support the preliminary preparation of samples generated from a small clinical
study. This included sample storage, weighing, aliquotting, homogenizing, and
separation of drugs and metabolites by high-performance liquid chromatography
(HPLC) with fraction collection.
Clinical study
Materials and methods
Radiolabelled compound. GI181771 was radiolabelled by introduction of a 14C-atom in a position
considered unlikely to be vulnerable to metabolic transformation. The radiolabelled drug (0.04mg) was
diluted with unlabelled GI181771 (3.03 g) to produce a speci®c activity of 44.65 Bqmg 1 .
Radiochemical purity of the labelled drug prior to dilution with unlabelled drug was 99.8%. The
chemical purity after dilution was 95.2% with the main impurities being water and solvents. The
radiochemical purity was not rechecked following dilution due to the limitations in assaying drug of
such low speci®c activity.
Stable isotopic-labelled compound. [2H5]-GI181771 was prepared for use as the internal standard for
the assay of GI181771 by liquid chromatography with tandem mass spectrometric
detection (LC-MS-MS). The chemical purity of this material was >98.6%.
Dosing and sample collection. Six healthy male human volunteers, aged 23±37 years, received a single
oral administration of [14C]-GI181771 at a mean dosage of 2.7mg in 5ml polyethylene glycol 400
(Union Carbide Corporation, Danbury, CT, USA). The radiolabel dose was to be limited to that which
would produce an exposure to ionizing radiation of 1mSv, which is equivalent to a 4-h exposure to
environmental (background) ionizing radiation in the UK. This exposure is the limit below which one is
exempt from requiring a certi®cate from the UK Department of Health’s Administration of
Radiolabelled Substance Advisory Committee (ARSAC) to administer radioactive medicinal products
to human subjects in the UK. The initial target exposure was 0.9 mSv, but the actual average dose of
radioactivity administered to each volunteer was 121Bq, producing exposure to ionizing radiation of
0.06 mSv. The exposure was as low as this for speci®c logistical reasons, which arose during the planning
of the study. The total dose to be administered was reduced from the initially planned target dose and
the radioactive dose was also reduced as a direct result. It was felt that reliable data could still be
obtained at this dose level and the study therefore proceeded using this lower total dose and resultant
lowered exposure to ionizing radiation.
Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24h
post-dose. After clotting and centrifugation, serum was transferred to polypropylene tubes and stored
frozen. Urine samples were collected predose and 0±12, 12±24, 24±48, 48±72, 72±96 and 96±120 h post-
dose. The weights of the collections were recorded and an aliquot stored frozen prior to analysis.
Faeces samples were collected predose and 0±24, 24±48, 48±72, 72±96 and 96±120 h post-dose. The
complete collections were stored frozen and weights recorded prior to processing.
Preliminary preparation of faeces and urine samples for analysis by AMS. Faeces samples (50±180 g)
were weighed into 1.2 litre containers and smaller samples were weighed into 250ml containers. Making
the assumption that 1 g faeces was equivalent to 1ml, 3 vols methanol (Rathburn Chemicals Ltd,
Walkerburn, UK) were added. Samples were thawed and homogenized with an Ultra Turrax
homogenizer (Brunner Scienti®c, Unit 4C, Hunmanby, Filey, UK). The ®nal homogenate appeared
as a ®ne suspension and was stored at nominally 208C. Triplicate aliquots were taken from di erent
positions from within each resuspended homogenate and were sent on solid CO2 to CBAMS Ltd for
Accelerator mass spectrometry 621
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analysis by AMS. Aliquots of neat urine were sent frozen to CBAMSLtd for analysis by AMS. Samples
sent to CBAMS Ltd could be shipped as non-radioactive due to the extremely low quantities of
radioactivity involved, with consequent reductions in costs and bureaucracy.
Serum sample preparation for analysis by AMS. Aliquots of neat serum were sent frozen to CBAMS
Ltd for analysis by AMS. This method of analysis could not distinguish the very low concentrations of
radioactivity present in serum samples against the endogenous background radiocarbon in neat serum,
following administration of such a low dose of radioactivity. In an attempt to enhance the signal:noise
ratio, the endogenous radioactivity was reduced through removal of carbon-containing components by
precipitation of the serum proteins prior to analysis by AMS. An aliquot (400 ml) of each serum sample
was vortex mixed with 800 ml acetonitrile (Rathburn Chemicals). After centrifugation, 800 ml of the
supernatant was subjected to analysis by AMS.
Faecal extracts: preparation prior to fraction collection from HPLC. To allow metabolic pro®ling of the
faecal samples, selected predose and 0±48 h post-dose collection faecal samples were extracted and
fractionated by HPLC. Twenty millilitres of faecal homogenate from each sample was centrifuged. The
supernatant was concentrated by evaporation under a stream of nitrogen to a ®nal volume of up to 2ml.
Aliquots (100 ml) were fractionated by HPLC and sent to CBAMS Ltd for analysis by AMS.
Radiochromatograms were constructed from the radioactivity in the HPLC fractions.
Serum samples: preparation prior to fraction collection from HPLC. Serum samples from all of the
volunteers were combined into three pools according to times after dosing: 0.5±0.75, 2±6 and 12±16 h.
This resulted in up to 2ml serum from each of these times after dosing. Acetonitrile (2 vols) was added
to each pooled sample, vortex mixed and centrifuged. The supernatant was concentrated by evaporation
under a stream of nitrogen and reconstituted in ¹150ml 50% acetonitrile:50% water (v/v). An aliquot
(100ml) was fractionated by HPLC and the fractions were sent to CBAMS Ltd for analysis by AMS.
HPLC fractionation and metabolite pro®ling of serum and faeces. Aliquots (100 ml) of the sample of
precipitated serum or faecal extract were injected on to an Inertsil ODS2 (250£ 4.6mm i.d., 5 mm)
analytical column, which was eluted under gradient conditions at a ¯ow rate of 1mlmin 1. Mobile
phase A was 0.1% v/v tri¯uoroacetic acid in water and mobile phase B was 95% v/v acetonitrile in 0.1%
v/v tri¯uoroacetic acid (in water). The mobile phase was a linear gradient which started at 75% A and
25% B, rose to 90% B over 30min and returned to the starting conditions from 35 to 45min. The column
was maintained at ambient temperature. The column eluant was monitored at A240 nm. Column eluant
fractions were collected every 0.5min from 5 to 6 and from 14 to 30min from the point of injection. A
Gilson 233XL Fraction Collector (Anachem Ltd, Luton, UK) run from Unipoint v.1.02 was used. On
this system, the retention times of GI181771 and its glucuronide were 24 and 20min respectively. The
column eluant fractions (0.5ml) were sent frozen on solid carbon dioxide to CBAMSLtd for analysis by
AMS.
Graphitization of samples. In order to measure the 14C content of samples by AMS, the carbon in the
samples was ®rst converted to graphite by CBAMS Ltd using a previously described method (Vogel
1992). In instances where insu cient carbon was present in samples, a carrier of known total carbon
content and carbon isotope inventory was added. The carrier used was usually tributyrin (1,2,3-
tributyrylglycerol; Sigma-Aldrich Company Ltd, Poole, UK).
C,H,N analysis. C,H,N analysis was conducted by CBAMS Ltd on samples submitted for analysis by
AMS. It was necessary to determine the percentage carbon content in samples so as to assess the volume
or mass of sample required to produce good graphite. The determination also allowed conversion of the
results output from the AMS which was expressed as 14Cmg 1 carbon, to total 14C sample 1 and
subsequent conversion to the commonly used units of radioactivity of dpmml 1 or dpmg 1 of sample.
Following sample addition and any pretreatment, tin capsules were closed and pressed prior to being
loaded into the autosampler of a C,H,N analyser (Model NA2100 Brew Analyser, Elemental
MicroAnalysis, Okehampton, UK). Pretreatment of samples included drying for faecal homogenates
and serum extracts. A calibration curve of urea standards was prepared and used to determine the
carbon content of each sample.
AMS analysis. The AMS sample wheel into which graphite-containing cathodes were placed was
inserted into the ion source of the AMS instrument (5MV 15SDH-2 Pelletron AMS system, National
Electrostatics Corporation, Middleton, WI, USA) at CBAMS Ltd. The multicathode negative-ion
source generated a caesium (Cs‡) ion beam that was accelerated onto each cathode’s graphite surface in
sequence. The resulting negative carbon ion beam contained 12C , 13C and 14C and other ions such
as 16O .
622 G. Young et al.
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The carbon ion beam was pre-accelerated, passed through a spherical electrostatic analyser and then
progressed towards the injection magnet. Output of 12C was typically 1±100 mA. The magnet was set to
inject 12C (150ms), 13C (600ms) and 14C (0.1 s) ions sequentially normally at 68 keV; one combined
measurement on each isotope in turn corresponded to one cycle. The carbon ion beam was accelerated
towards the positive centre terminal of the tandem Pelletron accelerator through an Einzel lens. The
terminal voltage used for this series of analyses was 4.5MV with a particle energy of ¹22.5MeV. At the
central terminal, electrons were stripped from the carbon atom in an argon gas collision cell to yield
positively charged carbon ions (12;13;14C‡1 to ‡6). C4‡ ions were selected for measurement as these were
the most abundant at this energy. These ions were accelerated away from the positive centre terminal
and onwards towards the electrostatic quadrupole triplet and analysing magnet.
Immediately past the post-analysing magnet, 12C4‡ and 13C4‡ ions were measured as an ion current
in o set Faraday cups. 14C4‡ ions were passed down the high-energy beam line, through an electrostatic
quadrupole doublet and a cylindrical electrostatic analyser. From here, the ions entered a gas ionization
detector where they were collected on anodes (four in total), which measured the energy loss and total
energy of each ion. Other interfering non-14C4‡ ions were generally prevented from entering the gas
ionization detector by the combinations of electrostatic analysers, magnets, slits and charge state
separation. Vacuum pressures of¹10 9 Torr were maintained in the beam line and 10 6 Torr in the ion
source. Ion transmission through the instrument was between 30 and 60%. A schematic of the AMS
instrument is shown in ®gure 2.
Overall time for analysis of each sample ranged from 5 to 25min consisting of a burn-in time of 600
cycles (60.4 s) and sample analysis of 500±5000 cycles (50.4±504 s) conducted a minimum of three times
and a maximum of ®ve. In some instances long analysis times were required to improve the precision of
the data from samples, such as serum and serum extracts, containing very low levels of radiocarbon
against relatively high background levels.
For each AMS run, in addition to cathodes containing graphitized samples, cathodes containing
standards or blanks were included as quality controls.
Determination of limit of quanti®cation (LOQ) for analysis by AMS. The determination of LOQ for
analysis of samples by AMS was of critical importance since all samples analysed contained measurable
background levels of radiocarbon. Analysis of controls and predose samples were used to estimate
contributions of radiocarbon present as background and those values were subtracted from the post-
dose sample results.
Limits of quanti®cation for faeces, urine, neat serum and precipitated serum extracts were calculated
from an analysis of variance of the predose controls and ®nal sample equivalents measured in dpmml 1
or dpmg 1. Two background readings per subject, deemed to be ideally required in the calculation of
the LOQ, were not available from samples generated from within the study. Samples from collections at
the latest time points after dosing were thus considered to be equivalent to predose samples since by this
time the levels of radioactivity appeared to have returned to predose levels. Limits of quanti®cation, for
Accelerator mass spectrometry 623
Figure 2. Schematic of the AMS instrument at The Centre for Biomedical Accelerator Mass
Spectrometry Ltd. Reproduced by kind permission of CBAMS Ltd.
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reconstructed radiochromatograms of HPLC fractions, were calculated from an analysis of variance of
the fractions contained within de®ned background regions of interest, in dpm per fraction.
Two components of variance were calculated: between-subject variation and within-subject
variation of predose or backgrounds. Both contributed to the overall variation associated with the
LOQ.
A pooled estimated standard deviation was calculated as follows:
¼ ˆ

¼2B ‡ ¼2W
q
where ¼2B is between-subject predose or background variance and ¼
2
W is within-subject predose or
background variance.
Using criteria as de®ned in a Glaxo Wellcome Research and Development internal policy (based
on the International Committee on Harmonization (ICH) Guideline 1996) for faeces, urine, neat
serum and precipitated serum extracts, the limit of quanti®cation was estimated using the increase
above the background readings (5¼), whereas for HPLC fractions the LOQ determination included
background (5¼‡mean background). 95% con®dence intervals of the limits of quanti®cation were also
calculated.
LC-MS-MS analysis of GI181771. Serum samples were prepared for analysis of GI181771 by liquid-
chromatography with detection by tandem mass spectrometry. Calibration standards of GI181771 in
human serum were prepared over the range 10±1500 pgml 1. All samples and standards were extracted
by solid-phase extraction on a Packard MultiPROBE (Packard Instruments Ltd, Pangbourne, UK).
Extraction was carried out on 50mg Varian C18 Microlute II SPE 96-well blocks (Porvair Sciences
Ltd, Shepperton, UK). The blocks were conditioned with 0.5ml methanol (Fisher Scienti®c,
Loughborough, UK) followed by 0.5ml water. The blocks were loaded with 0.5ml serum sample
diluted with 0.5ml internal standard in 20% v/v formic acid (BDH, Poole, UK) in water. The blocks
were washed sequentially with 0.5ml 20% v/v formic acid then 0.5ml 40% v/v methanol and analytes of
interest were then eluted with 0.75ml ethyl acetate (Fisher Scienti®c). The resulting extracts were
evaporated to dryness under a stream of nitrogen (nominally heated to 378C) and reconstituted in 100 ml
50% mobile phase A, 50% mobile phase B prior to analysis by liquid chromatography with tandem mass
spectrometric detection (LC-MS-MS). Mobile phase A was 0.01% formic acid in water:methanol (95:5
v/v) and mobile phase B was 0.01% formic acid in water:methanol (5:95 v/v). The serum extracts (50 ml)
were analysed on a Perkin-Elmer Sciex API 3000 mass spectrometer (PE Sciex, Foster City, CA, USA)
using TurboIonspray and selected ion monitoring. The liquid chromatography was performed on a
50£ 2mm i.d. Phenomenex Luna C18 (5mm) analytical column maintained at nominally 408C. The
mobile phase was a linear gradient which started at 50% A and 50% B, rose to 80% B over 2min and
returned to the starting conditions from 3.1 to 4 min, at a ¯ow rate of 0.8mlmin 1. The transitions
of the protonated molecule, m/z 606.2 to the fragment ion m/z 443.2 were monitored for GI181771 and
transitions of the protonated molecule m/z 611.2 to the fragment ion m/z 448.2 were monitored for the
internal standard [2H5]-GI181771. The method was validated and quality control acceptance criteria
were applied to indicate inaccuracy of the method to be <15%.
Results
The recovery of the administered radioactive dose in faeces from six human
volunteers over 5 days was determined (table 1). The majority of the dose, >59%,
was excreted in the faeces within the ®rst 48h. After 5 days, a mean total of 92% of
the dose could be accounted for in the faeces. Volunteer 64 was excluded from
calculation of the means, as collection of faeces from this volunteer was incom-
plete. In four of the six volunteers an average of 99.2% of the dose was recovered in
the faeces over the 5 days.
The recovery of the administered dose in urine from six human volunteers over
the ®rst 2 days after dose was determined (table 2). All of the values obtained from
urine were below LOQ. The mean total recovery in urine was <6.5% of the dose
with LOQ from 0.4 to 3.8% of the dose.
Animal studies with oral administration of [14C]-GI181771 showed low
recovery of radiocarbon in the urine suggesting that <1% of the dose was absorbed
(unpublished data). The results in this study in human volunteers indicate
similarly low urinary excretion of drug-related material in humans.
624 G. Young et al.
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Selected neat serum samples, those taken at 0.25±1.5 h after dose, were initially
analysed directly by AMS to produce the concentration of radioactivity in ng
GI181771 equivalents ml 1 serum. All concentrations were below the LOQ of
161 ngml 1. The parent drug concentrations at these times, analysed separately,
rose to ¹3ngml 1. The sensitivity of the AMS assay was such that the serum
concentration of radiocarbon could not be compared with the concentrations of
parent drug.
Subsequent sample preparation of all serum samples by protein precipitation
resulted in an improvement in sensitivity. Removal of the majority of carbon in the
sample, not derived from the dose, lead to reduction in the background signal.
Results were corrected for recovery of radioactivity based on the known extraction
e ciency of 105% for [14C]-GI181771 by serum protein precipitation (table 3).
This, >100% recovery, indicated exclusion of [14C]-GI181771 from the pellet such
that the apparent concentration measured in the extract supernatant was an
overestimate of the true concentration. The assumption was made that the
[14C]-GI181771 related compounds found in the serum of dosed volunteers
showed the same degree of recovery as [14C]-GI181771. The radiocarbon present
in the precipitated serum samples was expressed as ng equivalents of
GI181771ml 1 after subtraction of the predose levels. Over 25% of the values
were quanti®able, above the LOQ of¹2.0 ngml 1, with concentrations ranging up
to ¹9.6 ngml 1.
An example of the data produced, for serum samples, by AMS and LC-MS-
MS is shown in ®gure 3. The pro®les obtained indicated that the concentration of
radioactive drug-related material in serum was generally higher than concentra-
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Table 1. Percent recovery of radiocarbon in faeces following oral administration of 2.7mg [14C]-
GI181771 to male human volunteers.
Volunteer number
Collection Mean SD
time (h) 61 62 63 64* 65 66 (%) (%)
0±24 11.8 <6.3 34.0 38.0 43.6 103.0 38.5 38.9
24±48 85.5 44.6 53.4 n.s. 15.8 <6.0 39.9 28.7
48±72 1.2 19.2 8.7 n.s. 40.3 <5.8 13.9 16.1
72±96 <6.2 <7.4 <2.2 n.s. <3.3 <6.4 <5.1 n.c.
96±120 n.s. <3.7 <3.2 <5.2 <6.4 <8.9 <5.5 n.c.
Total 98.5 63.8 96.1 38*.0 99.7 103.0 92.2 16.1
*Excluded from mean calculations.
n.c., Not calculated: n.s., no sample.
Table 2. Percent recovery of radiocarbon in urine following oral administration of 2.7mg [14C]-
GI181771 to male human volunteers.
Volunteer number
Collection Mean
time (h) 61 62 63 64 65 66 (%)
0±12 <3.7 <2.4 <1.4 <0.4 <1.3 <3.7 <2.2
12±24 <2.7 <1.5 <1.4 <1.8 <1.4 <0.9 <1.6
24±48 <3.8 <3.2 <2.5 <1.6 <2.0 <3.1 <2.7
Total <10.2 <7.1 <5.3 <3.8 <4.7 <7.7 <6.5
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tions of parent drug. Although there were insu cient data to allow for a calcula-
tion of areas under the serum radiocarbon:time curve (AUC), peak concentrations
of radiocarbon may be up to eight times higher than concentrations of parent drug
in serum of some volunteers.
A trend was evident indicating that the volunteers with the higher radiocarbon
concentrations in serum also had the higher concentrations of GI181771 in serum,
adding con®dence that the data obtained were reliable.
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Table 3. Concentration of radioactivity in extracted serum (ng equivalents GI181771ml 1) following
oral administration of 2.7mg [14C]-GI181771 to male human volunteers.
Volunteer number
Sampling
time (h) 61 62 63 64 65 66
Predose 0.00 0.00 0.00 0.00 0.00 0.00
0.25 <2.02 <2.02 2.66 <2.02 <2.02 <2.02
0.5 2.97 3.95 9.55 <2.02 2.46 <2.02
0.75 3.28 3.97 8.92 <2.02 2.49 3.97
1 <2.02 2.48 7.45 <2.02 <2.02 4.71
1.5 <2.02 <2.02 5.38 <2.02 <2.02 2.66
2 n.s. <2.02 3.56 <2.02 <2.02 <2.02
2.5 <2.02 n.s. 4.31 <2.02 <2.02 <2.02
3 <2.02 <2.02 3.79 <2.02 <2.02 <2.02
4 2.63 <2.02 3.25 n.s. <2.02 <2.02
6 3.85 <2.02 <2.02 <2.02 <2.02 <2.02
8 <2.02 <2.02 <2.02 <2.02 <2.02 <2.02
12 n.s. <2.02 <2.02 <2.02 <2.02 <2.02
16 <2.02 <2.02 <2.02 <2.02 <2.02 <2.02
24 <2.02 <2.02 <2.02 <2.02 <2.02 <2.02
n.s., No sample.
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Figure 3. Example pro®les of concentrations of radiocarbon due to drug-related material and
concentrations of GI181771 in serum from a human male volunteer (no. 63) following oral
administration of 2.7mg [14C]-GI181771.
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A reconstructed radiochromatogram of HPLC separations from 10 times
concentrated faecal extracts taken from selected predose and post-dose samples
is shown in ®gure 4. The data indicated that radioactive material was mostly
excreted as unchanged GI181771. The same data are shown in ®gure 5 using a
magni®ed scale and they indicate that ¹0.2% of the radioactivity detected
corresponds to the retention time of a metabolite previously observed in rat
bile and in human, rat and cynomolgus monkey liver preparations (unpublished
data).
Results from the HPLC fractions of the pooled serum extracts showed no
obvious drug-related components. These samples had been converted to graphite
using an alternative to tributyrin as the carbon carrier, which contained minimal
radiocarbon, to reduce the background and improve sensitivity. Unfortunately due
to the very low levels of radioactivity (<0.01 dpmml 1) in all of the fractions,
background regions of interest could not be de®ned, the limit of quanti®cation
could not be calculated and therefore drug-related radioactivity could not be
determined.
In this study, LOQ for a range of biological matrices was determined (table 4).
Serum samples obtained from a placebo group dosed orally with the same dosing
vehicle (polyethylene glycol 400) as used in this study were processed to help
further the determination of LOQ. To provide an estimate of LOQ for each of the
matrices, a statistical analysis of background results was carried out. HPLC
fractions coinciding with background regions of interest were treated as back-
ground measurements for this purpose. LOQ was taken as ®ve times the pooled
standard deviation of the background measurements derived from the between-
and within-subject variations. LOQ was ¹0.9 dpmg 1 for faeces homogenate,
0.4dpmml 1 for neat serum and 0.2 dpmml 1 for neat urine. LOQ were lower for
Accelerator mass spectrometry 627
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Figure 4. Reconstructed radiochromatograms (AMS results) of HPLC separation of faecal extracts
from volunteers 63 and 66 following oral administration of 2.7mg [14C]-GI181771.
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Figure 5. Reconstructed radiochromatograms (AMS results) of HPLC separation of faecal extracts
from volunteers 63 and 66 following oral administration of 2.7mg [14C]-GI181771 ± expanded
y-axis.
Table 4. Limits of quanti®cation for analysis of biomedical matrices by AMS, as de®ned for this study
within Glaxo Wellcome Research and Development Ltd.
dpmg 1, dpmml 1 or dpm/fraction
LOQ
after predose of
background has
been subtracted
Volume or Mean 95%
Sample weight predose or SD CV Best Con®dence
description Matrix analysed background (pooled) (%) estimate interval
Faeces homogenate 50mg 0.60 0.17 28 0.86 0.58±1.97
Urine neat 200 ml 0.11 0.040 36 0.20 0.15±0.37
Serum neat 60 ml 0.57 0.087 15 0.43 0.28±0.96
Serum extract1 supernatant 800 ml 0.021 0.0011 5 0.005 0.004±0.011
Serum extract2 supernatant 800 ml 0.025 0.0042 17 0.021 0.017±0.026
LOQ
including background
HPLC fraction of mobile phase 100 ml 0.0027 0.0030 111 0.018 0.014±0.025
faecal extract3
HPLC fraction of mobile phase 150 ml 0.0011 0.0016 145 0.009 0.008±0.012
serum extract4
1Volunteer 63 was excluded, through application of a statistical test, as an outlier from the LOQ
calculation.
2Data generated from serum samples from subjects administered only with dosing vehicle (PEG
400). Calculation assumes 100% recovery after precipitation.
3 Pre- and post-dose fractions, contained within the de®ned background regions of interest (5±6,
14±18 and 28±30min), were used in calculation of LOQ.
4 Fractions were converted to graphite using an older (undisclosed) carbon source than Tributyrin.
As background regions of interest could not be de®ned all fractions were used in calculation of LOQ.
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samples that were processed further such that LOQ for serum extracts ranged
from 0.02 to 0.005 dpmml 1. Fractions from HPLC of faecal extracts produced an
LOQˆ 0.02 dpmml 1 and for serum extracts LOQˆ 0.009dpmml 1. As ex-
pected, samples containing either the least amount of total carbon or naturally
occurring radiocarbon have the least variation in background and have the lowest
LOQ for radiocarbon determinations. The data shown here represent a crude
estimation of the LOQ that may be found in these matrices. The values are based
on limited predose samples and approximations to predose samples, which were
analysed in triplicate for a set period: 100±500 s.
Discussion
AMS is now recognized as a useful addition to the tools available to those
involved in drug discovery and development. Glaxo Wellcome Research and
Development Ltd has been involved in the validation of AMS for biomedical
use through the conduct of studies in animals and has established a dedicated
laboratory for the preliminary sample handling involved. In the pilot clinical study
described, it has been successfully demonstrated that AMS can be used as a tool
for determining routes of excretion following administration of a very low dosage
of radiocarbon-labelled drug. Throughout the conduct of the work on the clinical
study and samples generated, contamination of samples with radiocarbon was not
encountered and this may well endorse the contamination containment precautions
taken by all involved. The approach taken by Glaxo Wellcome Research and
Development Ltd with regard to contamination containment was that of mini-
mizing risk and may have been overcautious, i.e. a specialized laboratory may not
be required so long as appropriate precautions are taken.
A mean dose of 2.7mg, 121 Bq (3.3 nCi) [14C]-GI181771 was administered to
six healthy human male volunteers and mass balance was achieved between
administered and recovered radiocarbon. The mean faecal recovery of radiocarbon
was 92% of the dose, mostly recovered in the ®rst 48h in the form of unchanged
drug. Radiocarbon was not detected in any of the samples of urine implying that
urine collected in the ®rst 48 h following dosing contained no more than 6.5% of
the dose. Concentrations of radioactivity in serum were measured using a
precipitation step to increase sensitivity and contained up to 10ng GI181771
equivalents ml 1. Comparison with parent drug levels indicated the presence of
systemically circulating metabolites.
It is clear that the LOQ for analysis of biomedical samples by AMS is
improved when `cleaner’ samples (those containing lowered levels of endogenous
material) are analysed as the impact of background radiocarbon is reduced.
Signal:noise ratios and hence limits of detection were improved signi®cantly
(ranging from 20- to 80-fold) by use of protein precipitation to `clean-up’ the
serum prior to analysis. The assumption was made that a high recovery of
radioactive drug-related components was achieved through this sample
preparation procedure. The estimate for LOQ obtained for serum extracts from
the dosed subjects, after excluding an outlier from the calculation, was
0.005dpmml 1, with a coe cient of variation (CV)ˆ 5%. This LOQ was used
in calculating the results for precipitated serum samples from the subjects dosed
with drug. The LOQ determined from the placebo-dosed subjects in a separate
study was 0.021 dpmml 1, with CVˆ 17%. This value was similar to that obtained
Accelerator mass spectrometry 629
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from subjects dosed with drug, with the outlier included (0.020 dpmml 1) and
may be a more typical value. The background level of radiocarbon in extracts of
serum may vary from one particular group of subjects to another, possibly due to
dietary di erences and thus result in a di erent LOQ being determined for each
individual study. It is likely that the use of plasma rather than serum may reduce
variability by removal of the variable protein recoveries associated with the clotting
process and leading to lower LOQ. Indeed CBAMS Ltd has determined
LOQˆ 0.01 dpmml 1 for neat plasma from studies conducted for other sponsors
(unpublished data). There is an intention to assess the variability in background
levels of radiocarbon in plasma from human volunteers in an AMS study, with a
view to recommending that plasma is used rather than serum in all future AMS
studies, conducted within Glaxo Wellcome Research and Development Ltd.
With regard to the LOQ determined in this study, precision would be
improved by increasing the AMS analysis time, but the time constraints encoun-
tered when processing hundreds of biomedical samples would need to be borne in
mind. A further study to examine speci®cally the limits of quanti®cation for
various matrices is, in our opinion, warranted.
Valuable lessons have been learned during the conduct of this study, which will
aid in the design of future studies where AMS is used. Administration of a dose of
radiolabel that produces the maximum exposure to ionizing radiation of 1mSv,
where no certi®cation is required from ARSAC, would likely improve sensitivity
¹17-fold over that observed in this study, where the exposure was only 0.06 mSv.
A robust determination of limits of quanti®cation for each matrix requires at least
two predose samples per subject, ideally taken several hours apart. These extra
predose samples would need to be included in any future study design. If
concentrations of drug-related radioactivity in serum equating to <0.4 dpmml 1
are expected, then a precipitation step may be required to provide adequate
sensitivity, involving both an estimation of recovery and carbon analysis of the
supernatant.
Future potential of AMS
AMS has the potential to provide supplemental information in studies where
conventional doses have been administered and sensitivity becomes an issue, for
example at later time-point sample collections, or to enable conduct of studies that
are currently not possible. The inherent sensitivity of this technique could be
harnessed to enable monitoring of drug-related analytes following administration
of very low doses. Such low dose studies, which have been termed `microdosing’
studies, may be of interest to the pharmaceutical industry. Through the use of
sample separation techniques coupled with AMS for o -line detection, as shown
here, pharmacokinetics of both parent drug molecule and total drug-related
material (drug and metabolites), could be elucidated. With the use of high speci®c
activity radiocarbon labelled drugs incorporated into a small, perhaps low mg or
even sub-mg, total dose it is envisaged that sensitivities in the high fgml 1 range
may be achievable. It is possible that the administration of such a small dose may
not require very much in the way of supporting safety information from toxicology
and ADME (absorption, distribution, metabolism and elimination) studies,
thereby speeding up the progression from drug discovery to ®rst clinical investiga-
tion. There may well be many caveats placed upon information obtained from
630 G. Young et al.
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microdosing studies, but should there be a desire to rank compounds according to
their pharmacokinetics or susceptibility to metabolism then this could be achieved
in human subjects earlier in a drug development programme than is currently the
norm. The authors believe that this type of approach, and its pros and cons, is
under consideration in a number of companies within the pharmaceutical industry.
AMS could also be of use in the reduction of numbers of animals used in drug
discovery pharmacokinetic and excretion balance studies. The small sample size
required for analysis by AMS, as low as 5 ml for plasma or serum, means that serial
blood sampling from small animals such as rodents is viable and the need for
composite study designs is reduced with consequent reduction in the number of
animals required.
One of the biggest drawbacks to the use of AMS in early drug discovery is
potentially the requirement for incorporation of the radioisotopic label within the
molecule of interest. If the technique is ever to be used as part of a screening
strategy for drug discovery candidates then incorporation of, for example, radio-
carbon would need to be higher in throughput than is currently the case.
With the advent of the use of AMS in the pharmaceutical industry, the way is
opened to reducing the use of relatively high levels of radioactivity for drug
discovery and development. Reduction in levels of radioactivity handled brings
with it not only ethical advantages associated with clinical use, but also a
reduction in the environmental issues involved in the handling and disposing of
radioactivity.
This paper has focussed on the use of AMS for the measurement of radio-
carbon, but it should be noted that other elemental isotopes may well be of
interest, for example 41Ca and 129I, both of which can be analysed using this
technique. 41Ca has been used to label human bones in studies to measure
bone turnover (Freeman et al. 1997). 131I and 125I are frequently used in radio-
immunoassays and AMS provides the alternative of using the more radiologically
safe 129I. Labelling of proteins or antibodies with 129I and subsequent analysis by
AMS could be of use in developing new therapies or diagnostic reagents.
AMS will no doubt be more widely used in biomedical investigations in the
future. The rate-limiting step in the analysis of samples is the sample preparation
which for radiocarbon involves the technically challenging combustion and
graphitization steps. It is envisaged that advances will be sought in interfacing
the AMS with some sort of on-line chromatography system for increased sample
throughput and improved ease of use. At present there is only one commercial
AMS facility in the UK for analysis of biomedical samples, but it may be that as
the technique matures in the biomedical area and as AMS instrument size and cost
potentially reduce, more will become available.
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A history of the use of AMS in GSK studies spanning the last 8 years (1998–2005) is presented, including use in pilot studies through
to clinical, animal and in vitro studies. A brief summary of the status of GSK’s in-house AMS capability is outlined and views on the
future of AMS in GSK are presented, including potential impact on drug development and potential advances in AMS technology.
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Keywords: Radiocarbon; Accelerator mass spectrometry; Pilot; Clinical; Drug; GlaxoSmithKline1. Introduction
Accelerator mass spectrometry (AMS) has been used in
GSK since 1998. All of the studies conducted to date have
been supported by Xceleron Ltd. (formerly CBAMS Ltd.)
with some sample preparation conducted at GlaxoSmithK-
line (GSK) Research and Development, including activities
such as fraction collection following HPLC. Dedicated lab-
oratories have been used throughout to minimise the risk
of contamination of samples destined for analysis by
AMS, although for a period a conventional laboratory
used previously for handling higher levels of radiocarbon
labelled samples was converted for use as an AMS sample
preparation area. At the time of writing this article (late
2005), GSK is in the process of establishing a new dedi-
cated sample preparation suite for AMS.
AMS has been used for atypical drug development pro-
jects to date, largely due to constraints such as the high cost
of AMS analysis under contract and sample throughput
limitations. The studies that have been conducted have
fallen into two fairly distinct categories: ‘‘true’’ AMS stud-
ies and ‘‘hybrid’’ studies. In the context of GSK experience,0168-583X/$ - see front matter  2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.nimb.2007.01.212
* Corresponding author. Tel.: +44 1920 882391; fax: +44 1920 884374.
E-mail address: Graeme.C.Young@gsk.com (G.C. Young).AMS studies are those where the level of radiocarbon
dosed was very limited. Studies have been categorised as
an AMS study when dosimetry limitations have occurred
due to tissue retention or protracted elimination of drug-
related material in non-clinical species. AMS study
categorisation has also occurred where a potent pharmaco-
phore has been dosed and so insuﬃcient radiocarbon could
be administered due to the low chemical dose of drug uti-
lised. Hybrid studies are those where conventional doses
of radioactivity have been administered but some of the
samples generated from the study were particularly low
in radiocarbon. Studies have been categorised as a ‘‘hybrid
study’’ when compounds have had very limited absorption,
resulting in low levels of radioactivity in the samples or
when investigation of late post-dose plasma sample time-
points was desired and again these were too low in activity
to be analysed with more conventional techniques such as
liquid scintillation counting (LSC).
The studies have been of a variety of designs and for a
variety of purposes including studies in animals and
humans, and in vitro studies. The studies have been both
investigative in nature and in some instances have been
key decision making studies to enable further progression
of a new chemical entity (NCE).
This paper provides outline details of these studies for
the purpose of highlighting uses of AMS for GSK, rather
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results.
GSK has started to establish a capability for conducting
AMS studies in-house and brief mention of this is
described below. Additionally, views are expressed regard-
ing the potential impact of AMS on drug development in
GSK and potential advances in the technology are
discussed.2. Studies at GSK using AMS
2.1. Pilot rat excretion balance study
Conducted in 1998, a pilot rat excretion balance study
was the ﬁrst study to be carried out by GSK using AMS
as the detection method. This work has been published pre-
viously [1] and so the details will not be discussed further
but it is mentioned here to provide a more complete picture
of the uses to which AMS has been put in GSK.2.2. Pilot low radioactive dose clinical study
Conducted in 1999, a pilot low radioactive dose clinical
study was the ﬁrst use of AMS for GSK in support of a
clinical study. As for the rat study above, this work has
been published previously [2], but again is mentioned here
for completeness.2.3. Serum metabolite proﬁling for ‘‘conventional dose’’
clinical study
Conducted in 2001, metabolite proﬁling for a conven-
tional dose clinical study was carried out, in Phase 2 of clin-
ical development, and involved the oral administration to
humans of a NCE at a dose of 84 lCi per subject i.e. a0.00
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Fig. 1. Reconstructed radiochromatogram showing retention times of know
volunteers. ‘‘M’’ numbers are used to assign many of the radioactive peaks obs
(square), 12 h post-dose serum (triangle).‘‘hybrid’’ type study. Most of the study support was con-
ducted using LSC, but levels of radioactivity in late time-
point serum samples were too low to allow metabolite
proﬁling by conventional means such as HPLC with radio-
chemical detection. In contrast, the levels of radioactivity
were too high for AMS and the samples were diluted by
a factor of 25 to bring them into the acceptable range. Sam-
ple proﬁling was conducted by HPLC with fraction collec-
tion then subsequent analysis of each fraction by AMS.
The amount of radioactivity injected onto the HPLC
ranged from 10 dpm down to 0.2 dpm and resulted in suc-
cessful assignment of major metabolites by co-chromatog-
raphy. Fig. 1 shows reconstructed chromatograms of
serum samples taken predose, 1 h (7.9 dpm on column)
and 12 h (3.4 dpm on column) after dose with assignments
of many of the radioactive peaks observed (metabolites
indicated using arbitrary ‘‘M’’ numbers). This study pro-
vided extremely useful experience in proﬁling with AMS
at comparatively low levels and provided information on
the nature of the drug-related material present in serum fol-
lowing administration of this new drug candidate.2.4. In vitro blood cell binding study
Conducted in 2001, an in vitro blood cell binding study
was carried out to investigate the extent of blood cell bind-
ing of a potent primary sulphonamide NCE. Prior work,
not reported here, had been conducted at elevated concen-
trations far above the anticipated therapeutic range for this
compound and it was decided to conduct a study at more
relevant concentrations, using AMS as the detection
method. Fig. 2 shows a bar chart indicating the degree of
binding determined and the degree of displacement which
occurred when the NCE was co-incubated at various
concentrations in the presence and absence of potentially15 20 25
ollection time (minutes)
Parent drug
M3
M4
n metabolites in serum following administration of a NCE to human
erved to known metabolites. Key: Pre-dose serum (·), 1 h post-dose serum
Fig. 2. In vitro blood cell binding and displacement of a NCE. The vertical bars represent data from experiments conducted using either LSC or AMS as
the detection technique. Key: Concentrations of NCE at 0.01 (Bar 1; AMS), 0.1 (Bar 2; AMS), 1 (Bar 3; AMS), 100 (Bar 4; LSC) and 1000 ng/mL (Bar 5;
LSC).
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amide). The lower concentrations of NCE (0.01, 0.1
and 1 ng/mL) were analysed by AMS and the higher con-
centrations (100 and 5000 ng/mL) were analysed by LSC.
The data generated showed that generally very similar
results were obtained at the elevated and the anticipated
therapeutic concentrations of the NCE, thus the use of
AMS detection had ‘‘validated’’ the work carried out at
supra-therapeutic concentrations.
2.5. Non-clinical study: excretion balance study in dogs
Conducted in 2003, a study in dogs involved the intrave-
nous administration of 1 lg/kg, delivering only 1 lCi to the
dogs, for the purpose of assessing routes of excretion, mass
balance and metabolite proﬁling for a NCE. The excretion
balance was successfully assessed using LSC with conﬁrma-
tion of some lower level samples using AMS, and metabo-
lite proﬁling was achieved for urine and plasma samples
using HPLC fractionation followed by AMS analysis.
2.6. Low radioactive dose clinical study
Conducted in 2004, a low radioactive dose clinical study
was used in making a decision on the progression of devel-
opment for a NCE, in Phase 1 of clinical development. The
study was a true AMS study with administration of only
500 nCi to each human volunteer. The dose used was
necessitated by predicted protracted elimination based
upon animal data for this NCE. Excreta and blood collec-
tions were made over several weeks following dose admin-
istration and all samples were analysed by AMS, for
excretion balance and total radiocarbon in blood/plasma.
Fig. 3 shows the cumulative excretion of radiolabelled
drug-related material with time. Periodic collections ofexcreta were used to allow an extended collection period
without having to keep the volunteers in the clinic for
longer than 15 days. The cumulative recovery obtained
was achieved by extrapolations based on plots of amount
excreted per day versus time. The mean total recovery from
excreta obtained, using this extrapolation method, was
>85%. Fig. 4 shows the total radiocarbon in plasma after
dosing. Both sets of data highlight the expected, protracted
elimination of drug-related material in humans and fully
justify the approach of using AMS and severely limiting
the radiocarbon dose administered versus a conventional
human ADME study where circa 100 lCi may be
administered.
2.7. Metabolite proﬁling of samples from a low radioactive
dose clinical study
Conducted in 2004, using samples generated from the
study mentioned (in Section 2.6) above, for investigations
of metabolite proﬁles in urine and plasma. Samples were
prepared and fractionated by HPLC and the fractions sub-
sequently analysed by AMS. The amounts of radioactivity
injected onto the HPLC column ranged from 5 dpm down
to 0.02 dpm. Fig. 5 shows the reconstructed radiochro-
matogram of a post-dose plasma sample, 0.06 dpm on col-
umn, and indicates that most major peaks observed were
attributable to known metabolites.
3. GSK’s in-house AMS capability
GSK ordered two 250 kV single stage accelerator mass
spectrometers (SSAMS) systems from National Electro-
statics Corp. (NEC), Wisconsin; one for a GSK site in
the UK and one for a site in the USA. Fig. 6 shows a sche-
matic of the GSK systems. The instruments have two ion
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Fig. 3. Plots of cumulative excretion of radiolabelled drug-related material with time following oral administration of a NCE (500 nCi) to healthy human
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G.C. Young, W.J. Ellis / Nucl. Instr. and Meth. in Phys. Res. B 259 (2007) 752–757 755
Fig. 6. Schematic of single stage AMS with dual 134 sample MC-SNICS. Reproduced by kind permission of NEC (National Electrostatics Corporation,
Wisconsin, USA).
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graphite samples. Specialised sample preparation laborato-
ries and instrument laboratories are being constructed at
the GSK sites and staﬀ are receiving training in sample
preparation and AMS operation. At the time of writing it
was envisaged that the GSK AMS systems will support real
studies from 2006.
4. Future of AMS in GSK
4.1. Potential impact on drug development
AMS in itself provides no direct structural identiﬁcation
and the information provided by the instrument needs to
be coupled with information from mass spectrometry
and/or nuclear magnetic resonance spectroscopy for full
structural identiﬁcation of the components detected. This
is only achievable if the doses selected, in the case of an
in vivo study are suﬃciently high in terms of chemical mass
of drug to allow application of the other techniques men-
tioned to be of value. Use of AMS for metabolite proﬁling
requires very robust chromatography since assignment of
peaks to parent or metabolites is often dependent on co-
chromatography for which standards of metabolites as
markers is often advantageous, as are other data such as
non-clinical metabolic pathway information. It is felt by
some that since there may be a heavy reliance on the
robustness of the chromatography used for separation of
components subsequently quantiﬁed by AMS, the use ofa second conﬁrmatory chromatography method may be
of use. It should also be noted that many clinical AMS
studies may not be low enough in radiocarbon dose level
to be categorised as exempt studies (as categorised by
ARSAC the Administration of Radioactive Substances
Advisory Committee, UK), but this is likely to be com-
pound and study objective dependent. The current situa-
tion in GSK is that AMS is focussed on use in support
of human ADME studies. Drug candidates administered
by the inhaled, intranasal and dermal routes tend to pro-
duce low systemic exposures and so AMS is required due
to its sensitivity advantages in dealing with samples gener-
ated from such studies. Additionally, low dose (potent)
oral compounds and poorly absorbed compounds also pro-
duce analytical challenges in terms of sensitivity which may
be addressed using AMS.
In the short term future, GSK is likely to harness the
sensitivity of AMS to impact on relevant clinical study
designs and perhaps use the technique in a wider range of
non-clinical studies. The in-house availability and accessi-
bility of AMS may well open up more opportunities for
use of AMS including those beyond the types of applica-
tions highlighted in the past use of AMS in GSK, above.
It is envisaged that conventional human ADME studies
will still be conducted in the short term, but that early clin-
ical AMS studies may be conducted, which will add value
to the conventional human ADME study and reduce risk
of surprises, later in development. Use of AMS early in
development may help with understanding the metabolism
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date’’ the selected toxicology species early on, thus provid-
ing a greater understanding of the safety of the NCE and
bringing value to the package of information used in sub-
missions to regulatory authorities.
In the longer term, AMS is likely to be applied to typical
as well as to atypical drugs in development, particularly in
supporting early proﬁling and quantiﬁcation of circulating
metabolites following administration of NCEs to humans.
There has been much talk about clinical microdosing of
late; the concept of using very low doses as a surrogate
for what is likely to occur at therapeutic doses, with poten-
tial use of AMS as the analytical tool. The authors are
aware of some of the potential advantages of microdosing
in relation to drug candidate selection, or de-selection, def-
inition of intravenous pharmacokinetics in cases where
drug solubility is dose limiting and so on. The authors
believe that GSK will remain open to the possibilities of
such applications of AMS and also in the potential advan-
tages to be gained in reducing the levels of radiocarbon
used in other studies, such as animal ADME studies. The
technique does provide the sensitivity to enable alternatives
to the conventional approaches in drug development. It
should be borne in mind that conducting more detailed
studies earlier in development can create diﬃculties in car-
rying on the progression of NCEs, as well as potentially
assisting progression. It is entirely possible, for example,
that an early clinical AMS study could highlight the pres-
ence of a metabolite that is unique to humans or for which
there is insuﬃcient safety cover in the animal toxicology
species and this may cause diﬃculties in the continuation
of clinical trials. Many seem agreed though that it is better
to have this information earlier, rather than later in a new
drug candidate’s development.
4.2. Potential advances in technology
GSK is interested in making advances in sample prepa-
ration for AMS such as automation of the graphitisation
process or identiﬁcation of an alternative process to that
being put in place at GSK, since sample preparation is cur-
rently the limiting step in throughput. The authors are
aware that others are looking into interfacing of theAMS to achieve either oﬀ-line or on-line coupling to
HPLC, CHN analyser or gas chromatograph and certainly
would encourage such activities. GSK recognises that the
instruments that it has purchased, are a ﬁrst step towards
bringing AMS into the mainstream of techniques in use
in drug development. These instruments really need to be
adapted or even replaced with ‘‘next generation’’ instru-
ments in order to move AMS forward signiﬁcantly.
5. Summary
AMS has been used in GSK with increasing frequency
and in an ever widening range of applications, including
clinical, animal and in vitro for both true AMS and hybrid
studies. The cost of future contract research support for
AMS studies was predicted to be high for GSK and so
the company has made the move into establishing an in-
house AMS capability. The main objective for GSK in
regard to AMS is to use it as one of a range of techniques
to aid in elucidating metabolism of new drug candidates in
humans, early in development. AMS technology appears to
be evolving quickly, so we can probably expect to see big
changes, in a relatively short timeframe, certainly the
authors believe that GSK will be taking an active interest
in the development of AMS, particularly in regard to sam-
ple preparation and interfacing with HPLC.
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ABSTRACT
(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-
2,1-benzoxaborole (GSK2251052) is a novel boron-containing an-
tibiotic that inhibits bacterial leucyl tRNA synthetase, and that
has been in development for the treatment of serious Gram-
negative infections. In this study, six healthy adult male subjects
received a single i.v. dose of [14C]GSK2251052, 1500 mg infused
over 1 hour. Blood, urine, and feces were collected over an ex-
tended period of 14 days, and accelerator mass spectrometry
was used to quantify low levels of radioactivity in plasma at later
time points to supplement the less-sensitive liquid scintillation
counting technique. An excellent mass balance recovery was
achieved representing a mean total of 98.2% of the dose, including
90.5% recovered in the urine. Pharmacokinetic analysis demon-
strated that radioactivity was moderately associated with the blood
cellular components, and together with GSK2251052, both were
highly distributed into tissues. The parent compound had a much
shorter half-life than total radioactivity in plasma, approximately
11.6 hours compared with 96 hours. GSK2251052 and its major
metabolite M3, which resulted from oxidation of the propanol side
chain to the corresponding carboxylic acid, comprised the majority
of the plasma radioactivity, 37 and 53% of the area under the
plasma versus time concentration curve from time zero to infinity,
respectively. Additionally, M3 was eliminated renally, and was
demonstrated to be responsible for the long plasma radioactivity
elimination half-life. A combination of in vitro metabolism experi-
ments and a pharmacokinetic study in monkeys with the inhibitor
4-methylpyrazole provided strong evidence that alcohol dehydro-
genase, potentially in association with aldehyde dehydrogenase,
is the primary enzyme involved in the formation of the M3
metabolite.
Introduction
GSK2251052 [(S)-3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-
1,3-dihydro-2,1-benzoxaborole hydrochloride], also known as AN3365,
is an antibacterial compound that has been in development for the
treatment of serious Gram-negative infections. Leucyl tRNA synthe-
tase (LeuRS) is an essential bacterial enzyme that catalyzes the
coupling of the amino acid leucine onto its corresponding leucine
transfer ribonucleic acid (tRNALeu), which is used by the ribosome for
protein synthesis. Inhibition of LeuRS prevents protein synthesis and
stops growth of the bacteria. Through the unique chemical binding
properties of the boron atom, GSK2251052 binds to the editing active
site of bacterial LeuRS and forms a boron adduct with the 39 terminus
of tRNALeu which locks the tRNALeu to LeuRS in an unproductive
state.
GSK2251052 has good in vitro activity against Enterobacteriaceae
and Pseudomonas aeruginosa, and was not affected by any of the
tested resistance mechanisms, including major efflux pumps, extended-
spectrum b-lactamase, Klebsiella pneumoniae carbapenemase, and
class C b-lactamase, which are known to be important contributors
to the resistance of Gram-negative bacteria (Schweizer, 2012). It is
acknowledged that there is a critical need for new antibiotics to treat
Gram-negative bacterial infections (Spellberg et al., 2008), and
GSK2251052 is one of several new compounds being developed that
target protein synthesis as a mechanism of action (Sutcliffe, 2011).
dx.doi.org/10.1124/dmd.112.050153.
s This article has supplemental material available at dmd.aspetjournals.org.
ABBREVIATIONS: ADH, alcohol dehydrogenase; AE, adverse event; ALDH, aldehyde dehydrogenase; AMS, accelerator mass spectrometry; API,
active pharmaceutical ingredient; AUC(0-t), area under the plasma versus time concentration curve from time zero to time of the measured
concentration; AUC(0-‘), area under the plasma versus time concentration curve from time zero to infinity; Cb, blood concentration; CLp, plasma
clearance; Cp, plasma concentration; GSK2251052, (S)-3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole; HPLC,
high-performance liquid chromatography; LC/MS/MS, liquid chromatography-tandem mass spectrometry; LeuRS, leucyl tRNA synthetase; LLQ,
lower limit of quantification; LSC, liquid scintillation counting; metabolite M3, (S)-3-(aminomethyl)-7-(carboxyethoxy)-1-hydroxy-1,3-dihydro-2,1-
benzoxaborole; 4-MP, 4-methylpyrazole; MRT, mean residence time; m/z, mass-to-charge ratio; S9, homogenate fraction obtained from
centrifugation at 9000g; tRNALeu, leucine transfer ribonucleic acid; Vss, volume of distribution at steady state; lz, terminal elimination rate constant.
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In this article, we describe the pharmacokinetics, metabolism, and
elimination of [14C]GSK2251052 in humans following a single i.v.
administration, which was one of the intended therapeutic routes of
administration. Sampling of blood, urine, and feces allowed the eval-
uation of mass balance, route(s) of elimination (renal or metabolic),
identification of primary metabolites, and a comparison of the exposure
and half-lives of both parent compound and total radioactivity, which
included metabolites. Additionally, the enzyme(s) responsible for the
metabolism of GSK2251052 was investigated by conducting in vitro
experiments and a nonclinical pharmacokinetic study.
Materials and Methods
Chemicals and Reagents
[14C]GSK2251052 hydrochloride (specific activity of 0.00865 mCi/mg,
stated radiochemical purity of 99.4%) (Fig. 1), GSK2251052 hydrochloride salt,
[2H2
13C]GSK2251052, and [2H2
13C]M3 [(S)-3-(aminomethyl)-7-(carboxyethoxy)-
1-hydroxy-1,3-dihydro-2,1-benzoxaborole] were supplied by GlaxoSmithKline
Active Pharmaceutical Ingredient (API) Chemistry and Analysis (Stevenage,
UK). Metabolite M3 was supplied by GlaxoSmithKline API Chemistry
and Analysis (Upper Merion, PA). Scintillation cocktails, Ultima Gold and
Ultima-Flo M, and Deepwell LumaPlate 96-well plates were obtained from
PerkinElmer (Boston, MA). For in vitro experiments, all subcellular fractions
(cynomolgus monkey and human) were supplied by Xenotech (Lenexa, KS).
All human subcellular fractions were supplied pooled of mixed gender, and the
monkey fractions were supplied pooled from male animals.
Formulated Drug
GlaxoSmithKline supplied nonsterile GSK2251052 hydrochloride salt
powder containing [14C]GSK2251052 hydrochloride, and the clinical site
prepared sterile GSK2251052 containing [14C]GSK2251052 solution for infu-
sion. Powder was dissolved in sterile water for injection to a concentration of
125 mg/ml and was sterilized via filtration. Then 12 ml of solution, equivalent
to 1500 mg of GSK2251052, was diluted to 250 ml with 0.9% NaCl injection
prior to infusion.
Synthesis of Metabolite M3
The synthesis of metabolite M3 is depicted in Fig. 2. GSK2251052 (hy-
drochloride) was neutralized with di-isopropylethylamine, and then the
corresponding free base was treated with benzyl bromide in methanol, in the
presence of potassium carbonate, to give the desired dibenzylamino protected
compound, which was then submitted to standard oxidation conditions using
chromium (VI) oxide (CrO3) in a mixture of acetic acid and acetone. The
corresponding carboxylic acid was isolated as the sodium salt after basic
workup. Hydrogenolysis of the N-benzyl groups using 5% palladium on carbon
as the catalyst in a mixture of tetrahydrofuran and aqueous HCl produced the
expected metabolite M3 as the hydrochloride salt.
Clinical Mass Balance Study
A phase I, open-label, nonrandomized, single-dose, single-center, mass balance
study was conducted to investigate the recovery, excretion, and pharmacokinetics
of GSK2251052 after i.v. administration. The study (NCI 01475695) was
conducted according to principles of good clinical practice, applicable reg-
ulatory requirements, and the Declaration of Helsinki. The in-life portion of
this study was conducted at PRA International, Stationsweg 163, 9471 GP
(Zuidlaren, The Netherlands). Following Independent Ethics Committee ap-
proval by the Stichting Beoordeling Ethiek Biomedisch Onderzoek (Assen,
The Netherlands) and collection of written informed consent, all subjects
underwent an initial screening assessment within 30 days prior to the first dose.
The screening included a medical history, physical evaluation, and clinical
laboratory tests. Exclusion criteria included regular use of tobacco or nicotine-
containing products (within 6 months prior to screening), a positive drug or
alcohol test, recent participation in another research trial with an investigational
product (i.e., within 30 days prior to screening), participation in a clinical trial
involving a 14C-labeled compound (within the last 12 months), and any pre-
existing conditions that would interfere with normal gastrointestinal anatomy,
motility, or hepatic or renal function which could interfere with the absorption,
metabolism, and/or excretion of the study drug. Use of vitamins, dietary and
herbal supplements, antacids, any prescription drugs, or grapefruit-containing
products within 7 days prior to the start of the dosing through to the follow-up
visit was prohibited. Six healthy adult male volunteers with a mean age of 42.2
years (S.D. 8.28 years), mean body weight of 83.1 kg (S.D. 3.41 kg), and mean
body mass index of 25.5 kg/m2 (S.D. 1.38 kg/m2) were enrolled in this study.
Five subjects were Caucasian and one subject was of Arabic/North-African
heritage.
The radiolabeled dose was calculated in accordance with the 1990 Rec-
ommendations of the International Commission on Radiologic Protection (ICRP
Publication 60; http://www.icrp.org/publication.asp?id=ICRP%20Publication%
2060) as implemented in the 1999 Ionizing Radiations Regulations. The cal-
culation was based on [14C]GSK2251052 data obtained from a quantitative
tissue distribution study conducted in rats. It was determined that, to comply
with the International Commission on Radiological Protection guidance limit of
100 mSv (microsievert), the maximum activity would be 0.69 MBq (18.8 mCi).
To ensure that this limit was not exceeded, a target dose of 15 mCi was
chosen. All subjects enrolled who met eligibility criteria were fasted at least
10 hours prior to receiving a single radiolabeled i.v. dose of 1500 mg of
[14C]GSK2251052 (15 mCi, 0.56 MBq) infused at a constant rate over 1 hour.
Following dosing, serial and intermittent whole-blood (including blood for
plasma), urine, and fecal samples were collected for a minimum of 336 hours
(14 days) postdose for study assessments (recovery, excretion, and pharma-
cokinetic). Safety was monitored throughout the study.
Venous blood samples were collected into tubes containing K2 EDTA as the
anticoagulant. All collection times listed are from the start of the 1-hour
infusion. Blood samples (6 ml) for the pharmacokinetic analysis of blood and
plasma radioactivity were collected predose and at 0.5, 1, 1.083, 1.25, 1.5, 2, 3,
4, 5, 6, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 240, 288, and 336
hours. Blood samples (2 ml) to prepare plasma for the pharmacokinetic analysis
of GSK2251052 and metabolite M3 were collected predose and at 1, 1.5, 2, 2.5,
3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours. Additional blood samples (4 ml)
were collected at 1, 6, and 12 hours to prepare plasma, which was acidified with
equal volumes of 50 mM citrate buffer (pH 4.0) and used to examine the
stability of a hypothetical acyl glucuronide metabolite of M3. Blood samples
(15 ml) to provide plasma for metabolite profiling were collected predose
and at 1, 6, 12, 24, 48, 96, 144, and 336 hours. The 96-, 144-, and 336-hour
plasma samples were subsequently used for the pharmacokinetic analysis of
GSK2251052 and M3. Urine was collected predose and at 0–6, 6–12, and
12–24 hours, and thereafter at 24-hour intervals through 336 hours, while feces
were collected predose and at 24-hour intervals through 336 hours.
Quantification of Radioactivity
Radioactivity in blood, plasma, urine, and feces were quantified at PRA
International by liquid scintillation counting (LSC) using a Packard 3100TR
liquid scintillation counter (Packard Instrument Company, Downers Grove, IL)
with low-level count mode. Aliquots of plasma (0.25–1 ml) and urine (1 ml)
were mixed directly with appropriate amounts of Ultima Gold scintillation
cocktail prior to analysis. Whole blood (0.5 ml) was incubated with 1 ml of
Solvable (PerkinElmer) for 1 hour at 60°C, and cooled prior to the addition
of 0.1 M EDTA (100 ml). The samples were decolorized by the addition ofFig. 1. Chemical structure of [14C]GSK2251052 showing location of the radiolabel.
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hydrogen peroxide (4  100 ml) followed by a 30-minute incubation at room
temperature, 20-minute incubation at 45°C, and 1-hour incubation at 60°C.
Ultima Gold scintillation cocktail was added to the cooled samples, which were
allowed to sit for at least 12 hours in the dark prior to analysis by LSC. Feces
were mixed with water (1–2 times the sample weight) and homogenized prior
to combustion of duplicate aliquots (0.5 g) using a PerkinElmer Model 307
sample oxidizer. The resulting 14CO2 was trapped in Carbo-Sorb, mixed with
Permafluor scintillation cocktail, and analyzed by LSC.
Accelerator Mass Spectrometry Analyses
Initially, plasma samples were analyzed for radioactivity using liquid scin-
tillation counting as described previously. Samples in which concentrations
were determined to be below the lower limit of quantification (LLQ; 870 ng
equivalents/ml, 20 dpm/ml) were reanalyzed by accelerator mass spectrometry
(AMS; LLQ 2.0 ng equivalents/ml, ;0.05 dpm/ml) at GlaxoSmithKline (Ware,
Hertfordshire, UK). Analysis by AMS requires conversion of samples via
a two-step process of oxidation to CO2 and then reduction to graphite (Vogel,
1992). The AMS provides an isotope ratio of [14C]:[12C] from which 14C per
milligram of carbon is derived (Klody et al., 2005). A carbon content of control
plasma of 4.38%, previously established using a Costech Carbon Analyzer
(Valencia, CA), was used as the basis for the carbon content of all plasma
samples analyzed. Untreated plasma sample aliquots (60 ml) were dried
together with copper oxide, sealed into evacuated quartz tubes, and heated at
900°C for 2 hours. The CO2 thus formed was cryogenically transferred into
evacuated tubes containing zinc powder, titanium hydride, and cobalt catalyst,
and the tubes were sealed. The reduction tubes were heated to 500°C for 4
hours, followed by 550°C for 6 hours to complete the graphitization process.
Carbon as graphite, deposited on the cobalt, was pressed into aluminum
cathodes and analyzed by AMS on a National Electrostatics Corp. (Middleton,
WI) 250-kV single-stage accelerator mass spectrometer (Young et al., 2008).
Control samples, including Australian National University (Acton, ACT,
Australia) sugar and sodium benzoate, were processed with the analytical run.
Instrument standards of pooled Australian National University and synthetic
graphite were used to normalize the data and check suitability of instrumental
background, respectively. The data from the AMS and carbon content analyses
were combined to provide radiocarbon levels for each sample, with background
subtraction of predose plasma concentration data as appropriate.
Sample Preparation for Metabolite Profiling
Urine. Urine was pooled across sampling times (0–120 hours) on a total
sample weight basis to produce a representative pool for each subject con-
taining $90% of the radioactivity excreted in the urine (90.2% of the dose).
Additionally, 120–336-hour urine samples from each subject were pooled in
the same manner, and equal volumes of each pool were combined to produce
a single composite sample. The pooled urine was centrifuged at ;21,000g for
10 minutes, and a portion of each supernatant (500–1500 ml) was profiled using
high-performance liquid chromatography (HPLC) with radiochemical de-
tection. Triplicate-weighed aliquots of urine (200–2000 ml) were assayed using
LSC before and after centrifugation to determine the recovery of radioactivity.
Feces. Feces were pooled across sampling times (0–120 hours) on a total
sample weight basis to produce a representative pool for each subject
containing $90% of the radioactivity excreted in the feces (6.0% of the dose).
Due to the low levels of radioactivity in fecal samples, two sets of fecal
homogenates were extracted in parallel. One set was used to monitor the
recovery of radioactivity, and the second set was used for profiling. The
homogenates (;1 g) were extracted twice by the addition of 4 volumes of
acetonitrile:methanol:water:formic acid (50%:25%:25%:1%, v/v/v/v) followed
by sonication for 20 minutes. Following each extraction, samples were centrifuged
at 1620g for 10 minutes at 25°C, and the supernatants were combined in tared
tubes. The total weights of the supernatants were determined, and triplicate-
weighed aliquots (100–1500 ml) were assayed using LSC to determine the
recovery of radioactivity. The supernatants were evaporated to dryness under
a stream of nitrogen and reconstituted in 500 ml of water:methanol (90:10, v/v)
before they were sonicated and centrifuged at 1620g for 10 minutes. The
supernatants were transferred to microcentrifuge tubes and centrifuged at
21,000g for 5 minutes. To increase the recovery of radioactivity, the residual
pellets were rinsed with 100 ml of water. Following centrifugation, the rinses
were combined with the corresponding extracts. The total weights of the
Fig. 2. The synthesis of metabolite M3.
1072 Bowers et al.
 at A
SPET Journals on N
ovem
ber 8, 2015
dm
d.aspetjournals.org
D
ow
nloaded from
 
extracts were determined, and triplicate-weighed portions (10–100 ml) were
analyzed using LSC to determine the recovery of radioactivity upon recon-
stitution. Portions (400 ml) of each fecal extract were profiled using HPLC
with radiochemical detection.
Metabolite Profiling and Identification
Urine and fecal samples were analyzed using an Agilent-1260 HPLC
system (Hewlett Packard, Palo Alto, CA) and a Waters Atlantis T3 column
(4.6  250 mm, 5 mm; Waters Corporation, Milford, MA). Mobile phase A
consisted of 100 mM ammonium acetate (pH 4.5, pH adjusted with 100 mM
acetic acid)/water (10:90, v/v), and mobile phase B consisted of 100 mM
ammonium acetate (pH 4.5)/methanol (10:90, v/v). The gradient was held at
starting conditions (10% B) from 0 to 10 minutes and increased linearly to 70%
B from 10 to 55 minutes, and then to 95% B from 55 to 55.1 minutes. The
gradient was held at 95% B from 55.1 to 60 minutes and returned to starting
conditions at 60.1 minutes and held for a further 5 minutes. The column was
allowed to equilibrate for an additional 10 minutes between injections. The
analyses were performed at 30°C and a flow rate of 1 ml/min. The HPLC
effluent was split, with 80% of the sample collected into deep-well LumaPlate-
96 solid scintillant microplates (PerkinElmer; 0.2 minutes/well) and the
remaining 20% directed to a Thermo Finnigan LTQ-Orbitrap Hybrid mass
spectrometer equipped with an ElectroSpray Ionization source (Thermo Sci-
entific, San Jose, CA) for metabolite identification. The LumaPlates, containing
dimethylsulfoxide (10 ml/well) to reduce nonspecific binding of drug-related
material, were dried on SPE Dry 96 Dual plate driers (Argonaut Technologies,
Foster City, CA) under a stream of heated nitrogen and analyzed using
a PerkinElmer TopCount NXT microplate scintillation counter (PerkinElmer
Life Sciences, Downers Grove, IL). Data from the TopCount NXT were
imported into Laura software (version 3.4.11; LabLogic Systems, Inc.,
Sheffield, UK), and the chromatograms were manually integrated. The lower
limits of radiochemical detection (defined as peak height) were determined
based on the proposal by Currie (1968) for the measurement of paired
radioactivity, and calculated using counting time (30 minutes) and instrument
background. Integrated peak areas of less than 3 times background are reported
as ,LLQ. Background was assigned for each run by selecting representa-
tive regions at the beginning and end of each chromatogram. The radioactive
drug-related components in feces and urine are reported as a percentage of
the administered dose, and as a percentage of the radioactivity in the matrix
(to 1 decimal place). Results were corrected for the recovery of radioactivity
following centrifugation (urine) or extraction and reconstitution (feces).
Metabolites were characterized using a ThermoFinnigan Orbitrap XL
(Thermo Scientific) mass spectrometer in the positive mode based on accurate
mass measurements from full-scan MS data [m/z (mas-to-charge ratio) 100–700
at 30,000 resolution]. Mass spectral data obtained from metabolites identified
in the preclinical species (unpublished observations) were also used in the
assignment of metabolite structures.
Monkey Pharmacokinetic Study with 4-Methylpyrazole
GSK2251052 was administered to cynomolgus monkeys (3 per sex per
group) as a single constant rate i.v. infusion over 1 hour at a dose level of 35
mg/kg, either alone or 1 hour after an oral gavage administration of the alcohol
dehydrogenase (ADH) inhibitor 4-methylpyrazole (4-MP) (Sigma-Aldrich,
St. Louis, MO). GSK2251052 was formulated at 7 mg/ml as a solution in 0.9%
sodium chloride injection, USP (saline), pH 5, and administered at a dose
volume of 5 ml/kg/h. 4-MP was formulated as a solution at 8.75 mg/ml in
purified water and administered to cynomolgus monkeys at a dose volume of 4
ml/kg. Venous blood samples (0.5 ml) for the plasma pharmacokinetic analysis
of GSK2251052 and M3 were collected into tubes containing K2 EDTA as the
anticoagulant predose and at 0.5, 0.92, 1.08, 1.25, 1.5, 2, 3, 5, 9, 24, 48, 72, 96,
and 120 hours. All times listed are from the start of the 1-hour infusion.
Quantification of GSK2251052 and Metabolite M3 in Monkey and Human
Plasma
The plasma concentrations of GSK2251052 and metabolite M3 were
measured using validated methods based on protein precipitation followed by
liquid chromatography-tandem mass spectrometry (LC/MS/MS) analysis.
Briefly, a 50-ml (human) or 15-ml (monkey) aliquot of plasma was added to
250 ml (human) or 100 ml (monkey) of methanol containing formic acid (0.1%
v/v), [2H2
13C]-GSK2251052, and [2H2
13C]-M3 (100 ng/ml each) in 96-deep-
well plates and vortex mixed for 10 minutes. The samples were then centrifuged
at 3000g for 5 minutes. For human samples, 225 ml of the supernatants were
transferred to clean 96-deep-well plates and dried under warm nitrogen before
reconstitution in 60 ml, 0.1% formic acid (v/v) in water. Monkey plasma
sample supernatants were diluted by adding 25–150 ml of 0.1% formic acid.
Between 1- and 5-ml aliquots of the reconstituted or diluted samples were
injected into an LC/MS/MS system consisting of a Waters Acquity ultra high-
pressure liquid chromatography (Waters Corporation), a Waters HSS T3
column (50  2.1 mm, 1.8 mm) at 50°C, and an MDS Sciex 4000 API-4000
mass spectrometer (Applied Biosystems/MDS Sciex, Concord, ON, Canada).
Mobile phase A consisted of water containing 0.1% formic acid (v/v), and
mobile phase B consisted of methanol: water:formic acid (50%:50%:0.1%, v/v/v).
The compounds were eluted from the column at a flow rate of 0.7 ml/min
and for human samples with a gradient starting at 22% B, which increased
linearly to 30% B from 0.5 to 1.51 minutes and returned to 22% B from 1.51 to
1.6 minutes. For monkey samples, the column was eluted isocratically, with
85% mobile phase A and 15% B. Tandem mass spectrometry analyses were
performed using a TurboIonSpray interface (Applied Biosystems/MDS Sciex)
operated in the positive mode and a probe temperature of 400°C. The analytes
were measured by multiple reaction monitoring of the following [M+H]+
transitions: GSK2251052 m/z 238 → 202 and metabolite M3 m/z 252 → 162.
The transitions monitored for the internal standards were 3 mass units higher
than the corresponding analyte. Data collection and integration were
performed using Analyst software (version 1.4.2; Applied Biosystems/MDS
Sciex). Quantification was based on analyte/internal standard peak area ratios
and calculated using a weighted 1/x2 linear regression model within
SMS2000 (version 2.3; GlaxoSmithKline, Research Triangle Park, NC).
The operating range of the assays for both analytes, GSK2251052 and M3,
was 5–10,000 ng/ml in human plasma and 100–200,000 ng/ml in monkey
plasma.
Pharmacokinetic Analysis
The plasma pharmacokinetic parameters were estimated by noncom-
partmental methods with either WinNonlin Professional Edition version 5.2
(Pharsight, Mountain View, CA) using actual pharmacokinetic sampling times
TABLE 1
Summary of human pharmacokinetic parameters of GSK2251052, M3, and total radioactivity after a single i.v. infusion dose of
[14C]GSK2251052 (1500 mg)
Matrix Analyte AUC(0-t)
a AUC(0-‘)
a Cmax
a CLa Vssa T1/2
b Tmax
b
mg × h/ml mg.h/ml mg/ml l/h l h h
Plasma GSK2251052 72.3 (7.34) 72.5 (7.41) 24.6 (14.5) 20.7 (7.41) 197 (8.87) 11.6 (9.96–12.1) 0.917 (0.50–0.92)
M3 101 (12.1) 103 (12.1) 1.77 (9.77) NA NA 77.3 (68.1–78.5) 7.00 (5.00–24.0)
Radioactivity 191 (10.0) 195 (9.90) 24.3 (16.1) 7.70 (9.90) 348 (12.6) 96.0 (86.2–117) 0.917 (0.92–0.92)
Whole blood Radioactivity 141 (20.8) 193 (21.1) 43.7 (10.2) 7.79 (21.1) 116 (17.8) 14.3 (7.28–16.1) 0.917 (0.92–0.92)
%CV, % coefficient of variation; NA, not applicable.
aGeometric mean (%CV).
bMedian (range).
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(human study), or WinNonlin Enterprise Edition version 4.1 using the nominal
sampling times (monkey study). The maximum observed plasma concentration
(Cmax), the time at which Cmax was observed, and the time to the last measur-
able concentration were determined directly from the raw concentration-time
data or using WinNonlin. The area under the concentration-time curve from
time zero to the last quantifiable time point [AUC(0-t)] and the area from time
zero to infinity [AUC(0-‘)] were calculated using the linear up/logarithmic
down trapezoidal method. The AUC(0-‘) was estimated as the sum of AUC(0-t)
plus Clast/lz, where Clast is the concentration at the last quantifiable time point.
The terminal elimination rate constant (lz) was estimated from linear regression
analysis of the log-transformed concentration-time profile. The number of
points included in the terminal phase was determined by visual inspection of
the semilog plots of the concentration-time profiles. The associated apparent
terminal elimination half-life (t1/2) was calculated as ln2/lz. Clearance was
calculated as dose/AUC(0-‘), and the volume of distribution at steady state was
calculated as CL * mean residence time (MRT), where MRT is the mean
residence time after i.v. administration.
For human samples, the percentage of radioactivity associated with blood
cells was calculated according to the equation 100 – [(Cp)(1 2 Hct)/(Cb) 
100], where Cp and Cb are the concentrations of radioactivity in plasma and
blood, respectively, and Hct is the hematocrit. The blood:plasma ratio was
calculated as Cb/Cp.
Investigations to Generate M3 Using In Vitro Systems
S9 and Microsomal Incubations. For incubations with NADP,
[14C]GSK2251052 (50 and 500 mM) was incubated with 4 mg/ml of monkey
S9 (homogenate fraction obtained from centrifugation at 9000g; liver, lung, and
kidney) or liver microsomes (monkey and human) in 50 mM potassium
phosphate buffer at pH 7.4 containing 5.5 mM glucose-6-phosphate, 0.44 mM
NADP, and 1.12 units/ml glucose-6-phosphate dehydrogenase. For incubations
with NAD+, [14C]GSK2251052 (500 mM) was incubated with 4 mg/ml S9
(monkey liver, lung, kidney, and human liver S9 only) or liver microsomes
(monkey and human) and 7.5 mM NAD+ in 30 mM sodium pyrophosphate
buffer at pH 7.4, or in 23 mM sodium pyrophosphate buffer at pH 8.4 or 8.8.
Incubations containing no NADP, NAD+, or S9 were used as negative
controls, whereas incubations containing 250 mM 7-ethoxycoumarin served as
positive controls. Where appropriate, 4-MP was added to incubations to yield
a final concentration of 0.6 mM.
Cytosol Incubations. [14C]GSK2251052 (500 mM) was incubated with 4
mg/ml of liver cytosol (monkey and human) containing 7.5 mM NAD+ in 30
mM sodium pyrophosphate buffer at pH 7.4 or 23 mM sodium pyrophosphate
buffer at pH 8.4. Incubations without NAD+ or liver cytosol were used as
negative controls. Where appropriate, 4-MP was added to incubations to yield
a final concentration of 0.6 mM. To verify ADH in the preparations of liver
cytosol, human and monkey liver cytosol (4 mg/ml) was incubated with 7.5
mM NAD+, ethanol (0.1%), and 30 mM sodium pyrophosphate buffer at pH
7.4. Incubations in the absence of ethanol or in the presence of 4-MP (0.6 mM)
were performed in parallel as controls. To assess the concentration-dependent
inhibitory effect of GSK2251052 on its own metabolism, [14C]GSK2251052
(1–50 mM) was incubated with human liver cytosol (1.5 mg/ml) in phosphate
buffer, pH 7.4, containing 7.5 mM NAD+ for up to 20 hours.
In Vitro Sample Preparation and Analysis. All samples from in vitro
incubations, except positive controls with ethanol, were run in triplicate for 1 or
3 hours in a shaking water bath set to 37°C and 100 rpm. Following incubation,
individual samples were quenched with acetonitrile such that the ratio of
acetonitrile was 45%. Samples were then centrifuged at approximately 21,000g
for 5 minutes to remove protein precipitate, and the supernatant was removed to
Fig. 3. Concentration-time plot: mean (n = 6) plasma con-
centrations of GSK2251052 (, ng/ml), M3 (s, ng/ml),
GSK2251052 + M3 (+, ng/ml), and total radioactivity (d, ng
equivalents/ml) obtained from a combination of LSC, AMS,
and LC/MS/MS analyses.
TABLE 2
Mean percentage of cumulative radioactivity recovered from six healthy male
subjects after a single 1500 mg i.v. infusion dose of [14C]GSK2251052
Time Period Urine Feces Total
h % dose % dose % dose
0–24 51.2 0.1 51.3
0–48 69.2 1.3 70.5
0–72 76.9 4.3 81.2
0–96 81.1 6.4 87.5
0–120 83.4 7.3 90.7
0–144 85.1 7.5 92.6
0–168 86.4 7.6 94.0
0–192 87.4 7.6 95.0
0–216 88.2 7.6 95.8
0–240 88.8 7.6 96.4
0–264 89.3 7.6 97.0
0–288 89.8 7.6 97.4
0–312 90.2 7.6 97.8
0–336 90.5 7.6 98.2
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a fresh vial. An aliquot (10 ml) of each supernatant, except 7-ethoxycoumarin,
was mixed with 5.0 ml Ultima Gold scintillation cocktail and analyzed using
liquid scintillation counting. Data obtained from liquid scintillation counting
were used to assess the recovery of radiocarbon in sample extracts.
Portions of the replicates were then pooled using equal volumes to produce
a single representative sample for each incubation condition. The pooled
portions were diluted with water 10-fold prior to analysis using HPLC as
described previously in the Metabolite Profiling and Identification section,
except that radiochemical detection was performed by a PerkinElmer Radio-
matic 625TR series flow scintillation analyzer with Laura version 3.4.11
software and Ultima Flo M scintillation fluid (3 ml/min).
Experiments to Assess the Formation of NADH. GSK2251052 (final
concentrations of 0.001, 0.01, 0.1, 1.0, and 10 mM) was incubated with human
liver cytosol (1.5 mg/ml), NAD+ (0.22 mM), and sodium pyrophosphate buffer,
pH 8.8 (22 mM), or potassium phosphate buffer, pH 7.4 (50 mM), at room
temperature. The incubations, in triplicate, were conducted in a 96-well plate
with the reactions started by addition of GSK2251052. The NADH produced
during GSK2251052 oxidation in the incubations was measured at an absor-
bance of 340 nm using a SpectraMax spectrophotometer (Molecular Devices,
Sunnyvale, CA). Incubations with the ADH inhibitor 4-MP (0.6 mM) were
included as positive inhibitor controls. Incubations without enzyme, NAD+, or
GSK2251052 were included as negative controls. Incubations containing eth-
anol in the absence of GSK2251052 were conducted to confirm metabolic
activity of the enzyme preparations. Cytosolic and purified ADH incubation
samples were analyzed by UV absorbance detection at 340 nm as a function of
time (every 60 seconds for1 hour, or every 2 minutes for 120 minutes). Rates of
NADH formation were calculated by monitoring the decrease in NADH
formation, and were expressed as the rate (slope).
Fig. 4. Representative HPLC radiochromatogram of pooled urine [0–120 hours (top) and 120–336 hours (bottom)] following a single 1500-mg i.v. infusion of GSK2251052
in humans. CPM, counts per minute.
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GSK2251052 (final concentrations of 1 and 10 mM) was incubated with
purified ADH (0.025 units/ml), NAD+ (7.5 mM), and potassium phosphate
buffer, pH 7.4 (50 mM), at room temperature, and samples were analyzed by
UV detection as described previously.
Results
Clinical Safety and Tolerability Data. All subjects completed the
study as planned and received the correct treatment in the fasting state.
The treatments were well tolerated with no deaths, serious adverse
events, or withdrawals due to adverse events (AEs) reported. Three
subjects (50%) reported AEs, all of which were mild in intensity
(headache, diarrhea, infrequent bowel movements, and insomnia) and
resolved during the study without treatment or intervention. Two
subjects experienced multiple AEs (infrequent bowel movements and
headache; insomnia and headache). None of the AEs were considered
to be related to the study drug.
Clinical Pharmacokinetic Results. Six healthy fasted males
received a single i.v. dose of 1500 mg of [14C]GSK2251052 (15
mCi) infused over 1 hour. The pharmacokinetic parameters for whole
blood and plasma radioactivity, GSK2251052, and M3 are presented
in Table 1, and the concentration-time profiles for plasma radioactivity
are shown in Fig. 3. The bioanalytical method was robust and
performed well, with quality control samples for both GSK2251052
and M3 demonstrating accuracy and precision in the range of
0.0–6.2% and 1.5–6.6%, respectively, during analysis of the study
samples. The half-life of radioactivity (96 hours) was notably longer
than that observed for the parent compound (11.6 hours). The plasma
concentration for M3 peaked at 7 hours, and the elimination half-life
was 77.3 hours, approaching that observed for total plasma radio-
activity. The plasma AUC(0-‘) values for GSK2251052 and M3 were
37 and 53% of the radioactivity AUC(0-‘) value, respectively. Relative
to total body water [42 l (Davies and Morris, 1993)], total radioactivity
and GSK2251052 were both highly distributed in tissues with volume
of distribution at steady state (Vss) values of 348 and 197 l, respec-
tively, and plasma clearance (CLp) for GSK2251052 was 20.7 l/h.
Blood-to-plasma-concentration ratios ranged from 1.03 to 2.03 through
24 hours postdose, and the calculated percentage of radioactivity
associated with red blood cells ranged from 44 to 71.9% through 24
hours postdose. The AUC(0-‘) of radioactivity in plasma and whole
blood were generally similar (2% difference).
Mass Balance and Excretion in Urine and Feces. The mean total
recovery of radioactivity was 98.2% (range of 92.7–99.9%) (Table 2),
with the majority of the dose (90.5%) excreted in the urine and fecal
elimination representing a minor route of elimination (7.6% of the
dose). Approximately 80% of the dose was recovered during the first
72 hours, and by 192 hours, 95% of the administered dose had been
recovered. Excretion of residual radioactivity into the urine continued
throughout the 336-hour collection period, which is consistent with
the long plasma half-life of M3.
Fig. 5. Representative HPLC radiochromatogram of pooled feces (0–120 hours) following a single 1500-mg i.v. infusion of GSK2251052 in humans. CPM, counts per
minute.
TABLE 3
Individual percentage of GSK2251052-related components in human excreta
(0-120 hours) after a single i.v. dose of 1500 mg of [14C]GSK2251052
Metabolite
% Administered Dose Recovered in Each Subject
101 102 103 104 105 106 Mean 6 S.D.
Urinea
GSK2251052 27.8 31.6 32.4 23.3 27.9 30.4 28.9 6 3.0
M1 BQL BQL BQL BQL BQL BQL BQL 6 NC
M2 BQL BQL BQL BQL BQL BQL BQL 6 NC
M3b 44.7 42.6 43.8 41.0 39.3 51.6 43.8 6 3.9
M7 BQL BQL BQL BQL BQL BQL BQL 6 NC
Total quantified 72.5 74.2 76.2 64.4 67.3 82.0 72.8 6 5.8
Total radioactivity 84.1 83.2 86.6 80.8 77.4 86.4 83.1 6 3.2
Feces
M1 1.2 1.3 1.1 2.3 0.8 1.8 1.4 6 0.5
M3 2.6 4.7 2.7 3.3 3.1 3.3 3.3 6 0.7
Total quantified 3.9 6.0 3.8 5.5 3.9 5.1 4.7 6 0.9
Total radioactivity 4.7 7.4 5.4 6.9 5.7 5.9 6.0 6 0.9
BQL, below quantification limit; NC, not calculated.
a120–336-hour urine samples from each subject were pooled proportionally by sample weight,
and equal volumes of each pool were combined to produce a single composite sample.
bM3 (5.9% of dose) was the only component detected in the composite sample.
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Metabolite Profiling and Characterization. Low levels of radio-
activity present in plasma precluded metabolite profiling analysis of
this particular matrix using conventional approaches. Representative
HPLC radiochromatograms of pooled urine (0–120 and 120–336
hours) and fecal extracts (0–120 hours) are shown in Figs. 4 and 5.
Individual and mean quantitative data for metabolites from the six
subjects are presented in Table 3. GSK2251052 and metabolite M3
represented a mean of 28.9 and 49.7% of the administered dose,
respectively, through 336 hours postdose in urine. Three minor
metabolites were also detected in urine and identified by mass
spectrometry (Supplemental Table 1), but were below the LLQ: M1
(deboronation, oxidation), M2 (deboronation), and M7 (N-acetylated
M3). The proposed metabolic scheme for GSK22520152 in humans is
shown in Fig. 6.
Mean combined extraction and reconstitution efficiencies of radio-
activity from the fecal homogenates were 94.8%. The principal com-
ponents in feces were metabolites M3 and M1, which represented
a mean of 3.3 and 1.4% of the dose through 120 hours postdose,
respectively. Unchanged GSK2251052 was not detected in feces.
Overall, at least 83% of the administered radioactivity was identified
in urine and feces.
In Vitro Investigations of the Enzyme Responsible for the
Formation of M3. The in vitro metabolism of [14C]GSK2251052 and
the formation of the oxidative metabolite M3 were investigated in
selected tissue subcellular fractions from cynomolgus monkey (liver
S9, cytosol, microsomes, as well as, lung and kidney S9) and human
(liver S9, cytosol, and microsomes). No metabolism of [14C]GSK2251052
or formation of metabolite M3 was observed in monkey liver, lung, or
kidney S9, or human liver microsomes in the presence of an NADPH
regeneration system (unpublished data). In contrast, in the presence of
NAD+, low (#10%) but detectable metabolism of [14C]GSK2251052
and the formation of M3 was observed in monkey liver S9, cytosol, and
microsomes (Table 4), but not in monkey lung and kidney S9, or in
human liver S9, cytosol, or microsomes (unpublished data). Additionally,
M3 was not observed in monkey liver S9 or cytosol containing NAD+
cofactor following incubation in the presence of the ADH inhibitor 4-MP.
Although M3 was not observed in human liver cytosolic and
purified ADH enzyme incubations, ADH involvement in GSK2251052
metabolism was further assessed by spectrophotometric measure-
ment of NADH produced in the incubations as a result of oxidation
to an aldehyde intermediate of M3. In human liver cytosol and
purified ADH enzyme incubations with GSK2251052, a time-dependent
Fig. 6. Proposed metabolites of GSK2251052 in humans.
TABLE 4
Percentage of GSK2251052 and M3 following 3-hour incubations of
[14C]GSK2251052 (500 mM) with NAD+ (7.5 mM) at pH 7.4, 8.4, and 8.8 in
monkey liver S9, cytosol, and microsomes
Peak
Percentage of Total Radioactivity (Peak Area)
S9 Cytosol Microsomes
pH 7.4 pH 8.4 pH 8.8 pH 7.4 pH 8.4 pH 7.4
M3 7.7 6.7 4.3 1.7 0.9 2.5
GSK2251052 87.8 85.6 89.0 88.7 97.7 87.9
Total 95.5 92.3 93.3 90.4 98.6 90.4
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increase in absorbance at 340 nm was observed. This increase in absor-
bance was dependent on the ADH cofactor, NAD+, and was not observed
in the presence of the ADH inhibitor, 4-MP (Fig. 7).
Pharmacokinetics of GSK2251052 in Monkeys Administered
4-MP. During a single 1-hour infusion of GSK2251052, following
an oral dose of 4-MP, a 53–63% decrease in the mean CLP of
GSK2251052 was observed (Table 5). This decrease in plasma
clearance resulted in a 2.0- to 2.7-fold increase in the mean AUC(0-‘)
values of GSK2252015 and an associated 79–91% decrease in sys-
temic exposure (mean plasma Cmax and AUC(0-t) values) of M3. The
ratio of the AUC values for M3 to GSK2251052 ranged from 0.49 to
1.3 when GSK2251052 was dosed alone; the ratio ranged from 0.04 to
0.09 when 4-MP was dosed with GSK2251052. However, the impact
of 4-MP on the mean GSK2251052 Cmax values was minimal. The
mean plasma half-life (t1/2) and MRT of GSK2251052 increased
55–70% and 2.2- to 2.3-fold, respectively, in the presence of 4-MP.
There was no impact of 4-MP on the mean Vss for GSK2251052. As
there were no significant differences in the pharmacokinetics between
male and female animals, for brevity, only data from male animals are
described in this paper.
Discussion
GSK2251052 is a novel, boron-containing antibiotic that inhibits
bacterial LeuRS and has been in development for the treatment of
serious Gram-negative infections. This investigation evaluated the
pharmacokinetics, metabolism, and excretion of GSK2251052 in
humans after a single i.v. dose (1500 mg) of [14C]GSK2251052
administered as an infusion over 1 hour. Additionally, the enzyme
believed to be responsible for the metabolism of GSK2251052 was
studied by conducting in vitro experiments and a nonclinical phar-
macokinetic study with the ADH inhibitor 4-MP. In the clinical study,
GSK2251052 was well tolerated with only mild adverse events reported.
This clinical study was designed with an extended collection period
(minimum of 14 days postdose) to provide the best opportunity for
complete recovery. The result was that mass balance was achieved, with
a large proportion of the radioactivity (mean 81.1%) recovered in urine
within 5 days following i.v. administration, and essentially complete
recovery (98.2%) in urine and feces by 14 days.
Total radioactivity and GSK2251052 were both highly distributed
in tissues with Vss values of 348 and 197 l, respectively, far exceeding
total body water (42 l) for a typical 70-kg male (Davies and Morris,
1993). On average, CLp was 20.7 l/h for GSK2251052. Since ap-
proximately 70% of GSK2251052 systemic CLp is nonrenal (un-
published observations) and based on a blood:plasma ratio of 1.5, the
average hepatic blood CL is 9.7 l/h, indicating that GSK2251052 is
a low-clearance compound relative to a hepatic blood flow of 87 l/h
(Davies and Morris, 1993). The mean AUC(0-‘) values of radioactivity
in plasma and whole blood were generally similar (2% difference),
indicating that radioactivity was moderately associated with red blood
cells.
LC/MS/MS quantification and subsequent pharmacokinetic analysis
of GSK2251052 and metabolite M3 demonstrated that the metabolite
had a significantly longer elimination half-life: 77.3 hours compared
with 11.6 hours for the parent compound. Consistent with these data,
plasma concentrations of metabolite M3 were measurable at the last
sampling time point, 336 hours (Fig. 3), in contrast to GSK2251052,
which was only measurable up to 96 hours. Using LSC, it was only
possible to quantify plasma radioactivity up to the 96-hour time point
due to the lack of sensitivity of this particular analytical approach.
Using AMS as a significantly more sensitive technique to determine
plasma radioactivity at later time points allowed construction of
the complete plasma concentration-time profile. It was then possible
to demonstrate that the combined GSK2251052 and metabolite
M3 plasma exposure (mean AUC(0-‘) of 37 and 53%, respectively)
Fig. 7. NADH formation (absorbance at 340 nm) in human liver cytosolic
incubations with the ADH probe substrate, ethanol, or GSK2251052 (1, 10, or 100
mM) for 60 or 120 minutes at pH 7.4.
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represented the significant majority of the plasma radioactivity AUC(0-‘).
Additionally, the elimination half-life of M3 (77.3 hours) approached
that of plasma radioactivity, 96 hours. Although an acyl glucuronide
conjugate of M3 had not been previously observed in other metab-
olism studies (unpublished data), analysis of acidified plasma from
this clinical study provided confirmation that such a conjugate, if
TABLE 5
Summary of pharmacokinetic parameters of GSK2251052 and M3 after a single i.v. infusion of GSK2251052 (35 mg/kg) alone or with a single oral gavage dose
of 4-MP (35 mg/kg) in male monkeys
Analyte Treatmenta AUC(0-‘)
b,c Cmax
b CL b Vss b MRT b T1/2
b Tmax
b
h × mg/ml mg/ml l/h/kg l/kg h h h
GSK2251052 Alone 60.7 (51.3–76.7) 46.0 (17.3–99.1) 0.60 (0.46–0.68) 3.04 (1.66–3.97) 4.9 (3.6–5.8) 5.4 (4.8–5.9) 0.92 (0.92–0.92)
Plus 4-MP 161 (148–18) 68.6 (21.9–161) 0.22 (0.19–0.24) 2.53 (1.99–2.88) 11 (10–12) 9.2 (8.6–9.7) 0.92 (0.92–0.92)
M3 Alone 52.3 (42.8–67.0) 4.15 (3.49–4.54) NA NA NA NA 3.0 (3.0–3.0)
Plus 4-MP 11.0 (9.49–13.0) 0.36 (0.32–0.42) NA NA NA NA 9.0 (9.0–48)
NA, not applicable.
aN = 3/treatment, and data from males shown only for brevity.
bValues are the mean and (range), except for Tmax, which is shown as the median (range).
cFor M3, AUC0-t.
Fig. 8. Individual plasma concentration-time profiles of GSK2251052 and M3 from LC/MS/MS analyses following a single i.v. infusion administration of GSK2251052 at
35 mg/kg alone or in combination with 4-MP at 35 mg/kg to male monkeys.
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present in plasma, would not hydrolyze and interfere with the quan-
titative assessment of M3.
Consistent with the plasma pharmacokinetic data, analysis of urine
demonstrated that metabolite M3 was a significant pathway of clear-
ance for GSK2251052, consisting of approximately 50% of the dose
recovered in that matrix. M3 was considered major as it represented
greater than 10% of drug-related exposure, and therefore, according to
the International Conference on Harmonization (Non-Clinical Safety
Studies for the Conduct of Human Clinical Trials for Pharmaceuticals,
International Conference on Harmonization Guidance M3(R2), 2009;
http://www.emea.europa.eu/pdfs/human/ich/028695en.pdf), was inves-
tigated further in the relevant toxicity species (unpublished data). In
addition to M3, three other minor metabolites of GSK2251052 were
also identified in this study. Metabolite M1, which results from
deboronation and oxidation of the propanol side chain, represented
1.4% of the dose recovered in the feces. M1 was also detected in urine
but below quantifiable levels, similar to the two other minor metabolites,
M2 and M7. Metabolite M3 results from a simple oxidation of the
propanol side chain to the corresponding carboxylic acid derivative;
however, it has been determined previously that the metabolite does
not appear to have significant antibacterial activity (Peter DeMarsh,
internal communication).
To assess the enzyme responsible for the formation of M3, a series
of in vitro studies were conducted using both human and monkey
hepatic and nonhepatic tissue subcellular fractions. The limited
formation of M3 in these experiments in the presence of NADPH
suggested that the metabolism of [14C]GSK2251052 was likely not
mediated by cytochrome P450 enzymes. Additionally, the low (#10%),
but detectable, formation of M3 observed in monkey liver S9 in the
presence of NAD+ was eliminated in the presence of 4-MP, a known
inhibitor of monkey liver ADH (Makar and Tephly, 1975). Although
M3 was not detected in human liver cytosolic or purified ADH
incubations fortified with NAD+, the NADH produced during
GSK2251052 oxidation could be assessed by the UV spectrophoto-
metric measurement of the conversion of NAD+ to NADH, which
results in a time-dependent increase in absorbance at 340 nm. The
NADH formation in these enzyme preparations was dependent on
the ADH cofactor, NAD+, and was not observed in the presence of the
ADH inhibitor 4-MP. Class I ADH enzymes (ADH1A, 1B, and 1C) are
highly sensitive to 4-MP, and demonstrate substrate inhibition at high
concentrations (Riveros-Rosas et al., 1997). Indeed, a concentration-
dependent inhibitory effect of GSK2251052 on its own metabolism
was observed as noted by the overlapping 340-nm absorbance spectra
at the highest concentration of GSK2251052 (100 mM) in the presence
of NAD+ compared with that observed in the presence of the ADH
inhibitor, 4-MP. In contrast, at a substrate concentration of 1 mM, time-
dependent absorbance changes were only observed with incubations
containing NAD+, and the absorbance spectrum was identical in the
absence or presence of cofactor and the ADH inhibitor 4-MP. Taken
together with consideration that M3 resulted from oxidation of the
propanol side chain to the corresponding carboxylic acid, the in vitro
data indicated that ADH may be involved in metabolism of
[14C]GSK2251052. To test this hypothesis, a pharmacokinetic in-
teraction study was designed and conducted in monkeys with
GSK2251052 and 4-MP. An i.v. administration of GSK2251052
to monkeys, in combination with an oral dose of 4-MP, markedly
decreased the plasma clearance of GSK2251052. The resultant in-
crease in GSK2251052 plasma exposure was observed with a con-
cordant reduction in M3 exposure (Fig. 8). Additionally, the terminal
half-life and MRT of GSK2251052 were markedly increased in the
presence of 4-MP, with no impact on Vss. Collectively, these exper-
iments provide strong evidence that ADH, potentially in association with
aldehyde dehydrogenase (ALDH), is the enzyme(s) involved in the
metabolism of GSK2251052 and formation of M3. Both ADH and
ALDH are polymorphic enzymes and critical players in ethanol me-
tabolism; ADH1B catalyzes the oxidation of ethanol to acetaldehyde,
and ALDH2 catalyzes the oxidation of acetaldehyde to acetate. Func-
tional polymorphisms in the ADH1B and ALDH2 genes (Agarwal, 2001)
have a significant influence on the activities of both enzymes, and are
stratified by race, with the ADH1B*2 (increased catalytic activity) and
ALDH2*2 (reduced catalytic activity) alleles being common in East
Asians and virtually absent in Caucasians (Eriksson et al., 2001).
Fig. 9. Summary of the routes of elimination of GSK2251052-related components in humans.
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Theoretically, subjects with increased or rapid ADH activity may
quickly metabolize GSK2251052, leading to lower parent concen-
trations, which in turn may impact efficacy. Subjects with reduced or
inactive ALDH activity may slowly or ineffectively metabolize the
aldehyde intermediate to the acid (M3).
In conclusion, following i.v. administration, the recovery of
[14C]GSK2251052 and related components from urine and feces was
essentially complete, with urine being the principal route of excretion
(Fig. 9). Metabolite M3, a product of oxidation of the propanol side
chain, was the primary metabolite of GSK2251052 and the predom-
inant circulating component in plasma. Our data suggest that M3 is
formed by ADH, potentially in association with ALDH. These are poly-
morphic enzymes, and therefore, the clinical exposure of GSK2251052
and M3 may vary between certain ethnic populations (Enomoto et al.,
1991; Chen et al., 2009).
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ABSTRACT
The metabolism and disposition of vilanterol, a novel long-acting b2-
adrenoceptor agonist (LABA) for inhalation use, was investigated
after oral administration in humans. Single oral administrations of up
to 500 mg of vilanterol were shown to be safe and well tolerated in
two clinical studies in healthy men. In a human radiolabel study, six
healthy men received a single oral dose of 200 mg of [14C]vilanterol
(74 kBq). Plasma, urine, and feces were collected up to 168 hours
after the dose and were analyzed for vilanterol, metabolites, and
radioactivity. At least 50% of the radioactive dose was orally
absorbed. The primary route of excretion of drug-related material
was via O-dealkylation to metabolites, which were mainly excreted in
urine. Vilanterol represented a very small percentage (<0.5%) of the
total drug-related material in plasma, indicative of extensive first-
pass metabolism. Circulating metabolites resulted mainly from O-
dealkylation and exhibited negligible pharmacologic activity. The
therapeutic dose level for vilanterol is 25 mg by the inhalation route.
At this low-dose level, the likelihood of pharmacologically inactive
metabolites causing unexpected toxicity is negligible. In addition to
providing an assessment of the disposition of vilanterol in human,
this work highlights a number of complexities associated with
determining human absorption, distribution, metabolism, and excre-
tion (ADME) for inhaled molecules—mainly related to the low
chemical doses and complications associated with the inhalation
route of administration.
Introduction
Vilanterol, GW642444, or 4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)
methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxyl methyl)
phenol, is a novel long-acting b2-agonist (LABA) with inherent 24-
hour activity for once-daily clinical treatment of chronic obstructive
pulmonary disease (COPD) and asthma in combination with the
inhaled novel corticosteroid fluticasone furoate, also active for 24
hours (Hanania et al., 2012; Lotvall et al., 2012). This publication
describes in vitro and clinical studies conducted to determine the
metabolism and disposition of vilanterol in humans. This information
is used to provide reassurance on the metabolite safety of vilanterol, to
assess any metabolite contribution to the pharmacology, and to define
the mechanisms of disposition and elimination that might be susceptible
to drug interactions or relevant to special patient populations.
Traditionally, the metabolism and disposition of a molecule is
determined after administration of a radioactive drug analog by the
intended clinical route and includes aspects such as radioactive recovery
in excreta, identification of metabolites, and quantitative radiometabolite
profiles, usually in plasma and excreta. This study is commonly referred
to as the human radiolabel study (HRS). There are many challenges
associated with the design and conduct of an HRS for low-dose
inhalation molecules such as vilanterol where the clinical dose is only
25 mg. These, as described here, considerably impacted the approaches
used to determine the metabolism and disposition of vilanterol.
Although precedent exists for dosing radiolabel by the inhalation
route (Affrime et al., 2000), for some molecules the inhalation route is
not necessarily the best or most feasible approach, especially if the
This work was funded by GlaxoSmithKline R&D, UK, as part of the
development program for vilanterol as a novel therapeutic agent. Data in this
manuscript correspond with clinical study numbers B2C106180 (GSK company
report GM2009/00020/00) and B2C106181 (GSK company report YM2010/
00088/00) with metabolite identifications reported in study number 10DMW020
(GSK company report 2011N115614). Hepatocyte incubations were reported in
GSK company report WD2006/02574/00. Pharmacologic activities of metabolites
were reported in GSK company report HR2008/00016/00. All authors were
employees of GlaxoSmithKline Research and Development Ltd. at the time of
conducting the work.
Primary Laboratory of Origin: Drug Metabolism and Pharmacokinetics Division,
GlaxoSmithKline Research and Development Ltd., Park Road, Ware, United
Kingdom
dx.doi.org/10.1124/dmd.112.048603.
ABBREVIATIONS: ADME, absorption, distribution, metabolism, and excretion; AMS, accelerator mass spectrometry; AUC(0–t), area under the
curve to last sample time where drug was measurable; COPD, chronic obstructive pulmonary disease; CRC, concentration–response curve; DMSO,
dimethyl sulfoxide; DRM, drug-related material; GSK, GlaxoSmithKline; HMR, Hammersmith Medicines Research Centre; HPLC, high-performance
liquid chromatography; HRS, human radiolabel study; LABA, long-acting b-agonist; LLQ, lower limit of quantification; LSC, liquid scintillation
counting; MS, mass spectrometry; NMR, nuclear magnetic resonance spectroscopy; NQ, nonquantifiable; PRA, Pharmaceutical Research
Associates; TR-FRET, time-resolved fluorescence resonance energy transfer.
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inhalation device and formulation are complex. Re-creating the com-
mercial physical form of a radioactive drug analog in its intended device
is difficult; thus, the quantitative information after inhalation of a
radioactive analog is not usually representative of the clinical situation.
Exhalation of radioactive drug after inhalation administration not only
creates safety and containment considerations but also makes it very
difficult to reliably quantify the administered radioactivity that is needed
to fully interpret excretion and metabolism data. Other challenges arise
due to the low chemical dose level of inhaled drugs, which limits the
radioactive dose and leads to biologic samples containing very low
concentrations of both metabolite chemical mass and radioactivity,
thereby impairing our ability to measure and identify metabolites. The
inhalation route provides few opportunities to adjust chemical and
radioactive doses to avoid these technical problems.
Further complications, specific to [14C]vilanterol, included radiol-
ysis of the [14C] isotope, which meant that it was unstable over the
periods required to support manufacture and release of either
intravenous or inhalation formulations, effectively ruling out these
routes of administration. Radiolysis limited the [14C]vilanterol specific
activity to 370 kBq/mg, also restricting the amount of radioactivity
that could be administered. The vilanterol HRS was, therefore,
conducted by the oral route using a dose level of 200 mg containing
only 74 kBq radioactivity. The oral dose level of 200 mg of [14C]
vilanterol was selected because it was higher than the inhaled clinical
dose of 25 mg, allowing sufficient administered radioactivity to
generate radioactive metabolite profiles for plasma, urine, and feces
using accelerator mass spectrometry (AMS) as a highly sensitive
radioactivity counter. The chemical structure of [14C]vilanterol
showing the position of the [14C] label is shown in Fig. 1. A
preceding clinical study (hereafter referred to as the tolerability study)
established the safety and tolerability of oral administrations up to
500 mg of unlabeled vilanterol.
The emergence of AMS as a very low level radioactivity counter
has enabled radioactive metabolite profiles to be generated in samples
containing very low levels of radioactivity. The radioactive dose of 74
kBq permitted traditional liquid scintillation counting (LSC) to be
used for some aspects of the study (e.g., radioactivity in urine and
feces), but AMS was essential for determining concentrations of
radioactivity in plasma and for metabolite profile work. Although AMS
is an excellent technique for low-level radioactivity measurement, it
Fig. 1. Metabolic scheme for vilanterol in humans. Chemical structures are shown for vilanterol and important human metabolites. 14C indicates the position of labeled
carbon.
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does not directly provide structural information to assist with metabolite
identification. The chemical dose level used here (200 mg) allowed
limited application of high-performance liquid chromatography–mass
spectrometry (HPLC-MS) to provide structural information on some
metabolites. The majority of human metabolite structures were,
however, assigned by chromatographic retention time comparison with
metabolites whose full identification was achieved in other samples
containing greater chemical mass (e.g., in vitro/in situ experiments or
animal studies). Thus, in vitro incubations conducted using mouse, rat,
dog, rabbit, and human hepatocytes that were the primary source of
metabolite structures are also described.
Materials and Methods
Vilanterol, [14C]vilanterol, and four potential metabolites (GW630200,
GSK167112, GW853734, and GSK932009) were supplied by Chemical
Development, GlaxoSmithKline (GSK) R&D, Stevenage, United Kingdom.
The specific activity of vilanterol was 370 kBq/mg. All other solvents and
reagents were of analytical grade and were purchased from commercial
suppliers.
Clinical Study Design, Study Centers, and Subjects The tolerability study
was an ascending-dose, single-center, open-label study in nine healthy men
conducted at Hammersmith Medicines Research Centre (HMR), London,
United Kingdom, between October 21, 2008 and December 17, 2008 (last
sample last visit). The HRS was a single-center, open-label study in six healthy
male volunteers conducted at Pharmaceutical Research Associates (PRA),
Zuidlaren, the Netherlands between May 18, 2010 and July 9, 2010. All
subjects provided written informed consent before participation, and the
protocols were approved by the investigational centers’ ethics committees. The
men were in good health as shown by medical examination, clinical chemistry,
hematology, and urine analysis. They were nonsmokers with no history of drug
or alcohol abuse, were taking no other medication at the time of each study, and
had taken no prescribed medication within 14 days of each study commencing.
The target radioactive dose of 74 kBq corresponds to an effective radioactive
dose of 20 mSv, which is considerably lower than the upper limit for both the
World Health Organization (,500 mSv) and International Commission on
Radiologic Protection (,100 mSv) category I exposures which are considered
variations in natural background radiation with a minimal risk. The effective
radioactive dose was calculated by the United Kingdom Health Protection
Agency according to the recommendations of the International Commission on
Radiologic Protection (ICRP, 1991).
Dose Formulation and Administration Vilanterol and [14C]vilanterol were
supplied to the study centers by GSK, Ware, UK, as sterile solutions. For the
tolerability study, a solution (5% ethanol in water) containing 50 mg/ml
vilanterol was supplied to HMR. The subjects received a single oral dose of
either 4 ml or 10 ml of this solution containing 200 or 500 mg of vilanterol,
respectively. For the HRS, a solution (80% ethanol in water) containing 200
mg/ml [14C]vilanterol (74 kBq/ml radioactivity) was supplied to PRA. For each
volunteer, the solution was diluted 1 in 20 with water by PRA. All subjects
received a single 20 ml oral dose containing 200 mg of [14C]vilanterol (74 kBq
radioactivity) administered via syringe. After administration of each vilanterol
solution, water (2  20 ml) was administered to the subject using the same
syringe to ensure that the complete dose was given. A third volume of water (20
ml) was drawn up into the syringe (HRS only) then dispensed into a suitable
container, and residual radioactivity was determined by liquid scintillation
counting (LSC). The total residual radioactivity was deducted from the
dispensed radioactivity to determine the overall administered radioactive dose.
Sample Collection Blood samples (2 ml in the tolerability study; 6 ml in the
HRS) were collected at predefined times up to 7 days after dosing via either an
indwelling cannula or by direct venipuncture into EDTA-containing poly-
propylene tubes. These were used for plasma measurement of vilanterol (both
studies) and radioactivity (HRS only). Additional blood (18 ml, HRS only) was
collected at 0.5, 3.5, and 24 hours after dosing and used for metabolic
investigations. Blood was placed on crushed ice before centrifugation in
a refrigerated centrifuge at approximately 1500g for 10 minutes to yield
plasma, which was then stored frozen at nominally 220°C. All urine and feces
(HRS only) were collected at 24-hour intervals up to at least 7 days after the
dose administration. The fecal and urine samples were stored frozen at 220°C
or less before analysis.
In Vitro Incubations [14C]Vilanterol was incubated at a concentration of 10
mM in the presence of mouse, rat, dog, rabbit, and human cryopreserved
hepatocytes (In Vitro Technologies Inc., Baltimore, MD) using Williams Medium
E incubation media supplemented with antibiotics, at 37°C for 24 hours. After
incubation, methanol (1.2 ml) was added to all hepatocyte incubations (0.6 ml),
the precipitate was centrifuged at 7500g at ambient temperature for 5 minutes,
and the supernatant was removed for further analysis.
Assay for Total Radioactivity (HRS Only) After measurement of the
volume of urine or weight of stool, the levels of radioactivity were determined
by LSC (Beckman LS series, Bucks, UK, or PerkinElmer Life Sciences, Bucks,
UK) with quench correction performed by an automatic external standard ratio
method, which was established using sealed 14C standards. Aliquots of liquid
samples (e.g., urine and dose dilutions) or extracts of samples were mixed with
scintillation fluid. Fecal samples were homogenized with a minimal amount of
water and reweighed. Aliquots of homogenized fecal material were combusted
using a Packard model 307 oxidizer (Canberra Packard, Didcot, UK) before the
radioassay. In some urine and feces samples, the levels of radioactivity were too
low to be determined by LSC. After their combustion to graphite, the levels of
radioactivity in these samples were determined via AMS (a 5 MV tandem
accelerator mass spectrometer) at Xceleron Ltd. (York, UK). The analysis of
plasma was conducted at GSK using AMS (a 250-kV single-stage accelerator
mass spectrometer; Young et al., 2008). The lower limit of quantitation (LLQ)
was previously established as 10% above endogenous background levels of
total radioactivity in human plasma with greater than 95% confidence limit
(data not shown). Based on the predose plasma values for the six men in the
human ADME study and the specific activity administered, this corresponded
to 2.45 pg equivalents of vilanterol/ml.
Determination of Radiochemical Purity (HRS Only) The radiochemical
purity of [14C]vilanterol solution was determined using the HPLC system
described here for metabolite analysis. The radiochemical purity of the
administered [14C]vilanterol determined on the day of dosing was 99.4%.
Quantification of Vilanterol in Plasma (Tolerability Study and HRS)
Concentrations of vilanterol in human plasma samples were determined using
analytical methods validated to GSK worldwide standard operating procedures,
which are based on guidelines set out by the US Food and Drug Administration.
The extraction method for vilanterol used solid-phase extraction to achieve a low
limit of quantitation (LLQ) of 10 pg/ml from a 200-ml aliquot of plasma where
[2H12]vilanterol was added as an isotopically labeled internal standard. Extracts
were analyzed using HPLC (Waters Acquity System; Waters, Milford, MA) and
tandem mass spectrometry (HPLC-MS/MS). The mass spectrometer used was an
API-4000 triple quadrupole using a TurboIonSpray interface (AB Sciex,
Framingham, MA) in positive mode with multiple reaction monitoring. The
mass transitions were 486 to 159 and 498 to 159 for vilanterol and [2H12]
vilanterol, respectively.
Quantification and Profiling of Metabolites An equal volume of plasma
from each man was pooled to produce a single discrete representative sample
per time point. A single discrete pooled human urine sample was prepared by
mixing proportional volumes of 0- to 24-hour urine collected from each
volunteer, which individually represented .95% of the radioactivity excreted
by this route. Representative fecal homogenates were obtained by pooling
across sampling times on a total sample weight basis to generate a discrete pool
containing 80% or greater of the radioactivity excreted in feces for each man.
These were subsequently pooled across individuals to obtain a single feces
homogenate sample representative of the whole study. Radioactive material
was extracted from plasma and feces samples by vortex-mixing successive
aliquots of acetonitrile. The extracts were evaporated to near dryness under
a stream of nitrogen before reconstitution in small volumes of ammonium
formate buffer (50 mM, pH 2.5) and acetonitrile. Plasma and feces extracts and
human urine were spiked with dimethyl sulfoxide (DMSO) solutions containing
authentic reference standards of vilanterol, GW630200, and GSK932009 as
chromatographic UV retention time markers. The spiked plasma, urine, and feces
samples were subsequently analyzed by HPLC with UV detection and
radiometric detection by offline AMS analysis. The supernatants from the
hepatocyte incubations were analyzed with no further treatment by use of HPLC
with offline radio detection by microtiter plate scintillation counting and HPLC-
MS.
Metabolism and Disposition of Vilanterol in Human 91
The chromatographic instrumentation consisted of an Agilent system (South
Queensferry, Scotland, UK), comprising a 1100 binary pump, column oven
(25°C), UV detector (l 275 nm), and autosampler, which was linked to
a fraction collector (Gilson, Luton, UK). A Luna Phenyl Hexyl RP column
(250  4.6 mm, 5-micron particle size) was used. The mobile phase consisted
of 50 mM ammonium formate, pH 2.5 (solvent A), and acetonitrile (solvent B;
supplied by Thermo Fisher Scientific, Loughborough, Leicestershire, UK) at
a flow rate of 1 ml/min. A linear gradient was used as follows: 10 to 37% B
over 13 minutes; 37 to 52% B by 14 minutes; 52% B to 64% B by 35 minutes;
64% B to 90% B by 40 minutes; conditions were held at 90% B until 45
minutes. The column was re-equilibrated for a minimum of 6 minutes after each
injection. Fractions from the HRS samples were collected into quartz glass
tubes (York Glassware Services, York, UK) every 30 seconds for offline
radiodetection by AMS. For hepatocyte samples, the HPLC fractions were
collected into 96-deep-well microtiter plates containing yttrium silicate solid
scintillant (PerkinElmer Life and Analytical Sciences) every 12 seconds. Each
HPLC eluate was evaporated to dryness in a drying oven overnight, and the
dried plates were sealed using a microplate heat sealing film (PerkinElmer Life
and Analytical Sciences). Radioactivity in each well was subsequently counted
using a TopCount NXT counter (PerkinElmer Life and Analytical Sciences).
Structural Identification of Metabolites Structural characterization was
performed on selected HRS samples by HPLC-MS using an Accela autosampler
and HPLC system coupled to an Orbitrap XL mass spectrometer with Xcalibur
software (Thermo Fisher Scientific, Hemel Hempstead, UK). The majority of
human metabolites were identified through chromatographic comparisons to
metabolites identified in other samples, such as the hepatocyte incubations.
Metabolites in the hepatocyte incubations were characterized using an Agilent
HP1100 autosampler and HPLC system coupled to a Micromass Quattro Micro
triple quadrupole mass spectrometer with MassLynx software (Waters MS
Technologies, Manchester, UK) or a ThermoFinnigan LTQ linear trap mass
spectrometer with Xcalibur software (Thermo Fisher Scientific). All mass
spectrometric analyses employed electrospray ionization in the positive and
negative ion modes. The flow was split 1:2 (Orbitrap) or 1:20 (Quattro and
LCT) between the mass spectrometers and fraction collector (CTC Analytics
HTX PAL).
Metabolites in human hepatocyte supernatant were also separated by pre-
parative HPLC using an Agilent series 1100 Preparative-LC system (Waldbronn,
Germany) for characterization by nuclear magnetic resonance spectroscopy
(NMR). Separations were performed on a Luna Phenyl Hexyl HPLC column
(250  10 mm i.d., 5-micron particle size) at ambient temperature with a mobile
phase of 50 mM ammonium formate (pH 2.5, solvent A) and acetonitrile/
methanol (20:80 v/v, solvent B) at a constant flow rate of 4 ml/min with an initial
gradient of 10% B increasing linearly to 37% B at 13 minutes, then to 52% B
at 14 minutes, 64% B at 25 minutes, and 90% B at 40 minutes where it was held
for a further 5 minutes. The HPLC eluent was collected into fractions, in a time-
slice mode, into two 96-deep-well plates using a frequency of 15 seconds per
fraction. This resulted in 180 fractions, each containing 1 ml of column eluent.
The flow was split 100:1 into a Micromass ZQ mass spectrometer (Waters MS
Technologies) that was fitted with an electrospray source operated in the positive
ionization mode. System control was mediated through MassLynx and
FractionLynx (Waters, Milford, MA).
The fractions were taken to dryness under nitrogen at 37°C within the 96-
deep-well plates using a Micro DS96 dry down station (Porvair Scientific Ltd.,
Shepperton, UK) and then reconstituted in approximately 0.6 ml of deuterium
oxide/acetonitrile (1:1) before being transferred to 5 mm NMR tubes. We
performed 1D proton NMR experiments on all 180 fractions using a Bruker
600 MHz spectrometer equipped with an inverse 5 mm TXI Cryo-Probe (1H/
13C/15N) operating at 600.13 MHz under the control of TopSpin software
(Bruker, Rheinstetten, Germany).
Accelerator Mass Spectrometry The 14C content of human plasma, fecal
homogenates, urine, plasma extracts, and HPLC fractions was measured by
AMS, which measures the radiocarbon content in a sample through separation
of the isotopes of carbon present by their different mass-to-charge ratios. Before
analysis by AMS, the samples were graphitized via a two-step process of
oxidation and reduction (Young et al., 2008). The graphite, containing a cobalt
catalyst, was packed into an aluminum cathode and loaded into a sample wheel
that was then placed into the ion source of the AMS instrument (either NEC 5
MV tandem or 250 KV single-stage AMS system; National Electrostatics
Corporation, Middleton, WI). A generic value of 4.14%, based on GSK
historical data, for the carbon content of plasma was used for any neat plasma
samples analyzed, and the values were adjusted appropriately to allow for any
dilution.
For fecal homogenates, the carbon content for each sample was measured
independently using an elemental analyzer (NA2100 Brewanalyser; CE
Instruments, Wigan, UK). The carbon content for the HPLC fractions and for
urine was deemed to be insignificant, so only the carbon content of the carbon
carrier was used in calculations to determine the 14C content based on the
determined 14C to 12C ratio in the samples. The AMS data, which are expressed
as the percentage of modern carbon, were used to calculate the dpm/ml sample,
where 100% modern carbon equals 0.01356 dpm/mg carbon.
Pharmacokinetic Calculations Pharmacokinetic analyses of plasma
vilanterol concentration–time data (tolerability study only) and 14C radioactiv-
ity concentration–time data (HRS only) were conducted using the non-
compartmental Model 200 (for extra vascular administration) of WinNonLin
Professional Edition version 5.2 (Pharsight Corporation, Cary, NC). Values for
the following pharmacokinetic parameters were estimated: the maximum
observed plasma concentration (Cmax), the first time to reach Cmax (tmax), the
concentration at last measurable time point (Ct), and the time of the last
observed plasma concentration (tlast). Where possible, the terminal plasma
elimination rate-constant (lz) was estimated from a log-linear regression
analysis of the terminal phase of the plasma concentration–time profile. The
area under the plasma concentration–time curve from time zero to the last
quantifiable time point (AUC0–t) and extrapolated to infinity (AUC0–‘) were
calculated by a combination of linear and logarithmic trapezoidal methods.
In Vitro Pharmacologic Activity of Metabolites The b1 and b2 activities
of vilanterol, GW630200 (M29), GSK932009 (M33), GSK167112 (M20), and
GW853734 (a potential metabolite of vilanterol undetected in animals or
human) were determined via cAMP TR-FRET LANCE (Time Resolved
Fluorescence Energy Transfer; PerkinElmer Life and Analytical Sciences)
agonist assays. These were either metabolites or potential metabolites of vilanterol
that were selected to represent routes of human metabolism. The compounds were
dissolved in DMSO at a concentration of 10 mM and serially diluted in DMSO
using a 1 in 4 dilution step to provide 11-point concentration–response curves
(CRCs). Chinese hamster ovary cells stably expressing either recombinant b1- or
b2-receptor were thawed at 37°C, diluted in phosphate buffered saline, and
centrifuged at 1500g for 5 minutes. Cells were resuspended (2 million cells/ml) in
a stimulation buffer (Hanks’ balanced salt solution containing 0.01% bovine
serum albumin, 500 mM 3-isobutyl-1-methylxanthine, 5 mM HEPES final assay
concentration, pH 7.4, with potassium hydroxide).
The in vitro activity against either b1 and b2 was measured by adding CRCs
of compound or controls, 100 nl/well to a white Greiner polypropylene low-
volume 384-well plate, to which the relevant cell suspension (10,000 cells/well
at 5ml addition) and antibody solution (stimulation buffer containing Alexia
Fluor 647at 5 ml/well) were added. Plates were incubated for 30 minutes at
room temperature, then the detection mixture was added (kit components:
detection buffer, europium W8044-labeled streptavidin, and biotin cAMP at 10
ml/well). Plates were covered and incubated at room temperature for 4 hours
before being analyzed on a Viewlux Microplate Imager (PerkinElmer Life and
Analytical Sciences).
Results
Demographic, Safety, and Tolerability Data Nine and six healthy
men were enrolled into the tolerability and HRS studies, respectively.
The demographic data from the tolerability study and HRS are shown
in Table 1. Vilanterol was safe and well tolerated after oral admin-
istrations up to 500 mg, with no drug-related adverse events or
clinically significant changes in vital signs (including heart rate and
electrocardiogram interval) observed. No concomitant medication was
reported for any subject during the studies.
Pharmacokinetics of Vilanterol and Radioactivity Pharmacoki-
netic data for vilanterol and 14C radioactivity in both studies are
summarized in Table 2. Plasma concentrations of vilanterol after oral
administration of 200 or 500 mg of vilanterol in the tolerability study
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were low (#24 and 65 pg/ml, respectively) and could only be
quantified up to 0.8 hours (median Tlast) after administration of 200 mg
and up to 2.8 hours (median Tlast) after the 500-mg dose. In the HRS,
vilanterol was only quantified in plasma (LLQ 10 pg/ml) in a single
individual (n = 1 of 6; subject 102) at 0.5 hours (14 pg/ml) and 3.0
hours (15 pg/ml) after the dose; at all other sampling times, vilanterol
concentrations were nonquantifiable (NQ). Because two NQ values
occurred in succession after the quantifiable concentration at 0.5
hours, the profile was deemed to have terminated at the first NQ value,
and the subsequent quantifiable concentration at 3.0 hours was omitted
from the pharmacokinetic calculations.
In contrast, the plasma concentrations of 14C radioactivity (total drug-
related material or DRM, representing vilanterol and its metabolites)
were substantially higher than the vilanterol concentrations (Fig. 2;
Table 2). For subject 102 (Table 2), the vilanterol Cmax (14 pg/ml)
represented a very small percentage (,0.5%) of the drug-related material
(DRM) where Cmax was 3148 pg vilanterol equivalents/ml (data not
shown). For the other subjects, where vilanterol concentrations were not
quantifiable, vilanterol Cmax was,10 pg/ml (the limit of quantitation for
the assay), which also corresponded to ,0.5% of the DRM Cmax (2060
pg equivalents/ml), indicating that vilanterol represented a small
proportion (,0.5%) of the total drug-related material in plasma.
Excretion of [14C]Vilanterol Drug-Related Material The cumu-
lative percentage recovery of administered radioactivity in urine and
feces is depicted in Fig. 3. DRM was mainly excreted in urine (50%
administered radioactivity or 70% of the recovered radioactivity). Fecal
excretion accounted for a further 21% of the administered radioactivity
(or 30% of the recovered radioactivity). Absorption of vilanterol was at
least 50% based on urinary recovery. The total recoveries of radioactivity
were relatively low (72% of the administered radioactivity). Excretion of
radioactivity was essentially complete by the end of day 4 (.99% of
recovered radioactivity), with,0.3% of administered radioactivity being
recovered, in total, between days 5 and 7 after dosing.
Metabolite Profiles Radiochromatograms of separated metabolites
were generated from HPLC eluate fractions using AMS as a highly
sensitive offline radiodetector. Representative radiochromatograms for
human plasma, urine, and feces are shown in Fig. 4, with each
radioactive peak given an alphabetical assignment (A to M). Solvent
extraction efficiencies were 64% for the 0.5-hour plasma (where
metabolites were quantified) and 75% from feces homogenates. The
solvent extraction efficiency from the 24-hour plasma sample was
very low, at ,10%. Low chemical mass precluded the generation of
interpretable MS spectra for all but a few metabolites. The majority of
metabolites were thus assigned by comparison of chromatographic
retention times to either authentic reference material or to metabolites
identified in other nonclinical studies (Table 3) where higher amounts
of metabolite had facilitated more detailed identifications. Characterized
metabolites were given a numerical designation preceded by the letter M
TABLE 1
Summary of subject disposition and demographic characteristics after oral administration of 200 or 500 mg of vilanterol
or 200 mg of [14C]vilanterol to men
Subject disposition and demographic characteristics are summarized from two clinical studies. In the first tolerability study subjects
received 200 or 500 mg of vilanterol. In the subsequent human radiolabel study, the subjects received 200 mg of [14C]vilanterol containing
74 kBq radioactivity.
Characteristics
Tolerability Study
GSK Study B2C106180
Human Radiolabel Study
GSK Study B2C106181
Number of subjects completed: n 9 6
Oral administration 200 or 500 mg of vilanterol 200 mg of [14C]vilanterol
Age (yr): mean (range) 33.1 (19–47) 43.3 (35–53)
Race, n (%)
White/Caucasian/European 7 (78) 6 (100)
Asian 1 (11)
African American 1 (11)
Ethnicity, n (%)
Not Hispanic or Latino 9 (100) 6 (100)
Body mass index (kg/m2): mean (range) 24.8 (21.3–29.0) 26.2 (21.8–28.8)
Height (cm): mean (range) 178 (166–186) 179 (163–189)
Weight (kg): mean (range) 78.5 (66.9–90.8) 83.9 (57.8–102)
TABLE 2
Pharmacokinetic parameters in human plasma for vilanterol and [14C] radioactivity after oral administration of 200 or 500 mg of vilanterol and 200 mg of [14C]vilanterol
Plasma AUC(0–t), Cmax, and Tmax of vilanterol and
14C radioactivity in plasma are shown after single oral administrations to healthy men in two clinical studies. For the tolerability study, the
parameters are presented for two dose levels after specific assay analysis for vilanterol. For the human radiolabel study, the parameters are presented from a single dose level and are calculated from the
mean specific assay data for vilanterol in all subjects, the specific assay data for vilanterol in subject 102 (the only subject with measurable concentrations), and the mean radioactivity measurements
(DRM) in all subjects presented as picogram equivalents of vilanterol per milliliter.
Tolerability Study
(200 or 500 mg of Vilanterol)
Human Radiolabel Study
(200 mg of [14C]Vilanterol)
200 mg n n1 500 mg n n1 Vilanterol Vilanterola n n1 Radioactivity n n1
AUC(0–t) (95% CI), pg×h/ml 21.8 (NC) 3 1 62.6 (25, 156) 6 0 NC NC 0 6 66,000 (52,000, 84,000)
b 6 0
Cmax (95% CI, pg/ml 18.5 (10, 33) 3 0 44.5 (32, 62) 6 0 NC 14 1 5 2060 (1580, 2700)
b 6 0
Tmax median [range], h 0.5 [0.25–0.5] 3 0 0.5 [0.25–1.0] 6 0 NC 0.5 1 5 3.0 [2.5–4.0] 6 0
Tlast median [range], h 0.8 [0.5–3.0] 3 0 2.8 [1.0–8.0] 6 0 NC 0.5 1 5 168 [168–168] 6 0
a Data are presented separately for subject 102 in whom there was a single quantifiable concentration of 14 pg/ml at 0.5 hours after dosing.
b Radioactivity concentrations are expressed in terms of picogram equivalents of vilanterol per milliliter.
CI, confidence interval; n, number of subjects with non-missing observations, including inputted NC values for AUC and Cmax; n
1, number of subjects for whom parameters cannot be derived
because of nonquantifiable concentrations; NC, not calculable due to insufficient data or concentrations below lower limit of quantification (10 pg/ml).
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(e.g., M1), each number representing a distinct metabolite structure.
Metabolite structures assigned to each radioactive peak, along with
supporting evidence from other studies, are shown in Table 3.
Plasma Metabolites HPLC radiochromatograms of human plasma
extracts from samples taken at 0.5 and 3.5 hours after dosing are
shown in Fig. 4. Radioactive peaks from the 0.5-hour sample time
(Cmax of vilanterol in plasma) are quantified in Table 4. The largest
radioactive peaks (F and G) were assigned as a mixture of O-
dealkylated metabolites (including M33/GSK932009 and M29/
GW630200). These metabolites represented approximately 33%
of plasma radioactivity in the 0.5-hour plasma extract. Peak J2
(assigned as M26, a C-dealkylated metabolite) and peak B (M1, an
Fig. 2. Mean concentrations of vilanterol and radioactivity in plasma after oral
administration of [14C]vilanterol to humans The difference in mean plasma
concentrations of radioactivity (pg equivalents DRM /ml) and concentrations of
unchanged vilanterol (pg/ml) are highlighted on this concentration–time semi-log
plot generated using data collected after a single oral administration of 200 mg of
[14C]vilanterol containing 74 kBq radioactivity.
Fig. 3. Mean percentage cumulative recovery of radioactivity in urine and feces
(expressed as % administered radioactivity) after oral administration of [14C]
vilanterol (74 kBq) to humans. Cumulative recovery of radioactivity is shown in
urine and feces collected for up to 7 days after a single oral administration of 200 mg
of [14C]vilanterol containing 74 kBq radioactivity. Mean data from six subjects is
presented.
Fig. 4. HPLC radiochromatograms of plasma, urine, and feces after oral administration of [14C]vilanterol to humans. Representative HPLC radiochromatograms are
presented after analysis of human plasma (0.5 and 3.5 hours: A and B) extracts, human urine (C), and human feces (D) extracts obtained after a single oral administration of
200 mg of [14C]vilanterol containing 74 kBq radioactivity. Structures assigned to peaks are depicted in Table 3.
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TABLE 3
A summary of the metabolite structures assigned to radiochromatographic peaks in human urine, feces, and plasma after a single oral administration of 200 mg of [14C]vilanterol
Chemical structures and supporting evidence from in vitro samples for metabolites assigned to radiochromatographic peaks detected in human urine, feces, and plasma obtained
after a single oral administration of 200 mg of [14C]vilanterol containing 74 kBq of radioactivity.
Peak Numerical Assignment Proposed Structure
Parent Ion
[M+H]+
MS/MS
Product Ionsa
1H NMR Chemical Shifts
Evidence Supporting Structural
Assignment
m/z ppm
A Void volume Not applicable Not
applicable
Not applicable Not applicable
B M1
(O-dealkylation,
oxidation and
O-glucuronidation)
476
440, 300,
282, 264,
246
No NMR from in vitro samplesb Peak B assigned as M1 based on
chromatographic retention time
comparison with mouse and rat
hepatocyte incubations
D,
E
M3
(O-dealkylation and
O-glucuronidation)
506b No NMR from in vitro samplesb Peaks D and E assigned as
a mixture of M3, M4, and M30
based on chromatographic
retention time comparisons to
mouse, rat, rabbit, dog, and
human hepatocyte incubations.
M4
(O-dealkylation,
oxidation and
O-glucuronidation)
520
484, 344,
326, 308,
250, 232
No NMR from in vitro samplesb
M30
(O-dealkylation and
oxidation)
330
282, 264,
246, 228
d ppm 7.26 (d, J = 1.6, 1H), 7.16
(dd, J = 8.3, 1.6, 1H), 6.84 (d, J
= 8.3, 1H), 4.86 (t, J = 6.5, 1H),
4.59 (s, 2H), 3.14 (d, J = 6.5,
2H), 3.00 (t, J = 7.9, 2H),
1.49–1.67 (m, 6H)
F M6
(O-dealkylation and
oxidation)
No MSb No NMR Peak F assigned as a mixture of O-
dealkylated metabolites based
on chromatographic retention
time comparisons to
metabolites indentified in other
studies.
M6 and M19 assigned based on
chromatographic comparisons
to rat bile (data not shown).
M7
(O-dealkylation and
oxidation)
314
296, 278
d ppm 7.76 (d, J = 2.3, 1H), 7.36
(dd, J = 8.5, 2.3, 1H), 6.87 (d, J
= 8.5, 1H), 4.89 (t, J = 7.1, 1H),
3.03 (t, J = 7.9, 2H), 2.27 (m,
2H) 1.64–1.70 (m, 4H), 1.33
(m, 2H)
M7 assigned based on
chromatographic comparison
with human hepatocyte
incubations.
M19 and M39
(O-dealkylation and
oxidation)
M19: No
MSb
M39: 344
308, 250,
232
No NMR M39, a metabolite identified in
human hepatocyte incubations
(Fig. 4) was detected by HPLC-
MS in human urine.
(continued )
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TABLE 3—Continued
Peak Numerical Assignment Proposed Structure
Parent Ion
[M+H]+
MS/MS
Product Ionsa
1H NMR Chemical Shifts
Evidence Supporting Structural
Assignment
m/z ppm
M29
(GW630200,
O-dealkylation)
330
294, 250,
232
d ppm 7.26 (d, J = 1.8, 1H), 7.15
(dd, J = 8.1, 1.8, 1H), 6.84 (d, J
= 8.1, 1H), 4.86 (t, J = 6.8, 1H),
4.59 (s, 2H), 3.61 (t, J = 5.1,
2H), 3.48 (t, J = 5.1, 2H), 3.45
(t, J = 6.7, 2H), 3.13 (d, J = 6.5,
2H), 2.99 (t, J = 8.3, 2H), 1.64
(m, 2H), 1.53 (m, 4H), 1.32 (m,
2H)
M29 was a major component in
incubations with human
hepatocytes (Fig. 4) and human
liver microsomes (data not
shown). Despite the availability
of reference standard
(GW630200), the presence of
this metabolite could not be
confirmed by HPLC-MS in
human urine.
G M33
(GSK932009,
O-dealkylation and
oxidation)
344
308, 250,
232
d ppm 7.26 (d, J = 2.2, 1H) 7.15
(dd, J = 8.3, 2.2, 1H), 6.84 (d, J
= 8.3, 1H), 4.86 (t, J = 6.7, 1H),
4.59 (s, 2H), 3.79 (s, 2H), 3.43
(t, J = 6.6, 2H), 3.14 (d, J = 6.7,
2H), 3.00 (t, J = 7.9, 2H), 1.64
(m, 4H), 1.54 (m, 2H), 1.33 (m,
2H)
Peak G assigned as M33 based on
chromatographic retention time
comparisons to standard
GSK932009. M33 was detected
by HPLC-MS in human urine.
I M20
(GSK1676112,
N-dealkylation)
322
159
No NMR from in vitro samplesb Peak I assigned as M20 based on
chromatographic retention time
comparison with standard
GSK1676112.
J Vilanterol 488
470, 452,
250, 234,
232, 159
d ppm 7.40 (d, J = 8.2, 2H), 7.30
(t, J = 8.2, 1H), 4.59 (s, 2H),
7.25 (d, J = 2.3, 1H), 7.13 (dd, J
= 8.2, 2.3), 6.82 (d, J = 8.2,
1H), 4.79 (dd, J = 9.1, 4.4, 1H),
4.77 (2, 2H), 3.66 (m, 2H), 3.56
(m, 2H), 3.42 (t, J = 6.6, 2H),
3.00 (m, 2H), 2.84 (d, J = 7.6,
2H), 1.56 (m, 2H), 1.49 (m,
2H), 1.28 (m, 4H)
Peak J assigned as a mixture of
unchanged vilanterol and M26
based on chromatographic
retention time comparisons to
vilanterol reference material
and M26 in rabbit and dog
hepatocyte incubations. M26
was detected by HPLC-MS in
human urine.
M26
(C-dealkylation:
oxidative cleavage of
the salicyl alcohol
moiety)
380
334, 234,
204, 176,
159
d ppm 7.42 (d, J = 8.0, 2H), 7.31
(t, J = 8.0, 1H), 3.66 (m, 2H),
3.56 (m, 2H), 3.42 (t, J = 6.7,
2H), 3.45 (s, 2H), 2.92 (m, 2H),
4.77 (s, 2H)
Using a second HPLC system
(data not shown) and specific
assays developed for vilanterol,
M26 was assigned as the major
component of peak J in human
urine and plasma, and vilanterol
was assigned as the major
component of peak J in human
fecal extracts.
K M16
(oxidation)
502
466, 264,
246
d ppm 7.75 (d, J = 2.3, 1H), 7.38
(dd, J = 8.6, 2.3, 1H), 7.35 (d, J
= 8.1, 2H), 7.24 (t, J = 8.1, 1H),
6.90 (d, J = 8.6, 1H), 4.91 (t, J
= 6.8, 1H), 4.83 (s, 2H), 3.73
(m, 2H), 3.61 (m, 2H), 3.46 (t, J
= 6.8, 2H), 3.18 (d, J = 6.8,
2H), 2.99 (t, J = 7.9, 2H)
Peak K assigned as M16 based on
chromatographic retention time
comparison with rabbit and dog
hepatocyte incubations.
C,
H
Unassigned Not applicable No MS No NMR No metabolite structures could be
assigned to these peaks.
a The m/z values are presented for the 14C isotope (major isotope for in vitro incubations).
b Additional nuclear magnetic resonance spectroscopy (NMR) and/or mass spectrometry (MS) data available from in situ or in vivo rat study to allow structural characterization of metabolite (data
not shown).
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O-dealkylated glucuronide conjugate) represented 18% and 13% of
plasma radioactivity in the 0.5-hour sample. No other radioactive peak
represented greater than 10% plasma drug-related material. All
systemically circulating metabolites, with the exception of peak K
(M16, an oxidative metabolite), were the products of O- or C-
dealkylation.
Urine and Feces Metabolites HPLC radiochromatograms of
pooled human urine and feces extracts are shown in Fig. 4 and are
quantified in Table 4. The largest radioactive peaks in human urine
and feces, as in plasma, were peaks F and G, assigned as a mixture of
O-dealkylated metabolites. Peaks F and G accounted for 50% of
urinary radioactivity, 35% of fecal radioactivity, and a combined 51%
of the recovered dose. Peaks B, D, and E (assigned as M1, M3, M4,
and M30) were also associated with O-dealkylation pathways and
represented a combined total of 32% urinary radioactivity, 14% fecal
radioactivity, or a combined 27% recovered radioactive dose. M26
was a minor urinary component. Unchanged vilanterol was not
detected in human urine but represented about 15% fecal radioactivity
(5% of the recovered dose).
In Vitro Metabolites HPLC radiochromatograms of mouse, rat,
dog, rabbit, and human hepatocyte incubations are shown in Fig. 5.
The main route of metabolism of vilanterol in human hepatocyte
incubations was O-dealkylation to yield M29 (GW630200) with
subsequent oxidation to M33 (GSK932009), M30, and M39. O-
dealkylation was also a notable route of metabolism in all animal
species except for the mouse, where direct glucuronidation of
vilanterol to yield M12 was the major pathway. O-glucuronidation
with O-dealkylation to M3 was a major pathway in the rat (M3). C-
Dealkylation of the salicyl alcohol moiety to M26 was a major
pathway in dog and rabbit hepatocytes.
Pharmacologic Activity of Metabolites The pharmacologic
activity of potential metabolites using human b1 and b2 cAMP LANCE
assays are shown in Table 5 along with their chemical structures. Tested
metabolites were representative of the main routes of human meta-
bolism. M29 (GW630200) and M33 (GSK932009) were major in vitro
pathways representing O-dealkylation. M20 (GSK1676112) and
GW853734 were investigated to understand the effect of N-
dealkylation (both halves of the molecule) on its pharmacologic
activity. All the cleaved structures tested were $2500 times less
potent compared with vilanterol on the b2–receptor, indicating that
metabolic cleavage largely removes the b2-agonist pharmacology
associated with vilanterol. Similarly, the metabolites and cleaved
analogs of vilanterol were either inactive against b1 or were of such
low potency that b-agonist-related effects would be unlikely in
humans.
Discussion
The results we describe provide an understanding of the metabolism
and disposition of vilanterol in humans. The oral route of
administration represents the swallowed portion of an inhaled dose;
based on urinary recovery of radioactivity (Fig. 3), at least 50% of the
vilanterol oral dose solution was absorbed. Metabolite profiles,
however, indicated that ,5% of the administered radioactivity was
associated with unchanged vilanterol in feces, potentially reflecting
the percentage of unabsorbed drug (Table 4). Therefore, oral
absorption of vilanterol is probably higher than the estimate based
on urinary excretion alone and is likely virtually complete. Systemic
exposure to vilanterol represented a very small proportion (,0.5%) of
DRM in plasma (Fig. 2) and, together with the presence of several
circulating metabolites, was indicative of extensive first-pass metab-
olism of vilanterol. Considered together, systemic vilanterol concen-
trations measured after inhalation administration thus are attributed to
absorption through the lung with little or no contribution from the
swallowed portion of the dose, which is well absorbed but undergoes
extensive first-pass metabolism.
The total recovery of radioactivity was relatively low (71.6% of the
administered radioactivity), and the precise cause is unknown but is
most likely attributed to technical reasons related to the low
radioactive dose (74 kBq; 25- to 50-fold lower than that used in
more traditionally designed studies) and the low vilanterol chemical
mass administered (200 mg). This results in excreta containing very
low mass concentrations, where the measurement of radioactivity
would be sensitive to very low levels of nonspecific binding to any
apparatus used. The mixed methods used for radioactivity measure-
ment may also have contributed to the low radioactive recovery.
Any concerns about the slow release of DRM from a depot within
the body or loss due to exhalation of radioactivity were not supported
by the data. By 4 days after dosing, elimination of radioactivity was
essentially complete (.99% of the recovered radioactivity detected in
urine or feces collections) with only ,0.3% of radioactivity recovered
within the next 3 days, and there was little evidence for substantial
metabolism associated with atoms close to the [14C] isotope to easily
explain exhalation of radioactivity as carbon dioxide. A retrospective
TABLE 4
Summary of vilanterol metabolites in human plasma, urine, and feces after oral administration of 200 mg of vilanterol
Metabolites of vilanterol are quantified in pooled plasma, urine, and feces obtained after a single oral administration of 200 mg of [14C]
vilanterol.
Peak ID
% Radioactivity in 0.5-Hour
Human Plasma
% Radioactivity in Urine and Fecal Extracts
(% recovered dose)
Pooled Urine Pooled Feces
A 8.7 ND 2.8 (0.8)
B (M1) 12.8 9.4 (6.6) ND
D (M3) ND 13.5 (9.5) ND
E (M30, M4) 7.3 9.0 (6.3) 13.8 (4.1)
F (M6, M7, M19, M29, M39) 32.5 31.0 (21.7) 21.5 (6.4)
G (M33) 19.3 (13.5) 33.9 (10.2)
H ND 2.0 (1.4) ND
I (M20) ,1 ND 1.3 (0.4)
J1, GW642444 (P) ND ND 15.4 (4.6)
J2 (M26) 17.7 6.5 (4.6) ND
K (M16) 6.0 ND ND
ND, not detected. Peak J was assigned as unchanged vilanterol in feces (J1) and M26 in plasma and urine (J2).
Metabolism and Disposition of Vilanterol in Human 97
analysis of mass balance data (Roffey et al., 2007) suggests that total
radioactive recovery in humans, using routine methodology, should
normally be 80% or greater. Roffey et al. conclude that a low mass
balance is more likely due to technical limitations, which often
confound the generation of a full mass balance and should not be
regarded as tissue sequestration per se.
The plasma half-life of radioactivity was very long (see Fig. 2), and
the low extraction efficiencies (,10% extracted at 24 hours after
dosing) were consistent with tight or covalent binding of DRM to
plasma protein rather than slow release of DRM from a depot. This
binding phenomenon, which occurs in many metabolism studies, is
accentuated when using the very high sensitivity conferred by AMS
when compared with traditional LSC counting.
The human metabolic profiles in human plasma, urine, and feces
(Fig. 4) were broadly similar to that observed using human
hepatocytes (Fig. 5). Elimination of vilanterol was mainly by
metabolism (Fig. 4; Table 4) followed by excretion of metabolites
in urine (70% of recovered radioactivity) and feces (30% of recovered
radioactivity). Direct secretion or direct conjugation of vilanterol were
not major routes of elimination, with less than 5% of the administered
dose associated with unchanged vilanterol. The major route of
metabolism (Fig. 1) was via O-dealkylation, with up to 78% of the
recovered dose (in all human excreta) eliminated as O-dealkylated
metabolites (Tables 3 and 4). N-Dealkylation and C-dealkylation were
minor pathways, representing a combined 5% of the recovered dose.
Although C-dealkylation is uncommon, it has been described
elsewhere as a route of metabolism for indacaterol, another b-agonist
(Kagan et al., 2012) that shares the same (amino-hydroxyethyl) phenol
moiety with vilanterol. Kagan et al. tentatively propose two
mechanisms for this carbon–carbon cleavage: one initiated by a one-
electron oxidation of the oxygen in the phenol moiety followed by
a b-scission reaction, and the other initiated by phenolic hydroxyl-
ation, subsequent keto/enol tautomerism, followed by a retro-Aldol
reaction. Both mechanisms are also feasible for the C-dealkylation of
vilanterol.
The proposed commercial dose for vilanterol is 25 mg, once daily,
by the inhalation route. All identified routes of metabolism for
vilanterol are associated with innocuous (as opposed to reactive)
Fig. 5. HPLC radiochromatograms of mouse, rat, dog, rabbit, human, and control hepatocyte incubations with [14C]vilanterol. Representative HPLC radiochromatograms
are presented after analysis of incubations of [14C]vilanterol with mouse- (A), rat- (B), dog- (C), rabbit- (D), and human- (E) cryopreserved hepatocytes. A control incubation
without hepatocytes (drug-only) is included for comparison (F).
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chemical mechanisms. The maximum daily body burden to any
metabolite does not exceed the vilanterol dose level of 25 mg/day,
which is negligible when compared with the 10-mg daily threshold
for clinical adverse drug reactions mediated by reactive metabolite
mechanisms proposed by a number of key opinion leaders (Uetrecht,
1999; Smith, 2005). In addition, at this low-dose level, the likelihood
of a metabolite causing new unexpected toxicity, unrelated to its
b-agonist pharmacology, is negligible. As a result, a major focus of
the metabolism work for vilanterol was to establish whether any
metabolites possessed b-agonist pharmacologic activity that could
result in unwanted systemic effects. First, after oral administration of
vilanterol at up to 500 mg, plasma concentrations of metabolites
were significantly higher than unchanged vilanterol as well as being
significantly greater than metabolite concentrations produced after
an inhaled administration at the lower therapeutic dose of 25 mg.
Despite the higher metabolite concentrations, there were no changes
in measured vital signs or heart rate in either clinical study,
indicating a lack of metabolite b-adrenergic activity. Second,
synthesized metabolites, representative of the major human meta-
bolic routes, were $2500 times less potent against b2-receptors
compared with vilanterol (Table 5). The synthesized metabolites
were either inactive against b1-receptors or of such low potency that
no b1-agonist-related effects would be seen in human after the
human daily dose. The metabolites tested represented both halves of
the molecule after cleavage metabolism and demonstrate how O- or
N-dealkylation considerably reduces potency against both b1- and
b2-receptors. The lack of potency associated with GW853734
demonstrates that N-dealkylation to metabolites where the [14C]
radioisotope label might be lost will also dramatically reduce
pharmacologic activity.
TABLE 5
Pharmacologic activity of selected human metabolites of vilanterol tested using human b1 and b2 cAMP LANCE assays
Pharmacologic activity is shown in terms of mean pEC50 for vilanterol, four human metabolites, and one potential metabolite.
Metabolite
Mean pEC50 (n = 7–24)
b1 b2
Vilanterol
7.0 10.4
GW630200 (M29)
5.7 7.0
GSK932009 (M33)
5.0 6.9
GSK1676112 (M20)
,4.5 5.0
GW853734 (potential metabolite – not detected in animals or
human)
5.3 5.4
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The metabolites detected in human matrices were also present in the
species used for toxicology assessment (data not shown), demonstrat-
ing their relevance to the assessment of safety for vilanterol in
humans. Additionally, all major routes of metabolism in human
hepatocytes were also shown in mouse, rat, dog, and rabbit hepatocyte
incubations. The largest radioactive chromatographic peaks in human
plasma after oral administration were peak G (M33/GSK932009) and
peak F [several O-dealkylated and oxidized metabolites including
GW630200, peak J2 (M26), and peak B (M1)] (see Fig. 4; Table 4).
These radioactive peaks each represented .10% plasma DRM (the
threshold for further investigation as recommended by ICH M3[R2]),
0.5 hours after an oral administration of vilanterol. It should be noted,
however, that the proposed commercial dose of vilanterol (25 mg) is
considerably lower than the 10-mg threshold proposed in ICH M3(R2)
guidance (International Committee on Harmonisation, 2009), below
which a more lenient threshold than 10% plasma DRM is deemed
appropriate. Concentrations of M33 (GSK932009) and M29
(GW630200) were measured in plasma from asthma and COPD
patients dosed up to 50 mg of vilanterol by the inhalation route and
were generally lower than the quantification limit (180 and 90 pg/ml,
respectively, data not shown). Both metabolites circulated at higher
concentrations in mice, rats, and dogs compared with humans, when
measured as part of the inhalation toxicology studies.
In summary, oral vilanterol is well absorbed in humans and is
subject to extensive first-pass metabolism to metabolites, with
negligible b-agonist pharmacologic activity. The metabolism of
vilanterol is mainly by O-dealkylation, and metabolites are excreted
both via feces and urine. To a large extent, the low dose levels often
associated with inhalation molecules (25 mg in this case) mitigate any
metabolite or metabolism safety concerns.
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ABSTRACT
The absorption, metabolism, and excretion of darapladib, a novel
inhibitor of lipoprotein-associated phospholipase A2, was investi-
gated in healthy male subjects using [14C]-radiolabeled material in
a bespoke study design. Disposition of darapladib was compared
following single i.v. and both single and repeated oral adminis-
trations. The anticipated presence of low circulating concentra-
tions of drug-related material required the use of accelerator mass
spectrometry as a sensitive radiodetector. Blood, urine, and feces
were collected up to 21 days post radioactive dose, and analyzed
for drug-related material. The principal circulating drug-related
component was unchanged darapladib. No notable metabolites
were observed in plasma post-i.v. dosing; however, metabolites
resulting from hydroxylation (M3) and N-deethylation (M4) were
observed (at 4%–6% of plasma radioactivity) following oral dosing,
indicative of some first-pass metabolism. In addition, an acid-
catalyzed degradant (M10) resulting from presystemic hydrolysis
was also detected in plasma at similar levels of ∼5% of radioactivity
post oral dosing. Systemic exposure to radioactive material was
reduced within the repeat dose regimen, consistent with the notion
of time-dependent pharmacokinetics resulting from enhanced
clearance or reduced absorption. Elimination of drug-related
material occurred predominantly via the feces, with unchanged
darapladib representing 43%–53% of the radioactive dose, and
metabolites M3 and M4 also notably accounting for ∼9% and 19% of
the dose, respectively. The enhanced study design has provided an
increased understanding of the absorption, distribution, metabolism
and excretion (ADME) properties of darapladib in humans, and
substantially influenced future work on the compound.
Introduction
Despite contemporary multidrug therapies (treatment with statins,
antiplatelet therapy, renin-angiotensin aldosterone system, and/or b
adrenergic blockade and diabetes control), there is still a large unmet
medical need to develop new strategies for the treatment of atherosclerotic
vascular disease. Lipoprotein-associated phospholipase A2 (Lp-PLA2)
has been identified as a risk marker in atherosclerosis (Thompson
et al., 2010) and is therefore a target for therapeutic intervention.
Darapladib (SB-480848 or N-[2-(diethylamino)ethyl]-2-(2-{[(4-fluo-
rophenyl)methyl]thio}-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyr-
imidin-1-yl)-N-{[4’-(trifluoromethyl)-4-biphenylyl]methyl}acetamide)
is a novel, selective, orally active inhibitor of Lp-PLA2, and is in late-
phase clinical development as a potential antiatherosclerotic agent
when administered in combination with current standard of care
treatment of patients with acute coronary syndrome or coronary heart
disease (Mohler et al., 2008; Serruys et al., 2008). It has been generally
safe and well tolerated in clinical studies completed to date. A dose of
160 mg produced significant and sustained inhibition of plasma Lp-
PLA2 activity and halted necrotic core progression, a key determinant of
plaque vulnerability (Serruys et al., 2008). This dose was therefore selected
for the ongoing pivotal outcomes studies.
The current study was designed to characterize the disposition and
metabolism of darapladib in healthy adult male volunteers following
single doses of i.v. as well as oral [14C]darapladib (Fig. 1). Early in
preclinical development, an N-desethyl metabolite (M4; SB-553253)dx.doi.org/10.1124/dmd.113.054486.
ABBREVIATIONS: AMS, accelerator mass spectrometry; AUC(0-t), area under the curve from time zero to time of last measured timepoint; AUC(0-t),
area under the curve from time zero to the next dosing interval; AUC(0-inf), area under the curve from time zero to infinity; darapladib (SB-480848), N-[2-
(diethylamino)ethyl]-2-(2-{[(4-fluorophenyl)methyl]thio}-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl)-N-{[4’-(trifluoromethyl)-4-biphenylyl]
methyl}acetamide; HLM, human liver microsome; HPLC, high-performance liquid chromatography; LLQ, lower limit of quantification; Lp-PLA2,
lipoprotein-associated phospholipase A2; LSC, liquid scintillation counting; M3 (SB-823094), N-[2-(diethylamino)ethyl]-2-(2-{[(4-fluorophenyl)methyl]
thio}-5-hydroxy-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl)-N-{[4’-(trifluoromethyl)-4-biphenylyl]methyl}acetamide; M4 (SB-553253),
N-[2-(ethylamino)ethyl]-2-(2-{[(4-fluorophenyl)methyl]thio}-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl)-N-{[4’-(trifluoromethyl)-4-
biphenylyl]methyl}acetamide; M7 (SB-735258), N-[2-(diethylamino)ethyl]-2-[2-(methyloxy)-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl]-
N-{[4’-(trifluoromethyl)-4-biphenylyl]methyl}acetamide; M10 (SB-554008), N-[2-(diethylamino)ethyl]-2-(2,4-dioxo-2,3,4,5,6,7-hexahydro-1H-cyclopenta
[d]pyrimidin-1-yl)-N-{[4’-(trifluoromethyl)-4-biphenylyl]methyl}acetamide; M11 (GSK219147), N-[2-(diethylamino)ethyl]-2-(4-oxo-2-thioxo-2,3,4,5,6,7-
hexahydro-1H-cyclopenta[d]pyrimidin-1-yl)-N-{[4’-(trifluoromethyl)-4-biphenylyl]methyl}acetamide; MS, mass spectrometry; MS/MS, tandem mass
spectrometry; NEC, National Electrostatics Corp.; NMR, nuclear magnetic resonance; PgP, P-glycoprotein; QC, quality control; Tmax, time of Cmax; lz,
terminal plasma elimination rate constant.
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was identified and found to be pharmacologically active, and this metabolite
has been assayed in all subsequent work, including the current study.
Preclinical excretion and metabolism studies in rats and dogs
estimated that darapladib absorption, based on the sum of biliary
secretion and urinary excretion of radioactive drug-related material,
was relatively low at approximately 4% of the dose, with the majority
of the dose eliminated apparently as unabsorbed drug via the feces
(M. Dave et al., data on file). The major route of elimination of
absorbed drug was via biliary secretion of metabolites (resulting
predominantly from N-deethylation and oxidation) and unchanged
darapladib, whereas direct intestinal secretion of darapladib (post i.v.
dosing) was also observed. Darapladib recovered in feces following an
oral dose in humans may therefore represent both biliary and/or
intestinal secretion, or simply unabsorbed drug. Administration of the
i.v. dose in this current study facilitates elucidation of the processes
involved in excretion, i.e., the extent to which darapladib is eliminated
in feces and urine as parent or metabolites.
In early clinical studies, it was noted that darapladib accumulates (at
30%–60%) in the systemic circulation after multiple oral doses. However,
this was less than predicted from the single-dose pharmacokinetics (PK)
data which suggested accumulation of 130%–200%. The ideal way to
investigate the reasons for this would be to administer radiolabeled
darapladib until steady-state conditions are achieved (10 days) and
compare the results to that following a single dose. Nonetheless,
radioactive exposure following this dosing regimen and utilizing
conventional radioactive doses would have been unacceptable.
Therefore, nonradiolabeled darapladib was administered for 10 days,
and on day 11, a single oral dose of [14C]darapladib was administered,
followed by three more doses of nonradiolabeled darapladib. This
allowed examination of the relative metabolic profile of [14C]darapladib
at steady-state compared with that following a single dose.
Dose levels of 8 mg (i.v. infusion), 80 mg (radiolabeled oral solution),
and 160 mg (nonradiolabeled enteric tablet) were selected based on each
providing similar systemic exposure. Accelerator mass spectrom-
etry (AMS) was used to determine levels of total radioactivity in plasma
samples (post oral administration) and plasma metabolite profiles from
all phases due to the very low levels of radioactivity in these samples.
Materials and Methods
Chemicals
[14C]Darapladib, darapladib, [13C6]darapladib (stable labeled in the phenyl
ring), and a number of synthetic standards were supplied by Chemical
Development, GlaxoSmithKline Research and Development Ltd. (Stevenage,
UK). Metabolite standards were as follows: N-[2-(diethylamino)ethyl]-2-(2-
{[(4-fluorophenyl)methyl]thio}-5-hydroxy-4-oxo-4,5,6,7-tetrahydro-1H-cyclo-
penta[d]pyrimidin-1-yl)-N-{[4’-(trifluoromethyl)-4-biphenylyl]methyl}acetamide
(coded M3, SB-823094); N-[2-(ethylamino)ethyl]-2-(2-{[(4-fluorophenyl)
methyl]thio}-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl)-N-{[4’-
(trifluoromethyl)-4-biphenylyl]methyl}acetamide (coded M4, SB-553253) and
[13C6]SB-553253 (stable labeled in the phenyl ring); N-[2-(diethylamino)
ethyl]-2-[2-(methyloxy)-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-
1-yl]-N-{[4’-(trifluoromethyl)-4-biphenylyl]methyl}acetamide (coded as M7,
SB-735258); N-[2-(diethylamino)ethyl]-2-(2,4-dioxo-2,3,4,5,6,7-hexahydro-1H-cyclo-
penta[d]pyrimidin-1-yl)-N-{[4’-(trifluoromethyl)-4-biphenylyl]methyl}acetamide
(coded as M10, SB-554008); and N-[2-(diethylamino)ethyl]-2-(4-oxo-2-thioxo-
2,3,4,5,6,7-hexahydro-1H-cyclopenta[d]pyrimidin-1-yl)-N-{[4’-(trifluoromethyl)-
4-biphenylyl]methyl}acetamide (coded as M11, GSK219147). All of these
materials were used as chromatographic, mass spectrometric, and/or nuclear magnetic
resonance (NMR) spectroscopy standards during the study (Fig. 1). Commercially
obtained chemicals and solvents were of high-performance liquid chromatography
(HPLC) or analytical grade. Liquid scintillation cocktails were obtained from
PerkinElmer LAS (UK) Ltd. (Beaconsfield, UK).
Sucrose (IAEA-C6) standard (certificated value = 1.506 times modern), from
the International Atomic Energy Agency (Vienna, Austria), was used as the source
of graphite (6.5 mg of sugar for each graphite produced) for use as the AMS
instrument normalization and process control standard.
Synthetic graphite 200 mesh (99.9999%), from Alfa Aesar (Heysham, UK),
was used as the AMS instrument background determination standard. All of the
reagents used in preparation of samples to graphite prior to analysis by AMS
were supplied by Sigma-Aldrich Company Ltd., Gillingham, UK.
Darapladib Formulations
The i.v. dose was prepared by taking 8 ml of [14C]darapladib (at 1 mg/ml;
6.25 mCi/ml) and diluting to 40 ml with normal saline to give a final i.v. dose of
8 mg of darapladib. The 40-ml i.v. solution was subsequently infused over a period
Fig. 1. Structure of [14C]darapladib and synthetic metabolites.
416 Dave et al.
 at A
SPET Journals on N
ovem
ber 7, 2015
dm
d.aspetjournals.org
D
ow
nloaded from
 
of 3 hours. The radiolabeled oral dose was prepared by mixing 3.2 ml of
[14C]darapladib (1 mg/ml; 6.25 mCi/ml) injection solution with 76.8 ml of non-
radiolabeled darapladib (1 mg/ml solution) to give a final oral solution dose of 80
mg of darapladib. Radiochemical purity determination of the dose formulations was
conducted and was .98% for the i.v. dose and .99% for each oral radiolabeled
dose. Nonradiolabeled darapladib (micronized) was supplied as enteric-coated 160-mg
white tablets.
Study Design and Subjects
The clinical study (GlaxoSmithKline SB-480848/015) was performed at
Covance Laboratories Inc. in conjunction with the Covance Clinical Research
Unit (Madison, WI) in accordance with Good Clinical Practice and the guiding
principles of the 1996 version of the Declaration of Helsinki. The protocol
including the proposed radioactive dose was reviewed by the GlaxoSmithKline
Global Safety Board and by the Covance Clinical Research Unit Institutional
Review Board. The total radioactive dose of 90 mCi was estimated using rat
whole-body autoradiography and excretion balance data and corresponded to
an effective dose of #1 mSv, which is approximately one-third of the annual
average background effective dose and within risk category IIa, in accordance
with the International Commission on Radiologic Protection. The amount of
radioactivity used for each phase also incorporated the anticipated analytical
requirements and study objectives. Written consent was obtained from all
subjects before any protocol-specific procedures were conducted.
Eight healthy male subjects (four white, three African American, one mixed
race), between 30 and 44 years of age, bodyweight .50 kg, and with a body
mass index between 19 and 32 kg/m2, were enrolled in this study with seven
completing all sessions (one subject was excluded from the final session due to
low recovery of radioactivity in the previous session). The study design was an
open-label, nonrandomized, three-session study in which darapladib was
administered to each subject over three sessions in the following order: a single
radiolabeled i.v. dose (session 1), a single radiolabeled oral dose (session 2),
and a series of nonradiolabeled repeat oral doses with a radiolabeled oral dose
administered on day 11 of 14 days of dosing (session 3). There was a minimum
21-day washout period between radioactive doses in each session. Subjects
were in good health, with no history of drug or alcohol abuse, and were taking
no other medication at the time of the study, with no prescribed medication
within 7 days (or 5 half-lives, whichever was longer) of the study commencing.
Study Procedures
On the morning of day 1 for session 1, all subjects received a single i.v.
infusion at a target dose of 8 mg (approximately 50 mCi) of [14C]darapladib in
40 ml of normal saline over 3 hours. After a washout period, on the morning of
day 1 for session 2, all subjects received a single oral administration at a target
dose of 80 mg (approximately 20 mCi) of [14C]darapladib as an 80-ml solution,
and were instructed to rinse their mouth with a further 100 ml of water and
swallow the water. After a further washout period, on the morning of day 1 for
session 3, seven subjects received a 160-mg dose of an enteric-coated
darapladib tablet, and subsequently received daily doses of a 160-mg enteric-
coated darapladib tablet on days 2–10. On the morning of day 11, subjects
received a single oral administration at a target dose of 80 mg (approximately
20 mCi) of [14C]darapladib as an 80-ml solution, with a further 100 ml of water.
Daily dosing of a 160-mg enteric-coated darapladib tablet continued on days
12–14.
After i.v. administration, blood samples (7 ml) for plasma total radioactivity,
unchanged darapladib, and SB-553253 analysis were collected into EDTA
tubes at predose and 0.5, 1, 2, 3 (immediately prior to termination of infusion),
3.5, 4, 5, 6, 7, 9, 12, 18, 24, 32, 48, 72, and 96 hours after the start of infusion.
Following oral administration in session 2 and on day 11 of session 3, blood
samples (7 ml) were collected at predose and 0.5, 1, 2, 3, 4, 6, 9, 12, 18, 24, 32,
48, 72, and 96 hours postdose. Additional samples (30 ml) were also collected
for metabolite analysis from subjects at 3, 12, 24, and 48 hours post start of i.v.
infusion or after oral administration (session 2 or following dosing on day 11 of
session 3). Blood samples were mixed, immediately chilled on crushed ice, and
centrifuged for 15 minutes at 1500g at approximately 4°C to obtain plasma.
Total radioactivity was measured using aliquots of plasma (0.06–0.5 ml); the
remaining plasma was stored at 270°C or less before the assay for darapladib
and SB-553253, or metabolite profiling by HPLC.
Urine samples from all three sessions were collected predose and between
0 and 6, 6 and 12, and 12 and 24 hours after drug administration and then at
24-hour intervals until 504 hours post i.v. infusion (session 1), 216 hours post
single oral dose (session 2), and 264 hours post day 11 dosing (session 3). For
each collection period, after thorough mixing, the weight and pH were
measured and recorded. A single subsample (50 ml) was removed from the
bulk sample and set aside for metabolite profiling and identification and stored
at220°C. Total radioactivity was measured using triplicate aliquots (approximately
1 ml) of urine.
Feces samples for all three sessions were collected quantitatively predose
and at 24-hour intervals for the same time periods described for urine. Feces
from each collection interval were weighed, mixed with deionized water
(approximately 1:1), and the total weight of the sample recorded prior to
homogenization. Total radioactivity was measured using triplicate aliquots
(0.3 g) of each feces homogenate. A single subsample (30 g) was removed from
the bulk sample and set aside for metabolite profiling and identification and
stored at 220°C.
Assay of Total Radioactivity by Liquid Scintillation Counting
Aliquots (0.5 ml) of plasma samples from session 1 were mixed with Ultima
Gold scintillation fluid [PerkinElmer LAS (UK) Ltd.] and analyzed by
liquid scintillation counting (LSC) using a low level scintillation counter
[PerkinElmer LAS (UK) Ltd.]. The lower limit of quantification (LLQ) was
1.0 darapladib nanogram equivalents per milliliter. Triplicate aliquots (1 ml)
of urine were also subjected to LSC following mixing with Ultima Gold
scintillation fluid. Triplicate aliquots (0.3 g) of feces homogenates were
weighed into Combustocones containing Combustopads for oxidation using
a Packard 307 automatic sample oxidizer [PerkinElmer LAS (UK) Ltd.]. The
14CO2 generated was collected by absorption in CarboSorb (8 ml) to which
Permafluor was added [PerkinElmer LAS (UK) Ltd.]. Radioactivity from
urine and feces was quantified using a liquid scintillation counter (Packard
Instrument Company, Downers Grove, IL) with automatic quench correction
using an external standard method (Botta et al., 1985). Prior to calculation of
individual results, a background count rate was determined and subtracted from
each sample count rate. The LLQ for liquid scintillation counting of urine samples
or those derived from feces was 4–110 ng of darapladib.
Assay of Total Radioactivity by AMS
Aliquots (0.06 ml) of plasma from session 2 and 3 samples were analyzed
by AMS and were first prepared so that the carbon within the samples was
harvested and converted to graphite. This involved a two-stage process of sample
combustion (oxidation) followed by graphitization (reduction) as detailed in a
previously published method (Young et al., 2008).
The carbon analysis was carried out using a Costech (Valencia, CA)
Elemental Combustion System (model 4010) CHNS-O Analyzer, supplied by
Pelican Scientific Ltd. (Chester, UK). The AMS instrument was manufactured
by National Electrostatics Corp. (NEC; Middleton, WI). The AMS instrument
was a 250 kV single stage accelerator mass spectrometer, and was operated via
NEC proprietary “AccelNET” software on a Linux operating system. Post
acquisition data processing was performed using the NEC software “abc.”
Further details of the operating conditions have been previously published
(Young et al., 2008).
The predose samples from session 1 were also analyzed by AMS and used as
background values for samples from sessions 2 and 3 (LLQ was 0.1 darapladib
nanogram equivalents per milliliter).
Darapladib and SB-553253 (M4) Quantification
Plasma concentrations of darapladib and SB-553253 were quantified using
a validated analytical method based on protein precipitation with acetonitrile-
ammonium formate pH 3.0, followed by HPLC–tandem mass spectrometry
(MS/MS) analysis. The LLQ for darapladib and SB-553253 was 0.1 and
0.25 ng/ml, respectively, using a 50-ml aliquot of human plasma with a higher
limit of quantification of 50 ng/ml for both compounds. Acetonitrile-
ammonium acetate pH 3.0 (75:25, v/v) containing internal standards
([13C6]darapladib and [
13C6]SB-553253, at concentrations of 2 and 5 ng/ml,
respectively) was added to the plasma samples. After vortex mixing, the
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deproteinized samples were centrifuged for 20 minutes at approximately 6800g.
The supernatant was analyzed using a TurboIonSpray Interface (Applied
Biosciences, Ontario, Canada) and multiple reaction monitoring. The chroma-
tography was performed using a 50  2.0 mm i.d. Mac Mod ACE C18 (3 m)
column (Chadds Ford, PA) and eluted at a flow rate of 0.75 ml/min. The isocratic
mobile phase consisted of 30% 2 mM ammonium formate (to pH 3.0 with formic
acid), 55% acetonitrile, and 15% water. The mass spectrometer used was a Sciex
API-4000 triple quadrupole mass spectrometer (Applied Biosciences, Ontario,
Canada) operated in positive ion mode. The temperature of the probe was
maintained at 650°C with a curtain gas setting of 20 and collision gas setting of
12. Darapladib and SB-553253 were monitored by multiple reaction monitoring
of 667–391 and 639–235, respectively. [13C6]Darapladib and [
13C6]SB-553253
were monitored by multiple reaction monitoring of 673–397 and 645–241,
respectively.
The concentrations of darapladib and SB-553253 in plasma samples were
calculated from calibration plots, constructed from analysis of calibration
standards prepared at known concentrations of darapladib and SB-553253 in
human plasma. A weighted 1/x2 linear regression was applied in each case over
the range 0.1–50 ng/ml for darapladib and 0.25–50 ng/ml for SB-553253.
Quality control (QC) samples, prepared at three different analyte concen-
trations and stored with study samples, were analyzed with each batch of samples
against separately prepared calibration standards. QC samples and calibration
standards were prepared using independently prepared stock solutions of darapladib
and SB-553253 reference materials. For the analysis to be acceptable, no more than
one-third of the QC results were to deviate from the nominal concentration by more
than 15%, and at least 50% of the results from each QC concentration were to be
within 15% of nominal.
Quantification and Profiling of Metabolites in Plasma, Urine, and Feces
Plasma samples taken at 3, 12, and 24 hours post dose were pooled using
volumes in proportion to the time interval between individual samples to
provide a single pool of plasma, representative of the pharmacokinetic area
under the curve (AUC) described by these time points, for each volunteer and
for each dose session (according to the method described by Hop et al., 1998).
Plasma samples at 48 hours post dose were not examined due to the very low
levels of radioactivity present. Representative samples of feces were pooled by
total weight ratio for each volunteer, to obtain a pool containing 90% or greater
of the radioactivity excreted via that route. For session 1 (i.v. dosing), this
ranged between 0- to 72-hour and 0- to 240-hour collections; for session 2
(single oral dose), this ranged between 0- to 72-hour and 0- to 240-hour
collections; and for session 3 (following dosing on day 11), this ranged between
0- to 96-hour and 0- to 120-hour collections. Urine was not analyzed from any
session due to the very low levels of drug-related material excreted in this
matrix.
All plasma sample pools were analyzed following dilution, rather than
solvent extraction, prior to HPLC-AMS analysis. Each pooled plasma sample
was diluted 20-fold [plasma–50 mM ammonium acetate (native pH)–10%
methanol (aqueous), 1:18:1, v/v) incorporating authentic nonradiolabeled
standards each at concentrations of 10 mg/ml. Each diluted plasma sample
was individually fractionated at a frequency of 0.2 minutes by HPLC, a carbon
carrier (2.6 ml of liquid paraffin; a source of carbon essentially containing no
14C) added to each fraction, followed by conversion to graphite and analysis of
radioactivity by AMS.
Fecal homogenates (approximately 2 g) were extracted by vortex mixing for
1 minute then rotary mixing for 30 minutes with 6 ml of methanol. After
centrifugation, the supernatant was removed, and the process was repeated.
Weighed aliquots were taken from the individual supernatants and assayed by
LSC. The two extracts for each sample were subsequently combined, and the
residual pellets were oxidized to determine the extent of any unextracted
radioactivity. Prior to radio-HPLC analysis, aliquots (0.5 ml) of each pooled
fecal extract were diluted 1:1 with 50 mM ammonium acetate (native pH). All
spiked control and blank control samples were subjected to the same methods
of pretreatment as detailed for test samples.
HPLC Method. The chromatographic instrument used consisted of an
Agilent 1100 series binary pump and column oven (40°C) (Agilent Tech-
nologies, Santa Clara, CA), with an autosampler (CTC Analysis LC PAL; CTC
Analytics AG, Zwingen, Switzerland) using a Waters Symmetry Shield RP8
column (25 cm  4.6 mm, 5m; Waters Corporation, Milford, MA). The mobile
phase consisted of 50 mM ammonium acetate (native pH) (solvent A) and
acetonitrile (solvent B) at a flow rate of 1 ml/min. A gradient was used, starting
at 5% B and held for 5 minutes, then additional linear changes to 35% B by 10
minutes, to 50% by 35 minutes, and to 95% by 45 minutes, with these con-
ditions being maintained for an additional 5 minutes.
HPLC column recoveries were determined on selected plasma samples only
using AMS through comparison of precolumn injectates with total radioactivity
of all fractions, and recoveries were 95% or greater in all cases.
Radio-HPLC data were captured off-line (Bruin et al., 2006) with chromato-
graphic fractions collected using a Gilson 222XL fraction collector into 96
deep-well microtiter LUMAPLATES containing yttrium silicate solid scintil-
lant [PerkinElmer LAS (UK) Ltd.]. Radioactivity determination was performed
by scintillation counting using a Packard Topcount NXT counter [PerkinElmer
LAS (UK) Ltd.]. HPLC-AMS data analysis was captured as previously
described.
Metabolites of interest were isolated by preparative HPLC (Agilent 1100
autosampler, UV detector, and binary pump; Agilent Technologies) with
a Zorbax SB C18 column (5 cm  21.2 mm, 5 m; Agilent Technologies). The
mobile phase consisted of 50 mM ammonium acetate (native pH) (solvent A)
and acetonitrile (solvent B) at a flow rate of 20 ml/min. A gradient was used,
starting at 5% B and held for 5 minutes, then additional linear changes to 35%
B by 10 minutes, to 50% by 35 minutes and held for 10 minutes, to 95% by
49.5 minutes, with these conditions being maintained for an additional 0.5
minute. Metabolite-containing fractions were taken to dryness and reconstituted
in 1:1 acetonitrile:D2O before being submitted for NMR analysis.
Structural Identification of Metabolites
Structural characterization was performed on selected samples by HPLC-
mass spectrometry (MS) using triple quadrupole Quattro Ultima and hybrid
quadrupole/time-of-flight Q-TOF Premier mass spectrometers (Waters MS
Technologies, Manchester, UK). Electrospray ionization, in the positive ion
mode, was used. The HPLC flow was split (1:3) between mass spectrometer
and waste or fraction collector.
Metabolites were identified based on charged molecular ions, mass accuracy,
and their collision-induced dissociation fragmentation (Oliveira and Watson,
2000). Authentic standards, when available, were used to compare chromato-
graphic retention times (in particular for drug-related material in plasma) and
fragmentation patterns. Supporting data from preclinical studies were also used
in the assignment of metabolite structures. For many metabolites, confirma-
tion of the structure has been obtained by 1H-NMR using a Bruker DRX-600
spectrometer (Bruker, Rheinstetten, Germany) equipped with an inverse
5-mm TCI Cryo-Probe (Bruker) (1H/13C/15N) operating at 600.40 MHz
under the control of Topspin v1.3 (Bruker). 1H-NMR spectra were acquired
using a standard nuclear overhauser effect spectroscopy with presaturation
(NOESYPRESAT) pulse sequence with spoil gradients for solvent suppres-
sion with time-shared double presaturation of the water and acetonitrile
frequencies. In these experiments, typically 256 transients were acquired into
65,536 data points over a spectral width of 12,019 Hz (20 ppm) with an
interscan delay of 2.4 seconds giving a pulse repetition time of 5 seconds.
Acquisition time was extended up to 4096 transients for some metabolites to
improve signal to noise. Fully characterized metabolites were designated by
the letter M followed by a number; where a synthetic standard was available,
a GSK (or SB) code number was assigned.
Pharmacokinetic Analysis
Actual blood collection times and the actual dose administered were used
for all pharmacokinetic calculations. Analysis of plasma total radioactivity,
darapladib, and SB-553253 concentration-time data was conducted using the
noncompartmental models 200 and 202 of WinNonlin Professional Edition
versions 4.1 and 5.2 (Pharsight Corporation, Mountain View, CA). Maximum
plasma concentration (Cmax) and time of Cmax (Tmax) were taken directly from
the pharmacokinetic concentration-time data. Where data permit, the terminal
plasma elimination rate constant (lz) was estimated from log-linear regression
analysis of the terminal phase of the plasma concentration-time profile. The
number of points included in the terminal phase was determined by visual
inspection of the semilog plots of the plasma concentration-time profiles. The
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associated elimination half-life was calculated as ln2/ lz. Values of area under
the curve from time zero to last measured timepoint (AUC0-t) and area under
the curve from time zero to infinity (AUC0-inf) were calculated using linear
trapezoidal method for each incremental trapezoid and the logarithmic
trapezoidal method for each decremental trapezoid. After i.v. administration
only, systemic clearance was calculated as dose divided by AUC0-inf, and the
volume of distribution was the product of systemic clearance and the mean
residence time as determined by moment analysis. Concentration units for
radioactivity are expressed as nanogram equivalents of darapladib/milliliter and
as dpm/ml.
Due to the relatively long plasma half-life of total radioactivity and the
sensitivity of the AMS analysis, many predose plasma samples contained total
radioactivity concentrations that were above the LLQ (0.1 darapladib nanogram
equivalents per milliliter). In many cases, the predose plasma radioactive
concentrations (in dpm/ml) were .5% of the observed maximum plasma
concentration in the same profile, thus correction was made for each individual
plasma total radioactivity concentration-time profile to subtract, at each sampling
time, the residual plasma total radioactivity concentrations resulting from the
previous dose. The correction process involved initial determination of the
terminal elimination rate constant (lz) of total radioactivity in the plasma profile
from the previous dose period (i.e., from the plasma profile before the profile to
be corrected). Thus, pharmacokinetics calculations were first performed using the
original, uncorrected plasma concentration-time profiles to determine the required
lz values. This initial lz value was then used to calculate a plasma concentration
decay profile from the predose total radioactivity concentration (above the LLQ)
for each plasma profile using the following equation:
Cti ¼ Ct0•eðlz•tiÞ
where Cti is the concentration at the i
th sampling time, with Ct0 as the predose
(time zero) concentration. The corrected plasma concentration-time profile was
then calculated by subtracting the residual concentration at each time point (per
decay curve) from the original concentration.
In Vitro Reaction Phenotyping
[14C]Darapladib was incubated at 5 and 50 mM with human liver microsomes
(HLMs), at 2 mg/ml microsomal protein and 37°C, in phosphate buffer (50 mM,
pH 7.4). Reactions were started by the addition of prewarmed cofactor solution [a
NADPH regenerating system containing 1.7 mg of NADP, 7.8 mg of glucose-6-
phosphate, and 6 units of glucose-6-phosphate dehydrogenase per milliliter of 2%
(w/v) sodium hydrogen carbonate] and performed in the presence and absence of
the selective cytochrome P450 inhibitors: furafylline (CYP1A2), quercetin
(CYP2C8), sulphaphenazole (CYP2C9), quinidine (CYP2D6), and ketoconazole
(CYP3A). [14C]Darapladib was also incubated with Supersomes (BD Gentest,
Woburn, MA), overexpressing individual cytochrome P450 enzymes 1A2, 2C8,
2C9, 2C19, 2D6, or 3A4. All incubations were terminated by addition of
acetonitrile and were centrifuged (at approximately 13,000g), and supernatants
removed for analysis by HPLC-MS.
In Vitro Bacterial Incubations
[14C]Darapladib was incubated at a concentration of 5 mM in an anaerobic
environment at 37°C for 72 hours in the presence of individually cultured
bacteria: Enterococcus faecalis, Escherichia coli, Bifidus adolenscetis,
Bifidobacterium longum, Lactobacillus casei, Bacteroides vulgatus, and
Bacteroides thetaiotaomicron. These bacteria were selected based on their
known presence in the human gastrointestinal tract and their availability. After
the incubations, an equal volume of acetonitrile was added to each, and the
resultant samples were centrifuged (at approximately 3300g) and the super-
natants removed for analysis by HPLC-MS.
In Vitro Bacterial Mutation Assay
Both darapladib and SB-554008 (M10) were assessed in the bacterial
mutation assay (or Ames test). Genetically modified strains of Salmonella
typhimurium (TA98, TA100, TA1535, and TA1537) and Escherichia coli
(WP2 pKM101 and WP2 uvra pKM101) were used, in the presence and
absence of an exogenous mammalian oxidative metabolism system (Aroclor or
phenobarbital-induced rat liver post mitochondrial S9 fraction) using established
methodologies (Ames et al., 1973; Maron and Ames, 1983; Green, 1984). The
final volume of the S9 mix used was 500 ml/plate, with darapladib tested up to
5000 mg/plate and SB-554008 tested up to 500 mg/plate (concentration limited
by precipitation). An additional assessment of drug-related components present
under the conditions of the darapladib Ames test was conducted, using a
mammalian oxidative metabolism system comparable to that described earlier, to
assess the metabolism of darapladib (at concentrations of 25 and 100 mM).
Results
Demographic, Safety, and Tolerability Data
Eight healthy male subjects (four white, three African American,
one mixed race) were entered into the study, and seven subjects
completed all three sessions with one individual excluded due to lack of
compliance with sample collection during session 2. Following all three
sessions, the compound was regarded as generally safe and well tolerated,
and any adverse events reported were typically mild in nature (e.g.,
diarrhea, flatulence, dizziness, etc.).
Mass Balance of Total Radioactivity
The actual doses of i.v. and oral [14C]darapladib administered
ranged from 6.62 to 7.91 mg (41.4– 49.5 mCi, session 1), 75.3 to 78.8
mg (18.6–19.9 mCi, session 2), and 79.2 to 79.4 mg (19.2–20.0 mCi,
session 3), respectively. Mean cumulative excretion balance data
obtained from up to eight healthy male subjects following doses of
[14C]darapladib (i.v. and oral routes) are detailed in Table 1.
Following both i.v. and oral administration, total radioactivity was
eliminated almost exclusively in the feces, accounting for 85% of the
dose post i.v. infusion and 93%–95% following oral administration.
Total radioactivity recovered in urine was negligible (,1%) following
all dosing regimens over the respective collection periods (up to 216
or 504 hours post dose). Mean recoveries of approximately 90%–94%
of the radioactive dose were reached by 120 hours post oral
administration, with the remaining radioactivity recovered up to 216
or 264 hours post dose. Slower elimination of total radioactivity was
observed post i.v. administration, with only approximately 62%
recovered by 120 hours post dose and collections continuing to 504
hours, recovering 86% of the dose.
Pharmacokinetics
A summary of the plasma pharmacokinetic parameters for darapladib,
SB-553253 (M4), and total radioactivity after a single i.v. dose, a single
oral dose, and repeat dose oral administration is presented in Table 2.
Due to the relatively long half-life of total radioactivity, many predose
plasma samples in sessions 2 and 3 still contained levels of radioactivity
indicating that a small amount of circulating radioactivity remained after
the i.v. dose. Subtraction of the residual plasma radioactivity was
performed (as described in the Materials and Methods section), and
resulting parameters are summarized in Table 2. Mean (6 S.D.) plasma
concentrations of darapladib, SB-553253, and total radioactivity are
shown in Fig. 2. After i.v. administration, maximum darapladib con-
centrations were achieved, as expected, at the end of the 3-hour infusion,
with volume of distribution estimated at.800 l and low plasma clearance
of 17 l/h. After i.v. and single oral dose administration, the terminal half-
life of darapladib was similar, and relatively long at ;40 hours. After
single- and repeat-dose oral administrations, darapladib solutions were
absorbed slowly, with a median Tmax of 5 hours (single dose) and 6 hours
(repeat dose). The absolute bioavailability of darapladib solution was
12%, on average, comparing dose normalized exposures following single-
dose i.v. and single-dose oral administration. Due to the study design, no
estimate of oral bioavailability of the tablet was conducted within this
study. The mean area under the curve from time zero to next dosing
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interval [AUC(0-t)] following repeat oral dosing was approximately 50%
greater than AUC(0-t) following a single oral dose, indicating
accumulation; however, this degree of accumulation was less than
expected from single-dose exposure data [approximately 270%
accumulation was predicted from AUC(0-inf)/AUC(0-t) following
single-dose oral data]. This less than expected accumulation was consistent
with results observed from previous pharmacokinetic studies in healthy
volunteers (data on file).
The metabolite SB-553253 was rapidly formed following both i.v.
and oral administration of darapladib, with a Tmax similar to that of the
parent compound, although plasma concentrations of SB-553253 were
much lower, with exposure of SB-553253 (as estimated by the AUC)
being 0.2%, 1%, and 5% of parent darapladib following single i.v., single
oral, and repeat oral administration, respectively.
AUC(0-inf) and half-life parameters for total radioactivity were not
reported, as the sampling duration of 96 hours was too short relative to
the approximated half-life of radioactivity to adequately describe the
terminal elimination phase of plasma total radioactivity resulting in a
large extrapolation area. Pharmacokinetic parameters for total radioac-
tivity (nanogram equivalents) following repeat oral dosing could not
be generated due to the unknown dilution effect of nonradiolabeled
darapladib from dosing on days 1–10.
Metabolite Profiles
Plasma. Representative reconstructed radiochromatogram profiles
of individual time-adjusted pooled plasma samples from each dose
regimen are shown in Fig. 3. Quantification of drug-related material in
plasma from each dose regimen is summarized in Table 3.
Following i.v. infusion of [14C]darapladib, the predominant compo-
nent in plasma across all volunteers was unchanged darapladib, which
represented a mean of 89% of plasma radioactivity. The only other
radiolabeled component detected was SB-553253 (M4), which accounted
for approximately 1% of plasma radioactivity.
Following single oral administration of [14C]darapladib, unchanged
darapladib was again the principal radiolabeled component in plasma,
representing a mean of 75% of plasma radioactivity. Circulating
TABLE 1
Mean cumulative total radioactivity excreted in urine and feces (percentage of dose) after i.v. and oral administration of
[14C]darapladib to healthy volunteers
All urine and fecal radioactivity was determined using LSC
Elapsed Time
from Dose (h)
Intravenous Single Oral Repeat Dose Oral
n Urine Feces Total na Urine Feces Total nb Urine Feces Total
Predose 0.00 0.00 0.00
0–24 8 0.4 8.0 8.4 8 0.1 11.7 11.8 7 0.1 7.7 7.8
0–48 8 0.5 21.9 22.4 8 0.2 37.1 37.3 7 0.1 51.7 51.8
0–72 8 0.6 37.5 38.1 8 0.2 73.8 74.0 7 0.1 84.2 84.3
0–96 8 0.7 57.8 58.5 8 0.2 84.8 85.0 7 0.1 86.9 87.0
0–120 8 0.7 61.5 62.2 8 0.2 90.1 90.3 7 0.1 94.3 94.4
0–144 8 0.8 69.1 69.9 8 0.2 92.4 92.6 7 0.1 94.9 95.0
0–168 8 0.8 74.2 75.0 8 0.2 93.0 93.2 7 0.1 95.0 95.1
0–192 8 0.8 74.8 75.6 8 0.2 93.2 93.4 7 0.1 95.0 95.1
0–216 8 0.8 77.9 78.7 8 0.2 93.2 93.4 7 0.1 95.1 95.2
0–240 8 0.9 79.7 80.6 8 0.2 93.2 93.4 7 0.1 95.1 95.2
0–504c 8 0.9 85.5 86.4 8 0.2 93.2 93.4 7 0.1 95.2 95.3
aFecal data from subject 101 have been excluded from the calculation of fecal mean due to low balance recovery during single oral dose
regimen.
bSubject 101 excluded from this regimen due to low balance recovery during single oral administration regimen.
cIntravenous group samples collected for 504 hours, both single and repeat oral dose final sampling point was 264 hours post
(radioactive) dose.
TABLE 2
Geometric mean coefficient of variation (%) [CV%] pharmacokinetic parameters of total radioactivity, darapladib, and SB-553253 in plasma after i.v. and oral administration
of [14C]darapladib to healthy volunteers
Total radioactivity post i.v. administration was determined using LSC; total radioactivity post oral dosing was determined using AMS.
Parameter
Single-Dose Intravenous (n = 8) Single-Dose Oral (n = 8) Repeat-Dose Oral (n = 7)
Total
Radioactivity
Darapladib SB-553253
Total
Radioactivitya
Darapladib SB-553253
Total
Radioactivitya,b
Darapladib SB-553253
AUC(0-inf) (ng.h/ml) 491 (17.7) 603 (18.8)
AUC(0-t)
c (ng.h/ml) 567 (16.1) 405 (17.2) 0.614d (9.22) 1025 (20.0) 510 (17.4) 6.24 (31.4)
AUC(0-t) (ng.h/ml) 200 (13.8) 222 (14.2) 335 (18.5) 16.8 (19.1)
Cmax
e (ng/ml) 34.9 (20.6) 25.3 (12.4) 0.296 (11.0) 25.2 (17.9) 15.4 (16.7) 1.37 (14.9) 22.2 (17.4) 1.76 (33.2)
Tmax (h)
f 2.98 (2 - 5) 2.97 (2–3.53) 2.98 (2–3.5) 6 (3–6.02) 5.04 (4–6.02) 5.04 (3.02–6.02) 6 (4–6.03) 6 (2 – 6.03) 6 (3–6.03)
T1/2 (h) 40.9 (8.74) 40.4 (6.8)
CL (l/h) 11.2 (17.1) 17.3 (16.3)
Vss (l) 632.3 (19.1) 833 (17.7)
CL, systemic clearance; T1/2, elimination half-life; Vss, volume of distribution at steady-state.
aAUC and Cmax corrected for predose concentration (see detail in Materials and Methods section).
bRelative mean radioactive exposure (i.e., dpm only) was 320 dpm.h/ml on day 11 (compared with 420 dpm.h/ml on day 1).
cParameter units for total radioactivity are ng equiv.h/ml for all regimens.
dn = 2.
eParameter units for total radioactivity are ng equiv./ml for all regimens.
fMedian (range).
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metabolites were more notable and included: M3 (SB-823094), re-
sulting from hydroxylation of the cyclopenta pyrimidinone moiety;
SB-553253; M10 (SB-554008), a uracil derivative formed following
removal of the fluorobenzylthiol group; and a hydroxylated N-desethyl
metabolite (M16), each of which accounted for approximately 4%–5%
of plasma radioactivity. Any remaining metabolites each accounted for
,1% of plasma radioactivity.
The principal radiolabeled component in plasma samples obtained
following repeat oral administration was unchanged darapladib,
which represented a mean of 64% of plasma radioactivity. Circulating
metabolites observed included SB-823094 (M3), SB-553253, and
SB-554008 (M10), which individually accounted for means of
4%–6% of plasma radioactivity. Other metabolites were ob-
served, each accounting for 1% or less of the plasma radioactiv-
ity. Proposed structures and supporting spectral data are shown in
Table 4.
Urine. Negligible amounts (1% or less of the dose) were recovered
in urine across all three regimens, and therefore this matrix was not
examined further.
Feces. Radio-HPLC analyses of fecal extracts from i.v. and oral
administration of [14C]darapladib were similar. Representative radio-
chromatograms of pooled fecal extracts are shown in Fig. 4. Quantification
of drug-related material in feces from each dose regimen is summarized in
Table 3.
For the three dose regimens, mean recovery of radioactive material
from feces following solvent extraction ranged from 96% to 99%.
Radio-HPLC analysis of fecal extracts from all dose regimens revealed
the predominant radiolabeled component was unchanged darapladib,
although several other drug-related peaks were also evident. Follow-
ing i.v. administration, unchanged darapladib represented a mean of
approximately 55% of the fecal radioactivity (43% of the dose). The
predominant metabolites observed across all subjects were SB-553253
(M4) and SB-823094 (M3), accounting for means of 23% and 11% of
the fecal radioactivity (18% and 9% of the administered dose, respectively).
Following both single- and repeat-dose oral administration, unchanged
darapladib accounted for a mean of 53% of the radioactive dose
administered. As for i.v. administration, the predominant metabolites
post oral dosing were SB-553253 and SB-823094, accounting for
Fig. 2. Mean (6 S.D.) concentrations of total radioactivity, darapladib, and SB-553253 following single i.v. (A), single oral (B), and repeat dose oral administration (C) of
[14C]darapladib to human volunteers, and comparative total radioactivity profiles following single and repeat oral dose of [14C]darapladib to human volunteers (D).
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Fig. 3. Representative radiochromatograms of hu-
man plasma following single i.v. (A), single oral
(B), and repeat dose oral administration (C) of
[14C]darapladib to human volunteers.
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approximately 18% and 11% of the administered radioactive dose. A
number of minor metabolites were also observed across the dose
regimens representing ,4% of the dose and included SB-735258
(M7), SB-554008 (M10), M16 (hydroxylated SB-553253), and M19
(N-oxide). Proposed structures and supporting spectral data are shown
in Table 4.
In Vitro Incubations
Reaction Phenotyping. Incubations of [14C]darapladib with HLMs
showed NADPH-dependent metabolism to several metabolites, in-
cluding SB-553253 (M4) and SB-823094 (M3). Ketoconazole, a
CYP3A inhibitor, caused marked inhibition of darapladib metabolism,
whereas other cytochrome P450 inhibitors had no or minimal effects.
Metabolism of darapladib with expressed enzymes showed extensive
metabolism (up to 85% of parent metabolized) with CYP3A4, with
minor turnover in other expression enzymes, most notably CYP2C8.
Bacterial Incubations. Incubations of darapladib with various
human gut bacteria under anaerobic conditions produced no evidence
of metabolism with any of the strains used.
Ames Bacterial Mutation Assay. Darapladib did not induce point
(gene) mutation in Salmonella typhimurium (TA98, TA100, TA1535,
TA1537), either in the presence or absence of metabolic activation,
when tested up to 200 mg/plate (as limited by toxicity). Darapladib did
not induce point (gene) mutation in Escherichia coli (WP2 pKM101
and WP2 uvra pKM101), either in the presence or absence of
metabolic activation, when tested up to 5000 mg/plate. Similarly,
SB-554008 (M10) showed no increases in the numbers of revertant
colonies observed at any of the concentrations tested (up to 500 mg/
plate), in either the presence or absence of metabolic activation. The
metabolite SB-823094 was identified under the incubation and
metabolic activation conditions of the Ames assay of darapladib and
was not genotoxic.
Discussion
Following i.v. and oral administration of [14C]darapladib to
humans, total radioactivity was eliminated almost exclusively in the
feces (86%–95% of the dose). Recovery of the dose was considered
complete (Roffey et al., 2007) across all regimens (86%–95% of the
administered dose) but elimination was somewhat protracted, especially
following i.v. administration. Following oral dosing, between 90% and
94% of the dose had been recovered by 120 hours post dose, whereas
recovery of the i.v. dose was only around 62% at this time, with notable
amounts of dose continuing to be eliminated slowly thereafter. The
volume of distribution in humans was very high (.800 l), suggesting
notable tissue distribution. With a pKa of 8.4 (tertiary amine) and a log
P. 3.4, darapladib is a cationic amphiphilic drug, a common feature of
which is sequestration in lysosomes by a mechanism called pH
partitioning (Funk and Krise, 2012). As a result, cationic amphiphilic
drugs often have a large volume of distribution, protracted elimination,
and inhibit lysosomal lipid metabolism resulting in phospholipidosis
(Reasor and Kacew, 2001), which was observed in rats and mice
following dosing of darapladib at toxicological doses. It is therefore
considered that the slower elimination of a proportion of the radioactive
dose post i.v. dosing may represent more widespread tissue exposure to
darapladib via direct administration into the blood, when compared with
oral dosing where a large proportion of the dose is either unabsorbed
or removed via first-pass metabolism or elimination of the parent
compound prior to entering the systemic bloodstream (consistent with
the low absolute bioavailability of 12%). The plasma elimination half-
lives of darapladib post i.v. and oral dosing were consistent with prolonged
elimination, each around 40 hours.
The principal radiolabeled component observed in human plasma
following both i.v. and oral solution dosing of radiolabeled compound
was unchanged darapladib. The only metabolite observed in plasma
following i.v. dosing was SB-553253 (M4), albeit at very low levels
(1% of plasma radioactivity). Following oral administration, circulat-
ing metabolites were more evident, including SB-823094 (M3),
SB-553253, and SB-554008 (M10), each of which were present at
mean concentrations of around 5% of plasma radioactivity, and at low
absolute concentrations of less than 2 nanogram equivalents/milliliter.
The fact that metabolites are more prevalent in the circulation after
oral than after i.v. administration is indicative of first-pass metabolism,
and is consistent with the notable difference (50%–60%) in plasma
TABLE 3
Mean percentage of radioactivity of darapladib and its metabolites in human plasma and feces after i.v. and oral
administration of [14C]darapladib to healthy volunteers
Several metabolites, including M2, M6, M12, M21, and M22, observed in fecal extracts were detected by mass spectrometry only.
Plasma profiles were determined using HPLC AMS, whereas fecal profiles used off-line radio-HPLC.
Peak identification
Mean Percentage Plasma Radioactivity Mean % Matrix Radioactivity (mean % dose)
Plasma Feces
i.v. Single Oral Repeat Orale i.v. Single Oral Repeat Orale
Darapladib 89.2 75.3 64.2 54.5 (42.8) 57.5 (52.7) 55.8 (52.7)
M3 (SB-823094) ND 4.3 4.8 11.0 (8.6) 12.2 (11.1) 11.5 (10.8)
SB-553253 (M4) 1.2 4.1 4.0 23.3 (18.2) 20.4 (18.6) 18.5 (17.2)
SB-735258 (M7) ND 0.6 ND 1.3 (1.0) 1.2 (1.1) 1.2 (1.1)
M8 ND ND ND ND 2.1 (1.9) 1.8b (1.7)
M9 ND ND 0.7 ND BLQ 0.6a (0.5)
GSK219147 (M11) or M8 ND 0.6 1.0 2.1 (1.6) ND 1.8b (1.7)
SB-554008 (M10) ND 4.5c 5.7 5.0d (3.9) 4.2d (3.9) 4.3d (4.0)
M14 ND ND 0.4 BLQ BLQ 0.6a (0.5)
M16 ND 4.5c ND 5.0d (3.9) 4.2d (3.9) 4.3d (4.0)
M19 ND ND ND 5.0d (3.9) 4.2d (3.9) 4.3d (4.0)
BLQ, below limit of quantification; ND, not detected.
aMetabolites M9 and M14 coelute.
bMetabolites M8 and M11 coelute.
cMetabolites M10 and M16 coelute.
dMetabolites M10, M16, and M19 coelute (on a few occasions, some of these peaks were resolved but have been quantified as
a coeluting peak for consistency).
eThe repeat oral dose results–% dose results refers to only the radioactive dose administered on day 11.
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TABLE 4
Structural information on darapladib and its notable metabolites following administration of [14C]darapladib to human volunteers
Matrix Proposed Structure [M+H]+ Ion and MS-MS Product Ions 1H-NMR (600 Mhz, 1:1 ACN:D2O) (Where Available)
PL,FE
Darapladib
Accurate mass [M+H]+ 7.75 (d, 2H), 7.67 (d, 2H), 7.53 (d, 2H), 7.38 (d, 2H), 7.30 (dd,
2H), 6.90 (t, 2H), 4.79 (s, 2H), 4.65 (s, 2H), 4.30 (s, 2H), 3.67
(brt, 2H), 2.91 (t, 2H), 2.84 (q, 4H), 2.77 (t, 2H), 2.68 (t, 2H),
2.05 (m, 2H), 1.07 (t, 6H) Mixture of rotamers, major rotamer
assigned
Observed: 667.2728
Calculated: 667.2730
594, 486, 391, 351, 317, 235, 109
FE1
M2
Accurate mass [M+H]+ No NMR
Observed: 611.2112
Calculated: 611.2104
PL1,FE
SB-823094 (M3)
Accurate mass [M+H]+ 7.83 (d, 2H), 7.81 (d, 2H), 7.62 (d, 2H), 7.49 (d, 2H), 7.40 (dd,
2H), 7.08 (t, 2H), 5.18 (brm, 1H), 5.08 (s, 2H), 4.69 (s, 2H),
4.48 (s, 2H), 3.35 (t, 2H), 2.91 (ddd, 1H), 2.68 (ddd, 1H),
2.60 (t, 2H), 2.53 (q, 4H), 2.51 (m, 1H), 2.40 (m, 1H), 0.99
(t, 6H) Mixture of rotamers, major rotamer assigned
Observed: 683.2681
Calculated: 683.2679
610, 557, 502, 484, 391, 351,
333, 315, 235, 207, 109
PL,FE
SB-553253 (M4)
Accurate mass [M+H]+ 7.78 (d, 2H), 7.67 (d, 2H), 7.50 (d, 2H), 7.37 (d, 2H), 7.27 (dd,
2H), 6.88 (t, 2H), 4.67 (s, 2H), 4.59 (s, 2H), 4.27 (s, 2H), 3.77
(brt, 2H), 3.12 (t, 2H), 2.96 (q, 2H), 2.81 (t, 2H), 2.70 (t, 2H),
2.08 (m, 2H), 1.16 (t, 3H) Mixture of rotamers, major rotamer
assigned
Observed: 639.2408
Calculated: 639.2417
486, 431, 363, 323, 317, 235, 109
FE1
M6
Accurate mass [M+H]+
No NMRObserved: 573.2689
Calculated: 573.2692
391, 235, 205
(continued )
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TABLE 4—Continued
Matrix Proposed Structure [M+H]+ Ion and MS-MS Product Ions 1H-NMR (600 Mhz, 1:1 ACN:D2O) (Where Available)
PL1,FE
SB-735258 (M7)
Accurate mass [M+H]+ 7.85 (d, 2H), 7.79 (d, 2H), 7.79, (d, 2H), 7.41 (d, 2H), 4.78
(s, 2H), 4.70, (s, 2H), 3.91 (s, 3H), 2.76 (t, 2H), 2.68 (t, 2H),
1.05 (t, 6H) Some resonances obscured
Observed: 557.2751
Calculated: 557.2740
484, 391, 361, 351, 347, 235, 207, 127
PL1,FE1
M8
635 [M+H]+ No NMR
562, 235
FE1
M9
Accurate mass [M+H]+ No NMR
Observed: 515.2263
Calculated: 515.2270
PL,FE
SB-554008 (M10)
Accurate mass [M+H]+ 7.84 (d, 2H), 7.78 (d, 2H), 7.75, (d, 2H), 7.45 (d, 2H), 4.68
(s, 2H), 4.65, (s, 2H), 3.52 (t, 2H), 2.62 (t, 4H), 0.99 (t, 6H)
Some resonances obscured
Observed: 543.2554
Calculated: 543.2583
470, 235
PL,FE
GSK219147 (M11)
Accurate mass [M+H]+ 7.84 (d, 2H), 7.79 (d, 2H), 7.76, (d, 2H), 7.56 (d, 2H) remaining
resonances obscuredObserved: 559.2349
Calculated: 559.2355
486, 351, 235, 209
(continued )
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TABLE 4—Continued
Matrix Proposed Structure [M+H]+ Ion and MS-MS Product Ions 1H-NMR (600 Mhz, 1:1 ACN:D2O) (Where Available)
FE1
M12
Accurate mass [M+H]+ No NMR
Observed: 573..2511
Calculated: 573.2511
391, 309, 223, 209
PL1, FE
M14
Accurate mass [M+H]+ 8.12 (s, 1H), 7.85 (d, 2H), 7.79 (d, 2H), 7.78 (d, 2H), 7.44
(d, 2H), 4.96 (s, 2H), 4.71, (s, 2H) remaining resonances
obscured
Observed: 527.2634
Calculated: 527.2634
PL1,FE
M16
Accurate mass [M+H]+ 7.79 (d, 2H), 7.67 (d, 2H), 7.51 (d, 2H), 7.37 (d, 2H), 7.29 (dd,
2H), 6.90 (t, 2H), 5.16 (dd, 1H), 4.80 (s, 2H), 4.71 (s, 2H)
Mixture of rotamers, major rotamer assigned, remaining
signals obscured
Observed: 655.2363
Calculated: 655.2366
637, 529, 484, 363, 323, 315, 235, 207
FE
M19
Accurate mass [M+H]+ 7.78 (d, 2H), 7.68 (d, 2H), 7.53 (d, 2H), 7.40 (d, 2H), 7.29 (dd,
2H), 6.89 (t, 2H), 4.79 (s, 2H), 4.65 (s, 2H), 3.21 (t, 2H)
Mixture of rotamers, major rotamer assigned, remaining
signals obscured
Observed: 683.2712
Calculated: 683.2679
594
FE1
M21
Accurate mass [M+H]+ No NMR
Observed: 529.2424
Calculated: 529.2427
(continued )
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AUC and Cmax for total radioactivity compared with unchanged
darapladib. Incubations with HLMs showed that CYP3A is the main
enzyme responsible for darapladib metabolism, which is consis-
tent with intestinal and/or hepatic first-pass metabolism. Notably,
SB-554008 was not detected in any in vitro incubations using HLMs,
but is the major acid degradant of darapladib (e.g., dosed in solution)
in vivo. Moreover, the clinical formulation of darapladib has been
developed as an enteric coated tablet to minimize acid hydrolysis in
the stomach to SB-554008. Nonetheless, because of the nature and
objectives of this study, and the technical issues of developing
a protected radiolabeled formulation, [14C]darapladib was formulated
as a solution, and administered with food to minimize any acid degradation.
Since SB-554008 was seen in plasma following a single oral dose
but not post i.v. administration, it is inferred that a proportion of
SB-554008 is being generated presystemically. Bacterial incubations
with darapladib showed negligible metabolism, and therefore
SB-554008 observed post oral dosing of [14C]darapladib solution is
likely the result of acid hydrolysis in the stomach and is greater than
would be expected following administration of an enterically coated
darapladib tablet.
Whereas SB-553253 (M4) was quantified in plasma in preclinical
toxicology and clinical studies, SB-554008 had not been previ-
ously observed in preclinical species in either plasma or excreta, and
SB-823094 (M3) had not been previously quantified in plasma,
preclinically or clinically. Therefore, SB-554008 (M10) was potentially
human specific and SB-823094 potentially disproportionate (i.e., pres-
ent at higher plasma concentrations in humans than in preclinical
species), albeit present at very low levels in plasma. Both metabolites
were therefore evaluated for their genotoxicity potential prior to
entering the large phase III program [as recommended in the FDA
Guidance for Industry; Safety Testing of Drug Metabolites (2008)].
The presence of SB-823094 was demonstrated under the conditions of
the darapladib Ames test, but SB-554008 was absent and required
direct testing, which proved negative. Safety margins for general
toxicity were also established for both metabolites prior to the start of
phase III. Specific HPLC-MS/MS assays were developed, and the
exposures of SB-554008 and SB-823094 were determined in humans
post repeat dosing of the enteric clinical formulation, and in rats and
dogs (at no adverse effect dose levels), with preclinical exposure
margins for SB-823094 being established in both rats (;1.5-fold) and
dogs (;14-fold). Given the chiral nature of SB-823094, the formation
of each enantiomer was also confirmed, with no marked differences
between rats, dogs, and humans. Safety margins for SB-554008 were
attained in the dog only (;1.5-fold), whereas in the rat this metabolite
was present at lower concentrations than in humans, which is
consistent with the physiologic pH of the stomach in rats being higher
than dogs in both fed and fasted states (McConnell et al., 2008;
Sagawa et al., 2009). Interestingly, SB-554008 was not observed at all
systemically after a single oral dose of the enteric coated tablet in
humans (LLQ 0.1 ng/ml), whereas after a single oral solution dose of
[14C]darapladib, the mean individual pooled plasma concentration of
SB-554008 was up to 4.5 nanogram equivalents/milliliter, clearly
demonstrating that SB-554008 concentrations are substantially greater
after oral dosing of solution than an enteric coated tablet, which
protects darapladib from the low pH environment in the stomach.
SB-554008 is detectable at low concentrations after dosing to steady-state,
which is ascribed to the fact that, even at neutral pH, there is a very
slow rate of hydrolysis of darapladib.
The pharmacological activity of SB-823094 was similar to that of
darapladib and SB-553253, whereas that of SB-554008 was about
100-fold less. Since exposure to the metabolites in humans at steady
state was much lower than darapladib (means of #5% of parent based
on AUC), these metabolites are not expected to contribute significantly
to the pharmacological activity. Based on the genotoxicity evaluation,
general safety cover, and pharmacological activity, no further metabolite
work was conducted.
Darapladib was eliminated both by metabolism and as unchanged
drug, via the feces. The radiolabeled metabolite profiles in fecal extracts
from all three dosing regimens were very similar, qualitatively and
quantitatively, and were independent of the route and duration of
administration. Darapladib was the primary component in feces, represent-
ing 43%–53% of the dose, whereas SB-823094 and SB-553253 accounted
for 9%–19% of the dose. Several minor metabolites, each accounting
for less than 4% of the dose, were also observed. Based on the
structure of the metabolites, a simplified metabolic scheme is shown in
Fig. 5.
Minimal absorption can be estimated in humans from urinary excretion
post oral dosing or, where data exist, by comparing urinary excretion
following i.v. and oral administrations of a radiolabeled drug (Gibaldi
and Perrier, 1982). However, due to the negligible amounts of radioactive
drug-related material in urine following [14C]darapladib administration,
neither approach was undertaken. Alternatively, absorption can be
estimated from oral fecal metabolite profiles, assuming unchanged
darapladib observed in these profiles (53% of the dose) is unabsorbed,
and given the negligible degradation of darapladib by gastrointestinal
microbiota. Possible acid degradation of darapladib to SB-554008 (up
TABLE 4—Continued
Matrix Proposed Structure [M+H]+ Ion and MS-MS Product Ions 1H-NMR (600 Mhz, 1:1 ACN:D2O) (Where Available)
FE1
M22
Accurate mass [M+H]+ No NMR
Observed: 683.2683
Calculated: 683.2679
391,351,333,235
ACN, acetonitrile; FE, seen in feces; PL, seen in plasma; PL1/FE1, only seen in oral matrix.
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Fig. 4. Representative radiochromatograms of hu-
man fecal extracts following single i.v. (A), single
oral (B), and repeat dose oral administration (C) of
[14C]darapladib to human volunteers.
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to 4% of the dose) was also considered, and together suggest ab-
sorption of darapladib is at least 43% of the dose. Moreover, i.v. fecal
profiles showed a large proportion of the dose (43%) is secreted
unchanged (via bile and/or direct gut) into feces, and therefore, oral
absorption may well be substantially higher than the lower estimate of
43%. Absorption is defined as crossing the apical membrane of the
enterocytes, and as darapladib is both a CYP3A and P-glycoprotein
(PgP) substrate (as are metabolites SB-823094 and SB-553253), it is
postulated that the oral fecal profiles observed in humans reflect
metabolism and subsequent elimination at the level of the enterocyte
(Hochman et al., 2000; Paine et al., 2006). Previous lower estimates of
absorption from rats and dogs (based on urinary and biliary excretion
of drug-related material) do not allow for this gut wall elimination,
although a re-examination of oral fecal data in dogs suggested a higher
absorption of at least 41%; however, this information is not available
for rats. The similar levels of SB-823094 and SB-553253 in feces
following oral and i.v. dosing are thought to reflect the varying
contributions of hepatic and intestinal CYP3A to the overall metabolic
clearance of darapladib, depending on the route of administration.
The systemic exposure to radioactivity following a single oral
radioactive dose during steady-state dosing was about 30% lower than
that following the first single oral radioactive dose. This observation is
consistent with, and an independent confirmation of, the lower than
expected accumulation of darapladib on repeat dosing. Given the
CYP3A and Pgp substrate status of darapladib, the lower exposure to
radioactivity may indicate lesser absorption of darapladib across the
enterocyte after repeat oral dosing combined with greater extent of
first-pass metabolism and/or efflux transport as a result of induction of
enzyme and/or efflux transporter activity after repeat dosing. Due to
the complexity of AMS analysis and the decision to only profile time-
adjusted pooled plasma samples to 24 hours, it was not possible to
confirm whether enzyme induction is the mechanism underlying the
time-dependent pharmacokinetics. The question of CYP3A induc-
tion will be addressed in a planned drug-drug interaction study with
midazolam.
In summary, this unusual study design utilizing different routes of
administration, low-level AMS detection, and a repeat dose oral leg
has allowed an enhanced understanding of the relative absorption,
metabolism, and elimination of darapladib in humans, despite the
absence of absolute metabolite quantification post repeat dose.
The increased availability and acceptance of AMS within the
pharmaceutical industry (Smith 2011; Iyer et al., 2012; Lappin et al.,
2012; Vuong et al., 2012; Bowers et al., 2013; Harrell et al., 2013)
does facilitate replacing the traditional single-dose human radiolabeled
study with a design using repeated therapeutic doses incorporating
trace levels of radioactivity amenable to AMS detection, which in
Fig. 5. Simplified metabolic scheme for darapladib in humans.
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conjunction with MS and NMR techniques, would allow complete
determination of metabolism and disposition under the more relevant
steady-state conditions.
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Concomitant Oral and Intravenous
Pharmacokinetics of Dabrafenib, a BRAF
Inhibitor, in Patients With BRAF V600
Mutation‐Positive Solid Tumors
Cathrine L. Denton, PhD1, Elisabeth Minthorn, BS2, Stanley W. Carson, PharmD1,
Graeme C. Young, MSc3, Lauren E. Richards‐Peterson, PhD4, Jeffrey Botbyl, MS5,
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Abstract
Dabrafenib is an orally bioavailable, potent, and selective inhibitor of human wild‐type BRAF and CRAF kinases as well as mutant forms of BRAF kinase.
The aim of this phase 1, single‐center, open‐label study in four patients with BRAF mutation‐positive solid tumors was to determine the absolute
bioavailability of a 150 mg oral dose of dabrafenib. Amicrotracer study approach, in which a 50mg radiolabeled intravenous (IV) microdose of dabrafenib
was given concomitantly with a 150 mg oral dose, was used to simultaneously recover IV and oral pharmacokinetic parameters. The least squares mean
(90%CI) absolute bioavailability of dabrafenib (HPMC capsules) was 94.5% (81.3%, 109.7%). Median Tmax after oral administration was 2.0 hours and the
geometric mean terminal half‐life was 4.8 hours. The geometric mean clearance and volume of distribution after IV administration were 12.0 L/h and
45.5 L, respectively. Human clearance and volume of distribution at steady state were in agreement with predictions made using allometric scaling of
pharmacokinetic parameters from four preclinical species. In conclusion, dabrafenib absolute bioavailability was high, whereas first‐pass metabolismwas
low. Furthermore, the microtracer approach provided an innovative and efficient method for assessing the absolute bioavailability of dabrafenib in
patients with advanced cancer.
Keywords
bioavailability, dabrafenib, pharmacokinetic, intravenous, microtracer
Dabrafenib (GSK2118436) is an orally potent and
selective small‐molecule inhibitor of BRAF kinase
activity that is currently being developed for the treatment
of BRAF V600 mutation‐positive malignant melanoma.
Clinical activity was ﬁrst observed in a phase 1 ﬁrst‐time‐
in‐human (FTIH) study,1 and efﬁcacy of oral dabrafenib
150 mg twice daily was conﬁrmed in a randomized phase
3 study2 as well as a phase 2 study in patients with
melanoma.3
The pharmacokinetics of dabrafenib after oral admin-
istration was characterized in the FTIH study.1 Following
a single oral dose of 150 mg dabrafenib, median Tmax was
recorded 2 hours after dosing and the mean terminal half‐
life (t1/2) was 5.2 hours. Three major circulating metab-
olites were identiﬁed in the FTIH study and their
pharmacokinetics characterized. Based on data from the
mass balance study, the half‐lives of hydroxy‐, carboxy‐,
and desmethyl‐dabrafenib were 5.7, 17.5, and 20.4 hours,
respectively.4
Determination of absolute bioavailability improves our
understanding and is required by several regulatory
agencies, but such clinical studies have been fraught
with the challenges and delays associated with preparing
and administering a drug intravenously that has been
developed for oral use. The use of intravenous (IV)
radiolabeled microtracer studies offers an attractive
alternative to conducting conventional crossover‐design
absolute bioavailability studies and provides
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Pharmacokinetics
characterization of the IV pharmacokinetics of a new
compound. The microtracer approach involves adminis-
tration of an unlabeled oral therapeutic dose with
concomitant administration of a subtherapeutic radio-
labeled IV microdose (pharmacologically inactive). A
microdose is deﬁned as less than 1/100th of the calculated
clinical dose (based on animal data) needed to yield a
pharmacologic effect, up to a maximum of 100 mg.5,6 The
radiolabeled microdose produces trivial exposure to
ionizing radiation (<270 nCi), and does not require
additional IV toxicity studies or extensive IV formulation
development. The microtracer approach has the advantage
of simultaneous recovery of IV and oral pharmacokinetic
parameters to obtain within‐subject, within‐period com-
parison. As such, this approach reduces the variability of
recovered pharmacokinetic parameters, reduces the
number of subjects required, and provides a more precise
estimate of absolute bioavailability than does the use of a
traditional crossover design study. Microtracer studies
have been used successfully to determine the absolute
bioavailability of a number of compounds including
fexofenadine, IDX899 and IDX989, SRT‐2104
(GSK2245840), and saxagliptin.7–11
The purpose of this study was to characterize the oral
and IV pharmacokinetics and determine the absolute oral
bioavailability of dabrafenib using simultaneous admin-
istration of an unlabeled oral capsule dose (150 mg as two
75 mg capsules) and a radiolabeled IVmicrodose (50 mg)
in patients with BRAF mutation‐positive solid tumors.
Clinical pharmacokinetic parameters were compared with
preclinical pharmacokinetic parameters to better under-
stand the predictability of the preclinical models.
Methods
Clinical Study Design
The study protocol (BRF113479; ClinicalTrials.gov
identiﬁer NCT01340833) and consent form were ap-
proved by a duly constituted institutional review board
(Alpha Independent Review Board, San Clemente, CA),
and the study was conducted in accordance with Good
Clinical Practice and the guiding principles of the
Declaration of Helsinki at Comprehensive Clinical
Development NW, Inc. (Tacoma, WA). Signed and dated
written informed consent was obtained from each patient
before his or her participation in the study and before the
performance of any procedures.
This was a phase 1, single‐center, open‐label study in
patients with BRAF mutation‐positive solid tumors. After
obtaining informed consent, eligible participants were
admitted to the clinical research unit on day 1. After an
overnight fast, all participants received 150 mg of
dabrafenib (as mesylate salt) as two 75 mg hydroxypropyl
methylcellulose (HPMC) capsules and a single IV dose of
50 mg (7.4 kBq; 200 nCi) [14C] dabrafenib, infused over
15 minutes, starting 1.75 hours after the oral dose (to
coincide with oral Tmax). The actual measured IV dose was
determined by liquid scintillation counting of aliquots
(300 mL) of the administered dabrafenib IV solution, and
based on the predetermined speciﬁc activity of [14C]‐
labeled dabrafenib. The participants continued fasting for
4 hours after the oral dose. Blood samples (two 6 mL
samples at each time point) for analysis of dabrafenib,
[14C] dabrafenib, and total radioactivity were collected at
several time points through 72 hours after the oral dose.
The actual date and time of each blood sample collection
were recorded. Plasma was separated from blood by
centrifugation and stored frozen prior to analysis. After
completion of the study, all participants entered an open‐
label rollover study of dabrafenib (no washout period or
follow‐up visit required) and continued receiving dabra-
fenib (BRF114144, ClinicalTrials.gov identiﬁer
NCT01231594).
Dose Selection
The recommended oral dose for phase 2 and phase 3
studies was 150 mg twice daily administered as two
75 mg HPMC capsules. An IV dose of 50 mg was
selected, which is 3,000‐fold lower than the oral dose,
thus ﬁtting the criteria of a microdose (i.e., <100th of the
dose needed to yield a pharmacologic effect, up to a
maximum of 100 mg). The exact IV dose administered
was measured on site and used in absolute bioavailability
calculations.
Study Participants
Men or women were eligible if they were18 years of age
with BRAF mutation‐positive tumors, had an Eastern
Cooperative OncologyGroup (ECOG) performance status
of 0 or 1, and had adequate organ function. A body weight
of 45 kg and a body mass index of 19 kg/m2 and
35 mg/m2 were required. Participants were excluded if
they had received cancer therapy, an investigational
anticancer drug within 3 weeks, or any other investiga-
tional product within 30 days, ﬁve half‐lives, or twice the
duration of the biological effect of the investigational
product. In addition, patients were excluded if they had
participated in a 14C human research study within
12 months preceding the administration of study medica-
tion. Consumption of food, herbal remedies, or medication
known to interfere with cytochrome P (CYP) 3A,
CYP2C8, or P‐glycoprotein activity was prohibited.
Disease‐related exclusion criteria were the presence of
invasive non‐BRAF mutation‐positive malignancy or
presence of brain metastases that were symptomatic,
treated but not clinically stable, or asymptomatic/untreat-
ed and >1 cm in the longest dimension. Patients with a
corrected QT (QTc) interval480 ms (note that QTc was
assessed using Fridericia’s correction) or with conditions
affecting gastrointestinal absorption were excluded.
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Dabrafenib UHPLC‐MS/MS Analysis
Concentrations of dabrafenib in plasma samples at all time
points were determined using a validated analytical
ultrahigh performance liquid chromatography mass
spectrometry/mass spectrometry (UHPLC‐MS/MS)meth-
od, over the range of 1–1,000 ng/mL. Dabrafenib was
extracted from 50 mL of human plasma by liquid–liquid
extraction with ethyl acetate after the addition of
isotopically labeled internal standards ([2H9]‐dabrafenib).
Extracts (4 mL) were injected onto aWaters Acquity BEH
C18 column (50 mm  2.1 mm; Waters Corporation,
Milford, MA) maintained at 55°C. The mobile phase
consisted of 0.1% formic acid in water (solvent A) and
acetonitrile (solvent B). A ﬂow rate of 0.8 mL/min was
maintained for the entire run. The following 1.4‐min linear
gradient was used: start at 30% B, increase to 50% B over
0.5 minutes, maintain 50% B for 0.3 minutes, increase to
80% B over 0.2 minutes, and maintain at 80% B for
0.3 minutes. The column was reequilibrated after each
injection. Detection was performed by positive‐ion MS/
MS using a TurboIon spray interface on an API 4000mass
spectrometer (Applied Biosystems/MDS Sciex, Concord,
Ontario, Canada) with multiple reaction monitoring (m/z
520–m/z 277 for dabrafenib, m/z 529–m/z 280 for [2H9]‐
dabrafenib). Quantiﬁcation was performed against dabra-
fenib‐spiked recovery standards based on demonstrated
linearity with 1/x2 weighted regression.
Each batch of experimental samples was run against
freshly prepared calibration standards (n ¼ 10). Replicate
(n ¼ 4) quality control (QC) samples at three concen-
trations were stored and also analyzed alongside study
samples. For the analysis to be acceptable, no more than
one‐third of the total QC results and no more than one‐half
of the results from each concentration level could deviate
from the nominal concentration by >15% (actual,
<10.9%). In all cases, the coefﬁcient of variation between
the replicates could not deviate by>15% (actual,<5.6%).
The applicable analytic runs met all predeﬁned acceptance
criteria. Twelve study samples (16.7% of the total study
samples) were reanalyzed for incurred sample reproduc-
ibility (ISR), with all samples being within 20% of the
mean of the original and ISR results.
[14C] Dabrafenib and Total Radioactivity Analysis
Samples were analyzed for [14C] dabrafenib and total
plasma radioactivity using accelerator mass spectrometry
(AMS) by Xceleron (Germantown, MD). Prior to analysis
by AMS, the carbon within the samples was harvested and
converted to graphite. This involved a two‐stage process
of sample combustion (oxidation) followed by graphiti-
zation (reduction), as previously published.12 AMS
provides an isotope ratio from which total radiocarbon
per mg carbon is derived. The carbon content of plasma
was taken into account to allow correction of the AMS
data to determine the amount of radiocarbon in the
samples. Carbon analysis was undertaken using a Costech
Elemental Combustion System CHNS‐O Analyzer (Cost-
ech Analytical Technologies, Inc., Valencia, CA) supplied
by Pelican Scientiﬁc Ltd. (Cheshire, United Kingdom).
The AMS was a 250 kV Single Stage Accelerator Mass
Spectrometer (National Electrostatics Corp., Middleton,
WI), operated via NEC proprietary “AccelNET” software
on a Linux operating system. Post‐acquisition data
processing was performed using the NEC software
“abc.” Further details of the operating conditions have
been previously published.12 The lower limit of quantita-
tion (LLQ) and higher limit of quantitation (HLQ) for total
plasma radioactivity were 9.77 and 11,400 dabrafenib pg
equiv/mL for a 60‐mL aliquot of human plasma.
Plasma [14C] dabrafenib concentrations at all time
points were determined using a validated analytical
LC þ AMS method over the range of 1.86–456 pg/mL.
Dabrafenib (including [14C] dabrafenib as a tracer) was
extracted from 400 mL (2  200‐mL aliquots) of human
plasma by protein precipitation using three volumes of
acetonitrile containing nonlabeled dabrafenib at 10 mg/
mL as an internal standard (IS). The protein precipitation
plate was shaken for 5 minutes at medium setting on a
plate shaker. Samples were drawn through the plate under
vacuum and collected as two ﬁltrates into polypropylene
tubes. After drying one of the ﬁltrates under nitrogen until
100 mL remained, the second ﬁltrate was added and the
combined ﬁltrate was reduced to dryness under nitrogen at
20°C. The sample was reconstituted in 100 mL of 10‐mM
ammonium acetate (pH5) and 50 mLwas injected onto the
HPLC system. Isolation of dabrafenib was achieved using
a Poroshell 120 EC‐C18 column (2.7 mm packing,
3  50 mm; Agilent Technologies, Santa Clara, CA)
maintained at 30°C. The mobile phase consisted of
10 mM ammonium acetate (pH 5; A) and acetonitrile (B).
A ﬂow rate of 1 mL/min was maintained for the entire run.
The following 15‐minutes gradient was used: start at 5%
B, maintain at 5%B for 1 minutes, increase to 20%B over
1.4 minutes, increase to 35%B over 5.6 minutes, increase
to 95% B over 4 minutes, and maintain at 95% B for
0.8 minutes, then decrease to 5% B over 0.1 minutes. The
column was then reequilibrated at 5% B over 2.1 minutes.
The area of the UV response of the IS was recorded, and
the eluate corresponding to dabrafenib was collected as a
discrete fraction into a quartz tube for further processing
(to harvest graphite) and subsequent analysis by AMS.
The assay had a linear dynamic range of 1.86–456 pg/mL,
and quantiﬁcation was performed against dabrafenib‐
spiked recovery standards based on demonstrated linearity
with 1/x weighted regression.
During validation, QC samples (n ¼ 3) at three
concentrations were analyzed on two separate occasions.
Eight of nine assay results on day 1 and 7 of 9 on day 2
were within 20% (25% at LLQ) of the actual value.
Additionally, a set of spiked samples (n ¼ 5) at ﬁve
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concentrations ranging from 1.86–456 pg/mL was ana-
lyzed alongside the QC samples, giving a within‐run
precision of<13.6% and a 1/x‐weighted R2 value of 0.99.
Replicate (n ¼ 3) QC samples at three concentrations
were also analyzed alongside study samples. Only 2 of 36
samples failed to meet the established acceptance criteria
(20%) through four analytical runs. Ten study samples
(16%) were reanalyzed for ISR, with all samples being
within 20% of the mean of the original and ISR results.
Clinical Pharmacokinetics
Analysis of plasma concentration data via noncompart-
mental methods was conducted using WinNonlin Profes-
sional Edition version 5.2 (Pharsight Corporation,
Mountain View, CA) noncompartmental Model 200 (for
extravascular administration) for dabrafenib and non-
compartmentalModel 202 (for constant infusion) for [14C]
dabrafenib and total radioactivity by ICON Development
Solutions (Marlow, United Kingdom). Standard non-
compartmental pharmacokinetic parameters for dabrafe-
nib, [14C] dabrafenib, and total radioactivity were
estimated based on actual sampling times. Vss is described
as the volume of distribution at steady state, and is based
on mean residence time (MRT) and clearance (CL) where
Vss ¼ MRT(01)  CL.
Preclinical Pharmacokinetics
Preclinical studies were conducted to characterize the
IV and oral pharmacokinetic properties of dabrafenib in
mice, rats, dogs, and monkeys. All animal studies were
conducted in accordance with the GlaxoSmithKline
(GSK) policy on the care, welfare, and treatment of
laboratory animals, and were reviewed by the Institu-
tional Animal Care and Use Committee at GSK
(Collegeville, PA). The pharmacokinetics of dabrafe-
nib was studied in male CD‐1 mice, Sprague–Dawley
rats, beagle dogs, and cynomolgus monkeys after a
single IV bolus (mouse) or 1‐hour infusion (rat, dog,
and monkey) administration (n ¼ 3/species). Doses
were formulated in 1% DMSO and 10% Solutol in
saline (pH 5.0–5.5) for injection (rodent) or 1% DMSO
and 30% PEG400 in saline (pH 3.72 or 4.35) for
injection (dog or monkey). Oral exposure was also
determined after single oral gavage administration.
Oral solution doses were formulated as the free base in
1% DMSO and 10% Solutol in pH 5 water (rodent),
1% DMSO and 30% PEG400 in pH 4.07 water (dog), or
in water (pH 4.92) alone (monkey). Serial blood
samples were collected and assayed for dabrafenib by
protein precipitation followed by LC/MS/MS analysis,
and the resulting concentration–time data were ana-
lyzed by noncompartmental methods using WinNonlin
Professional version 4.1. The linear relationship
between log‐transformed body weight and log‐trans-
formed CL or Vss for all four preclinical species was
used to estimate human CL and Vss, prior to conducting
the FTIH clinical study.
Statistical Analysis
Summary statistics were calculated for each pharmacoki-
netic parameter for data from each of the preclinical
species and the human study. For calculation of absolute
bioavailability, a mixed‐effect model was ﬁt to dose‐
normalized, loge‐transformed area under the curve
(AUC[01]) with the subject as a random effect and
treatment as a ﬁxed effect (oral was the test, IV was the
reference). Dose‐normalized AUC(01) was obtained by
dividing AUC(01) by the corresponding dose of the
subject. The least squares mean difference and associated
90% CI in AUC(01) between the oral and IV doses were
obtained from the model. This least squares mean
difference was back‐transformed to provide a point
estimate and corresponding 90% CI for the absolute
bioavailability (F). The oral dose and the actual measured
IV dose were used in the calculation of absolute
bioavailability.
Results
Participants
Four patients (two men, two women; all were white) were
enrolled and underwent study procedures. Three patients
had stage IV BRAF mutation‐positive melanoma and one
had stage IV BRAF mutation‐positive small cell lung
cancer. All patients had an ECOG performance status of 1
at screening. All received the oral and IV doses as planned.
The measured IV dose of [14C] dabrafenib received by
each patient was between 53 and 59 mg, 106–118% of the
target dose.
Clinical Pharmacokinetics
Mean concentration–time proﬁles following oral and IV
microdose are illustrated in Figure 1. After IV administra-
tion, [14C] dabrafenib, and total radioactivity were
detectable in all four patients through 8 and 72 hours,
respectively. Pharmacokinetic parameters for [14C] dab-
rafenib and total radioactivity after IV administration and
for dabrafenib after oral administration are summarized in
Table 1.
For a targeted 3,000‐fold difference between IV and
oral dose, geometric mean Cmax and AUC(01) were 766‐
fold and 2,560‐fold lower, respectively, after IV micro-
dose relative to the oral dose. The least squares mean (90%
CI) absolute bioavailability of dabrafenib administered as
HPMC capsules was 94.5% (81.3%, 109.7%), with
individual values ranging from 79.3% to 105.9%.
Following IV administration, the geometric mean CL
and Vss of [
14C] dabrafenib were 12.0 L/h and 45.5 L,
respectively. Geometric mean apparent CL after oral
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administration was 14.0 L/h. Plasma concentrations of
[14C] dabrafenib and dabrafenib declined in a biexponen-
tial fashion, and the geometric mean half‐lives were
2.6 hours after IV [14C] dabrafenib administration and
4.8 hours after oral dabrafenib administration. Median
Tmax after oral administration was 2.0 hours and coincided
with the Tmax observed at the end of the IV infusion
(Table 1, Figure 1A and B).
Cmax and AUC(01) of total radioactivity were 1.3‐fold
and 10.5‐fold higher, respectively, than [14C]‐dabrafenib
after IV dosing, consistent with the presence of circulating
metabolites. The percentage of total radioactivity in the
form of parent compound was 9.6% as assessed by the
ratio of geometric mean plasma AUC(01) of [
14C]
dabrafenib to total plasma radioactivity (Table 1). Termi-
nal half‐life was 18.3 hours for total radioactivity
compared with 2.6 hours for [14C] dabrafenib.
Adverse Events
All reported adverse events (AEs) were grade 1 or grade 2
and resolved within 6 days of onset. The most common
AEwas ﬂushing (reported in two of four patients). All AEs
except for upper respiratory tract infection were consid-
ered related to treatment with the study medication. There
were no withdrawals due to AEs and no reports of AEs
related to changes in clinical laboratory tests, echocardio-
grams, or vital signs. There were no reports of serious AEs.
Preclinical Pharmacokinetics and Allometry
Dabrafenib pharmacokinetic parameters after oral and IV
dosing in preclinical species are summarized in Table 2.
Following IV administration, dabrafenib CL was low and
volume was small relative to body water in all preclinical
species, resulting in half‐lives ranging from 0.3 hours
(mouse and monkey) to 2.8 hours (dogs). Oral bioavail-
ability ranged from 46% to 82% across species and was
lowest in monkeys.
Based on preclinical pharmacokinetic parameters, CL
and volume in humans were originally predicted based on
allometric scaling methods. Figure 2 shows the linear
model used to describe the allometric relationship of log‐
Figure 1. (A) Individual plasma dabrafenib and [14C] dabrafenib
concentration versus time profiles after oral (150 mg) and IV (50 mg)
administration. The following symbols denote patient 1 (), patient 2
(&), patient 3 (&), and patient 4 (~). The dashed lines represent oral
dabrafenib, the solid lines represent IV [14C] dabrafenib. (B) Mean plasma
[14C] dabrafenib (solid line, ng/mL) and total radioactivity (dashed line, ng
equivalents of dabrafenib/mL) concentration versus time profile after
intravenous (IV; 50 mg) administration (N ¼ 4).
Table 1. Clinical Pharmacokinetics of Dabrafenib After Concomitant Oral and IV Administration (150 mg Dabrafenib Orally, 50 mg [14C]
Dabrafenib IV)
Parametera (units) Oral dabrafenib IV [14C] dabrafenib IV Total radioactivityb
Tmax (h) 2.0 (2.0, 4.0) 0.25 (0.22, 0.32) 0.29 (0.22, 0.33)
Cmax (ng/mL) 2,527 (1,318, 4,845) 3.3 (1.6, 6.8) 4.2 (2.0, 8.6)
AUC(0t) (ng  h/mL) 10,723 (6,989, 16,451) 4.1 (3.1, 5.3) 41.1 (21.4, 79.2)
AUC(01) (ng  h/mL) 10,751 (6,996, 16,523) 4.2 (3.2, 5.4) 43.9 (22.8, 84.5)
t1/2 (h) 4.8 (3.0, 7.6) 2.6 (1.8, 3.7) 18.3 (14.7, 22.7)
CL or CL/Fc (L/h) 14.0 (9.1, 21.4) 12.0 (9.2, 15.7) NA
Vss (L) NA 45.5 (28.1, 73.7) NA
Abbreviations: AUC, area under the curve; CL, clearance; F, absolute bioavailability; IV, intravenous; NA, not applicable; t1/2, half‐life; Vss, volume of distribution at
steady state.
aResults are presented as geometric mean (95% CI), except Tmax as median (range), N ¼ 4.
bRadioactivity concentrations are expressed as ng equivalents of dabrafenib/mL.
cCL for IV administration or CL/F for oral administration.
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transformed body weight and either CL or volume
between species. Accordingly, human CL and volume
were predicted to be 14.8 L/h (3.5 mL/min/kg) and 21.6 L
(0.31 L/kg), respectively, resulting in a half‐life of
61 min. Observed values for human CL and volume after
IV dosing of [14C] dabrafenib were 12.0 L/h and 45.5 L,
respectively, and as such were consistent with values
predicted from preclinical species.
Discussion
The primary objective of this study was to determine the
absolute bioavailability of dabrafenib using concomitant
administration of an unlabeled oral therapeutic dose (two
75 mgHPMC capsules) and a radiolabeled IVmicrotracer
dose (50 mg). The absolute bioavailability of a 150 mg
dose of dabrafenib was high (94.5%). Whereas the
estimate given in the current publication uses the actual
measured IV dose of [14C] dabrafenib to estimate
bioavailability, a preliminary estimate was published
using prescribed dose 84.2% (72.3–98.1%).13 Tradition-
ally, absolute bioavailability has been determined via a
randomized, 2‐period crossover study design and typically
requires 6–12 individuals. Although the sample size in
this study was small (four patients), the reduced variability
afforded by the microtracer approach, compared with the
2‐period crossover design, allows for a robust estimate of
absolute bioavailability.
The IV CL of dabrafenib was 12.0 L/h and, as such,
was30% of hepatic blood ﬂow (where the hepatic blood
ﬂow is 81 L/h,14 and the blood:plasma ratio is0.5). The
high absolute bioavailability and low CL suggested low
hepatic extraction of dabrafenib in addition to low ﬁrst‐
pass metabolism. Low ﬁrst‐pass metabolism likely
contributed to low variability in exposure after oral dosing
(28% between‐subject variation). Despite low CL,
dabrafenib t1/2 was short, likely due to a small volume
of distribution. Following oral administration, both the
Tmax and t1/2 observed in this study were consistent with
previous reports.11 Dabrafenib t1/2 was nearly twice as
long after oral administration as that after IV administra-
tion, suggesting prolonged absorption, that is, ﬂip–ﬂop
kinetics. Increased exposure to dabrafenib after oral
administration is therefore dependent on the prolonged
absorption phase, which contributes to a longer half‐life
and protracted decline in plasma concentrations than that
after IV administration.
A longer t1/2 was observed for total radioactivity than
for [14C] dabrafenib, likely due to the circulating
dabrafenib metabolites carboxy‐dabrafenib and des-
methyl‐dabrafenib, which have long t1/2 (17.5 and
20.4 hours, respectively) and display elimination rate‐
limited pharmacokinetics. In contrast, the t1/2 of hydroxy‐
dabrafenib after oral dosing was 5.7 hours, and the
pharmacokinetic proﬁle paralleled that of the parent. In
terms of total plasma radioactivity AUC(01), the parent
and the hydroxy‐, carboxy‐, and desmethyl‐dabrafenib
metabolites were found to account for 11%, 8%, 57%, and
3%, respectively, based on data from the mass balance
study.4 As observed in the present study, the fraction of
Table 2. Preclinical Pharmacokinetics After a Single IV or Oral Dose of Dabrafeniba
Specie Dose (IV/oral) (mg/kg) IV CL (mL/min/kg) IV Vss (L/kg) IV t1/2 (h) F (%)
Mouse 2.5/10 43.5 (6.8) 1.0 (0.1) 0.3 (0.1) 70b
Rat 2.0/4.0 17.6 (4.3) 1.0 (0.1) 0.7 (0.1) 77 (21)
Monkey 0.5/1.0 22.5 (1.8) 0.5 (0.1) 0.3 (0.1) 46 (4)
Dog 0.6/0.7 3.6 (0.3) 0.4 (0.1) 2.8 (0.7) 82 (12)
Abbreviations: CL, clearance; F, absolute bioavailability; IV, intravenous; t1/2, half‐life; Vss, volume of distribution at steady state.
aPharmacokinetic parameters reported as mean (SD), N ¼ 3.
bNoncrossover estimate of oral bioavailability from two separate studies.
Figure 2. Allometric scaling of dabrafenib clearance and volume. Linear
relationship between log‐transformed body weight (LogBwt) and log‐
transformed (A) clearance (LogCL) or (B) volume of distribution at
steady state (LogVss) in four preclinical species after intravenous
administration of dabrafenib. Linear regression equation and r2
(coefficient of determination) values are shown, inset.
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systemic parent AUC(01) compared with systemic total
radioactivity AUC(01) after IV administration was 9.6%,
generally consistent with both the value observedwith oral
dosing and the low ﬁrst‐pass metabolism.
The estimate of human CL from preclinical pharmaco-
kinetic data was within 20% of the observed value in our
study. For volume of distribution, the observed Vss was
about twofold higher than the predicted value. From a
qualitative standpoint, however, scaling from preclinical
data was consistent with the observed clinical data in that
IV CL was low and volume was small relative to body
water in preclinical species. Allometric scaling of
dabrafenib t1/2 in humans was estimated to be 61 minutes
and, as such, was expected to pose a challenge to adequate
dosing in the clinic. The uncertainty surrounding allome-
tric predictions of human pharmacokinetics was addressed
by including both single‐dose and repeat‐dose regimens in
a ﬂexible FTIH study during which the pharmacokinetics
of dabrafenib was monitored.1 Decisions about adequate
dosing frequency could thus be made based on emerging
pharmacokinetic data.
In conclusion, the IV microtracer study approach
revealed the contribution of high oral bioavailability with
low ﬁrst‐pass metabolism, a prolonged absorption phase,
and the presence of long half‐life metabolites to the
pharmacokinetics of dabrafenib. Furthermore, this ap-
proach shortened the study time frame and allowed for
simultaneous collection of IV and oral pharmacokinetic
parameters, thus reducing variability. Particularly, where
patients as clinical research participants are concerned, IV
microtracer studies offer an innovative and efﬁcient
approach for assessing absolute bioavailability and may
be applied across a range of therapeutic areas and
compound classes.
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AIMS
The aim of this phase 1, single centre, open label study in four patients
with solid tumours was to determine the absolute bioavailability of a
2 mg oral dose of trametinib. Trametinib is an orally bioavailable,
reversible and selective allosteric inhibitor of MEK1 and MEK2
activation and kinase activity.
METHODS
A microtracer study approach, in which a 5 μg radiolabelled i.v.
microdose of trametinib was given concomitantly with an unlabelled
2 mg oral tablet formulation, was used to recover i.v. and oral
pharmacokinetic parameters, simultaneously.
RESULTS
The least-squares mean (90% confidence interval) absolute
bioavailability of trametinib (2 mg tablet) was 72.3% (50.0%, 104.6%).
Median tmax after oral administration was 1.5 h and the geometric mean
terminal half-life was 11 days. The geometric mean clearance and
volume of distribution after i.v. administration were 3.21 l h−1 and 976 l,
respectively, resulting in a terminal elimination half-life of 11 days.
CONCLUSIONS
Trametinib absolute bioavailability was moderate to high, whereas first
pass metabolism was low.
WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Following oral dosing of 2 mg trametinib, median
tmax was 1.5 h and the mean effective half-life (t1/2)
was approximately 4 days. Trametinib is greater
than 95% protein bound. Trametinib accumulates
about six-fold with repeat daily dosing, and the
concentration–time profiles showed a flat profile at
steady-state with a low peak : trough ratio.
• The absolute bioavailability of trametinib has not
been previously reported.
• The microtracer approach has been used previously
to recover i.v. and oral pharmacokinetic parameters,
simultaneously, which are used to estimate absolute
bioavailability.
• Determination of absolute bioavailability improves
our understanding of the clinical pharmacology of a
compound.
WHAT THIS STUDY ADDS
• Trametinib has moderate to high bioavailability
(72.3%) following oral administration of a 2 mg
tablet.
• The i.v. microtracer study approach revealed the
contribution of high oral bioavailability with low
first pass metabolism and a prolonged terminal
elimination phase to the pharmacokinetics of
trametinib.
British Journal of Clinical
Pharmacology
DOI:10.1111/bcp.12373
524 / Br J Clin Pharmacol / 78:3 / 524–532 © 2014 The British Pharmacological Society
Introduction
Trametinib is a reversible, highly selective allosteric inhibi-
tor of MEK1/MEK2 activation and kinase activity [1, 2]
which has been approved in the United States for the
treatment of BRAF V600E or V600K mutation-positive
melanoma. Clinical activity of trametinib in unresectable,
BRAF V600 mutation-positive melanoma was observed in
phase 1, 2 and 3 studies [3–5]. Significant improvement in
overall survival and progression free survival over
dacarbazine or paclitaxel was confirmed in the pivotal
phase 3 study (METRIC) [5].
The pharmacokinetics (PK) of trametinib after
oral administration were characterized in the first-
time-in-human (FTIH) study [6]. Following oral dosing
of 2 mg trametinib, median tmax was 1.5 h and the
mean effective half-life (t1/2) was approximately
4 days. Trametinib accumulates about six-fold with repeat
daily dosing and the concentration–time profiles showed
a flat profile at steady-state with a low peak : trough
ratio.
Determination of absolute bioavailability improves
our understanding of the clinical pharmacology of a
compound (e.g. by characterizing the i.v. phar-
macokinetics) and is required by several regulatory
agencies [7]. Conventional crossover studies have
been fraught with the challenges and delays asso-
ciated with preparing and administering a drug in-
travenously that has been developed for oral use.
The use of i.v. radiolabelled microtracer studies has
become an attractive alternative to conducting con-
ventional crossover design absolute bioavailability
studies and provides characterization of the i.v. PK
of a new compound. The microtracer approach in-
volves administration of an unlabelled oral therapeutic
dose with concomitant administration of a subthe-
rapeutic radiolabelled i.v. microdose (pharmacologi-
cally inactive). A microdose is defined as less than
1/100th of the calculated clinical dose (based on animal
data) needed to yield a pharmacologic effect, up to a
maximum of 100 μg [8, 9]. The radiolabelled micro-
dose (<270 nCi) produces trivial exposure to ionizing
radiation and does not require additional i.v. toxicity
studies or extensive i.v. formulation development. The
microtracer approach has the advantage of simultaneous
recovery of i.v. and oral pharmacokinetic parameters
to obtain within-subject, within-period comparison. As
such, this approach reduces the variability of recovered
pharmacokinetic parameters, reduces the number of
subjects required and provides a more precise esti-
mate of absolute bioavailability than does the use
of a traditional crossover design study. I.v. radiolabelled
microtracer studies have been widely implemented
at GlaxoSmithKline (GSK) within clinical pharmacology
programmes and across diverse therapeutic areas. Micro-
tracer studies have been used successfully to determine
the absolute bioavailability of several compounds at
GSK (dabrafenib [7], SRT-2104 (GSK2245840) [10], and
GSK962040 [11]) and elsewhere (fexofenadine, IDX899,
IDX989 and saxagliptin (dapagliflozin, SCH 900518) [12–
17]) using either the marketed oral formulation or an oral
microdose as the test treatment.
The purpose of this study was to characterize the
oral and i.v. PK and to determine the absolute oral
bioavailability of trametinib using simultaneous adminis-
tration of an unlabelled oral dose (2 mg tablet) and a
radiolabelled i.v. microdose (5 μg) in patients with solid
tumours.
Methods
Clinical study design
The study protocol (MEK115064; ClinicalTrials.gov identi-
fier NCT01416337) and consent form were approved by a
duly constituted institutional review board (Alpha Inde-
pendent Review Board, San Clemente, CA, USA), and the
study was conducted in accordance with good clinical
practice and the guiding principles of the Declaration of
Helsinki at Comprehensive Clinical Development NW, Inc
(Tacoma, WA, USA). Signed and dated written informed
consent was obtained from each patient before his or her
participation in the study and before any study-related
procedures were performed.
This was a phase 1, single centre, open label study in
patients with solid tumours. After obtaining informed
consent, eligible participants were admitted to the clinical
research unit on day −1. After fasting overnight for 8 h, all
participants received trametinib as a single 2 mg tablet
(with 240 ml water) and a single i.v. dose of 5 μg (7.4 kBq,
200 nCi) [14C]-trametinib, administered 1.5 h after the oral
dose (to coincide with oral tmax). The participants contin-
ued fasting for 4 h after the oral dose. The 5 μg (1 ml)
i.v. microdose of [14C]-trametinib (in 5% hydroxypropyl
β-cyclodextrin [Cavitron] for injection) was injected as a
slow i.v. push over 1 min into the infusion line through a ‘Y’
injection port co-administered with either a 50 ml solution
of normal saline or 5% dextrose administered at a rate of
10 ml min−1. All excipients used in the i.v. formulation had
GRAS (generally regarded as safe) status. The i.v. infusion
was given in the arm not being used for PK sampling.
Blood samples (two 6 ml samples at each time point)
for analysis of trametinib, [14C]-trametinib and total radio-
activity were collected at several time points through 10 h
on day 1 (pre-dose and 0.5, 1, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8,
10 h) and at single time points on days 2, 3, 4, 5, 8 and 11
after the oral dose. The actual date and time of each blood
sample collection were recorded. Blood samples were
stored on wet ice for a maximum of 1 h before plasma was
separated from blood by centrifugation at 4°C and stored
at −70°C prior to analysis. After completion of the study, all
participants entered an open label rollover study of
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trametinib (no washout period or follow-up visit re-
quired) and continued receiving trametinib (MEK114375,
ClinicalTrials.gov identifier NCT01376310).
Dose selection
The recommended oral dose of trametinib is 2 mg once
daily. The highest dosage strength (2 mg tablet) was used
in this study. An i.v. dose of 5 μg was selected, which is
400-fold lower than the oral dose, thus fitting the criteria of
a microdose (i.e. less than 100th of the dose needed to
yield a pharmacologic effect, up to a maximum of 100 μg)
[8, 9]. Due to the very low i.v. dose, a target detection limit
of 2.5 pg ml−1 was considered acceptable to characterize
the PK profile of trametinib. The lower limit achieved in
developing the assay was 1.1 pg ml−1.
Study participants
Men or women were eligible if they were ≥18 years of age
with solid tumours, had an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1, and had
adequate organ function (total bilirubin ≤1.5 times
ULN, ALT ≤2.5 times ULN, creatinine ≤1.5 times ULN,
Cockroft–Gault creatinine clearance ≥50 ml min−1, 24 h
urine creatinine clearance ≥50 ml min−1, LVEF ≥LLN by
ECHO orMUGA). A bodyweight of ≥45 kg and a bodymass
index between 19 and 45 kg m−2 were required. Partici-
pants were excluded if they had received cancer therapy
with delayed toxicity within 3 weeks, chemotherapy
without delayed toxicity within 2 weeks, an investigational
anticancer drug within 28 days, or any other investiga-
tional product within 30 days, five half-lives or twice the
duration of the biological effect of the investigational
product. In addition, patients were excluded if they
had participated in a 14C human research study within
12 months preceding administration of the study medica-
tion. Consumption of food, herbal remedies or medication
known to interfere with cytochrome P450 (CYP) 3A activity
was prohibited, although it was later confirmed that the
major pathway of elimination of trametinib is not medi-
ated by CYP3A4. Subjects with untreated leptomeningeal
or brain metastases or spinal cord compression were
excluded. Subjects with a Fridericia-corrected QT interval
(QTcF) or Bazett-corrected QT interval (QTcB) ≥480 ms, with
history or evidence of cardiovascular risk, with a history of
interstitial lung disease or pneumonitis, with a history of
retinal vein occlusion or central serous retinopathy or with
conditions affecting gastrointestinal absorption were
excluded.
Trametinib HPLC/MS/MS analysis
Trametinib was extracted from human plasma samples
with an isotopically labelled standard ([13C6]-trametinib) by
liquid-liquid extraction using ethyl acetate. Extracts were
injected onto a BEH C18 column (50 × 2.1 mm, 1.7 μm;
Waters Corporation, Milford, MA, USA), maintained at 65°C
and elutedwith a binarymobile phase gradient using 0.1%
formic acid in water (A) and 0.1% formic acid in acetonitrile
(B), with a constant flow rate of 0.7 ml min−1. The initial
mobile phase condition of 50 : 50 A : B was held until
0.8 min, when the composition changed to 35 : 65 A : B.
From 0.81 to 1.0 min, the mobile phase held at 20:80 A:B
and reverted back to the initial conditions (50 : 50 A : B) at
1.1 min. Detection was performed by positive ion MS/MS
with multiple reaction monitoring (m/z 616 to m/z 491 for
trametinib). The lower limit of quantification (LLQ) for
trametinib was 0.25 ng ml−1 for a 50 μl aliquot of human
plasma with a higher limit of quantification (HLQ) of
250 ng ml−1. Quality control samples (QC), prepared at
three different analyte concentrations (four replicates per
concentration) and stored with the study samples, were
analyzed with each batch of samples against separately
prepared calibration standards. For the analysis to be
acceptable, no more than one-third of the total QC results
and no more than one-half of the results from each
concentration level were to deviate from the nominal
concentration by more than 15%. Data acquisition and
quantitation were performed with Analyst version 1.4.2.
The applicable analytical runs met all predefined run
acceptance criteria.
[14C]-trametinib and total radioactivity analysis
Samples were analyzed for [14C]-trametinib and total
plasma radioactivity using accelerator mass spectrometry
(AMS). Prior to analysis by AMS, the carbon within the
samples was harvested and converted to graphite. This
involved a two stage process of sample combustion (oxi-
dation) followed by graphitization (reduction), as previ-
ously published [18]. AMS provides an isotope ratio from
which total radiocarbon per mg carbon is derived. The
carbon content of plasma was taken into account to allow
correction of the AMS data to determine the total amount
of radiocarbon in the samples. Carbon analysis was under-
taken using a Costech Elemental Combustion System
CHNS-O Analyzer (Costech Analytical Technologies,
Inc, Valencia, CA, USA) supplied by Pelican Scientific Ltd
(Cheshire, UK). The AMS was a 250 kV Single Stage
Accelerator Mass Spectrometer (National Electrostatics
Corp., Middleton, WI, USA), operated via NEC proprietary
‘AccelNET’ software on a Linux operating system. Post-
acquisition data processing was performed using the NEC
software ‘abc.’ Further details of the operating conditions
have been previously published [18]. The LLQ for total
radioactivity was 0.95 pg equiv ml−1.
Plasma [14C]-trametinib concentrations at all time
points were determined with a validated analytical LC
+ AMS method over the range of 1.1 to 101 pgml−1.
Trametinib (including [14C]-trametinib as a tracer) was
extracted from 200 μl of human plasma by protein precipi-
tation using three volumes of acetonitrile containing non-
labelled trametinib at 2 μgml−1 as an internal standard (IS).
The samples were vortex-mixed and centrifuged at 3000 ×
g; the resultant supernatant was removed and dried using
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a vacuum centrifuge. The sample was reconstituted in
250 μl of acetonitrile/water (50 : 50) and 50 μl was injected
onto the HPLC system. Isolation of trametinib was
achieved using a Phenomenex Synergi-Polar column
(4 μm packing, 4.6 × 250 mm) maintained at 30°C. The
mobile phase consisted of 10 mM ammonium acetate
(pH 5) (A) and acetonitrile (B). A flow rate of 1 ml min−1 was
maintained for the entire run. The following 70 min gradi-
ent was used: started at 5% B, increased to 20% B over
5 min, increased to 60% B over 40 min, increased to 95% B
over 5 min and maintained at 95% B for 5 min, and
decreased to 5% B over 5 min. The column was then
re-equilibrated at 5% B over 5 min. The area of the u.v.
response of the IS was recorded, and the eluate corre-
sponding to trametinib was collected as a discrete fraction
into a quartz tube for further processing to harvest graph-
ite and subsequent analysis by AMS. The assay had a linear
dynamic range of 1.1 to 101 pgml−1 and quantification
was performed against trametinib-spiked recovery stand-
ards based on demonstrated linearity with non-weighted
linear regression.
During method validation, concentrations of [14C]-
trametinib in validation samples were determined on two
occasions. Five of 33 validation samples failed to meet the
acceptance criteria of being within 20% of the actual con-
centrations (25% at LLOQ). The bias was assessed to be
<10% with a precision of <17.3%.
Study samples were analyzed as four separate batches
with QC samples included in each batch. Individual QC
results were deemed acceptable if the calculated concen-
tration was within 20% of the actual concentration, and
the analytical run was accepted if no more than one-third
of the QCs exceeded the acceptable limit with at least one
QC sample at each concentration within the acceptable
limit. Only two of 36 samples failed tomeet the established
acceptance criteria (±20%) through four analytical runs.
Eight study samples (≈11%) were re-analyzed for
incurred sample reproducibility (ISR) with all samples
being within 20% of the mean of the original and ISR
result.
Clinical pharmacokinetics
Analysis of plasma concentration data via non-
compartmental methods was conducted using WinNonlin
Professional Edition version 5.2 (Pharsight Corporation,
Mountain View, CA, USA) non-compartmental Model 200
(for extravascular administration) for trametinib and non-
compartmental Model 202 (for constant infusion) for [14C]-
trametinib and total radioactivity by ICON Development
Solutions (Marlow, UK). Standard non-compartmental PK
parameters, including maximum concentration (Cmax), tmax,
area under the concentration–time curve from time zero
to 244 h or to infinity (AUC(0,tlast) and AUC(0,∞), respec-
tively) and half-life (t1/2) for trametinib, [14C]-trametinib and
total radioactivity, were estimated based on actual sam-
pling times. Systemic clearance (CL) and apparent oral
clearance (CL/F) were determined after i.v. and oral dosing,
respectively. Vss is described as the volume of distribution
at steady-state following i.v. dosing and is based on mean
residence time (MRT) and CL, where Vss =MRT(0,∞) ×CL. Vd,z
is described as the volume of distribution during the ter-
minal phase and is calculated as dosei.v./(λz × AUC(0,∞)i.v.),
where λz is the terminal slope elimination rate constant
and AUC(0,∞)i.v. following i.v. administration of trametinib
is defined above.
Statistical analysis
Summary statistics are reported for each PK parameter. For
calculation of absolute bioavailability, a mixed-effect
model (SAS, version 9.1.3, on the Windows SAS platform)
was fitted to dose-normalized, loge-transformed area
under the curve (AUC(0,tlast) or AUC(0,∞)) with the subject
as a random effect and treatment as a fixed effect (oral
was the test, i.v. was the reference). Dose-normalized
AUC(0,tlast) or AUC(0,∞) was obtained by dividing
AUC(0,tlast) or AUC(0,∞) by dose for each subject. The least-
squares mean difference and associated 90% confidence
intervals (CIs) in AUC(0,tlast) or AUC(0,∞) between the oral
and i.v. doses were obtained from the model. This least-
squares mean difference was back-transformed to pro-
vide a point estimate and corresponding 90% CI for the
absolute bioavailability (F). Due to the long elimination
half-life and large extrapolation of area, the estimate of
bioavailability is also reported based on AUC(0,tlast).
Results
Participants
Four patients (two White men and two White women;)
were enrolled and underwent study procedures. All
patients had metastatic (stage IV) cancer at screening,
including oesophageal cancer, non-small cell lung cancer
(NSCLC), ocularmelanoma and bladder cancer. All patients
had an ECOG performance status of 0 or 1 at screening. All
received the oral and i.v. dose as planned.
Clinical pharmacokinetics
The geometric least squares mean (90% CI) absolute
bioavailability (F) of the 2 mg trametinib tablet were 72.3%
(50.0%, 104.6%) and 84.2% (66.1%, 107.2%) based on
AUC(0,tlast) and AUC(0,∞), respectively. Individual values
ranged from 45.7% to 92.8% and from 65.9% to 109%
when F was determined using AUC(0,tlast) and AUC(0,∞),
respectively.
Individual concentration–time profiles following oral
dose and i.v. microdose are illustrated in Figure 1. Selected
PK parameters for trametinib observed following oral
administration and for [14C]-trametinib and total radio-
activity following i.v. administration are summarized in
Table 1. For a 400-fold difference in dose, trametinib geo-
metric mean Cmax and AUC(0,tlast) were 76-fold and 289-fold
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Figure 1
(A) Individual plasma trametinib and [14C]-trametinib concentration vs. time profiles after oral (2 mg) and i.v. (5 μg) administration. Individual patients are
denoted by symbols and colours. The dashed lines represent oral trametinib; the solid lines represent i.v. [14C]-trametinib. Inset shows detail from 0 to 24 h
post-dose
Table 1
Clinical pharmacokinetics of trametinib after concomitant oral and i.v. administration (2 mg trametinib orally, 5 μg [14C]-trametinib i.v.)
Parameter (units) Trametinib (oral) [14C]-trametinib (i.v.) Total radioactivity* (i.v.)
tmax† (h) 1.50 0.08 0.08
(1.00, 1.58) (0.08, 0.08) (0.08,0.08)
Cmax‡ (ng ml–1) 8.03 0.105 0.118
[118] [71] [54]
(2.56, 24.31) (0.044, 0.190) (0.058, 0.177)
AUC(0,t)‡ (ng ml–1 h) 248 0.858 1.68
[83] [57] [56]
(99.8, 580) (0.546, 1.76) (1.18, 3.60)
AUC(0,∞) (ng ml–1 h) 525 1.56 4.92§, 5.91§
[36] [31]
(333, 783)‡ (1.26, 2.39)‡
t1/2 (h) 264 229 643§, 176§
[62] [39]
(130, 481)‡ (144, 348)‡
CL or CL/F‡ (l h–1) 3.81 3.21 ND
[36] [31]
(2.56, 6.01) (2.09, 3.97)
Vss‡ (l) ND 976 ND
[79]
(385, 1836)‡
Vd,z‡ (l) ND 1060 ND
[75]
(435, 1985)‡
t1/2, half-life; tmax, time to reach Cmax; Vss, volume of distribution at steady state; Vd,z, volume of distribution during the terminal phase. *Total radioactivity concentration units are
ng equivalents trametinib ml−1. †tmax results are presented as median (minimum, maximum). ‡Results are presented as geometric mean [%CV] (minimum, maximum) for n >2.
§Elimination half-life and AUC(0,∞) for total radioactivity were estimated in only two of four subjects; individual subject values are listed. AUC(0,∞), area under the concentration–
time curve from time zero to infinity; AUC(0,t), area under the concentration–time curve from time zero to time t; CL, systemic clearance; CL/F, apparent oral clearance; Cmax,
maximum concentration; ND, not determined.
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lower, respectively, after i.v, microdose relative to the oral
dose. Geometric mean i.v. trametinib plasma clearance,
Vd,z, and Vss were 3.21 l h−1, 1060 l and 976 l, respectively,
after administration of i.v. microdose. Apparent clearance
following oral dose of trametinib was 3.81 l h−1.
The median trametinib tmax after oral administration
was 1.5 h and coincided with the tmax observed at the end
of the i.v. infusion (0.08 h post-end of infusion). After tmax, a
rapid distribution phase was observed as plasma concen-
trations decreased five-fold and 21-fold from tmax to 24 h
post-oral and i.v. dose, respectively (Figure 1). The rapid
distribution phase was followed by a prolonged terminal
elimination phase after both oral and i.v. administration.
The geometricmean terminal phase half-life for trametinib
after oral dose and i.v. microdose administrationwas 264 h
(≈11 days) and 229 h (≈10 days), respectively.
Mean profiles of [14C]-trametinib and total radioactivity
plasma concentration over time are shown in Figure 2.
Trametinib as parent accounted for 52% (range: 43%–
63%) of the total radioactivity observed after a single i.v.
dose.
As shown in Figure 1, the rank order for each subject
was consistent following oral and i.v. dosing, such that
subjects with comparatively high exposure following oral
administration also had high exposure after i.v. adminis-
tration. This was further investigated by examining rela-
tionships between exposure and subject characteristics.
Figure 3 shows trametinib and [14C]-trametinib AUC(0,tlast)
and Cmax values by gender and by body weight. There was
an apparent inverse relationship between body weight
and trametinib exposure. Female subjects had higher
exposure, consistent with their lower body weight.
Adverse events
All reported adverse events (AEs) were grade 1 and non-
recurrent and most (except headache, ecchymosis and
excoriation in one subject) resolved by the time subjects
transitioned to the rollover study to continue receiving
trametinib. None of the AEs was considered related to
treatment with the study medication. There were no with-
drawals due to AEs and no reports of AEs related to
changes in clinical laboratory tests, echocardiograms or
vital signs. There were no reports of serious AEs.
Discussion
The primary objective of this study was to determine the
absolute bioavailability (F) of trametinib after concomitant
administration of a radiolabelled i.v. microtracer dose
(5 μg) and an unlabelled oral therapeutic dose (2 mg tablet
formulation). To enable determination of concentrations
following administration of the 5 μg i.v. microtracer
dose, an AMS assay was validated with a lower limit of
quantitation of 1.1 pg ml−1. Based on AUC(0,tlast), the abso-
lute bioavailability of trametinib was 72.3% (range, 45.7%–
92.8% indicating moderate to high bioavailability of the
2 mg tablet following oral administration.
Trametinib had low i.v. plasma CL of 3.21 l h−1 (0.94 l h−1
blood clearance), which is approximately 1% of liver blood
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Figure 2
Mean plasma [14C]-trametinib (solid line, ng ml−1) and total radioactivity (dashed line, ng equivalents of trametinib ml−1) concentration vs. time profile after
i.v.; 5 μg administration (n = 4). Inset shows detail from 0 to 24 h post-dose. , [14C]-trametinib; , total radioactivity
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flow (where liver blood flow is 81 l h−1 [19] and a
blood : plasma ratio of 3.4). High absolute bioavailability
and low clearance suggest low hepatic extraction and
limited first pass metabolism of trametinib. A large Vss
(976 l) suggests that trametinib distributes considerably to
tissues. The distribution is rapid, as evidenced by the large
initial decrease in concentrations after a single oral and i.v.
dose (5- and 21-fold decrease within 24 h of tmax, respec-
tively). Under steady-state conditions, a low peak : trough
ratio of 1.8 was observed in subjects after once daily
dosing of trametinib (2 mg) in the FTIH study. This may be
attributable to the fact that the distribution processes are
less pronounced with repeat dosing [6].
Subjects with comparatively high exposure following
oral administration also had high exposure after i.v. ad-
ministration. In addition, female subjects with lower body
weight had higher exposure compared with male subjects
with higher body weight, consistent with results from the
population PK analysis where oral clearance (CL/F) was
affected by both gender and weight, whereas the distribu-
tional clearance was affected by body weight [20].
The estimated half-lives after oral and i.v. admini-
stration were 11 and 10 days, respectively. The half-life
determined in the food effect study (MEK113709 [21])
was approximately 5 days, likely due the shorter sampling
period (up to 7 days) while the accumulation half-life was
only 4 days. Using a population PK model, estimated ter-
minal half-lives were 3.9 and 4.8 days for male and female
subjects, respectively, and were consistent with the effec-
tive half-life [20]. Despite a lengthy elimination phase, it is
expected that steady-state exposure following repeat
daily dosing of 2 mg will be reached within 15 to 20 days.
This is because the AUC attributed to the long elimination
phase contributes little to total AUC.
Trametinib profiles following both oral and i.v. ad-
ministration showed an initial rapid distribution phase
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Individual AUC(0,tlast) and Cmax values for a single 2 mg oral dose of trametinib (A,C) or a single 5 μg i.v. dose of [14C]-trametinib (B,D). Symbols denote male
(triangles) and female (circles) subjects
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followed by a protracted elimination phase likely reflective
of slow elimination from deep compartments. It has been
shown that parent trametinib, but not metabolites, prefer-
entially distributes to red blood cells and this accounts for
the initial rapid distribution phase [22] and is supportive of
the observation that following a single i.v. dose, parent
trametinib accounts for 52% (range 43%–63%) of the
total radioactivity in plasma. Following repeat dosing, as
steady-state is reached, the fraction of parent trametinib in
plasma accounts for >75%, while the twometabolites each
accounted for approximately 10% of total radioactivity.
Given the long elimination half-life relative to the
sample collection period and large extrapolation of
AUC(0,∞), the primary estimate of F was based on
AUC(0,tlast). In general, estimates of F using AUC(0,∞)
agreed (within 17%) with estimates using AUC(0,tlast),
except for one subject in whom the estimate of absolute
bioavailability differed from that in the other three sub-
jects by 44%. This subject had an elimination half-life for
trametinib in plasma that was 1.5 times higher than the
geometric mean half-life. For two subjects, accurate esti-
mation of elimination half life (and AUC(0,∞)) was not pos-
sible due to a relatively flat elimination phase of the
plasma concentration–time curve.
In conclusion, the i.v. microtracer study approach
revealed the contribution of moderate/high oral bioavail-
ability with low first pass metabolism and a prolonged
terminal elimination phase to the PK of trametinib.
Although this study had its limitations due to the study
population, namely the small number of patients, the
advantages of this approach was a shorter study time
frame (compared with a traditional crossover design) and
simultaneous collection of i.v. and oral pharmacokinetic
parameters with reduced variability. In the case of
trametinib, which has a long half-life, the i.v. microtracer
approach is especially useful. This approach obviates the
need for a lengthy washout period required in a conven-
tional crossover study, and allows patients to receive treat-
ment without delay by entering into the rollover study
and also allows recruitment of a small number of patients
while recovering the necessary PK parameters. As such,
i.v. microtracer studies offer an innovative and efficient
approach for assessing absolute bioavailability andmay be
applied across a range of therapeutic areas and compound
classes.
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